

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**Cumulative Supplement 12
December 2016**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 12
December 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

BD RX INC
(BD RX)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

PROSAM LABS LLC
(PROSAM LABS)

HIKMA MAPLE LTD
(HIKMA MAPLE)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

OXFORD PHARMACEUTICALS LLC
(OXFORD PHARMS)

EUROHEALTH INTERNATIONAL SARL
(EUROHLTH INTL SARL)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)	17528 2664 (15.2%)	17765 2665 (15%)	18130 2646 (14.6%)
MULTISOURCE	14487 (84.5%)	14558 (84.4%)	14864 (84.8%)	15100 (85%)	15484 (85.4%)
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)	14731 (84%)	14968 (84.3%)	15355 (84.7%)
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)	133 (0.8%)	132 (0.7%)	129 (0.7%)
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)
NEW MOLECULAR ENTITIES APPROVED	28	9	20	8	7
NUMBER OF APPLICANTS	1011	1007	1023	1027	1051

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book(EOB)query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL					
ABACAVIR SULFATE					
AA	HETERO LABS LTD III	EQ 20MG BASE/ML	A201107	001	Sep 26, 2016 Sep NEWA
ZIAGEN					
AA	+ VIIV HLTHCARE	EQ 20MG BASE/ML	N020978	001	Dec 17, 1998 Sep CFTG
TABLET;ORAL					
ABACAVIR SULFATE					
AB	STRIDES ARCOLAB LTD	EQ 300MG BASE	A091050	001	Oct 28, 2016 Oct NEWA
AB	STRIDES PHARMA	EQ 300MG BASE	A091050	001	Oct 28, 2016 Nov CAHN

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL					
ABACAVIR SULFATE AND LAMIVUDINE					
AB	TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246	001	Sep 29, 2016 Sep NEWA
EPZICOM					
AB	+ VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004 Sep CFTG

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL					
ACAMPROSATE CALCIUM					
AB	+ GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013 May CRLD

ACARBOSE

TABLET;ORAL					
ACARBOSE					
AB	WEST-WARD PHARMS INT	25MG	A078470	001	May 07, 2008 Nov CAHN
AB		50MG	A078470	002	May 07, 2008 Nov CAHN
AB		100MG	A078470	003	May 07, 2008 Nov CAHN

ACETAMINOPHEN

SOLUTION;IV (INFUSION)					
ACETAMINOPHEN					
AP	PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016 May NEWA
AP	SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016 Mar NEWA
OFIRMEV					
AP	+ MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010 Mar CFTG

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL					
BUTALBITAL AND ACETAMINOPHEN					
AA	CNTY LINE PHARMS	325MG;50MG	A205120	001	Oct 30, 2015 Aug CAHN
AA	MIKART INC	300MG;50MG	A207386	001	Nov 15, 2016 Oct NEWA
AA	+ NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011 Oct CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL					
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	+ MAYNE PHARMA INC	325MG;50MG;40MG	A089007	001	Mar 17, 1986 Aug CAHN
	+ METRIC	325MG;50MG;40MG	A089007	001	Mar 17, 1986 Jun CAHN
AB	+ NEXGEN PHARMA	300MG;50MG;40MG	A040885	001	Nov 16, 2009 Oct CFTG
AB	NUVO PHARM INC	300MG;50MG;40MG	A207118	001	Oct 28, 2016 Oct NEWA
TABLET;ORAL					
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
>A> AA	CNTY LINE PHARMS	325MG;50MG;40MG	A204984	001	Jan 10, 2017 Dec NEWA
	@ INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008 Jan CAHN
	@ SUN PHARM INDS	325MG;50MG;40MG	A040601	001	Jul 29, 2005 Jan CAHN
FIORICET					
AA	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984 May CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL					
FIORICET W/ CODEINE					
AB	+ ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992 Jul CAHN
AB	+ ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992 Apr CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

LARKEN LABS INC

325MG; 30MG; 16MG

A204209 001 Sep 30, 2016 Sep NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ FRONTIDA BIOPHARM

300MG; 15MG

A089671 001 Feb 10, 1988 Sep CAHN

@

300MG; 30MG

A089672 001 Feb 10, 1988 Sep CAHN

@

300MG; 60MG

A089673 001 Feb 10, 1988 Jul CAHN

@ SUN PHARM INDS

300MG; 60MG

A089673 001 Feb 10, 1988 Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

ZYFREL

AA CYPRESS PHARM INC 325MG/15ML; 7.5MG/15ML

A090468 001 Apr 14, 2016 Apr NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ACTAVIS LABS FL INC

300MG; 5MG

A206470 001 Jun 02, 2016 May NEWA

AA

300MG; 7.5MG

A206470 002 Jun 02, 2016 May NEWA

AA

300MG; 10MG

A206470 003 Jun 02, 2016 May NEWA

@ ALLERGAN SALES LLC

500MG; 10MG

A040148 002 Feb 14, 1997 Jun CAHN

AA AMNEAL PHARMS

300MG; 10MG

A207137 001 Nov 29, 2016 Nov NEWA

AA AMNEAL PHARMS NY

325MG; 7.5MG

A040746 002 May 10, 2016 Apr NEWA

@ APIL

500MG; 10MG

A040148 002 Feb 14, 1997 Nov CAHN

AA LARKEN LABS INC

325MG; 5MG

A202935 002 Jun 15, 2016 Jun NEWA

AA

325MG; 7.5MG

A202935 003 Jun 15, 2016 Jun NEWA

AA

325MG; 10MG

A202935 004 Jun 15, 2016 Jun NEWA

AA NOVEL LABS INC

300MG; 5MG

A206142 001 Nov 14, 2016 Nov NEWA

AA

300MG; 7.5MG

A206142 002 Nov 14, 2016 Nov NEWA

AA

300MG; 10MG

A206142 003 Nov 14, 2016 Nov NEWA

AA

325MG; 5MG

A206245 001 Dec 01, 2016 Nov NEWA

AA

325MG; 7.5MG

A206245 002 Dec 01, 2016 Nov NEWA

AA

325MG; 10MG

A206245 003 Dec 01, 2016 Nov NEWA

PAR PHARM

300MG; 5MG

A205001 001 Jul 05, 2016 Jun NEWA

AA

300MG; 7.5MG

A205001 002 Jul 05, 2016 Jun NEWA

AA

300MG; 10MG

A205001 003 Jul 05, 2016 Jun NEWA

RHODES PHARMS

325MG; 5MG

A202991 001 Apr 12, 2016 Mar NEWA

AA

325MG; 7.5MG

A202991 002 Apr 12, 2016 Mar NEWA

AA

325MG; 10MG

A202991 003 Apr 12, 2016 Mar NEWA

TRIS PHARMA INC

300MG; 5MG

A202214 004 Mar 15, 2016 Jun NEWA

AA

300MG; 7.5MG

A202214 005 Mar 15, 2016 Jun NEWA

AA

300MG; 10MG

A202214 006 Mar 15, 2016 Jun NEWA

NORCO

AA ALLERGAN SALES LLC

325MG; 2.5MG

A040148 004 Jul 07, 2014 Jun CAHN

AA +

325MG; 5MG

A040099 001 Jun 25, 1997 Jun CAHN

AA

325MG; 5MG

A040148 005 Jul 07, 2014 Jun CAHN

AA +

325MG; 7.5MG

A040148 003 Sep 12, 2000 Jun CAHN

AA +

325MG; 10MG

A040148 001 Feb 14, 1997 Jun CAHN

APIL

325MG; 2.5MG

A040148 004 Jul 07, 2014 Nov CAHN

AA +

325MG; 5MG

A040099 001 Jun 25, 1997 Nov CAHN

AA

325MG; 5MG

A040148 005 Jul 07, 2014 Nov CAHN

AA +

325MG; 7.5MG

A040148 003 Sep 12, 2000 Nov CAHN

AA +

325MG; 10MG

A040148 001 Feb 14, 1997 Nov CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

AA + MALLINCKRODT INC

325MG/5ML; 5MG/5ML

A040680 001 Sep 29, 2006 Aug CRLD

AA

325MG/5ML; 5MG/5ML

A040680 001 Sep 29, 2006 May CMFD

ROXICET

@ ROXANE

325MG/5ML; 5MG/5ML

A089351 001 Dec 03, 1986 Aug DISC

@ WEST-WARD PHARMS INT

325MG/5ML; 5MG/5ML

A089351 001 Dec 03, 1986 Nov CAHN

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA ALVOGEN MALTA

325MG; 5MG

A202677 003 Mar 08, 2016 Feb NEWA

AA

325MG; 7.5MG

A202677 001 Jul 26, 2012 Jan CAHN

AA

325MG; 10MG

A202677 002 Jul 26, 2012 Jan CAHN

AMNEAL PHARMS NY

325MG; 7.5MG

A040778 002 Jun 27, 2014 Apr NEWA

AA CEROVENE INC

325MG; 5MG

A207574 001 Dec 13, 2016 Nov NEWA

AA MAYNE PHARMA INC

325MG; 2.5MG

A090177 001 Oct 20, 2008 Feb CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA		325MG;5MG	A090177	002	Oct 20, 2008	Feb CAHN
AA		325MG;7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
AA		325MG;10MG	A090177	004	Oct 20, 2008	Feb CAHN
	@	500MG;7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
	@	650MG;10MG	A090177	006	Oct 20, 2008	Feb CAHN
ROXICET						
AA	WEST-WARD PHARMS INT	325MG;5MG	A087003	001		Nov CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ATLAS PHARMS LLC	325MG;37.5MG	A202076	001	Mar 30, 2012	May CAHN
----	------------------	--------------	---------	-----	--------------	----------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar NEWA
AB	NOVAST LABS LTD	500MG	A203434	001	Sep 30, 2016	Sep NEWA

TABLET;ORAL

ACETAZOLAMIDE

AB	HERITAGE PHARMA	125MG	A205530	001	Oct 27, 2016	Oct NEWA
AB		250MG	A205530	002	Oct 27, 2016	Oct NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Sep CAHN
----	----------------------	--------------------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb NEWA
AP	FRESENIUS KABI USA	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Sep CAHN

TABLET, EFFERVESCENT;ORAL

CETYLEV

	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan NEWA
+		2.5GM	N207916	002	Jan 29, 2016	Jan NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB	IMPAX LABS INC	10MG	A202552	001	Dec 23, 2015	Aug CAHN
AB		17.5MG	A202552	002	Dec 23, 2015	Aug CAHN
AB		22.5MG	A202552	003	Dec 23, 2015	Aug CAHN
AB		25MG	A202552	004	Dec 23, 2015	Aug CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994	Mar CAHN
---	---------------------	----------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

	@ RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb DISC
AB	ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016	Mar NEWA

OINTMENT;TOPICAL

ACYCLOVIR

AB	FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016	Apr NEWA
>A> AB	TARO	5%	A205469	001	Dec 21, 2016	Dec NEWA

TABLET;BUCCAL

SITAVIG

+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan CAHN
---	------------------	------	---------	-----	--------------	----------

TABLET;ORAL

ACYCLOVIR

>D> AB	APOTEX INC	400MG	A077309	001	Sep 29, 2005	Dec CAHN
>A> AB		400MG	A077309	001	Sep 29, 2005	Dec CAHN
>D> AB		800MG	A077309	002	Sep 29, 2005	Dec CAHN
>A> AB		800MG	A077309	002	Sep 29, 2005	Dec CAHN

TABLET;ORAL

ACYCLOVIR

@ SUN PHARM INDS LTD

400MG

A074980 001 Sep 30, 1998 Feb DISC

@

800MG

A074980 002 Sep 30, 1998 Feb DISC

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

@ AMPHASTAR PHARMS INC

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Jun CAHN

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Jun CAHN

@ BEDFORD

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Feb DISC

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Feb DISC

AP +

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Feb CTEC

@ EUROHLTH INTL SARL

EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Apr CAHN

@

EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Apr CAHN

AP

HIKMA PHARMS LLC

EQ 500MG BASE/VIAL

A205771 001 Feb 29, 2016 Feb NEWA

+

EQ 1GM BASE/VIAL

A205771 002 Feb 29, 2016 Feb CRLD

AP

EQ 1GM BASE/VIAL

A205771 002 Feb 29, 2016 Feb NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

AB

TARO

0.3%

A208322 001 Jun 23, 2016 Jun NEWA

SOLUTION;TOPICAL

ADAPALENE

AB

CALL INC

0.1%

A203981 001 Sep 23, 2016 Sep NEWA

AB +

0.1%

A204593 001 Jan 05, 2016 Sep CTEC

ADENOSINE

SOLUTION;IV (INFUSION)

ADENOSINE

AP +

TEVA PHARMS USA

60MG/20ML (3MG/ML)

A077425 001 Aug 29, 2013 Apr CRLD

AP +

90MG/30ML (3MG/ML)

A077425 002 Aug 29, 2013 Apr CRLD

ALBUTEROL SULFATE

SOLUTION;INHALATION

ALBUTEROL SULFATE

@ HI TECH PHARMA

EQ 0.083% BASE

A075063 001 Feb 09, 1999 Mar DISC

@ LANDELA PHARM

EQ 0.083% BASE

A077569 001 Apr 04, 2006 Mar DISC

AN +

NEPHRON

EQ 0.083% BASE

A074880 001 Sep 17, 1997 Mar CRLD

@ TEVA PHARMS

EQ 0.083% BASE

A075343 001 Nov 09, 1999 Mar DISC

@ WATSON LABS INC

EQ 0.083% BASE

A076370 001 Nov 24, 2003 Mar DISC

TABLET;ORAL

ALBUTEROL SULFATE

@ DAVA PHARMS INC

EQ 2MG BASE

A072860 002 Dec 20, 1989 Oct CMS1

AB

SUN PHARM INDS

EQ 2MG BASE

A072637 002 Dec 05, 1989 Mar CAHN

AB

EQ 4MG BASE

A072637 001 Dec 05, 1989 Mar CAHN

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

+ ROXANE

EQ 70MG BASE/75ML

A090520 001 Feb 25, 2013 Aug CRLD

+ WEST-WARD PHARMS INT

EQ 70MG BASE/75ML

A090520 001 Feb 25, 2013 Nov CAHN

FOSAMAX

@ MERCK

EQ 70MG BASE/75ML

N021575 001 Sep 17, 2003 Aug DISC

TABLET;ORAL

ALENDRONATE SODIUM

>A>

AB

DR REDDYS LABS LTD

EQ 5MG BASE

A079049 003 Aug 04, 2008 Dec CMS1

>A>

AB

IMPAX LABS INC

EQ 10MG BASE

A079049 004 Aug 04, 2008 Dec CMS1

AB

EQ 5MG BASE

A075710 001 Feb 06, 2008 Aug CAHN

AB

EQ 10MG BASE

A075710 002 Feb 06, 2008 Aug CAHN

AB

EQ 35MG BASE

A075710 003 Feb 06, 2008 Aug CAHN

AB

EQ 40MG BASE

A075710 004 Feb 06, 2008 Aug CAHN

AB

EQ 70MG BASE

A075710 005 Feb 06, 2008 Aug CAHN

AB

JUBILANT CADISTA

EQ 5MG BASE

A090557 001 Feb 18, 2010 Jun CAHN

AB

EQ 10MG BASE

A090557 002 Feb 18, 2010 Jun CAHN

AB

EQ 35MG BASE

A090557 003 Feb 18, 2010 Jun CAHN

AB

EQ 70MG BASE

A090557 004 Feb 18, 2010 Jun CAHN

@ UPSHER-SMITH LABS

EQ 5MG BASE

A075871 001 Apr 22, 2009 Oct CAHN

@

EQ 10MG BASE

A075871 002 Apr 22, 2009 Oct CAHN

@

EQ 35MG BASE

A075871 004 Apr 22, 2009 Oct CAHN

@

EQ 40MG BASE

A075871 003 Apr 22, 2009 Oct CAHN

TABLET;ORAL

ALENDRONATE SODIUM

@

EQ 70MG BASE

A075871 005 Apr 22, 2009 Oct CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

MERCK

EQ 70MG BASE;2,800 IU

N021762 001 Apr 07, 2005 Aug CMFD

+

EQ 70MG BASE;5,600 IU

N021762 002 Apr 26, 2007 Aug CMFD

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB UNICHEM LABS LTD 10MG

A203192 001 Jan 28, 2016 Jan NEWA

ALISKIREN HEMIFUMARATE

TABLET;ORAL

TEKTURNA

NODEN PHARMA

EQ 150MG BASE

N021985 001 Mar 05, 2007 Oct CAHN

+

EQ 300MG BASE

N021985 002 Mar 05, 2007 Oct CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

NODEN PHARMA

EQ 150MG BASE;12.5MG

N022107 001 Jan 18, 2008 Oct CAHN

EQ 150MG BASE;25MG

N022107 002 Jan 18, 2008 Oct CAHN

+

EQ 300MG BASE;12.5MG

N022107 003 Jan 18, 2008 Oct CAHN

+

EQ 300MG BASE;25MG

N022107 004 Jan 18, 2008 Oct CAHN

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

>D> AB APOTEX INC 100MG

A077353 001 Sep 08, 2005 Dec CAHN

>A> AB 100MG

A077353 001 Sep 08, 2005 Dec CAHN

>D> AB 300MG

A077353 002 Sep 08, 2005 Dec CAHN

>A> AB 300MG

A077353 002 Sep 08, 2005 Dec CAHN

AB INDOCO REMEDIES 100MG

A204467 001 Jul 28, 2016 Jul NEWA

AB 300MG

A204467 002 Jul 28, 2016 Jul NEWA

AB SUN PHARM INDS 300MG

A071450 001 Jan 09, 1987 Mar CAHN

ZYLOPRIM

AB SEBELA IRELAND LTD 100MG

N016084 001 Jan CAHN

AB + 300MG

N016084 002 Jan CAHN

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALLOPURINOL SODIUM

AP WEST-WARD PHARMS INT EQ 500MG BASE/VIAL

A076870 001 Aug 26, 2004 Oct CAHN

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB AJANTA PHARMA LTD EQ 6.25MG BASE

A205523 001 Mar 03, 2016 Feb NEWA

AB EQ 12.5MG BASE

A205523 002 Mar 03, 2016 Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

>A> AB AMNEAL PHARMS EQ 0.5MG BASE

A206647 001 Dec 22, 2016 Dec NEWA

>A> AB EQ 1MG BASE

A206647 002 Dec 22, 2016 Dec NEWA

AB WEST-WARD PHARMS INT EQ 0.5MG BASE

A200652 001 May 04, 2015 Nov CAHN

AB EQ 1MG BASE

A200652 002 May 04, 2015 Nov CAHN

LOTRONEX

AB SEBELA IRELAND LTD EQ 0.5MG BASE

N021107 002 Dec 23, 2003 Feb CAHN

AB + EQ 1MG BASE

N021107 001 Feb 09, 2000 Feb CAHN

ALPRAZOLAM

CONCENTRATE;ORAL

ALPRAZOLAM

+ WEST-WARD PHARMS INT 1MG/ML

A074312 001 Oct 31, 1993 Nov CAHN

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@	ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010	Jan DISC
@		1MG	A077198	002	May 13, 2010	Jan DISC
@		2MG	A077198	003	May 13, 2010	Jan DISC
@		3MG	A077198	004	May 13, 2010	Jan DISC
@	COREPHARMA	0.5MG	A077996	001	Jan 31, 2007	Mar DISC
@		1MG	A077996	002	Jan 31, 2007	Mar DISC
@		2MG	A077996	003	Jan 31, 2007	Mar DISC
@		3MG	A077996	004	Jan 31, 2007	Mar DISC
@	IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan DISC
@		1MG	A077968	003	May 24, 2007	Jan DISC
@		2MG	A077968	002	May 24, 2007	Jan DISC
@		3MG	A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

AP	WEST-WARD PHARMS INT	0.5MG/ML	A074815	001	Jan 20, 1998	Sep CAHN
	EDEX					
	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN
	SUPPOSITORY;URETHRAL					
	MUSE					
+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
AB	NEWGEN PHARMS LLC	100MG	A207570	001	Sep 30, 2016	Sep NEWA
AB	WATSON LABS INC	100MG	A208107	001	Dec 06, 2016	Nov NEWA
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

>D>	+	USL PHARMA	100MG	A076186	001	Dec 16, 2002	Dec CTEC
>A>	AB	+	100MG	A076186	001	Dec 16, 2002	Dec CTEC
>A>	AB	WATSON LABS INC	100MG	A208096	001	Dec 15, 2016	Dec NEWA

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA
	@	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992	Oct CAHN
AP	+		EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Sep CAHN
	@		EQ 250MG BASE/ML	A063275	001	May 18, 1992	Oct CAHN
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Sep CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
	CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
	CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1

INJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May NEWA
---	-------------	-----	---------	-----	--------------	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@	IDT AUSTRALIA LTD	100MG	A085261	003		May CAHN
@		100MG	A085262	002		May CAHN
@		200MG	A085261	002		May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	APOTEX INC	200MG	A078578	001	Nov 06, 2008	Nov CAHN
AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May NEWA
AB	MURTY PHARMS	100MG	A077069	003	Oct 04, 2016	Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

@	ANI PHARMS INC	10MG	A085031	002		Sep CMS1
@		50MG	A085031	003		Sep CMS1
@		75MG	A085031	004		Sep CMS1
@	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar DISC
@		10MG	A089399	002	Jul 14, 1987	Mar DISC
AB		10MG	A089399	002	Jul 14, 1987	Mar CAHN
@		25MG	A040816	001	Jun 27, 2008	Mar DISC
@		25MG	A089399	001	Jul 14, 1987	Mar DISC
AB		25MG	A089399	001	Jul 14, 1987	Mar CAHN
@		50MG	A040816	003	Jun 27, 2008	Mar DISC
@		50MG	A089399	003	Jul 14, 1987	Mar DISC
AB		50MG	A089399	003	Jul 14, 1987	Mar CAHN
@		75MG	A040816	004	Jun 27, 2008	Mar DISC
@		75MG	A089399	004	Jul 14, 1987	Mar DISC
AB		75MG	A089399	004	Jul 14, 1987	Mar CAHN

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@	100MG	A040816	005	Jun 27, 2008	Mar	DISC
	@	100MG	A089399	005	Jul 14, 1987	Mar	DISC
AB		100MG	A089399	005	Jul 14, 1987	Mar	CAHN
	@	150MG	A040816	006	Jun 27, 2008	Mar	DISC
	@	150MG	A089399	006	Jul 14, 1987	Mar	DISC
AB		150MG	A089399	006	Jul 14, 1987	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Jul	CAHN
@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Jul	CAHN
@	SUN PHARM INDS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Mar	CAHN
@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Mar	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG;2MG	A071077	001	Nov 12, 1986	Mar	CAHN
@		10MG;4MG	A071078	001	Nov 12, 1986	Mar	CAHN
@		25MG;2MG	A070297	001	Nov 12, 1986	Mar	CAHN
@		25MG;4MG	A071079	001	Nov 12, 1986	Mar	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016	May	NEWA
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Feb	CAHN
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Feb	CAHN
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Feb	CAHN
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun	NEWA
AB		EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun	NEWA
AB		EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun	NEWA
	@ SUN PHARM INDS	EQ 2.5MG BASE	A078081	001	Jan 31, 2008	Mar	CAHN
	@	EQ 5MG BASE	A078081	002	Jan 31, 2008	Mar	CAHN
	@	EQ 10MG BASE	A078081	003	Jan 31, 2008	Mar	CAHN
AB	WEST-WARD PHARMS INT	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Nov	CAHN
AB		EQ 5MG BASE	A077262	002	Jul 09, 2007	Nov	CAHN
AB		EQ 10MG BASE	A077262	003	Jul 09, 2007	Nov	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A206137	001	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A206137	002	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;25MG;40MG	A206137	003	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A206137	004	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;25MG;40MG	A206137	005	Oct 26, 2016	Oct	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Oct	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Oct	NEWA
AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Oct	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Oct	NEWA
AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Oct	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A203580	002	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;25MG;40MG	A203580	003	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Oct	NEWA
	TRIBENZOR						
AB	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010	Oct	CFTG
AB		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010	Oct	CFTG
AB		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010	Oct	CFTG
AB		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010	Oct	CFTG
AB	+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010	Oct	CFTG

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	AJANTA PHARMA LTD	EQ 5MG BASE;20MG	A207216	001	Oct 28, 2016	Oct	NEWA
AB		EQ 5MG BASE;40MG	A207216	002	Oct 28, 2016	Oct	NEWA
AB		EQ 10MG BASE;20MG	A207216	003	Oct 28, 2016	Oct	NEWA
AB		EQ 10MG BASE;40MG	A207216	004	Oct 28, 2016	Oct	NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE;20MG	A206884	001	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;40MG	A206884	003	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;20MG	A206884	002	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;40MG	A206884	004	Oct 26, 2016	Oct	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Oct	NEWA
AB	TORRENT PHARMS LLC	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Nov	NEWA
AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Nov	NEWA
AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Nov	NEWA
AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Nov	NEWA
AZOR							
AB	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007	Oct	CFTG
AB		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007	Oct	CFTG
AB		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007	Oct	CFTG
AB	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007	Oct	CFTG

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;40MG	A205234	001	Nov 17, 2016	Nov	NEWA
AB		EQ 5MG BASE;80MG	A205234	003	Nov 17, 2016	Nov	NEWA
AB		EQ 10MG BASE;40MG	A205234	002	Nov 17, 2016	Nov	NEWA
AB		EQ 10MG BASE;80MG	A205234	004	Nov 17, 2016	Nov	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr	NEWA
AB		EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Sep	NEWA
AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Sep	NEWA
AB	PAR PHARM INC	EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Oct	CMS1

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan	NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr	CRLD
LOTION; TOPICAL							
AMMONIUM LACTATE							
AB	+ PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr	CRLD

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@ UPSHER-SMITH LABS

25MG
 @ 50MG
 @ 100MG
 @ 150MG

A072943 001 Jun 28, 1991 Nov CAHN
 A072944 001 Jun 28, 1991 Nov CAHN
 A072878 001 Jun 28, 1991 Nov CAHN
 A072879 001 Jun 28, 1991 Nov CAHN

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

250MG

A065016 001 Apr 08, 1999 Feb DISC

@

500MG

A065016 002 Apr 08, 1999 Feb DISC

TABLET;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

500MG

A065059 001 Nov 24, 2000 Feb DISC

@

875MG

A065059 002 Nov 24, 2000 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

125MG

A065021 001 Dec 23, 1999 Feb DISC

@

250MG

A065021 002 Dec 23, 1999 Feb DISC

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+ VERNALIS R AND D LTD

775MG

N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

>D> AB CITRON PHARMA LLC

500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG

A206006 001 Oct 07, 2016 Dec CAHN

AB

500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG

A206006 001 Oct 07, 2016 Sep NEWA

>A> AB RISING PHARMS INC

500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG

A206006 001 Oct 07, 2016 Dec CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB AUROBINDO PHARMA LTD

200MG/5ML;EQ 28.5MG BASE/5ML

A201090 001 Dec 20, 2011 Feb CDFR

AB

400MG/5ML;EQ 57MG BASE/5ML

A201090 002 Dec 20, 2011 Feb CDFR

AB

600MG/5ML;EQ 42.9MG BASE/5ML

A201091 001 Dec 20, 2011 Feb CDFR

@ SUN PHARM INDS LTD

200MG/5ML;EQ 28.5MG BASE/5ML

A065132 001 Mar 19, 2003 Feb DISC

@

400MG/5ML;EQ 57MG BASE/5ML

A065132 002 Mar 19, 2003 Feb DISC

@

600MG/5ML;EQ 42.9MG BASE/5ML

A065207 002 Jan 30, 2007 Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB HIKMA PHARMS

875MG;EQ 125MG BASE

A203824 001 Aug 23, 2016 Aug NEWA

>A> AB

MICRO LABS LTD INDIA

250MG;EQ 125MG BASE

A205707 001 Dec 30, 2016 Dec NEWA

>A> AB

500MG;EQ 125MG BASE

A205707 002 Dec 30, 2016 Dec NEWA

>A> AB

875MG;EQ 125MG BASE

A204755 003 Dec 30, 2016 Dec NEWA

@ SUN PHARM INDS LTD

875MG;EQ 125MG BASE

A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SANDOZ

200MG;EQ 28.5MG BASE

A065065 001 Apr 18, 2002 Jul DISC

@

400MG;EQ 57MG BASE

A065065 002 Apr 18, 2002 Jul DISC

@ SUN PHARM INDS LTD

200MG;EQ 28.5MG BASE

A065161 001 Dec 03, 2003 Feb DISC

@

400MG;EQ 57MG BASE

A065161 002 Dec 03, 2003 Feb DISC

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

NEOS THERAPS

EQ 3.1MG BASE

N204326 001 Jan 27, 2016 Jan NEWA

EQ 6.3MG BASE

N204326 002 Jan 27, 2016 Jan NEWA

EQ 9.4MG BASE

N204326 003 Jan 27, 2016 Jan NEWA

EQ 12.5MG BASE

N204326 004 Jan 27, 2016 Jan NEWA

EQ 15.7MG BASE

N204326 005 Jan 27, 2016 Jan NEWA

+

EQ 18.8MG BASE

N204326 006 Jan 27, 2016 May CRLD

EQ 18.8MG BASE

N204326 006 Jan 27, 2016 Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB IMPAX LABS

1.25MG;1.25MG;1.25MG;1.25MG

A076852 001 Feb 16, 2016 Feb NEWA

AB

2.5MG;2.5MG;2.5MG;2.5MG

A076852 002 Feb 16, 2016 Feb NEWA

AB

3.75MG;3.75MG;3.75MG;3.75MG

A076852 003 Feb 16, 2016 Feb NEWA

AB

5MG;5MG;5MG;5MG

A076852 004 Feb 16, 2016 Feb NEWA

AB

6.25MG;6.25MG;6.25MG;6.25MG

A076852 005 Feb 16, 2016 Feb NEWA

AB

7.5MG;7.5MG;7.5MG;7.5MG

A076852 006 Feb 16, 2016 Feb NEWA

AB

TEVA

1.25MG;1.25MG;1.25MG;1.25MG

A077488 001 Apr 29, 2013 Feb CTNA

AB

2.5MG;2.5MG;2.5MG;2.5MG

A077488 002 Apr 29, 2013 Feb CTNA

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG; 5MG; 5MG; 5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

@	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@		100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug CAHN
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Aug CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Aug CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

@	UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Oct CAHN
@		EQ 1MG BASE	A076683	002	Apr 18, 2005	Oct CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

@	SANDOZ	1MG	A079007	001	Jun 28, 2010	Aug DISC
AB	WEST-WARD PHARMS INT	1MG	A078485	001	Jun 28, 2010	Nov CAHN

APRACLOINIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

IOPIDINE

AT	+	NOVARTIS PHARMS CORP	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Nov CAHN
	+		EQ 1% BASE	N019779	001	Dec 31, 1987	Nov CAHN

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120	001	Sep 21, 2016	Sep NEWA
----	-------------	------------------------	---------	-----	--------------	----------

ARIPIRAZOLE

INJECTABLE;INTRAMUSCULAR

ABILIFY

@	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
---	--------	-------------------------	---------	-----	--------------	----------

SOLUTION;ORAL

ARIPIRAZOLE

AA	+	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	---	---------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ARIPIRAZOLE

AB	ACCORD HLTHCARE	2MG	A206251	001	Dec 07, 2016	Nov NEWA
AB		5MG	A206251	002	Dec 07, 2016	Nov NEWA
AB		10MG	A206251	003	Dec 07, 2016	Nov NEWA
AB		15MG	A206251	004	Dec 07, 2016	Nov NEWA
AB		20MG	A206251	005	Dec 07, 2016	Nov NEWA
AB		30MG	A206251	006	Dec 07, 2016	Nov NEWA
AB	AJANTA PHARMA LTD	2MG	A206174	001	Sep 12, 2016	Aug NEWA
AB		5MG	A206174	002	Sep 12, 2016	Aug NEWA
AB		10MG	A206174	003	Sep 12, 2016	Aug NEWA
AB		15MG	A206174	004	Sep 12, 2016	Aug NEWA

TABLET;ORAL

ARIPIIPRAZOLE

AB		20MG	A206174	005	Sep 12, 2016	Aug NEWA
AB		30MG	A206174	006	Sep 12, 2016	Aug NEWA
AB	AMNEAL PHARMS	2MG	A204838	001	Jun 17, 2016	Jun NEWA
AB		5MG	A204838	002	Jun 17, 2016	Jun NEWA
AB		10MG	A204838	003	Jun 17, 2016	Jun NEWA
AB		15MG	A204838	004	Jun 17, 2016	Jun NEWA
AB		20MG	A204838	005	Jun 17, 2016	Jun NEWA
AB		30MG	A204838	006	Jun 17, 2016	Jun NEWA
AB	MACLEODS PHARMS LTD	2MG	A204111	001	Oct 07, 2016	Sep NEWA
AB		5MG	A204111	002	Oct 07, 2016	Sep NEWA
AB		10MG	A204111	003	Oct 07, 2016	Sep NEWA
AB		15MG	A204111	004	Oct 07, 2016	Sep NEWA
AB		20MG	A204111	005	Oct 07, 2016	Sep NEWA
AB		30MG	A204111	006	Oct 07, 2016	Sep NEWA
AB	SCIEGEN PHARMS INC	2MG	A206383	001	Sep 29, 2016	Sep NEWA
AB		5MG	A206383	002	Sep 29, 2016	Sep NEWA
AB		10MG	A206383	003	Sep 29, 2016	Sep NEWA
AB		15MG	A206383	004	Sep 29, 2016	Sep NEWA
AB		20MG	A206383	005	Sep 29, 2016	Sep NEWA
AB		30MG	A206383	006	Sep 29, 2016	Sep NEWA
>A> AB	STASON PHARMS	2MG	A091279	001	Jan 09, 2017	Dec NEWA
>A> AB		5MG	A091279	002	Jan 09, 2017	Dec NEWA
>A> AB		10MG	A091279	003	Jan 09, 2017	Dec NEWA
>A> AB		15MG	A091279	004	Jan 09, 2017	Dec NEWA
>A> AB		20MG	A091279	005	Jan 09, 2017	Dec NEWA
>A> AB		30MG	A091279	006	Jan 09, 2017	Dec NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

@ OTSUKA

10MG

N021729 002 Jun 07, 2006 May DISC

@

15MG

N021729 003 Jun 07, 2006 May DISC

ARIPIIPRAZOLE

+ ALEMBIC PHARMS LTD

10MG

A202102 001 Apr 28, 2015 May CRLD

15MG

A202102 002 Apr 28, 2015 May CTEC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB	LUPIN LTD	50MG	A200751	001	Nov 28, 2016	Nov NEWA
AB		150MG	A200751	003	Nov 28, 2016	Nov NEWA
AB		200MG	A200751	004	Nov 28, 2016	Nov NEWA
AB		250MG	A200751	005	Nov 28, 2016	Nov NEWA
AB	MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Apr CMFD
AB		150MG	A200043	002	Jun 01, 2012	Apr CMFD
AB		250MG	A200043	003	Jun 01, 2012	Apr CMFD
AB	NATCO PHARMA LTD	50MG	A202768	001	Nov 28, 2016	Nov NEWA
AB		150MG	A202768	002	Nov 28, 2016	Nov NEWA
AB		250MG	A202768	003	Nov 28, 2016	Nov NEWA
	NUVIGIL					
AB	CEPHALON	50MG	N021875	001	Jun 15, 2007	Apr CTEC
AB		150MG	N021875	003	Jun 15, 2007	Apr CTEC
AB		200MG	N021875	005	Mar 26, 2009	Nov CTEC
AB	+	250MG	N021875	004	Jun 15, 2007	Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

FOREST LABS LLC

EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ASPIRIN AND CAFFEINE			
	@ NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007 Jan CAHN
FIORINAL					
AA	+ ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	005	Apr 16, 1986 Apr CAHN
TABLET;ORAL		BUTALBITAL, ASPIRIN AND CAFFEINE			
AA	PHARMACEUTICS INTL	325MG;50MG;40MG	A204195	001	Sep 22, 2016 Sep NEWA

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL		BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE			
AB	MAYNE PHARMA INC	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015 Aug CAHN
FIORINAL W/CODEINE					
AB	+ ALLERGAN SALES LLC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL		CARISOPRODOL AND ASPIRIN			
AB	+ HERITAGE PHARMS INC	325MG;200MG	A089594	001	Mar 31, 1989 Jun CRLD
AB	INGENUS PHARMS NJ	325MG;200MG	A040832	001	Jan 07, 2010 Jan CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL		CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE			
AB	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010 Mar CMFD
	@	325MG;200MG;16MG	A040860	001	Jan 07, 2010 Jan CAHN
AB	+ SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996 Mar CTEC
	+ SOMA COMPOUND W/ CODEINE	325MG;200MG;16MG	A040118	001	Apr 16, 1996 Jan CRLD
	@ MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983 Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL		ASPIRIN AND DIPYRIDAMOLE			
AB	AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016 Oct CMFD
	@	25MG;200MG	A206392	001	Mar 08, 2016 Apr DISC
AB		25MG;200MG	A206392	001	Mar 08, 2016 Feb NEWA

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL		YOSPRALA			
	ARALEZ PHARMS	81MG;40MG	N205103	001	Sep 14, 2016 Sep NEWA
	+	325MG;40MG	N205103	002	Sep 14, 2016 Sep NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL		OXYCODONE AND ASPIRIN			
AA	MAYNE PHARMA INC	325MG;4.8355MG	A091670	001	Mar 16, 2011 Aug CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL		OXYCODONE AND ASPIRIN			
	@ SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998 Mar CAHN
	@	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982 Mar CAHN

ATENOLOL

TABLET;ORAL		ATENOLOL			
AB	ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992 Jan CAHN
AB		50MG	A072303	001	Jul 15, 1988 Jan CAHN
AB		100MG	A072304	001	Jul 15, 1988 Jan CAHN
	@ NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009 Aug DISC
	@	50MG	A078254	002	Sep 25, 2009 Aug DISC
	@	100MG	A078254	003	Sep 25, 2009 Aug DISC
TENORMIN					
AB	ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990 Jan CAHN
AB		50MG	N018240	001	Jan CAHN
AB	+	100MG	N018240	002	Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jan CAHN
AB	SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar CAHN
	TENORETIC 100					
AB	+ ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN
	TENORETIC 50					
AB	ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

>A>	AB	INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Dec NEWA
>A>	AB		EQ 20MG BASE	A204846	002	Jan 09, 2017	Dec NEWA
>A>	AB		EQ 40MG BASE	A204846	003	Jan 09, 2017	Dec NEWA
>A>	AB		EQ 80MG BASE	A204846	004	Jan 09, 2017	Dec NEWA
	AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
	AB		EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
	AB		EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
	AB		EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	NANJING KING-FRIEND	10MG/ML	A091489	001	Feb 17, 2012	Sep CAHN
AP	+ WEST-WARD PHARMS INT	10MG/ML	A074901	001	Jul 18, 1997	Oct CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	NANJING KING-FRIEND	10MG/ML	A091488	001	Feb 17, 2012	Sep CAHN
AP	+ WEST-WARD PHARMS INT	10MG/ML	A074900	001	Jul 18, 1997	Sep CAHN

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

>A>	ISOPTO ATROPINE					
>A>	ALCON RES LTD	1%	N208151	001	Dec 01, 2016	Dec NEWA
>A>	NOVARTIS PHARMS CORP	1%	N208151	001	Dec 01, 2016	Dec CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+ WEST-WARD PHARMS INT	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Nov CAHN
	TABLET; ORAL					
	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE					
	@ SUN PHARM INDS	0.025MG;2.5MG	A085506	001		Mar CAHN
	LONOX					
	@ SANDOZ	0.025MG;2.5MG	A085311	002		Aug DISC

AURANOFIN

CAPSULE; ORAL

RIDAURA

	+ SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan CAHN
--	----------------------	-----	---------	-----	--------------	----------

AVANAFIL

TABLET; ORAL

STENDRA

	METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012	Oct CAHN
		100MG	N202276	002	Apr 27, 2012	Oct CAHN
	+	200MG	N202276	003	Apr 27, 2012	Oct CAHN

AXITINIB

TABLET; ORAL

INLYTA

	PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr CAHN
	+	5MG	N202324	002	Jan 27, 2012	Apr CAHN

AZACITIDINE

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Apr NEWA
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Sep NEWA
	POWDER; IV (INFUSION), SUBCUTANEOUS					
	AZACITIDINE					
	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Apr NEWA

AZATHIOPRINE

TABLET;ORAL
IMURAN

AB	+ SEBELA IRELAND LTD	50MG	N016324	001		Jan CAHN
----	----------------------	------	---------	-----	--	----------

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION
AZATHIOPRINE SODIUM

	+ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995	Sep CAHN
--	------------------------	--------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A203660	001	Nov 08, 2016	Oct NEWA
>D> AT	APOTEX INC	0.05%	A078621	001	Aug 03, 2009	Dec CAHN
>A> AT		0.05%	A078621	001	Aug 03, 2009	Dec CAHN

SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE

AB	WEST-WARD PHARMS INT	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Nov CAHN
----	----------------------	-----------------------	---------	-----	--------------	----------

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL
EDARBI

	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jan CAHN
	+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jan CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL
EDARBYCLOR

	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan CAHN
	+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL
AZITHROMYCIN

BX	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Apr CTEC
BX		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Apr CTEC

AZTREONAM

INJECTABLE;INJECTION
AZTREONAM

	@ EUROHLTH INTL SARL	1GM/VIAL	A065286	001	Mar 23, 2011	Mar DISC
	@	2GM/VIAL	A065286	002	Mar 23, 2011	Mar DISC
	@ WEST-WARD PHARMS INT	1GM/VIAL	A065286	001	Mar 23, 2011	Sep CAHN
	@	2GM/VIAL	A065286	002	Mar 23, 2011	Sep CAHN

BACLOFEN

INJECTABLE;INTRATHECAL
BACLOFEN

AP	SINTETICA SA	0.05MG/ML	A091193	001	May 03, 2016	Apr NEWA
AP		0.5MG/ML	A091193	002	May 03, 2016	Apr NEWA
AP		2MG/ML	A091193	003	May 03, 2016	Apr NEWA
	LIORESAL					
AP	+ SAOL THERAPS RES LTD	0.05MG/ML	N020075	003	Nov 07, 1996	May CAHN
AP	+	0.5MG/ML	N020075	001	Jun 17, 1992	May CAHN
AP	+	2MG/ML	N020075	002	Jun 17, 1992	May CAHN

TABLET;ORAL
BACLOFEN

AB	IMPAX LABS	10MG	A077971	001	Oct 26, 2007	Nov CMS1
AB	LANNETT	10MG	A077241	002	Jul 06, 2007	Oct CMS1
AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan CMS1
	@ WATSON LABS	10MG	A072824	001	Sep 18, 1991	Nov DISC

TABLET;ORAL

BACLOFEN

@

20MG

A072825 001 Sep 18, 1991 Nov DISC

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>D>	AB	APOTEX INC	750MG	A077883	001	Dec 28, 2007	Dec CAHN
>A>	AB		750MG	A077883	001	Dec 28, 2007	Dec CAHN
	AB	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Nov CAHN

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan NEWA
---	--------	--------------	---------	-----	--------------	----------

PASTE;ORAL

VARIBAR

+	BRACCO	40% (92GM/230ML)	N208844	001	Oct 14, 2016	Oct NEWA
---	--------	------------------	---------	-----	--------------	----------

SUSPENSION;ORAL

READI-CAT 2

+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA
---	--------	----------------	---------	-----	--------------	----------

READI-CAT 2 SMOOTHIES

	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan NEWA
--	--------	----------------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC

5MG

A076267 001 Feb 11, 2004 Jan DISC

@

10MG

A076267 002 Feb 11, 2004 Jan DISC

@

20MG

A076267 003 Feb 11, 2004 Jan DISC

@

40MG

A076267 004 Feb 11, 2004 Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ACTAVIS LABS FL INC

5MG;6.25MG

A076342 001 Feb 11, 2004 Jan DISC

@

10MG;12.5MG

A076342 002 Feb 11, 2004 Jan DISC

@

20MG;12.5MG

A076342 003 Feb 11, 2004 Jan DISC

@

20MG;25MG

A076342 004 Feb 11, 2004 Jan DISC

@ IVAX SUB TEVA PHARMS

5MG;6.25MG

A076348 001 Feb 11, 2004 Mar DISC

@

10MG;12.5MG

A076348 002 Feb 11, 2004 Mar DISC

@

20MG;12.5MG

A076348 003 Feb 11, 2004 Mar DISC

@

20MG;25MG

A076348 004 Feb 11, 2004 Mar DISC

@ SUN PHARM INDS LTD

5MG;6.25MG

A077483 001 Sep 08, 2005 Mar DISC

@

10MG;12.5MG

A077483 002 Sep 08, 2005 Mar DISC

@

20MG;12.5MG

A077483 003 Sep 08, 2005 Mar DISC

@

20MG;25MG

A077483 004 Sep 08, 2005 Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP ACCORD HLTHCARE

25MG/VIAL

A205574 001 May 19, 2016 May NEWA

AP 100MG/VIAL

A205574 002 May 19, 2016 May NEWA

>A> AP BRECKENRIDGE PHARM

25MG/VIAL

A205447 001 Dec 29, 2016 Dec NEWA

>A> AP 100MG/VIAL

A205447 002 Dec 29, 2016 Dec NEWA

AP GLENMARK PHARMS LTD

25MG/VIAL

A204771 001 Mar 24, 2016 Mar NEWA

AP 100MG/VIAL

A204771 002 Mar 24, 2016 Mar NEWA

AP HOSPIRA INC

25MG/VIAL

A204086 001 May 20, 2016 May NEWA

AP 100MG/VIAL

A204086 002 May 20, 2016 May NEWA

AP INNOPHARMA LICENSING

25MG/VIAL

A205476 001 Mar 24, 2016 Mar NEWA

AP 100MG/VIAL

A205476 002 Mar 24, 2016 Mar NEWA

TREANDA

AP + CEPHALON

25MG/VIAL

N022249 002 May 01, 2009 Mar CFTG

AP 100MG/VIAL

N022249 001 Mar 20, 2008 Mar CFTG

SOLUTION;IV (INFUSION)

BENDEKA

+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Sep CRLD
---	--------------	---------------------	---------	-----	--------------	----------

BENZONATATECAPSULE;ORAL
BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL;TOPICAL
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	TOLMAR	5%;1.2%	A203688	001	Aug 25, 2016	Aug NEWA
----	--------	---------	---------	-----	--------------	----------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

AKTIPAK

+	CUTANEA	5%;3%
+		5%;3%

N050769	001	Nov 27, 2000	Sep CTNA
N050769	001	Nov 27, 2000	Feb CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

@ IMPAX LABS 50MG

A040845	001	Nov 18, 2008	Mar DISC
---------	-----	--------------	----------

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Jul CAHN
AA		1MG	A204713	002	Apr 14, 2015	Jul CAHN
AA		2MG	A204713	003	Apr 14, 2015	Jul CAHN
	@ FRONTIDA BIOPHARM	1MG	A081264	001	Jan 23, 1992	Sep CAHN
	@	2MG	A081265	001	Jan 23, 1992	Jul CAHN
AA	VINTAGE	0.5MG	A040715	001	Aug 27, 2007	Oct CMS1
AA		1MG	A040715	002	Aug 27, 2007	Oct CMS1

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL

SERNIVO

+ PROMIUS PHARMA LLC EQ 0.05% BASE/SPRAY

N208079	001	Feb 05, 2016	Feb NEWA
---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Mar CAHN
----	-----------------	------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan CAHN
----	---------------------	--------------	---------	-----	--------------	----------

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S

+ NOVARTIS PHARMS CORP EQ 0.25% BASE

N019845	001	Dec 29, 1989	Nov CAHN
---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS	5MG
@	10MG
@	25MG
@	50MG
@ SUN PHARM INDS INC	5MG
@	10MG
@	25MG
@	50MG

A040739	001	Nov 01, 2006	Mar DISC
A040741	001	Nov 01, 2006	Mar DISC
A040740	001	Nov 01, 2006	Mar DISC
A040721	004	Nov 01, 2006	Mar DISC
A040897	001	Apr 22, 2009	Oct DISC
A040897	002	Apr 22, 2009	Oct DISC
A040897	003	Apr 22, 2009	Oct DISC
A040897	004	Apr 22, 2009	Oct DISC

DUVOID

AA	BI-COASTAL PHARMA	10MG	A086262	001		Jul CAHN
AA		25MG	A086263	001		Jul CAHN
AA		50MG	A085882	003		Jul CAHN

BIMATOPROSTSOLUTION/DROPS; TOPICAL
BIMATOPROST

AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr NEWA
----	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDETABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC

	@ SEBELA IRELAND LTD	262.4MG, N/A, N/A, N/A, 250MG, N/A, N/A, N/A, 500MG	N050719	001	Aug 15, 1996	Jan CAHN
--	----------------------	---	---------	-----	--------------	----------

BISOPROLOL FUMARATETABLET; ORAL
BISOPROLOL FUMARATE

	@ FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul CAHN
	@	10MG	A075474	002	Oct 25, 2002	Jul CAHN
AB	+ MYLAN	10MG	A075831	002	Dec 14, 2005	Aug CRLD
	@ SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Mar CAHN
	@	10MG	A075474	002	Oct 25, 2002	Mar CAHN
	ZEBETA					
	@ TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Aug DISC
	@	10MG	N019982	001	Jul 31, 1992	Aug DISC

BIVALIRUDININJECTABLE; INTRAVENOUS
BIVALIRUDIN

AP	FRESENIUS KABI USA	250MG/VIAL	A090189	001	Oct 28, 2016	Oct NEWA
----	--------------------	------------	---------	-----	--------------	----------

BLEOMYCIN SULFATEINJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP	WEST-WARD PHARMS INT	EQ 15 UNITS BASE/VIAL	A065042	002	Oct 17, 2001	Sep CAHN
AP		EQ 30 UNITS BASE/VIAL	A065042	001	Oct 17, 2001	Sep CAHN

BOCEPREVIRCAPSULE; ORAL
VICTRELIS

	@ MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Jun DISC
--	---------------------	-------	---------	-----	--------------	----------

BOSUTINIB MONOHYDRATETABLET; ORAL
BOSULIF

>A>	+ PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012	Dec CAHN
>A>		EQ 500MG BASE	N203341	002	Sep 04, 2012	Dec CAHN
>D>	+ WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Dec CAHN
>D>		EQ 500MG BASE	N203341	002	Sep 04, 2012	Dec CAHN

BRETYLIUM TOSYLATEINJECTABLE; INJECTION
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986	Sep DISC
	@	200MG/100ML	N019121	002	Apr 29, 1986	Sep DISC
	@	400MG/100ML	N019121	003	Apr 29, 1986	Sep DISC

BRIMONIDINE TARTRATE; BRINZOLAMIDESUSPENSION/DROPS; OPHTHALMIC
SIMBRINZA

	+ NOVARTIS PHARMS CORP	0.2%; 1%	N204251	001	Apr 19, 2013	Nov CAHN
--	------------------------	----------	---------	-----	--------------	----------

BRINZOLAMIDESUSPENSION/DROPS; OPHTHALMIC
AZOPT

	+ NOVARTIS PHARMS CORP	1%	N020816	001	Apr 01, 1998	Nov CAHN
--	------------------------	----	---------	-----	--------------	----------

BRIVARACETAMSOLUTION; INTRAVENOUS
BRIVIACT

	+ UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA
	+ UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	May CMS1

SOLUTION; ORAL							
BRIVIACT							
+	UCB INC	10MG/ML	N205838	001	May 12, 2016	May CMS1	
+		10MG/ML	N205838	001	Feb 18, 2016	Feb NEWA	
TABLET; ORAL							
BRIVIACT							
	UCB INC	10MG	N205836	001	May 12, 2016	May CMS1	
		10MG	N205836	001	Feb 18, 2016	Feb NEWA	
		25MG	N205836	002	May 12, 2016	May CMS1	
		25MG	N205836	002	Feb 18, 2016	Feb NEWA	
		50MG	N205836	003	May 12, 2016	May CMS1	
		50MG	N205836	003	Feb 18, 2016	Feb NEWA	
		75MG	N205836	004	May 12, 2016	May CMS1	
		75MG	N205836	004	Feb 18, 2016	Feb NEWA	
+		100MG	N205836	005	May 12, 2016	May CMS1	
+		100MG	N205836	005	Feb 18, 2016	Feb NEWA	
<u>BROMFENAC SODIUM</u>							
SOLUTION/DROPS; OPHTHALMIC							
BROMSITE							
+	INSITE VISION INC	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Apr NEWA	
+	SUN PHARMA GLOBAL	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jul CAHN	
<u>BROMOCRIPTINE MESYLATE</u>							
CAPSULE; ORAL							
BROMOCRIPTINE MESYLATE							
AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD
		PARLODEL					
AB		US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Nov CMFD
	@		EQ 5MG BASE	N017962	002	Mar 01, 1982	Jan DISC
TABLET; ORAL							
BROMOCRIPTINE MESYLATE							
AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN
		PARLODEL					
AB		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr CMFD
	@		EQ 2.5MG BASE	N017962	001		Jan DISC
<u>BROMPHENIRAMINE MALEATE</u>							
TABLET; ORAL							
BROMPHENIRAMINE MALEATE							
	@ UPSHER-SMITH LABS	4MG	A083215	001			Oct CAHN
<u>BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
SYRUP; ORAL							
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE							
AA	ACELLA PHARMS LLC	2MG/5ML; 10MG/5ML; 30MG/5ML	A203375	001	Sep 20, 2016	Sep NEWA	
<u>BUDESONIDE</u>							
CAPSULE; ORAL							
BUDESONIDE							
AB		ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar NEWA
AB		ALVOGEN MALTA	3MG	A206724	001	Nov 23, 2016	Nov NEWA
AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Aug CAHN
ENTOCORT EC							
AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May CAHN
SUSPENSION; INHALATION							
BUDESONIDE							
AN		APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun CMFD
AN			0.5MG/2ML	A078202	002	Mar 30, 2009	Jun CMFD
AN		IMPAX LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Aug CAHN
AN			0.5MG/2ML	A078404	002	Jul 31, 2012	Aug CAHN
AN		TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA
<u>BUMETANIDE</u>							
INJECTABLE; INJECTION							
BUMETANIDE							
AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun CAHN
AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION
EXPAREL

+ PACIRA PHARMS INC 133MG/10ML (13.3MG/ML) N022496 001 Oct 28, 2011 Sep CMFD

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 0.25% A207183 001 May 13, 2016 May NEWA
AP 0.5% A207183 002 May 13, 2016 May NEWA

INJECTABLE; SPINAL
BUPIVACAINE HYDROCHLORIDE

AP CLARIS 0.75% A207266 001 Jul 25, 2016 Jul NEWA

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION
PROBUPHINE

+ BRAEBURN PHARMS INC EQ 80MG BASE/IMPLANT N204442 001 May 26, 2016 Jun CAHN
+ TITAN PHARMS EQ 80MG BASE/IMPLANT N204442 001 May 26, 2016 May NEWA

INJECTABLE; INJECTION
BUPRENORPHINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT EQ 0.3MG BASE/ML A076931 001 Mar 02, 2005 Oct CAHN

TABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB SUN PHARM INDS LTD EQ 2MG BASE A201760 001 Jan 29, 2016 Jan NEWA
AB EQ 8MG BASE A201760 002 Jan 29, 2016 Jan NEWA
AB WEST-WARD PHARMS INT EQ 2MG BASE A078633 001 Oct 08, 2009 Nov CAHN
AB + EQ 8MG BASE A078633 002 Oct 08, 2009 Nov CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB KREMERS URBAN PHARMS EQ 2MG BASE; EQ 0.5MG BASE A205022 001 Sep 19, 2016 Sep NEWA
AB EQ 8MG BASE; EQ 2MG BASE A205022 002 Sep 19, 2016 Sep NEWA
AB SUN PHARM INDS LTD EQ 8MG BASE; EQ 2MG BASE A201633 002 Aug 05, 2016 Jul NEWA
AB WEST-WARD PHARMS INT EQ 2MG BASE; EQ 0.5MG BASE A203326 001 Jun 27, 2014 Nov CAHN
AB EQ 8MG BASE; EQ 2MG BASE A203326 002 Jun 27, 2014 Nov CAHN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
AB SUN PHARM INDS LTD EQ 2MG BASE; EQ 0.5MG BASE A201633 001 Aug 05, 2016 Jul NEWA
ZUBSOLV
OREXO US INC EQ 0.7MG BASE; EQ 0.18MG BASE N204242 006 Oct 04, 2016 Oct NEWA
EQ 1.4MG BASE; EQ 0.36MG BASE N204242 001 Jul 03, 2013 Jul CAHN
EQ 2.9MG BASE; EQ 0.71MG BASE N204242 005 Jun 04, 2015 Jul CAHN
+ EQ 5.7MG BASE; EQ 1.4MG BASE N204242 002 Jul 03, 2013 Jul CAHN
EQ 8.6MG BASE; EQ 2.1MG BASE N204242 003 Dec 11, 2014 Jul CAHN
EQ 11.4MG BASE; EQ 2.9MG BASE N204242 004 Dec 11, 2014 Jul CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HYDROCHLORIDE

>D> AB APOTEX INC 75MG A076143 001 Jan 17, 2006 Dec CAHN
>A> AB 75MG A076143 001 Jan 17, 2006 Dec CAHN
>D> AB + 100MG A076143 002 Jan 17, 2006 Dec CAHN
>A> AB + 100MG A076143 002 Jan 17, 2006 Dec CAHN
AB + 100MG A076143 002 Jan 17, 2006 Sep CRLD
AB HERITAGE PHARMA 75MG A206975 001 Aug 19, 2016 Aug NEWA
AB 100MG A206975 002 Aug 19, 2016 Aug NEWA
WELLBUTRIN
@ GLAXOSMITHKLINE 75MG N018644 002 Dec 30, 1985 Sep DISC
@ 100MG N018644 003 Dec 30, 1985 Sep DISC

TABLET, EXTENDED RELEASE; ORAL
BUPROPION HYDROCHLORIDE

AB1 INVAGEN PHARMS 100MG A206674 001 Feb 09, 2016 Jan NEWA
AB3 150MG A206556 001 Aug 26, 2016 Aug NEWA
AB1 150MG A206674 002 Feb 09, 2016 Jan NEWA
AB1 200MG A206674 003 Feb 09, 2016 Jan NEWA
AB3 300MG A206556 002 Aug 26, 2016 Aug NEWA
AB1 SCIEGEN PHARMS INC 100MG A205794 001 Mar 01, 2016 Feb NEWA
AB1 150MG A205794 002 Mar 01, 2016 Feb NEWA
AB2 150MG A206122 001 Aug 17, 2016 Aug NEWA
AB1 200MG A205794 003 Mar 01, 2016 Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CONTRAVE

+ OREXIGEN 90MG; 8MG N200063 001 Sep 10, 2014 Apr CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPIRONE HYDROCHLORIDE

AB	HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun	CAHN
AB		10MG	A204582	002	Sep 18, 2015	Jun	CAHN
AB		15MG	A204582	003	Sep 18, 2015	Jun	CAHN
AB		30MG	A204582	004	Sep 18, 2015	Jun	CAHN
AB	IMPAX LABS INC	5MG	A074253	001	Mar 28, 2001	Aug	CAHN
AB		10MG	A074253	002	Mar 28, 2001	Aug	CAHN
AB		15MG	A074253	003	Mar 13, 2002	Aug	CAHN
AB	MYLAN	5MG	A076008	003	Mar 01, 2002	Nov	CMS1
AB		7.5MG	A076008	002	Jul 08, 2013	Oct	NEWA
AB		10MG	A076008	004	Mar 01, 2002	Nov	CMS1
AB		15MG	A076008	005	Mar 28, 2001	Nov	CMS1

BUSULFAN

INJECTABLE; INJECTION
BUSULFAN

AP LUITPOLD PHARMS INC 6MG/ML A202259 001 Dec 22, 2015 Mar CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
BUTOCONAZOLE NITRATE
@ PERRIGO PHARMA INTL 2%

N019881 001 Feb 07, 1997 Jun CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

@ CLARIS 2MG/ML
BUTORPHANOL TARTRATE PRESERVATIVE FREE
@ CLARIS 1MG/ML
@ 2MG/ML

A075697 001 Oct 23, 2001 Jan CAHN
A075695 001 Oct 23, 2001 Mar CAHN
A075695 002 Oct 23, 2001 Mar CAHN

SPRAY, METERED; NASAL
BUTORPHANOL TARTRATE

AB	APOTEX INC	1MG/SPRAY	A075499	001	Dec 04, 2002	Sep	CAHN
AB	WEST-WARD PHARMS INT	1MG/SPRAY	A075824	001	Mar 12, 2002	Nov	CAHN

CABERGOLINE

TABLET; ORAL
CABERGOLINE

@ IMPAX LABS INC 0.5MG

A077843 001 Jul 03, 2007 Mar DISC

CABOZANTINIB S-MALATE

TABLET; ORAL
CABOMETYX

EXELIXIS INC EQ 20MG BASE
EQ 40MG BASE
+ EQ 60MG BASE

N208692 001 Apr 25, 2016 Apr NEWA
N208692 002 Apr 25, 2016 Apr NEWA
N208692 003 Apr 25, 2016 Apr NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS
CAFCIT

AP	+ WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Sep	CAHN
----	------------------------	------------------------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL
CAFCIT

AA	+ WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Sep	CAHN
----	------------------------	------------------------------------	---------	-----	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

+ HORIZON PHARMA 100MG; 2MG A086557 001 Oct 04, 1983 Jan CAHN

CALCIFEDIOLCAPSULE, EXTENDED RELEASE;ORAL
RAYALDEE

+ OPKO IRELAND GLOBAL 0.03MG N208010 001 Jun 17, 2016 Jun NEWA

CALCIPOTRIENECREAM;TOPICAL
CALCIPOTRIENE

AB GLENMARK PHARMS 0.005% A205772 001 Jun 09, 2015 Mar CAHN

CALCITONIN SALMON RECOMBINANTSPRAY, METERED;NASAL
FORTICAL

@ UPSHER SMITH 200 IU/SPRAY N021406 001 Aug 12, 2005 Sep DISC

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB BIONPHARMA INC 0.25MCG A091174 001 May 24, 2013 Jan CAHN

AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN

AB WEST-WARD PHARMS INT 0.25MCG A076917 001 Mar 27, 2006 Nov CAHN

INJECTABLE;INJECTION
CALCITRIOL

AKORN 0.001MG/ML A078066 001 Jan 29, 2008 Feb CTEC

@ ROCKWELL MEDCL 0.001MG/ML A076206 001 Sep 17, 2003 Feb DISC

SOLUTION;ORAL
CALCITRIOL

AA WEST-WARD PHARMS INT 1MCG/ML A076242 001 Jul 18, 2003 Nov CAHN

CALCIUM ACETATECAPSULE;ORAL
CALCIUM ACETATE

AB AMNEAL PHARMS 667MG A201658 001 Oct 06, 2014 Nov CPOT

AB ECI PHARMS LLC EQ 169MG CALCIUM A203298 001 Jul 26, 2016 Oct CAHN

AB 667MG A203298 001 Jul 26, 2016 Nov CPOT

AB HERITAGE PHARMS INC 667MG A202315 001 Jun 29, 2015 Nov CPOT

AB INVAGEN PHARMS 667MG A203135 001 Feb 07, 2013 Nov CPOT

AB LOTUS PHARM CO LTD EQ 169MG CALCIUM A203298 001 Jul 26, 2016 Jul NEWA

AB LUPIN LTD 667MG A202127 001 Jul 09, 2015 Nov CPOT

AB NOSTRUM LABS INC 667MG A203179 001 Oct 26, 2015 Nov CPOT

AB PADDOCK LLC 667MG A091312 001 Jun 01, 2012 Nov CPOT

AB ROXANE 667MG A077728 001 Feb 26, 2008 Nov CPOT

AB WEST-WARD PHARMS INT 667MG A077728 001 Feb 26, 2008 Nov CAHN

PHOSLO

@ FRESENIUS MEDCL 333.5MG N021160 001 Apr 02, 2001 Nov CPOT

@ 667MG N021160 002 Apr 02, 2001 Nov CPOT

PHOSLO GELCAPS

AB + FRESENIUS MEDCL 667MG N021160 003 Apr 02, 2001 Nov CPOT

SOLUTION;ORAL

PHOSLYRA

+ FRESENIUS MEDCL 667MG/5ML N022581 001 Apr 18, 2011 Nov CPOT

TABLET;ORAL

CALCIUM ACETATE

AB HERITAGE PHARMS INC 667MG A202885 001 Jan 22, 2015 Nov CPOT

AB INVAGEN PHARMS 667MG A202420 001 Feb 05, 2013 Nov CPOT

AB PADDOCK LLC 667MG A091561 001 Apr 13, 2011 Nov CPOT

@ ROXANE 667MG A077693 001 Jan 30, 2008 Nov CPOT

@ WEST-WARD PHARMS INT 667MG A077693 001 Jan 30, 2008 Nov CAHN

ELIPHOS

AB + CYPRESS PHARM 667MG A078502 001 Nov 25, 2008 Nov CPOT

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

@ B BRAUN 510MG/100ML;30GM/100ML;200MG/100ML N018807 001 Aug 26, 1983 Oct DISC
;9.2GM/100ML;9.6GM/100ML@ 510MG/100ML;30GM/100ML;200MG/100ML N018807 003 Aug 26, 1983 Oct DISC
;9.4GM/100ML;11GM/100ML

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

@ B BRAUN 510MG/100ML;50GM/100ML; N018807 002 Aug 26, 1983 Oct DISC

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

200MG/100ML;9.2GM/100ML;9.6GM/100M

L

@	510MG/100ML;50GM/100ML;200MG/100ML	N018807	004	Aug 26, 1983	Oct DISC
	;9.4GM/100ML;11GM/100ML				

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	002		Feb DISC
---	-----------------	---	---------	-----	--	----------

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	003		Feb DISC
---	-----------------	---	---------	-----	--	----------

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988	Feb DISC
---	-----------------	---	---------	-----	--------------	----------

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001		Feb DISC
---	-----------------	--	---------	-----	--	----------

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982	Feb DISC
---	-----------------	---	---------	-----	--------------	----------

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982	Feb DISC
---	-----------------	---	---------	-----	--------------	----------

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988	Feb DISC
---	-----------------	---	---------	-----	--------------	----------

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC
---	-----------------	--	---------	-----	--------------	----------

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;30MG/100ML;450MG/100ML	N018460	007	Jan 29, 1986	Oct DISC
---	---------	---	---------	-----	--------------	----------

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@	B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;30MG/100ML;450MG/100ML	N018460	005	Nov 02, 1983	Oct DISC
---	---------	---	---------	-----	--------------	----------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@	B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	009	Jan 29, 1986	Oct DISC
---	---------	---	---------	-----	--------------	----------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC
--	-----------------	---	---------	-----	--------------	----------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb CTEC
--	-----------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N016682	001		Aug CRLD
----	---	-----------------	---	---------	-----	--	----------

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

	JANSSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016	Sep NEWA
--	-----------------	------------	---------	-----	--------------	----------

50MG;1GM

N205879	002	Sep 20, 2016	Sep NEWA
---------	-----	--------------	----------

150MG;500MG

N205879	003	Sep 20, 2016	Sep NEWA
---------	-----	--------------	----------

+

150MG;1GM

N205879	004	Sep 20, 2016	Oct CRLD
---------	-----	--------------	----------

150MG;1GM

N205879	004	Sep 20, 2016	Sep NEWA
---------	-----	--------------	----------

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

AB		MACLEODS PHARMS LTD	4MG	A203813	001	Dec 05, 2016	Nov NEWA
----	--	---------------------	-----	---------	-----	--------------	----------

AB			8MG	A203813	002	Dec 05, 2016	Nov NEWA
----	--	--	-----	---------	-----	--------------	----------

AB			16MG	A203813	003	Dec 05, 2016	Nov NEWA
----	--	--	------	---------	-----	--------------	----------

AB			32MG	A203813	004	Dec 05, 2016	Nov NEWA
----	--	--	------	---------	-----	--------------	----------

CANGRELORPOWDER; IV (INFUSION)
KENGREAL

+ CHIESI USA INC 50MG/VIAL N204958 001 Jun 22, 2015 Jul CAHN

CAPECITABINETABLET; ORAL
CAPECITABINE

AB	ROXANE	150MG	A200483	001	Jul 14, 2016	Jul	NEWA
AB		500MG	A200483	002	Jul 14, 2016	Jul	NEWA
AB	SHILPA MEDICARE LTD	150MG	A207456	001	Dec 12, 2016	Nov	NEWA
AB		500MG	A207456	002	Dec 12, 2016	Nov	NEWA
AB	WEST-WARD PHARMS INT	150MG	A200483	001	Jul 14, 2016	Nov	CAHN
AB		500MG	A200483	002	Jul 14, 2016	Nov	CAHN

CAPTOPRILTABLET; ORAL
CAPTOPRIL

	@ APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar	DISC
	@	25MG	A074737	002	Oct 28, 1998	Mar	DISC
	@	50MG	A074737	003	Oct 28, 1998	Mar	DISC
	@	100MG	A074737	004	Oct 28, 1998	Mar	DISC
AB	HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun	CAHN
AB		25MG	A074505	002	Feb 13, 1996	Jun	CAHN
AB		50MG	A074505	003	Feb 13, 1996	Jun	CAHN
AB		100MG	A074505	004	Feb 13, 1996	Jun	CAHN
AB	PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jul	CMFD
AB		25MG	A074477	002	Feb 13, 1996	Jul	CMFD
AB		50MG	A074477	003	Feb 13, 1996	Jul	CMFD
AB		100MG	A074477	004	Feb 13, 1996	Jul	CMFD
	@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan	DISC
	@	25MG	A074363	002	Nov 09, 1995	Jan	DISC
	@	50MG	A074363	003	Nov 09, 1995	Jan	DISC
	@	100MG	A074363	004	Nov 09, 1995	Jan	DISC
	@ STASON	12.5MG	A074677	004	May 30, 1997	Mar	DISC
	@	25MG	A074677	002	May 30, 1997	Mar	DISC
	@	50MG	A074677	001	May 30, 1997	Mar	DISC
	@	100MG	A074677	003	May 30, 1997	Mar	DISC

CARBAMAZEPINECAPSULE, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan	CAHN
AB		200MG	A076697	002	May 20, 2011	Jan	CAHN
AB		300MG	A076697	003	May 20, 2011	Jan	CAHN

SOLUTION; IV (INFUSION)
CARNEXIV

+ LUNDBECK LLC 200MG/20ML (10MG/ML) N206030 001 Oct 07, 2016 Oct NEWA

TABLET; ORAL

CARBAMAZEPINE

>D>	AB	APOTEX INC	200MG	A075948	001	Feb 27, 2002	Dec	CAHN
>A>	AB		200MG	A075948	001	Feb 27, 2002	Dec	CAHN

CARBIDOPATABLET; ORAL
CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPATABLET; ORAL
CARBIDOPA AND LEVODOPA

	@ IDT AUSTRALIA LTD	10MG; 100MG	A073586	001	Jun 29, 1995	May	CAHN
	@	25MG; 100MG	A073587	001	Jun 29, 1995	May	CAHN
	@	25MG; 250MG	A073620	001	Jun 29, 1995	May	CAHN
AB	MAYNE PHARMA	10MG; 100MG	A073618	001	Aug 28, 1992	Aug	CAHN
AB		25MG; 100MG	A073589	001	Aug 28, 1992	Aug	CAHN
AB		25MG; 250MG	A073607	001	Aug 28, 1992	Aug	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

MIKART INC

6MG

A207484 001 May 31, 2016 May NEWA

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@ WEST-WARD PHARMS INT

50MG/VIAL

A076099 001 Oct 14, 2004 Oct CAHN

@

150MG/VIAL

A076099 002 Oct 14, 2004 Oct CAHN

@

450MG/VIAL

A076099 003 Oct 14, 2004 Oct CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

@ ACTAVIS TOTOWA

50MG/5ML (10MG/ML)

A078732 001 Feb 06, 2012 Apr DISC

@

150MG/15ML (10MG/ML)

A078732 002 Feb 06, 2012 Apr DISC

@

450MG/45ML (10MG/ML)

A078732 003 Feb 06, 2012 Apr DISC

@

600MG/60ML (10MG/ML)

A078732 004 Feb 06, 2012 Apr DISC

AP NANJING KING-FRIEND

50MG/5ML (10MG/ML)

A077096 001 Jun 14, 2005 Oct CAHN

AP 150MG/15ML (10MG/ML)

A077096 002 Jun 14, 2005 Oct CAHN

AP 450MG/45ML (10MG/ML)

A077096 003 Jun 14, 2005 Oct CAHN

AP 600MG/60ML (10MG/ML)

A077096 004 Jun 03, 2013 Oct CAHN

AP SANDOZ INC

50MG/5ML (10MG/ML)

A078280 001 May 08, 2008 Feb CAHN

AP 150MG/15ML (10MG/ML)

A078280 002 May 08, 2008 Feb CAHN

AP 450MG/45ML (10MG/ML)

A078280 003 May 08, 2008 Feb CAHN

AP SANJA PHARMS CO

50MG/5ML (10MG/ML)

A205487 001 Mar 28, 2016 Mar NEWA

AP 150MG/15ML (10MG/ML)

A205487 002 Mar 28, 2016 Mar NEWA

AP 450MG/45ML (10MG/ML)

A205487 003 Mar 28, 2016 Mar NEWA

AP WEST-WARD PHARMS INT

50MG/5ML (10MG/ML)

A077244 001 Oct 15, 2004 Oct CAHN

AP 150MG/15ML (10MG/ML)

A077244 002 Oct 15, 2004 Oct CAHN

AP 450MG/45ML (10MG/ML)

A077244 003 Oct 15, 2004 Oct CAHN

AP 600MG/60ML (10MG/ML)

A077244 004 Jan 20, 2006 Oct CAHN

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

ONYX THERAP

30MG/VIAL

N202714 002 Jun 03, 2016 Jun NEWA

+

60MG/VIAL

N202714 001 Jul 20, 2012 Feb CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AB AUROBINDO PHARMA

250MG

A040792 002 Nov 08, 2016 Oct NEWA

>D> AB INDICUS PHARMA

250MG

A205126 001 Jul 08, 2015 Dec CAHN

>D> AA 350MG

A205126 002 Jul 08, 2015 Dec CAHN

AA INGENUS PHARMS NJ

350MG

A040823 001 Oct 22, 2008 Jan CAHN

AB STRIDES PHARMA

250MG

A205513 001 Nov 12, 2015 May CAHN

AA 350MG

A205513 002 Nov 12, 2015 May CAHN

>A> AB WILSHIRE PHARMS INC

250MG

A205126 001 Jul 08, 2015 Dec CAHN

>A> AA 350MG

A205126 002 Jul 08, 2015 Dec CAHN

CARVEDILOL

TABLET; ORAL

COREG

AB SMITHKLINE BEECHAM

3.125MG

N020297 004 May 29, 1997 May CAHN

AB 6.25MG

N020297 003 Sep 14, 1995 May CAHN

AB + 12.5MG

N020297 002 Sep 14, 1995 May CAHN

AB 25MG

N020297 001 Sep 14, 1995 May CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SMITHKLINE BEECHAM

10MG

N022012 001 Oct 20, 2006 May CAHN

20MG

N022012 002 Oct 20, 2006 May CAHN

+

40MG

N022012 003 Oct 20, 2006 May CAHN

80MG

N022012 004 Oct 20, 2006 May CAHN

CASPOFUNGIN ACETATE

>A>	POWDER;IV (INFUSION)						
>A>	CASPOFUNGIN ACETATE						
>A> AP	FRESENIUS KABI USA	50MG/VIAL	N206110	001	Dec 30, 2016	Dec	NEWA
>A> AP		70MG/VIAL	N206110	002	Dec 30, 2016	Dec	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL

CEFADROXIL

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb	DISC
@		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb	DISC
@		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb	DISC

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan	NEWA
	@ WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988	Oct	CAHN
	@	EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988	Oct	CAHN
	@	EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988	Oct	CAHN
	@	EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988	Oct	CAHN
	@	EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988	Oct	CAHN
	@	EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988	Oct	CAHN

CEFDITOREN PIVOXIL

TABLET;ORAL

SPECTRACEF

@	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr	DISC
@		400MG	N021222	002	Jul 21, 2008	Apr	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	NEWA
>A> AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091048	001	Jan 04, 2017	Dec	NEWA
>A> AP		EQ 2GM BASE/VIAL	A091048	002	Jan 04, 2017	Dec	NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb	NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb	NEWA
	CLAFORAN						
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun	DISC
	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun	DISC
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
	CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan	CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan	CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan	CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan	CAHN
	CEFOTETAN						
>A> AP	HIKMA FARMACEUTICA	EQ 1GM BASE/VIAL	A091031	001	Oct 26, 2011	Dec	CAHN
>A> AP		EQ 2GM BASE/VIAL	A091031	002	Oct 26, 2011	Dec	CAHN
>D> AP	WEST-WARD PHARM CORP	EQ 1GM BASE/VIAL	A091031	001	Oct 26, 2011	Dec	CAHN

INJECTABLE; INJECTION
CEFOTETAN

>D> AP	EQ 2GM BASE/VIAL	A091031	002	Oct 26, 2011	Dec CAHN
	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER				
+	B BRAUN EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun CMS2
+	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun CMS2

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	ACS DOBFAR SPA EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
AP	EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
AP	EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN
	CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER				
AP	+ B BRAUN EQ 1GM BASE/VIAL	N065214	001	Mar 10, 2006	Aug CRLD
AP	+ EQ 2GM BASE/VIAL	N065214	002	Mar 10, 2006	Aug CRLD

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

@	SUN PHARM INDS LTD EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
@	EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC

TABLET; ORAL

CEFPODOXIME PROXETIL

@	SUN PHARM INDS LTD EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
@	EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

@	PERNIX THERAP EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun DISC
---	-----------------------------	---------	-----	--------------	----------

FOR SUSPENSION; ORAL

CEDAX

@	PERNIX THERAP EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun DISC
@	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
CEFTRIAXONE

@	HOSPIRA INC EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr DISC
@	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr DISC
@	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr DISC
@	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr DISC

ROCEPHIN

@	HOFFMANN LA ROCHE EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr DISC
@	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

@	BEDFORD EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun DISC
@	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun DISC
@	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun DISC
@	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun DISC
AP	QILU PHARM CO LTD EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jun NEWA
AP	EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jun NEWA
AP	EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jun NEWA
AP	EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jun NEWA

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

	GLAXOSMITHKLINE EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb CTEC
+	EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb CTEC

CEFUROXIME AXETIL

@	SUN PHARM INDS LTD EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
@	EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC

TABLET; ORAL

CEFUROXIME AXETIL

@	SUN PHARM INDS LTD EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb DISC
@	EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb DISC
@	EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb DISC

CEFUROXIME SODIUMINJECTABLE;INJECTION
ZINACEF

AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan CAHN
		ZINACEF IN PLASTIC CONTAINER					
		@ IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan CAHN
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
		ZINACEF					
AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan CAHN

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB		AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan NEWA
AB			100MG	A206827	002	Feb 01, 2016	Jan NEWA
AB			200MG	A206827	003	Feb 01, 2016	Jan NEWA
AB			400MG	A206827	004	Feb 01, 2016	Jan NEWA
AB		MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb NEWA
AB			100MG	A204590	002	Mar 16, 2016	Feb NEWA
AB			200MG	A204590	003	Mar 16, 2016	Feb NEWA
AB			400MG	A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

		@ SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb DISC
		@	EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb DISC
		KEFLEX					
AB		PRAGMA PHARMS LLC	EQ 250MG BASE	N050405	002		Jul CAHN
AB			EQ 500MG BASE	N050405	003		Jul CAHN
AB	+		EQ 750MG BASE	N050405	005	May 12, 2006	Jul CAHN
		FOR SUSPENSION;ORAL					
		KEFLEX					
		@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar CAHN
		@	EQ 125MG BASE/5ML	N050406	001		Mar CAHN
		@	EQ 250MG BASE/5ML	N050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
AA	+	PERRIGO R AND D	5MG/5ML	A078398	001	Jun 17, 2008	Aug CRLD
		@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE

>D>	AB	APOTEX INC	30MG	A091260	001	Aug 25, 2011	Dec CMS1
		CEVIMELINE HYDROCHLORIDE					
>A>	AB	APOTEX INC	30MG	A091260	001	Aug 25, 2011	Dec CMS1
>A>	AB	NOVEL LABS INC	30MG	A204746	001	Dec 30, 2016	Dec NEWA
	AB	WEST-WARD PHARMS INT	30MG	A091591	001	Jul 08, 2013	Nov CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

		@ UPSHER-SMITH LABS	5MG	A084678	001		Oct CAHN
		@	10MG	A084041	001		Oct CAHN
		@	25MG	A084679	002		Nov CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

LIBRAX

	+	VALEANT PHARMS	5MG;2.5MG	N012750	001		Jul NEWA
--	---	----------------	-----------	---------	-----	--	----------

CHLORHEXIDINE GLUCONATESOLUTION; DENTAL
PERIOGARD

AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

CHLOROPROCAINE HYDROCHLORIDEINJECTABLE; INJECTION
CHLOROPROCAINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	2%	A040273	001	Sep 09, 1998	Sep	CAHN
AP		3%	A040273	002	Sep 09, 1998	Sep	CAHN

CHLOROQUINE PHOSPHATETABLET; ORAL
CHLOROQUINE PHOSPHATE

@	IMPAX LABS	EQ 150MG BASE	A080880	001		Mar	DISC
@		EQ 300MG BASE	A040516	001	Aug 29, 2003	Mar	DISC

CHLORPHENIRAMINE MALEATETABLET; ORAL
CHLORPHENIRAMINE MALEATE

@	AUROLIFE PHARMA LLC	4MG	A080961	001		Mar	CAHN
@	SUN PHARM INDS	4MG	A080700	001		Jun	CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATETABLET, EXTENDED RELEASE; ORAL
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

@	SPRIASO LLC	8MG; 54.3MG	N206323	001	Jun 22, 2015	Jun	DISC
---	-------------	-------------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION; ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Feb	CAHN
----	------------------	----------------------------	---------	-----	--------------	-----	------

CHLORPROPAMIDETABLET; ORAL
CHLORPROPAMIDE

@	AUROLIFE PHARMA LLC	100MG	A088725	001	Aug 31, 1984	Mar	CAHN
@		250MG	A088726	001	Aug 31, 1984	Mar	CAHN

GLUCAMIDE

>A>	@ ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Dec	CAHN
>D>	@ TEVA PHARMS USA	250MG	A088641	001	Oct 11, 1984	Dec	CAHN

CHLORTHALIDONETABLET; ORAL
CHLORTHALIDONE

AB	MYLAN	25MG	A086831	002		Jan	CTEC
AB	SUN PHARM INDS	25MG	A089286	002	Jul 21, 1986	Jan	CMS1

CHLORZOXAZONETABLET; ORAL
CHLORZOXAZONE

@	AUROLIFE PHARMA LLC	250MG	A089852	001	May 04, 1988	Feb	CAHN
@		500MG	A089853	001	May 04, 1988	Feb	CAHN
+	MIKART	750MG	A040861	002	Jun 01, 2010	Apr	CRLD
+	MIKART INC	250MG	A207483	001	Jun 24, 2016	Jun	NEWA
@	SUN PHARM INDS	500MG	A089970	001	Sep 27, 1990	Mar	CAHN
AA	+	WATSON LABS	A089859	001	May 04, 1988	Jul	CRLD

CHOLINE C-11INJECTABLE; INTRAVENOUS
CHOLINE C-11

>A>	AP	WA UNIV SCH MED	4-33.1mCi/ML	A208413	001	Jan 10, 2017	Dec	NEWA
-----	----	-----------------	--------------	---------	-----	--------------	-----	------

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE; ORAL
FENOFIBRIC ACID

AB	IMPAX LABS INC	EQ 45MG FENOFIBRIC ACID	A200264	001	Sep 07, 2016	Aug	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A200264	002	Sep 07, 2016	Aug	NEWA

CICLESONIDEAEROSOL, METERED; INHALATION
ALVESCO

+ TAKEDA GMBH 0.08MG/INH N021658 002 Jan 10, 2008 Jan CRLD

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

>D>	AB	APOTEX INC	50MG	A077030	001	Dec 10, 2004	Dec CAHN
>A>	AB		50MG	A077030	001	Dec 10, 2004	Dec CAHN
>D>	AB		100MG	A077030	002	Dec 10, 2004	Dec CAHN
>A>	AB		100MG	A077030	002	Dec 10, 2004	Dec CAHN
		@ FRONTIDA BIOPHARM	50MG	A077208	002	Mar 29, 2006	Jul CAHN
		@	100MG	A077208	001	Mar 29, 2006	Jul CAHN
		@ SUN PHARM INDS	50MG	A077208	002	Mar 29, 2006	Jun CAHN
		@	100MG	A077208	001	Mar 29, 2006	Jun CAHN
AB	+	TEVA	50MG	A077027	001	Nov 24, 2004	Jun CRLD
AB	+		100MG	A077027	002	Nov 24, 2004	Jun CRLD
AB		WEST-WARD PHARMS INT	50MG	A077024	001	May 17, 2005	Nov CAHN
AB			100MG	A077024	002	May 17, 2005	Nov CAHN

CIMETIDINETABLET; ORAL
CIMETIDINE

@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Oct CAHN
@	300MG	A074506	002	Jan 24, 1996	Oct CAHN
@	400MG	A074506	003	Jan 24, 1996	Oct CAHN
@	800MG	A074506	004	Jan 24, 1996	Oct CAHN

CIPROFLOXACIN HYDROCHLORIDEOINTMENT; OPHTHALMIC
CILOXAN

	+	NOVARTIS PHARMS CORP	EQ 0.3% BASE	N020369	001	Mar 30, 1998	Nov CAHN
		SOLUTION/DROPS; OPHTHALMIC					
		CILOXAN					
AT	+	NOVARTIS PHARMS CORP	EQ 0.3% BASE	N019992	001	Dec 31, 1990	Nov CAHN
		CIPROFLOXACIN HYDROCHLORIDE					
AT		TELIGENT PHARMA INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jul CAHN
		TABLET; ORAL					
		CIPROFLOXACIN HYDROCHLORIDE					
		@ IDT AUSTRALIA LTD	EQ 100MG BASE	A075939	001	Mar 03, 2005	May CAHN
		@	EQ 250MG BASE	A075939	002	Jun 09, 2004	May CAHN
		@	EQ 500MG BASE	A075939	003	Jun 09, 2004	May CAHN
		@	EQ 750MG BASE	A075939	004	Jun 09, 2004	May CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDESOLUTION/DROPS; OTIC
OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE; 0.025% N208251 001 Apr 29, 2016 Apr NEWA

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONESUSPENSION/DROPS; OTIC
CIPRO HC

+ NOVARTIS PHARMS CORP EQ 0.2% BASE; 1% N020805 001 Feb 10, 1998 Nov CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC	212.6MG; EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan DISC
@	425.2MG; EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan DISC

CIPROFLOXACIN; DEXAMETHASONESUSPENSION/DROPS; OTIC
CIPRODEX

+ NOVARTIS PHARMS CORP 0.3%; 0.1% N021537 001 Jul 18, 2003 Nov CAHN

CISPLATININJECTABLE;INJECTION
CISPLATIN

AP	WEST-WARD PHARMS INT	1MG/ML	A075036	001	Nov 07, 2000	Oct CAHN
----	----------------------	--------	---------	-----	--------------	----------

CITALOPRAM HYDROBROMIDESOLUTION;ORAL
CITALOPRAM HYDROBROMIDE

AA	+ WEST-WARD PHARMS INT	EQ 10MG BASE/5ML	A077043	001	Dec 13, 2004	Nov CAHN
----	------------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

>D> AB	APOTEX INC	EQ 10MG BASE	A077046	001	Nov 24, 2004	Dec CAHN
>A> AB		EQ 10MG BASE	A077046	001	Nov 24, 2004	Dec CAHN
	@ SUN PHARM INDS	EQ 10MG BASE	A077052	001	Jul 03, 2006	Mar CAHN
	@	EQ 20MG BASE	A077052	002	Jul 03, 2006	Mar CAHN
	@	EQ 40MG BASE	A077052	003	Jul 03, 2006	Mar CAHN
>D> AB	TORPHARM	EQ 20MG BASE	A077046	002	Nov 24, 2004	Dec CAHN
>A> AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Dec CAHN
>D> AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Dec CAHN
>A> AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Dec CAHN

CLADRIBINEINJECTABLE;INJECTION
CLADRIBINE

AP	WEST-WARD PHARMS INT	1MG/ML	A075405	001	Feb 28, 2000	Oct CAHN
----	----------------------	--------	---------	-----	--------------	----------

CLARITHROMYCINTABLET;ORAL
CLARITHROMYCIN

AB	WEST-WARD PHARMS INT	250MG	A065178	002	May 25, 2004	Nov CAHN
AB		500MG	A065178	001	May 25, 2004	Nov CAHN

TABLET, EXTENDED RELEASE;ORAL
CLARITHROMYCIN

AB	ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb NEWA
	@ IDT AUSTRALIA LTD	500MG	A065250	001	Aug 25, 2005	May CAHN
AB	+ MAYNE PHARMA	500MG	A065154	001	May 18, 2005	Aug CAHN

CLEVIDIPINEEMULSION;INTRAVENOUS
CLEVIPREX

+	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Aug CAHN
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Aug CAHN
+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Aug CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	May NEWA
----	------------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATECREAM;VAGINAL
CLINDESSE

+	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004	Jun CAHN
---	---------------------	------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

AP	@ WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987	Oct CAHN
		EQ 150MG BASE/ML	A062889	001	Apr 25, 1988	Oct CAHN
	@	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988	Oct CAHN
	@	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989	Oct CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

>A> AT	@ INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Oct CAHN
	TELIGENT PHARMA INC	EQ 1% BASE	A206945	001	Dec 30, 2016	Dec NEWA

CLINDAMYCIN PHOSPHATE; TRETINOINGEL;TOPICAL
VELTIN

BX	+ AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010	Jan CAHN
----	-------------------	-------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

CREAM;TOPICAL				
CLOBETASOL PROPIONATE (EMOLLIENT)				
	@ INGENUS PHARMS LLC	0.05%	A075733	001 Aug 22, 2001 Oct CAHN
LOTION;TOPICAL				
CLOBETASOL PROPIONATE				
AB	TELIGENT PHARMA INC	0.05%	A208667	001 Nov 29, 2016 Nov NEWA
OINTMENT;TOPICAL				
CLOBETASOL PROPIONATE				
AB	+ FOUGERA PHARMS	0.05%	A074407	001 Feb 23, 1996 Mar CRLD

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
ANAFRANIL				
AB	+ MALLINCKRODT LLC	25MG	N019906	001 Dec 29, 1989 Jan CRLD
AB		50MG	N019906	002 Dec 29, 1989 Jan CRLD

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL				
CLONIDINE				
AB	MAYNE PHARMA	0.1MG/24HR	A079090	001 Aug 20, 2010 Aug CAHN
AB		0.2MG/24HR	A079090	002 Aug 20, 2010 Aug CAHN
AB		0.3MG/24HR	A079090	003 Aug 20, 2010 Aug CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL				
CLONIDINE HYDROCHLORIDE				
	@ AUROLIFE PHARMA LLC	0.1MG	A070887	001 Aug 31, 1988 Feb CAHN
	@	0.2MG	A070886	001 Aug 31, 1988 Feb CAHN
	@	0.3MG	A071294	001 Aug 31, 1988 Feb CAHN
>D> AB	CARLSBAD	0.1MG	A202297	001 Jun 13, 2013 Dec CAHN
>D> AB		0.2MG	A202297	002 Jun 13, 2013 Dec CAHN
>D> AB		0.3MG	A202297	003 Jun 13, 2013 Dec CAHN
>A>	@ CHARTWELL MOLECULES	0.2MG	A071784	001 Apr 05, 1988 Dec CAHN
>D>	@ DAVA PHARMS INC	0.2MG	A071784	001 Apr 05, 1988 Dec CAHN
AB	FRONTIDA BIOPHARM	0.1MG	A070925	001 Sep 04, 1987 Jul CAHN
AB		0.2MG	A070924	001 Sep 04, 1987 Jul CAHN
AB		0.3MG	A070923	001 Sep 04, 1987 Jul CAHN
>A> AB	YUNG SHIN PHARM	0.1MG	A202297	001 Jun 13, 2013 Dec CAHN
>A> AB		0.2MG	A202297	002 Jun 13, 2013 Dec CAHN
>A> AB		0.3MG	A202297	003 Jun 13, 2013 Dec CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL				
CLOPIDOGREL BISULFATE				
	@ ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001 May 28, 2013 Jun DISC
AB	SUN PHARM INDS	EQ 75MG BASE	A078133	001 Jun 10, 2013 Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL				
CLORAZEPATE DIPOTASSIUM				
	@ AUROLIFE PHARMA LLC	3.75MG	A072219	001 Aug 26, 1988 Apr CAHN
	@	7.5MG	A072220	001 Aug 26, 1988 Feb CAHN
	@	15MG	A072112	001 Aug 26, 1988 Feb CAHN
TABLET;ORAL				
CLORAZEPATE DIPOTASSIUM				
	@ AUROLIFE PHARMA LLC	3.75MG	A072512	001 May 11, 1990 Mar CAHN
	@	7.5MG	A072513	001 May 11, 1990 Mar CAHN
	@	15MG	A072514	001 May 11, 1990 Feb CAHN
TRANXENE				
	@ RECORDATI RARE	3.75MG	N017105	006 Jun DISC

CLOTTRIMAZOLE

TROCHE/LOZENGE;ORAL				
CLOTTRIMAZOLE				
AB	+ WEST-WARD PHARMS INT	10MG	A076387	001 Jul 29, 2004 Nov CAHN

CLOZAPINETABLET; ORAL
CLOZAPINE

AB	AUROBINDO PHARMA LTD	25MG	A206433	001	Nov 29, 2016	Nov	NEWA
AB		50MG	A206433	002	Nov 29, 2016	Nov	NEWA
AB		100MG	A206433	003	Nov 29, 2016	Nov	NEWA
AB		200MG	A206433	004	Nov 29, 2016	Nov	NEWA
AB	MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015	Aug	CAHN
AB		100MG	A203807	002	Sep 17, 2015	Aug	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Feb	CAHN
----	------------------	----------------------	---------	-----	--------------	-----	------

COLCHICINE

CAPSULE; ORAL

MITIGARE

+	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Mar	CRLD
---	-------------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

COLCRYS

+	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Oct	CTEC
AB	+	0.6MG	N022352	001	Jul 29, 2009	Sep	CFTG

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB	INGENUS PHARMS NJ	0.5MG; 500MG	A040618	001	May 13, 2008	Jan	CAHN
----	-------------------	--------------	---------	-----	--------------	-----	------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Feb	CAHN
---	-----------------	--	---------	-----	--	-----	------

CORTICOTROPIN

INJECTABLE; INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS 40 UNITS/ML

N008975 001 Feb CAHN

@ 80 UNITS/ML

N008975 002 Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML

N009854 001 Feb CAHN

>A> CRISABOROLE

>A> OINTMENT; TOPICAL

>A> EUCRISA

>A>	+	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016	Dec	NEWA
-----	---	-------------------	----	---------	-----	--------------	-----	------

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

FULYZAQ

+	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Jun	CAHN
---	-----------------	-------	---------	-----	--------------	-----	------

CROTAMITON

LOTION; TOPICAL

CROTAN

AT	MARNEL PHARMS	10%	A087204	001		Aug	CAHN
----	---------------	-----	---------	-----	--	-----	------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP	SOMERSET THERAPS LLC	1MG/ML	A206503	001	Dec 11, 2015	Mar	CAHN
----	----------------------	--------	---------	-----	--------------	-----	------

AP	WEST-WARD PHARMS INT	1MG/ML	A080515	002		Oct	CMFD
----	----------------------	--------	---------	-----	--	-----	------

DODEX

>A>	@	ORGANON SUB MERCK	1MG/ML	A083022	001		Dec	DISC
-----	---	-------------------	--------	---------	-----	--	-----	------

SPRAY, METERED;NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
AMRIX

AB TEVA PHARMS INTL 15MG N021777 001 Feb 01, 2007 Nov CTEC
15MG N021777 001 Feb 01, 2007 Oct CAHN
+ 30MG N021777 002 Feb 01, 2007 Nov CTEC
AB + 30MG N021777 002 Feb 01, 2007 Oct CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

@ TWI PHARMS INC 15MG
@ 30MG

A091281 001 Jan 31, 2013 Oct DISC
A091281 002 Jan 31, 2013 Oct DISC

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB FRONTIDA BIOPHARM 5MG A073541 002 Apr 06, 2006 Jul CAHN
AB 10MG A073541 001 May 23, 1995 Jul CAHN
@ UPSHER-SMITH LABS 5MG A072854 002 Feb 03, 2006 Oct CAHN
@ 10MG A072854 001 Nov 19, 1991 Oct CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYCLOGYL

>D> AT + ALCON 0.5% A084109 001 Dec CAHN
>D> AT + 1% A084110 001 Dec CAHN
>D> + ALCON LABS INC 2% A084108 001 Dec CAHN
>A> AT + NOVARTIS PHARMS CORP 0.5% A084109 001 Dec CAHN
>A> AT + 1% A084110 001 Dec CAHN
>A> + 2% A084108 001 Dec CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYCLOMYDRIL

>D> + ALCON 0.2%;1% A084300 001 Dec CAHN
>A> + NOVARTIS PHARMS CORP 0.2%;1% A084300 001 Dec CAHN

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL
@ 1GM/VIAL
@ 2GM/VIAL

N012142 003 Mar DISC
N012142 004 Aug 30, 1982 Mar DISC
N012142 005 Aug 30, 1982 Mar DISC

TABLET;ORAL

CYCLOPHOSPHAMIDE

@ ROXANE 25MG
@ 50MG

A040032 001 Aug 17, 1999 Oct DISC
A040032 002 Aug 17, 1999 Oct DISC

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

AB1 MAYNE PHARMA 25MG A065044 002 Dec 20, 2000 Aug CAHN
AB1 100MG A065044 001 Dec 20, 2000 Aug CAHN

EMULSION;OPHTHALMIC
RESTASIS MULTIDOSE

+ ALLERGAN 0.05%

N050790 002 Oct 27, 2016 Nov NEWA

INJECTABLE;INJECTION
CYCLOSPORINE

AP WEST-WARD PHARMS INT 50MG/ML A065004 001 Oct 29, 1999 Sep CAHN

SOLUTION;ORAL
CYCLOSPORINE

AB1 MAYNE PHARMA 100MG/ML A065054 001 Dec 18, 2001 Aug CAHN

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A> AA PATRIN PHARMA INC 2MG/5ML A204823 001 Dec 27, 2016 Dec NEWA

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A> AA APEX PHARMS INC 4MG A207783 001 Dec 29, 2016 Dec NEWA
AA APPCO PHARMA LLC 4MG A206553 001 Nov 29, 2016 Nov NEWA

TABLET;ORAL							
CYPROHEPTADINE HYDROCHLORIDE							
AA	INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan	CAHN
<u>CYTARABINE</u>							
INJECTABLE;INJECTION							
CYTARABINE							
AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
AP		20MG/ML	A200916	001	Dec 13, 2011	Mar	CAHN
AP	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Sep	CAHN
AP		500MG/VIAL	A071472	001	Aug 02, 1989	Sep	CAHN
AP		1GM/VIAL	A074245	001	Aug 31, 1994	Sep	CAHN
AP		2GM/VIAL	A074245	002	Aug 31, 1994	Sep	CAHN
<u>DACARBAZINE</u>							
INJECTABLE;INJECTION							
DACARBAZINE							
AP	WEST-WARD PHARMS INT	200MG/VIAL	A075812	001	Jun 15, 2001	Oct	CAHN
AP		500MG/VIAL	A075812	002	Oct 31, 2002	Oct	CAHN
<u>DACLATASVIR DIHYDROCHLORIDE</u>							
TABLET;ORAL							
DAKLINZA							
	BRISTOL-MYERS SQUIBB	EQ 90MG BASE	N206843	003	Apr 13, 2016	Apr	NEWA
<u>DACTINOMYCIN</u>							
INJECTABLE;INJECTION							
DACTINOMYCIN							
	@ EUROHLTH INTL SARL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Feb	DISC
	@ WEST-WARD PHARMS INT	0.5MG/VIAL	A090304	001	Mar 16, 2010	Oct	CAHN
<u>DALBAVANCIN HYDROCHLORIDE</u>							
POWDER; IV (INFUSION)							
DALVANCE							
+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jan	CDFR
<u>DANAZOL</u>							
CAPSULE;ORAL							
DANAZOL							
AB	LANNETT	50MG	A077246	002	Apr 19, 2007	Sep	NEWA
AB		100MG	A077246	003	Apr 19, 2007	Sep	NEWA
<u>DANTROLENE SODIUM</u>							
FOR SUSPENSION;INTRAVENOUS							
RYANODEX							
+	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jun	CRLD
INJECTABLE;INJECTION							
DANTROLENE SODIUM							
AP	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Feb	NEWA
<u>DAPSONE</u>							
GEL;TOPICAL							
ACZONE							
+	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016	Feb	NEWA
TABLET;ORAL							
DAPSONE							
AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Mar	CAHN
AB		100MG	A205429	002	Jan 07, 2016	Mar	CAHN
AB	NORTH CREEK PHARMS	25MG	A204074	001	May 10, 2016	Apr	NEWA
AB		100MG	A204074	002	May 10, 2016	Apr	NEWA
AB	NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016	Apr	NEWA
AB		100MG	A203887	002	May 06, 2016	Apr	NEWA
AB	PAR PHARM INC	25MG	A206505	001	Dec 01, 2016	Nov	NEWA
AB		100MG	A206505	002	Dec 01, 2016	Nov	NEWA
<u>DAPTOMYCIN</u>							
POWDER;INTRAVENOUS							
CUBICIN							
AP	+ CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan	CDFR
AP	+ CUBIST PHARMS LLC	500MG/VIAL	N021572	002	Sep 12, 2003	Aug	CAHN

POWDER; INTRAVENOUS							
CUBICIN RF							
	+	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016	Aug NEWA
DAPTOMYCIN							
AP		CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016	Jun NEWA
AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR
AP		TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Mar NEWA
POWDER; IV (INFUSION)							
CUBICIN							
	@	CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR
	@	CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003	Aug CAHN
<u>DARIFENACIN HYDROBROMIDE</u>							
TABLET, EXTENDED RELEASE; ORAL							
DARIFENACIN HYDROBROMIDE							
AB		AUROBINDO PHARMA LTD	EQ 7.5MG BASE	A206743	001	Sep 19, 2016	Sep NEWA
AB			EQ 15MG BASE	A206743	002	Sep 19, 2016	Sep NEWA
AB		CIPLA LTD	EQ 7.5MG BASE	A207664	001	Sep 01, 2016	Aug NEWA
AB			EQ 15MG BASE	A207664	002	Sep 01, 2016	Aug NEWA
AB		JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Oct NEWA
AB			EQ 15MG BASE	A205550	002	Oct 12, 2016	Oct NEWA
AB		TORRENT PHARMS LTD	EQ 7.5MG BASE	A205209	001	Nov 17, 2016	Nov NEWA
AB			EQ 15MG BASE	A205209	002	Nov 17, 2016	Nov NEWA
ENABLEX							
AB		APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR</u>							
TABLET, EXTENDED RELEASE; ORAL							
VIEKIRA XR							
	+	ABBVIE INC	EQ 200MG BASE; 8.33MG; 50MG; 33.33MG	N208624	001	Jul 22, 2016	Jul NEWA
<u>DASATINIB</u>							
TABLET; ORAL							
DASATINIB							
AB		APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
AB			50MG	A202103	002	Jun 10, 2016	May NEWA
AB			70MG	A202103	003	Jun 10, 2016	May NEWA
AB			100MG	A202103	004	Jun 10, 2016	May NEWA
SPRYCEL							
AB		BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
AB			50MG	N021986	002	Jun 28, 2006	May CFTG
AB			70MG	N021986	003	Jun 28, 2006	May CFTG
AB	+		100MG	N021986	004	May 30, 2008	May CFTG
<u>DAUNORUBICIN CITRATE</u>							
INJECTABLE, LIPOSOMAL; INJECTION							
DAUNOXOME							
	@	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	May DISC
<u>DAUNORUBICIN HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CERUBIDINE							
AP	+	WEST-WARD PHARMS INT	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Sep CAHN
DAUNORUBICIN HYDROCHLORIDE							
AP	+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Sep CAHN
<u>DEFERASIROX</u>							
TABLET, FOR SUSPENSION; ORAL							
DEFERASIROX							
AB		ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB			250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB			500MG	A203560	003	Jan 26, 2016	Jan NEWA
EXJADE							
AB		NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB			250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+		500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

AP	WEST-WARD PHARMS INT	500MG/VIAL	A078086	001	May 30, 2007	Oct CAHN
AP		2GM/VIAL	A078086	002	May 30, 2007	Oct CAHN

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)
DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar NEWA
+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Aug CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar DISC
@		300MG	A065094	002	Mar 22, 2004	Mar DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016	Oct NEWA
AB		25MG	A205153	002	Oct 28, 2016	Oct NEWA
AB		50MG	A205153	003	Oct 28, 2016	Oct NEWA
AB		75MG	A205153	004	Oct 28, 2016	Oct NEWA
AB		100MG	A205153	005	Oct 28, 2016	Oct NEWA
AB		150MG	A205153	006	Oct 28, 2016	Oct NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun CAHN
AB		25MG	A207433	002	May 05, 2016	Jun CAHN
AB		50MG	A207433	003	May 05, 2016	Jun CAHN
AB		75MG	A207433	004	May 05, 2016	Jun CAHN
AB		100MG	A207433	005	May 05, 2016	Jun CAHN
AB		150MG	A207433	006	May 05, 2016	Jun CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr NEWA
AB		25MG	A207433	002	May 05, 2016	Apr NEWA
AB		50MG	A207433	003	May 05, 2016	Apr NEWA
AB		75MG	A207433	004	May 05, 2016	Apr NEWA
AB		100MG	A207433	005	May 05, 2016	Apr NEWA
AB		150MG	A207433	006	May 05, 2016	Apr NEWA
	NORPRAMIN					
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
AB		25MG	N014399	001		Jan CAHN
AB		50MG	N014399	003		Jan CAHN
AB		75MG	N014399	004		Jan CAHN
AB	+	100MG	N014399	005		Jan CAHN
AB		150MG	N014399	006		Jan CAHN

DESLOMATADINE

SOLUTION; ORAL
DESLOMATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May NEWA
----	------	----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

>D>	AB	APOTEX INC	0.01MG/SPRAY	A076703	001	Jan 27, 2005	Dec CAHN
>A>	AB		0.01MG/SPRAY	A076703	001	Jan 27, 2005	Dec CAHN

STIMATE (NEEDS NO REFRIGERATION)

+	CSL BEHRING	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Aug CPOT
---	-------------	--------------	---------	-----	--------------	----------

TABLET; ORAL

DESMOPRESSIN ACETATE

>D>	AB	APOTEX INC	0.1MG	A077414	001	Mar 07, 2006	Dec CAHN
>A>	AB		0.1MG	A077414	001	Mar 07, 2006	Dec CAHN
>D>	AB		0.2MG	A077414	002	Mar 07, 2006	Dec CAHN
>A>	AB		0.2MG	A077414	002	Mar 07, 2006	Dec CAHN

TABLET;ORAL

DESMOPRESSIN ACETATE

	@ FERRING	0.1MG	N021795	001	May 08, 2008	Jun	DISC
	@	0.2MG	N021795	002	May 08, 2008	Jun	DISC
AB	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug	CAHN
AB		0.2MG	A077122	002	Jan 25, 2006	Aug	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	+ DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	002	Aug 12, 1999	Sep	CRLD
AB	MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Aug	CAHN
AB		0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Aug	CAHN
	ORTHO-CEPT						
	@ JANSSSEN PHARMS	0.15MG;0.03MG	N020301	002	Dec 14, 1992	Sep	DISC
	VOLNEA						
AB	SANDOZ INC	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug	NEWA

DESONIDE

CREAM;TOPICAL

DESONIDE

AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

>A>	AB	AKORN	0.05%	A203787	001	Jan 06, 2017	Dec	NEWA
>A>	AB	LUPIN ATLANTIS	0.05%	A208163	001	Jan 10, 2017	Dec	NEWA
>A>	AB		0.25%	A208164	001	Jan 09, 2017	Dec	NEWA

TOPICORT

>D>	+	TARO	0.05%	A073210	001	Nov 30, 1990	Dec	CTEC
>A>	AB	+	0.05%	A073210	001	Nov 30, 1990	Dec	CTEC

GEL;TOPICAL

DESOXIMETASONE

AB	GROUPE PARIMA INC	0.05%	A204675	001	Aug 12, 2016	Aug	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	0.25%	A204965	001	Nov 07, 2016	Oct	NEWA	
>A>	AB	G AND W LABS INC	0.25%	A206740	001	Dec 23, 2016	Dec	NEWA
AB	GROUPE PARIMA INC	0.25%	A204272	001	Nov 30, 2016	Nov	NEWA	
AB	LUPIN ATLANTIS	0.05%	A208044	001	Dec 12, 2016	Nov	NEWA	
AB		0.25%	A208104	001	Dec 01, 2016	Nov	NEWA	
AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr	NEWA	
AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May	CAHN	
AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb	NEWA	
	TOPICORT							
AB	+ TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	Nov	CFTG	

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul	NEWA
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul	NEWA
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul	NEWA
AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb	NEWA
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb	NEWA
AB	WEST-WARD PHARMS INT	EQ 50MG BASE	A204082	001	Feb 16, 2016	Nov	CAHN
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Nov	CAHN
	PRISTIQ						
AB	WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul	CFTG

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

+	WEST-WARD PHARMS INT	1MG/ML	A088252	001	Sep 01, 1983	Nov	CAHN
---	----------------------	--------	---------	-----	--------------	-----	------

SOLUTION;ORAL

DEXAMETHASONE

+	WEST-WARD PHARMS INT	0.5MG/5ML	A088248	001	Sep 01, 1983	Nov	CAHN
---	----------------------	-----------	---------	-----	--------------	-----	------

SUSPENSION/DROPS;OPHTHALMIC
MAXIDEX

+ NOVARTIS PHARMS CORP		0.1%	N013422	001		Nov	CAHN
TABLET;ORAL							
DEXAMETHASONE							
@ IDT AUSTRALIA LTD		0.75MG	A080399	001		May	CAHN
@ SUN PHARM INDS		0.25MG	A084013	001		Mar	CAHN
@		0.25MG	A084764	001		Mar	CAHN
@		0.5MG	A084084	001		Mar	CAHN
@		0.5MG	A084766	001		Mar	CAHN
@		0.75MG	A084081	001		Mar	CAHN
@		0.75MG	A084765	001		Mar	CAHN
@		1.5MG	A084086	001		Mar	CAHN
@		1.5MG	A084763	001		Mar	CAHN
BP	WEST-WARD PHARMS INT	0.5MG	A084611	001		Nov	CAHN
BP		0.75MG	A084613	001		Nov	CAHN
BP		1MG	A088306	001	Sep 15, 1983	Nov	CAHN
AB		1.5MG	A084610	001		Nov	CAHN
BP		2MG	A087916	001	Aug 26, 1982	Nov	CAHN
BP		4MG	A084612	001		Nov	CAHN
BP	+	6MG	A088316	001	Sep 15, 1983	Nov	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION							
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE							
AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar CTNA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC							
MAXITROL							
>D> AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Dec CAHN
>A> AT	+	NOVARTIS PHARMS CORP	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Dec CAHN
SUSPENSION/DROPS;OPHTHALMIC							
MAXITROL							
AT	+	NOVARTIS PHARMS CORP	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Nov CAHN

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC							
TOBRADEX							
>D>	+	ALCON	0.1%;0.3%	N050616	001	Sep 28, 1988	Dec CAHN
>A>	+	NOVARTIS PHARMS CORP	0.1%;0.3%	N050616	001	Sep 28, 1988	Dec CAHN
SUSPENSION/DROPS;OPHTHALMIC							
TOBRADEX							
>D> AB	+	ALCON	0.1%;0.3%	N050592	001	Aug 18, 1988	Dec CAHN
>A> AB	+	NOVARTIS PHARMS CORP	0.1%;0.3%	N050592	001	Aug 18, 1988	Dec CAHN
TOBRADEX ST							
>D>	+	ALCON PHARMS LTD	0.05%;0.3%	N050818	001	Feb 13, 2009	Dec CAHN
>A>	+	NOVARTIS PHARMS CORP	0.05%;0.3%	N050818	001	Feb 13, 2009	Dec CAHN

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL							
DEXILANT SOLUTAB							
	+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION							
DEXMEDETOMIDINE HYDROCHLORIDE							
AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan NEWA
AP		ACTAVIS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204686	001	Oct 17, 2016	Oct NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar NEWA
AP		SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May NEWA
PRECEDEX							
	+	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015	Aug CAHN
AB		10MG	A079108	002	Aug 05, 2015	Aug CAHN
AB		15MG	A079108	003	May 19, 2014	Aug CAHN
AB		20MG	A079108	004	Dec 21, 2015	Aug CAHN
AB		30MG	A079108	005	Nov 21, 2013	Aug CAHN
AB	PAR PHARM INC	5MG	A202842	001	Nov 30, 2016	Nov NEWA
AB		10MG	A202842	002	Nov 30, 2016	Nov NEWA
AB		15MG	A202842	003	Nov 30, 2016	Nov NEWA
AB		20MG	A202842	004	Nov 30, 2016	Nov NEWA
AB		25MG	A202842	005	Nov 30, 2016	Nov NEWA
AB		30MG	A202842	006	Nov 30, 2016	Nov NEWA
AB		35MG	A202842	007	Nov 30, 2016	Nov NEWA
AB		40MG	A202842	008	Nov 30, 2016	Nov NEWA
	FOCALIN XR					
AB	NOVARTIS	25MG	N021802	008	Apr 21, 2011	Nov CFTG
AB		35MG	N021802	007	Apr 21, 2011	Nov CFTG

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
AB		5MG	A201231	002	Sep 24, 2015	Feb CAHN
AB		10MG	A201231	003	Sep 24, 2015	Feb CAHN
AB	TRIS PHARMA INC	2.5MG	A207901	001	Aug 26, 2016	Aug NEWA
AB		5MG	A207901	002	Aug 26, 2016	Aug NEWA
AB		10MG	A207901	003	Aug 26, 2016	Aug NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A207321	001	Nov 28, 2016	Nov NEWA
AP	WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Oct CAHN
AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Oct CAHN
	TOTECT					
+	CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

AB	MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Aug CAHN
AB		10MG	A076137	002	Jan 18, 2002	Aug CAHN
AB		15MG	A076137	003	Jan 18, 2002	Aug CAHN
AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

	@ COREPHARMA	5MG	A090652	001	Mar 07, 2014	Sep DISC
	@	10MG	A090652	002	Mar 07, 2014	Sep DISC
	@ IDT AUSTRALIA LTD	5MG	A085370	001		Aug CAHN
AA	NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA		10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA		10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	50MG/ML	A207449	001	Oct 21, 2016	Oct NEWA
----	--------------------	---------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986	Sep DISC
--	-----------	---	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;2	N017484	001		
	0MG/100ML;12MG/100ML;260MG/100ML				

Feb CMS1

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;	N018840	001	Jun 29, 1983	
	120MG/100ML;220MG/100ML				

Feb CMS1

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	2.5GM/100ML;450MG/100ML	N016697	001		
----	---	-----------------	-------------------------	---------	-----	--	--

Oct CRLD

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+	HOSPIRA	5GM/100ML;225MG/100ML	N017606	001			
---	---------	-----------------------	---------	-----	--	--	--

Oct CRLD

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

+	HOSPIRA	5GM/100ML;300MG/100ML	N017799	001			
---	---------	-----------------------	---------	-----	--	--	--

Oct CRLD

DIAZEPAM

CONCENTRATE;ORAL

DIAZEPAM INTENSOL

AA	+	WEST-WARD PHARMS INT	5MG/ML	A071415	001	Apr 03, 1987	Nov CAHN
----	---	----------------------	--------	---------	-----	--------------	----------

INJECTABLE;INJECTION

DIAZEPAM

	@	EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan CAHN
--	---	--------------------	--------	---------	-----	--------------	----------

+	HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Nov CPOT	
---	---------	-------------------	---------	-----	--------------	----------	--

+		50MG/10ML (5MG/ML)	A071583	001	Oct 13, 1987	Nov CPOT	
---	--	--------------------	---------	-----	--------------	----------	--

	@	WEST-WARD PHARMS INT	5MG/ML	A070311	001	Dec 16, 1985	Oct CAHN
--	---	----------------------	--------	---------	-----	--------------	----------

	@		5MG/ML	A070312	001	Dec 16, 1985	Oct CAHN
--	---	--	--------	---------	-----	--------------	----------

	@		5MG/ML	A070313	001	Dec 16, 1985	Oct CAHN
--	---	--	--------	---------	-----	--------------	----------

	@		5MG/ML	A071308	001	Jul 17, 1987	Oct CAHN
--	---	--	--------	---------	-----	--------------	----------

	@		5MG/ML	A071309	001	Jul 17, 1987	Oct CAHN
--	---	--	--------	---------	-----	--------------	----------

	@		5MG/ML	A071310	001	Jul 17, 1987	Oct CAHN
--	---	--	--------	---------	-----	--------------	----------

SOLUTION;ORAL

DIAZEPAM

AA		LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun NEWA
----	--	----------------------	---------	---------	-----	--------------	----------

AA	+	ROXANE	5MG/5ML	A070928	001	Apr 03, 1987	Jun CFTG
----	---	--------	---------	---------	-----	--------------	----------

AA	+	WEST-WARD PHARMS INT	5MG/5ML	A070928	001	Apr 03, 1987	Nov CAHN
----	---	----------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

DIAZEPAM

		DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan CMS1
--	--	-----------------	-----	---------	-----	--------------	----------

			5MG	A070228	003	Sep 26, 1985	Jan CMS1
--	--	--	-----	---------	-----	--------------	----------

AB		MAYNE PHARMA	2MG	A071134	001	Feb 03, 1987	Aug CAHN
----	--	--------------	-----	---------	-----	--------------	----------

AB			5MG	A071135	001	Feb 03, 1987	Aug CAHN
----	--	--	-----	---------	-----	--------------	----------

AB			10MG	A071136	001	Feb 03, 1987	Aug CAHN
----	--	--	------	---------	-----	--------------	----------

	@	UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Oct CAHN
--	---	-------------------	-----	---------	-----	--------------	----------

	@		5MG	A070303	001	Dec 20, 1985	Oct CAHN
--	---	--	-----	---------	-----	--------------	----------

	@		10MG	A070304	001	Dec 20, 1985	Oct CAHN
--	---	--	------	---------	-----	--------------	----------

DICHLORPHENAMIDE

TABLET;ORAL

DARANIDE

>A>		@ STRONGBRIDGE US	50MG	N011366	001		Dec CAHN
-----	--	-------------------	------	---------	-----	--	----------

>D>		@ TARO PHARMS NORTH	50MG	N011366	001		Dec CAHN
-----	--	---------------------	------	---------	-----	--	----------

	@		50MG	N011366	001		Nov CAHN
--	---	--	------	---------	-----	--	----------

KEVEYIS

>A>		STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015	Dec CAHN
-----	--	-----------------	------	---------	-----	--------------	----------

>D>		TARO PHARMS NORTH	50MG	N011366	002	Aug 07, 2015	Dec CAHN
-----	--	-------------------	------	---------	-----	--------------	----------

			50MG	N011366	002	Aug 07, 2015	Nov CAHN
--	--	--	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB		BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb NEWA
----	--	----------------	------	---------	-----	--------------	----------

ZIPSOR

AB	+	DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb CFTG
----	---	-------------	------	---------	-----	--------------	----------

FOR SOLUTION;ORAL							
CAMBIA							
AB	+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr CFTG
DICLOFENAC POTASSIUM							
AB		PAR FORM	50MG	A202964	001	May 02, 2016	Apr NEWA
TABLET;ORAL							
CATAFLAM							
		@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Mar DISC
DICLOFENAC POTASSIUM							
AB	+	MYLAN	50MG	A075463	001	Jul 26, 1999	Mar CRLD
		@ SUN PHARM INDS	50MG	A075470	001	Feb 21, 2002	Jun CAHN

DICLOFENAC SODIUM

GEL;TOPICAL							
DICLOFENAC SODIUM							
AB		AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar NEWA
AB		GLENMARK PHARMS LTD	3%	A208301	001	Sep 13, 2016	Aug NEWA
AB		TARO	3%	A206298	001	Apr 28, 2016	Apr NEWA
VOLTAREN							
AB	+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CFTG
SOLUTION;TOPICAL							
DICLOFENAC SODIUM							
AT		AMNEAL PHARMS	1.5%	A206116	001	Sep 02, 2016	Aug NEWA
AT		TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May CAHN
SOLUTION/DROPS;OPHTHALMIC							
DICLOFENAC SODIUM							
AT		RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL							
DICLOFENAC SODIUM							
AB	+	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb CRLD
VOLTAREN-XR							
		@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL							
DICLOFENAC SODIUM AND MISOPROSTOL							
AB		AMNEAL PHARMS	50MG;0.2MG	A203995	001	Nov 25, 2016	Nov NEWA
AB			75MG;0.2MG	A203995	002	Nov 25, 2016	Nov NEWA
AB		EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB			75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL							
DICYCLOMINE HYDROCHLORIDE							
		@ SUN PHARM INDS	10MG	A084505	001	Oct 21, 1986	Mar CAHN
INJECTABLE;INJECTION							
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)							
AP		EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar CMS1
AP		WEST-WARD PHARMS INT	10MG/ML	A040465	001	Jun 30, 2003	Sep CAHN
SYRUP;ORAL							
DICYCLOMINE HYDROCHLORIDE							
+		MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan CRLD
TABLET;ORAL							
DICYCLOMINE HYDROCHLORIDE							
		@ SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985	Mar CAHN

DIENOEST; ESTRADIOL VALERATE

TABLET;ORAL							
ESTRADIOL VALERATE AND DIENOEST							
AB		WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	A202349	001	May 06, 2016	Apr NEWA
NATAZIA							
AB	+	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	N022252	001	May 06, 2010	Apr CFTG

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL							
DIETHYLPROPION HYDROCHLORIDE							
		@ COREPHARMA	25MG	A040828	001	Nov 05, 2008	Mar DISC
TENUATE							
AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Apr CAHN

TABLET;ORAL
TENUATE

AA + ALLERGAN SALES LLC 25MG N011722 002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
TENUATE DOSPAN

AB + ACTAVIS LABS UT INC 75MG N012546 001 Apr CAHN

AB + ALLERGAN SALES LLC 75MG N012546 001 Mar CAHN

DIFLUNISAL

TABLET;ORAL
DIFLUNISAL

@ IDT AUSTRALIA LTD 500MG A074604 001 Jun 10, 1996 May CAHN

DIFLUPREDNATE

EMULSION;OPHTHALMIC
DUREZOL

+ NOVARTIS PHARMS CORP 0.05% N022212 001 Jun 23, 2008 Nov CAHN

DIGOXIN

INJECTABLE;INJECTION
LANOXIN

AP + COVIS PHARMA SARL 0.25MG/ML N009330 002 Jun CAHN

+ COVIS PHARMA SARL 0.1MG/ML N009330 004 Jun CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILACOR XR

@ ALLERGAN SALES LLC 120MG N020092 001 May 29, 1992 Jul CAHN

@ 180MG N020092 002 May 29, 1992 Jul CAHN

@ 240MG N020092 003 May 29, 1992 Jul CAHN

DILTIAZEM HYDROCHLORIDE

@ ACTAVIS LABS FL INC 120MG A074852 001 Oct 10, 1997 Jan DISC

@ 180MG A074852 002 Oct 10, 1997 Jan DISC

@ 240MG A074852 003 Oct 10, 1997 Jan DISC

AB3 VALEANT PHARMS NORTH 120MG A075116 001 Dec 23, 1999 Jan CAHN

AB3 180MG A075116 002 Dec 23, 1999 Jan CAHN

AB3 240MG A075116 003 Dec 23, 1999 Jan CAHN

AB3 300MG A075116 004 Dec 23, 1999 Jan CAHN

DILTZAC

>D> AB4 APOTEX INC 120MG A076395 001 Feb 01, 2006 Dec CAHN

>A> AB4 120MG A076395 001 Feb 01, 2006 Dec CAHN

>D> AB4 180MG A076395 002 Feb 01, 2006 Dec CAHN

>A> AB4 180MG A076395 002 Feb 01, 2006 Dec CAHN

>D> AB4 240MG A076395 003 Feb 01, 2006 Dec CAHN

>A> AB4 240MG A076395 003 Feb 01, 2006 Dec CAHN

>D> AB4 300MG A076395 004 Feb 01, 2006 Dec CAHN

>A> AB4 300MG A076395 004 Feb 01, 2006 Dec CAHN

>D> AB4 360MG A076395 005 Feb 01, 2006 Dec CAHN

>A> AB4 360MG A076395 005 Feb 01, 2006 Dec CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP + AMPHASTAR PHARMS INC 5MG/ML A074617 001 Feb 28, 1996 Jun CAHN

AP + EUROHLTH INTL SARL 5MG/ML A074617 001 Feb 28, 1996 Apr CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE;INTRAVENOUS
IMAGENT

>D> @ IMCOR PHARMS CO 0.92MG/VIAL;0.092MG/VIAL N021191 001 May 31, 2002 Dec CAHN

>A> @ VESSELON SPV LLC 0.92MG/VIAL;0.092MG/VIAL N021191 001 May 31, 2002 Dec CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

+ FERRING PHARMS INC 10MG N020411 001 Mar 30, 1995 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	50MG	A083567	001		Jul	CAHN
@	HIKMA PHARMS	50MG	A083567	001		Feb	CAHN
@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar	CAHN
@		50MG	A089489	001	Jan 02, 1987	Jun	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998	Jun	CAHN
AP	+	EUROHLTH INTL SARL	5MG/ML	A074939	001	Apr 13, 1998	Apr	CAHN
AP		WEST-WARD PHARMS INT	5MG/ML	A074521	001	Oct 18, 1996	Oct	CAHN

TABLET; ORAL

DIPYRIDAMOLE

@	IDT AUSTRALIA LTD	25MG	A086944	002	Apr 16, 1991	May	CAHN
@		50MG	A087562	001	Feb 25, 1992	May	CAHN
@		75MG	A087561	001	Feb 25, 1992	May	CAHN
@	LANNETT	25MG	A040898	001	Apr 23, 2008	Aug	DISC
@		50MG	A040898	002	Apr 23, 2008	Aug	DISC
@		75MG	A040898	003	Apr 23, 2008	Aug	DISC
@	PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990	Jul	DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
@		EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN
AB	MAYNE PHARMA	EQ 100MG BASE	A070173	001	May 31, 1985	Aug	CAHN
AB		EQ 150MG BASE	A070174	001	May 31, 1985	Aug	CAHN
@	SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985	Mar	CAHN
@		EQ 150MG BASE	A070352	001	Dec 17, 1985	Mar	CAHN

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB		WEST-WARD PHARMS INT	250MG	A202652	001	Feb 05, 2014	Nov	CAHN
AB			500MG	A202652	002	Feb 05, 2014	Nov	CAHN
AB		DISULFIRAM						
AB		ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan	CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB		IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Nov	CMFD
	@		EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb	DISC
AB			EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Nov	CMFD
	@		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb	DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

@	TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Jan	CAHN	
AP		WEST-WARD PHARMS INT	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994	Sep	CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016	Jun	NEWA
	80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016	Jun	NEWA
	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016	Jun	NEWA

SOLUTION; IV (INFUSION)

DOCETAXEL

EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan	CAHN
	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan	CAHN
	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan	CAHN

DOFETILIDECAPSULE;ORAL
DOFETILIDE

AB	TIGER PHARMS LLC	0.125MG	A207058	001	Jun 06, 2016	May NEWA
AB		0.25MG	A207058	002	Jun 06, 2016	May NEWA
AB		0.5MG	A207058	003	Jun 06, 2016	May NEWA
	TIKOSYN					
AB	PFIZER	0.125MG	N020931	001	Oct 01, 1999	May CFTG
AB		0.25MG	N020931	002	Oct 01, 1999	May CFTG
AB	+	0.5MG	N020931	003	Oct 01, 1999	May CFTG

DOLASETRON MESYLATEINJECTABLE;INJECTION
ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan CAHN
+		12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan CAHN
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Jan CAHN
@		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jun DISC
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jan CAHN

TABLET;ORAL

ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan CAHN
+		100MG	N020623	002	Sep 11, 1997	Jan CAHN

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jun NEWA
		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb NEWA	
>D>	AB	HIKMA PHARMS	5MG	A090247	001	May 31, 2011	Dec DISC
>A>	@	5MG	A090247	001	May 31, 2011	Dec DISC	
>D>	AB	10MG	A090247	002	May 31, 2011	Dec DISC	
>A>	@	10MG	A090247	002	May 31, 2011	Dec DISC	
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar NEWA	
AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan NEWA	
AB	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Jun CAHN	
AB	UNICHEM LABS LTD	5MG	A203656	001	Jun 23, 2016	Jun NEWA	
AB		10MG	A203656	002	Jun 23, 2016	Jun NEWA	

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

@	SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar CAHN
@		10MG	A077975	001	Dec 11, 2009	Mar CAHN
AB	UNICHEM LABS LTD	5MG	A204831	001	Nov 10, 2016	Oct NEWA
AB		10MG	A204831	002	Nov 10, 2016	Oct NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

	FOREST LABS LLC	10MG;7MG	N206439	003	Jul 18, 2016	Aug NEWA
		10MG;21MG	N206439	004	Jul 18, 2016	Aug NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@	LANNETT HOLDINGS INC	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014	Aug DISC
---	----------------------	-------------------------	---------	-----	--------------	----------

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	+	WEST-WARD PHARMS INT	20MG/ML	N014879	001		Oct	CAHN
		DOXAPRAM HYDROCHLORIDE						
AP		AMPHASTAR PHARMS INC	20MG/ML	A076266	001	Jan 10, 2003	Jun	CAHN
AP		EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Apr	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar CAHN
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar CAHN
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar CAHN
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@	SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar CAHN
@		EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar CAHN
@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar CAHN
@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar CAHN

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan NEWA

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

AB	RISING PHARMS INC	0.5MCG	A201518	001	Sep 09, 2016	Aug NEWA
AB		1MCG	A201518	002	Sep 09, 2016	Aug NEWA
AB		2.5MCG	A201518	003	Sep 09, 2016	Aug NEWA
AB	WEST-WARD PHARMS INT	0.5MCG	A091433	001	Sep 23, 2011	Nov CAHN
AB		1MCG	A091433	002	Jan 14, 2014	Nov CAHN
AB		2.5MCG	A091433	003	Jan 14, 2014	Nov CAHN

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
AP	HECTOROL					
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	May CRLD
AP		200MG/100ML	A203622	002	Jun 27, 2014	May CRLD
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	May CRLD
AP	+	200MG/100ML	N050629	002	May 03, 1988	May CRLD
	@ SANDOZ INC	2MG/ML	A200146	001	Jul 18, 2012	Nov DISC
AP	WEST-WARD PHARMS INT	2MG/ML	A062975	001	Mar 17, 1989	Sep CAHN
AP	+	10MG/VIAL	A062921	001	Mar 17, 1989	Sep CAHN
AP	+	20MG/VIAL	A062921	002	Mar 17, 1989	Sep CAHN
AP	+	50MG/VIAL	A062921	003	Mar 17, 1989	Sep CAHN
AP		200MG/100ML	A064097	001	Sep 13, 1994	Sep CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb NEWA

TABLET; ORAL

DOXYCYCLINE

@	SUN PHARM INDS	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun CAHN
@		EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun CAHN
@		EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

ACTICLATE CAP

+	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr NEWA
---	-------------	--------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

AB	AMNEAL PHARMS	EQ 100MG BASE	A207289	001	Jun 27, 2016	Jun NEWA
AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar CAHN

INJECTABLE; INJECTION									
DOXYCYCLINE									
AP	+	@ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Oct	CAHN	
			EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988	Sep	CAHN	
		@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Oct	CAHN	
		@	EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988	Sep	CAHN	
DOXYCYCLINE HYCLATE									
		@ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	Oct	CAHN	
		@	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	Oct	CAHN	
TABLET; ORAL									
DOXYCYCLINE HYCLATE									
AB		@ COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar	DISC	
		SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar	CAHN	
AB			EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar	CAHN	
		@ VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar	DISC	
TABLET, DELAYED RELEASE; ORAL									
DORYX									
AB		MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jul	CTNA	
AB			EQ 50MG BASE	N050795	006	Dec 19, 2014	May	CFTG	
AB			EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	CFTG	
AB	+		EQ 200MG BASE	N050795	005	Apr 11, 2013	May	CFTG	
DORYX MPC									
	+	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Jul	CTNA	
			EQ 60MG BASE	N050795	007	May 20, 2016	May	NEWA	
			EQ 120MG BASE	N050795	008	May 20, 2016	Nov	CRLD	
			EQ 120MG BASE	N050795	008	May 20, 2016	Jul	CTNA	
			EQ 120MG BASE	N050795	008	May 20, 2016	May	NEWA	
DOXYCYCLINE HYCLATE									
		@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar	DISC	
		@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar	DISC	
AB		MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May	NEWA	
AB			EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	NEWA	
AB			EQ 200MG BASE	A090431	005	May 19, 2016	May	NEWA	
AB		PRINSTON INC	EQ 150MG BASE	A207494	001	Nov 15, 2016	Oct	NEWA	
AB			EQ 200MG BASE	A207494	002	Nov 15, 2016	Oct	NEWA	
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>									
TABLET, DELAYED RELEASE; ORAL									
DICLEGIS									
AB	+	DUCHESNAY	10MG; 10MG	N021876	001	Apr 08, 2013	Aug	CFTG	
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE									
AB		ACTAVIS LABS FL INC	10MG; 10MG	A205811	001	Aug 19, 2016	Aug	NEWA	
TABLET, EXTENDED RELEASE; ORAL									
BONJESTA									
	+	DUCHESNAY	20MG; 20MG	N209661	001	Nov 07, 2016	Nov	NEWA	
<u>DROSPIRENONE; ETHINYL ESTRADIOL</u>									
TABLET; ORAL									
MELAMISA									
AB		NOVAST LABS LTD	3MG; 0.02MG	A202016	001	Jan 26, 2016	Jan	NEWA	
TABLET; ORAL-28									
DROSPIRENONE AND ETHINYL ESTRADIOL									
AB		ACCORD HLTHCARE	3MG; 0.03MG	A207245	001	Nov 22, 2016	Nov	NEWA	
AB		APOTEX INC	3MG; 0.03MG	A205876	001	Sep 21, 2016	Sep	NEWA	
AB		GLENMARK PHARMS LTD	3MG; 0.03MG	A204848	001	Mar 25, 2016	Mar	NEWA	
AB		MAYNE PHARMA	3MG; 0.03MG	A090081	001	Sep 07, 2010	Aug	CAHN	
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM</u>									
TABLET; ORAL									
BEYAZ									
AB		BAYER HLTHCARE	3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG	N022532	001	Sep 24, 2010	Sep	CFTG	
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM									
AB		WATSON LABS INC	3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG	A203593	001	Oct 11, 2016	Sep	NEWA	
AB			3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG	A203594	001	Oct 11, 2016	Sep	NEWA	
SAFYRAL									
AB	+	BAYER HLTHCARE	3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG	N022574	001	Dec 16, 2010	Sep	CFTG	

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

>A>	AB	AJANTA PHARMA LTD	EQ 20MG BASE	A208706	001	Jan 06, 2017	Dec NEWA
>A>	AB		EQ 30MG BASE	A208706	002	Jan 06, 2017	Dec NEWA
>A>	AB		EQ 60MG BASE	A208706	003	Jan 06, 2017	Dec NEWA
	AB	HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul NEWA
	AB		EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul NEWA
	AB		EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul NEWA

DUTASTERIDECAPSULE;ORAL
DUTASTERIDE

AB	ASCENT PHARMS INC	0.5MG	A206574	001	Oct 21, 2016	Oct NEWA
AB	AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr CAHN
AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA
AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May NEWA
AB	STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar CAHN
AB	WEST-WARD PHARMS INT	0.5MG	A202204	001	Nov 23, 2015	Nov CAHN

DYPHYLLINETABLET;ORAL
LUFYLLIN

@	MEDA PHARMS	200MG	A084566	001		Jun DISC
@		400MG	A084566	002		Jun DISC

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL
ECOZA

+	EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013	Jul CAHN
AB	TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May CAHN
	SPECTAZOLE					
@	ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Jul CAHN

EDROPHONIUM CHLORIDEINJECTABLE;INJECTION
TENSILON PRESERVATIVE FREE

@	TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan CAHN
---	---------------------	---------	---------	-----	--	----------

EFAVIRENZTABLET;ORAL
EFAVIRENZ

AB	MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb NEWA
AB	MYLAN PHARMS INC	600MG	A091471	001	Feb 17, 2016	Jun CAHN
	SUSTIVA					
AB	+ BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb CFTG

ELBASVIR; GRAZOPREVRTABLET;ORAL
ZEPATIER

+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan NEWA
---	-------------------	------------	---------	-----	--------------	----------

ELUXADOLINETABLET;ORAL
VIBERZI

	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015	May CAHN
+		100MG	N206940	002	May 27, 2015	May CAHN

EMEDASTINE DIFUMARATESOLUTION/DROPS;OPHTHALMIC
EMADINE

+	NOVARTIS PHARMS CORP	0.05%	N020706	001	Dec 29, 1997	Nov CAHN
---	----------------------	-------	---------	-----	--------------	----------

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

>A>	TABLET, EXTENDED RELEASE;ORAL						
>A>	SYNJARDY XR						
>A>	BOEHRINGER INGELHEIM	5MG;1GM	N208658	001	Dec 09, 2016	Dec	NEWA
>A>		10MG;1GM	N208658	002	Dec 09, 2016	Dec	NEWA
>A>		12.5MG;1GM	N208658	003	Dec 09, 2016	Dec	NEWA
>A>	+	25MG;1GM	N208658	004	Dec 09, 2016	Dec	NEWA

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
ODEFSEY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Apr	CAIN
---	---------------------	---------------------------------	---------	-----	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
ODEFSEY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Mar	NEWA
---	---------------------	---------------------------------	---------	-----	--------------	-----	------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
DESCOVY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Apr	NEWA
---	---------------------	--------------------	---------	-----	--------------	-----	------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TRUVADA

GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Mar	NEWA
	133MG;200MG	N021752	003	Mar 10, 2016	Mar	NEWA
	167MG;250MG	N021752	004	Mar 10, 2016	Mar	NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL
EPANED

SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016	Sep	NEWA
-------------------	--------	---------	-----	--------------	-----	------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D> AB	APOTEX INC	5MG;12.5MG	A076486	001	Oct 27, 2004	Dec	CAHN
>A> AB		5MG;12.5MG	A076486	001	Oct 27, 2004	Dec	CAHN
>D> AB		10MG;25MG	A076486	002	Oct 27, 2004	Dec	CAHN
>A> AB		10MG;25MG	A076486	002	Oct 27, 2004	Dec	CAHN
	@ UPSHER-SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001	Oct	CAHN
	@	10MG;25MG	A076116	002	Sep 19, 2001	Oct	CAHN

ENALAPRILAT

INJECTABLE;INJECTION
ENALAPRILAT

AP	+	AMPHASTAR PHARMS INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jun	CAHN
AP	+	EUROHLTH INTL SARL	1.25MG/ML	A075634	001	Aug 22, 2000	Apr	CAHN

ENFLURANE

LIQUID;INHALATION
ENFLURANE

@ PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994	Aug	DISC
--------------------	-------	---------	-----	--------------	-----	------

ENTECAVIR

TABLET;ORAL
ENTECAVIR

AB		CIPLA LTD	0.5MG	A206872	001	Dec 06, 2016	Nov	NEWA
AB			1MG	A206872	002	Dec 06, 2016	Nov	NEWA
AB		PAR PHARM INC	0.5MG	A206294	001	Nov 23, 2016	Nov	NEWA
AB			1MG	A206294	002	Nov 23, 2016	Nov	NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS
AKOVAZ

+	FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016	Apr	NEWA
---	--------------------	---------	---------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	ALCON RES LTD	0.05%	A203384	001	Dec 07, 2016	Nov NEWA
AT	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Mar CAHN

EPINEPHRINE

INJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE

@	FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999	Mar CMS1
@		5MG/ML	N007942	001		Mar CMS1

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q

BX	+ KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Mar CAHN
BX		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Mar CAHN

TWINJECT 0.15						
@ AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May DISC	

TWINJECT 0.3						
@ AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May DISC	

SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul CAIN	
--------------------	---------------------------------	---------	-----	--------------	----------	--

EPINEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb CDFR	
--------------------	---------------------------------	---------	-----	--------------	----------	--

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

AP	IMPAX LABS INC	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Aug CAHN
AP		200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Aug CAHN
AP	WEST-WARD PHARMS INT	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007	Sep CAHN
AP		200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007	Sep CAHN

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	Nov NEWA
AP		75MG/100ML	A205581	002	Dec 08, 2016	Nov NEWA
	@ TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015	Aug DISC

ERGOCALCIFEROL

CAPSULE;ORAL
DRISDOL

AA	+ US PHARM HOLDINGS	50,000 IU	N003444	001		Jan CAHN
	VITAMIN D					
AA	BIONPHARMA INC	50,000 IU	A080704	001		Jan CAHN

ERGOLOID MESYLATES

TABLET;ORAL
ERGOLOID MESYLATES

AB	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar CAHN
----	----------------	-----	---------	-----	--------------	----------

TABLET;SUBLINGUAL
ERGOLOID MESYLATES

@	SUN PHARM INDS	0.5MG	A087407	001		Jun CAHN
@		1MG	A087552	001		Jun CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL
ERGOMAR

+	TERSERA THERAP	2MG	A087693	001	Feb 24, 1983	Aug CAHN
---	----------------	-----	---------	-----	--------------	----------

ERYTHROMYCIN

SOLUTION;TOPICAL
C-SOLVE-2

@	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb DISC
---	----------------	----	---------	-----	--------------	----------

ERYTHRO-STATIN

@	HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb DISC
---	----------------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan CRLD
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan CRLD

ESCITALOPRAM OXALATE

SOLUTION; ORAL
ESCITALOPRAM OXALATE

AA		MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar NEWA
----	--	---------------------	-----------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
ESMOLOL HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	10MG/ML	A076323	001	Aug 10, 2004	Oct CAHN
----	--	----------------------	---------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr NEWA
---	-----------------	---------------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

+	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun CRLD
---	-----------------	-----------------------	---------	-----	--------------	----------

		2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr NEWA
--	--	-----------------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr NEWA
----	--	----------------------	--------------	---------	-----	--------------	----------

AB			EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr NEWA
----	--	--	--------------	---------	-----	--------------	----------

BX		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr CTEC
----	--	---------------------	--------------	---------	-----	--------------	----------

BX			EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr CTEC
----	--	--	--------------	---------	-----	--------------	----------

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Jul NEWA
----	--	----------------------	-------------------	---------	-----	--------------	----------

AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul NEWA
----	--	--	-------------------	---------	-----	--------------	----------

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE STRONTIUM

>D>		HANMI PHARM CO LTD	24.65MG	N202342	001	Aug 06, 2013	Dec CAHN
-----	--	--------------------	---------	---------	-----	--------------	----------

>D>	+		49.3MG	N202342	002	Aug 06, 2013	Dec CAHN
-----	---	--	--------	---------	-----	--------------	----------

>A>		R2 PHARMA LLC	24.65MG	N202342	001	Aug 06, 2013	Dec CAHN
-----	--	---------------	---------	---------	-----	--------------	----------

>A>	+		49.3MG	N202342	002	Aug 06, 2013	Dec CAHN
-----	---	--	--------	---------	-----	--------------	----------

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

AB		MAYNE PHARMA	1MG	A074921	001	Jul 10, 1997	Aug CAHN
----	--	--------------	-----	---------	-----	--------------	----------

AB	+		2MG	A074921	002	Jul 10, 1997	Aug CAHN
----	---	--	-----	---------	-----	--------------	----------

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr CAHN
---	--------------------	-------	---------	-----	--------------	----------

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

BX		ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
----	--	--------------------	--------------	---------	-----	--------------	----------

BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
----	--	--	-------------	---------	-----	--------------	----------

BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
----	--	--	--------------	---------	-----	--------------	----------

BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN
----	--	--	------------	---------	-----	--------------	----------

TABLET; ORAL

ESTRADIOL

AB		EPIC PHARMA INC	0.5MG	A040275	001	Dec 29, 1998	Oct CMFD
----	--	-----------------	-------	---------	-----	--------------	----------

AB			1MG	A040275	002	Dec 29, 1998	Oct CMFD
----	--	--	-----	---------	-----	--------------	----------

AB			2MG	A040275	003	Dec 29, 1998	Oct CMFD
----	--	--	-----	---------	-----	--------------	----------

AB		MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Aug CAHN
----	--	--------------	-------	---------	-----	--------------	----------

AB			1MG	A040114	001	Mar 14, 1996	Aug CAHN
----	--	--	-----	---------	-----	--------------	----------

AB			2MG	A040114	002	Mar 14, 1996	Aug CAHN
----	--	--	-----	---------	-----	--------------	----------

TABLET; VAGINAL

ESTRADIOL

AB		AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	Aug CMFD
----	--	---------------	-------	---------	-----	--------------	----------

TABLET;VAGINAL									
VAGIFEM									
AB	+	NOVO NORDISK INC	10MCG		N020908	002	Nov 25, 2009	Aug	CTEC
<u>ESTRADIOL ACETATE</u>									
INSERT, EXTENDED RELEASE;VAGINAL									
FEMRING									
		APIL	EQ 0.05MG BASE/24HR		N021367	001	Mar 20, 2003	Jan	CAHN
	+		EQ 0.1MG BASE/24HR		N021367	002	Mar 20, 2003	Jan	CAHN
TABLET;ORAL									
FEMTRACE									
		APIL	0.45MG		N021633	001	Aug 20, 2004	Jan	CAHN
			0.9MG		N021633	002	Aug 20, 2004	Jan	CAHN
	+		1.8MG		N021633	003	Aug 20, 2004	Jan	CAHN
<u>ESTRADIOL HEMIHYDRATE</u>									
EMULSION;TOPICAL									
ESTRASORB									
	+	EXELTIS USA INC	0.25%		N021371	001	Oct 09, 2003	Jun	CAHN
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>									
TABLET;ORAL									
AMABELZ									
AB		LUPIN LTD	0.5MG;0.1MG		A203339	001	Jun 20, 2016	Jun	NEWA
AB			1MG;0.5MG		A203339	002	Jun 20, 2016	Jun	NEWA
<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>									
TABLET;ORAL									
CENESTIN									
	@	TEVA BRANDED PHARM	0.3MG		N020992	001	Jun 21, 2002	Jun	DISC
	@		0.45MG		N020992	005	Feb 05, 2004	Jun	DISC
	@		0.625MG		N020992	002	Mar 24, 1999	Jun	DISC
	@		0.9MG		N020992	003	Mar 24, 1999	Jun	DISC
	@		1.25MG		N020992	004	Mar 13, 2000	Jun	DISC
<u>ESTROGENS, CONJUGATED SYNTHETIC B</u>									
TABLET;ORAL									
ENJUVIA									
	@	TEVA WOMENS	0.625MG		N021443	003	May 10, 2004	Jun	DISC
	@		1.25MG		N021443	004	May 10, 2004	Sep	DISC
<u>ESZOPICLONE</u>									
TABLET;ORAL									
ESZOPICLONE									
AB		AUROBINDO PHARMA LTD	1MG		A208451	001	Sep 15, 2016	Sep	NEWA
AB			2MG		A208451	002	Sep 15, 2016	Sep	NEWA
AB			3MG		A208451	003	Sep 15, 2016	Sep	NEWA
AB		WEST-WARD PHARMS INT	1MG		A091153	001	Apr 15, 2014	Nov	CAHN
AB			2MG		A091153	002	Apr 15, 2014	Nov	CAHN
AB			3MG		A091153	003	Apr 15, 2014	Nov	CAHN
<u>ETEPLIRSEN</u>									
SOLUTION;IV (INFUSION)									
EXONDYS 51									
	+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)		N206488	001	Sep 19, 2016	Sep	NEWA
	+		500MG/10ML (50MG/ML)		N206488	002	Sep 19, 2016	Sep	NEWA
<u>ETHACRYNATE SODIUM</u>									
INJECTABLE;INJECTION									
ETHACRYNATE SODIUM									
AP		MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL		A204634	001	Aug 23, 2016	Aug	NEWA
<u>ETHACRYNIC ACID</u>									
TABLET;ORAL									
EDECIN									
AB	+	ATON	25MG		N016092	001		Jun	CFTG
ETHACRYNIC ACID									
AB		EDENBRIDGE PHARMS	25MG		A205609	001	Jun 30, 2016	Jun	NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan NEWA
	ZOVIA 1/35E-28					
AB	MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Aug CAHN
	ZOVIA 1/50E-28					
AB	+ WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM

AB	LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB	AMNEAL PHARMS	0.03MG;0.15MG	A203871	001	Nov 13, 2015	Jul CAHN
AB		0.03MG,0.01MG;0.15MG,N/A	A203872	001	Dec 22, 2015	Nov CAHN
AB	HAUPT PHARMA	0.03MG,0.01MG;0.15MG,N/A	A203872	001	Dec 22, 2015	Jul CMS1
AB	MAYNE PHARMA	0.02MG,0.01MG;0.1MG,N/A	A200407	001	Oct 25, 2011	Aug CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
AB	MAYNE PHARMA	0.03MG,0.01MG;0.15MG,N/A	A078834	001	May 31, 2011	Aug CAHN
	QUARTETTE					
AB	+ TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar CFTG

TABLET;ORAL-21

TRIVORA-21

	@ MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997	Aug CAHN
--	----------------	---	---------	-----	--------------	----------

TABLET;ORAL-28

AFIRMELLE

AB1	AUROBINDO PHARMA LTD	0.02MG;0.1MG	A206886	001	Nov 14, 2016	Oct NEWA
	AYUNA					
AB	AUROBINDO PHARMA LTD	0.03MG;0.15MG	A206866	001	Sep 23, 2016	Sep NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	May CAHN
AB		0.03MG;0.15MG	A201095	001	Dec 08, 2014	Jul CAHN
AB1	+ MAYNE PHARMA	0.02MG;0.1MG	A076625	001	Nov 18, 2004	Aug CAHN
AB2	+	0.02MG;0.1MG	A077681	001	May 31, 2006	Aug CAHN
	LEVORA 0.15/30-28					
AB	+ MAYNE PHARMA	0.03MG;0.15MG	A073594	001	Dec 13, 1993	Aug CAHN
	TRIVORA-28					
AB	+ MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	002	Dec 18, 1997	Aug CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

	@ ALLERGAN SALES LLC	0.035MG;0.5MG	N017566	001		Apr CAHN
	NORINYL 1+35 21-DAY					
AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar CAHN
	TRI-NORINYL 21-DAY					
	@ MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984	Aug CAHN

TABLET;ORAL-28

BREVICON 28-DAY

AB	ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar CAHN
	CYONANZ					
AB	AUROBINDO PHARMA LTD	0.035MG;0.5MG	A207055	001	Oct 21, 2016	Oct NEWA
	NORETHINDRONE AND ETHINYL ESTRADIOL					
AB	MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Aug CAHN
	NORINYL 1+35 28-DAY					
AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar CAHN
	NYLIA 1/35					
AB	AUROBINDO PHARMA LTD	0.035MG;1MG	A207056	001	Oct 21, 2016	Oct NEWA
	NYLIA 7/7/7					
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A207054	001	Oct 21, 2016	Oct NEWA
	TRI-NORINYL 28-DAY					
AB	+ MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Aug CAHN

TABLET, CHEWABLE; ORAL
FEMCON FE

AB	+	APIL	0.035MG; 0.4MG	N021490	001	Nov 14, 2003	Jan CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+	APIL	0.025MG; 0.8MG	N022573	001	Dec 22, 2010	Jan CAHN
AB		LUPIN LTD	0.035MG; 0.4MG	A091332	001	Mar 23, 2016	Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL
TAYTULLA

	+	APIL	0.02MG; 1MG	N204426	001	Apr 19, 2013	Aug CTNA
	@		0.02MG; 1MG	N204426	001	Apr 19, 2013	Apr CAHN

TABLET; ORAL
FEMHRT

AB		APIL	0.0025MG; 0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
LERIBANE							
AB		NOVAST LABS LTD	0.0025MG; 0.5MG	A203435	002	Jun 03, 2016	May NEWA
AB			0.005MG; 1MG	A203435	001	Jun 03, 2016	May NEWA

LO LOESTRIN FE

AB	+	APIL	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010	May CFTG
	+		0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010	Jan CAHN

LOESTRIN 24 FE

AB		APIL	0.02MG; 1MG	N021871	001	Feb 17, 2006	Aug CAHN
----	--	------	-------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

>A> AB		JAI PHARMA LTD	0.005MG; 1MG	A207259	001	Dec 27, 2016	Dec NEWA
--------	--	----------------	--------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		JAI PHARMA LTD	0.01MG, 0.01MG; 1MG, N/A	A205049	001	May 31, 2016	May NEWA
----	--	----------------	--------------------------	---------	-----	--------------	----------

TABLET; ORAL-21

LOESTRIN 21 1.5/30

AB		APIL	0.03MG; 1.5MG	N017875	001		Apr CAHN
----	--	------	---------------	---------	-----	--	----------

LOESTRIN 21 1/20

AB		APIL	0.02MG; 1MG	N017876	001		Apr CAHN
----	--	------	-------------	---------	-----	--	----------

MICROGESTIN 1.5/30

AB		MAYNE PHARMA	0.03MG; 1.5MG	A075548	002	Jul 30, 2003	Aug CAHN
----	--	--------------	---------------	---------	-----	--------------	----------

MICROGESTIN 1/20

AB		MAYNE PHARMA	0.02MG; 1MG	A075647	002	Jul 30, 2003	Aug CAHN
----	--	--------------	-------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	0.02MG; 1MG	A206969	001	Jan 20, 2016	Jan NEWA
----	--	---------------------	-------------	---------	-----	--------------	----------

TABLET; ORAL-28

ESTROSTEP FE

AB	+	APIL	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N020130	002	Oct 09, 1996	Jan CAHN
----	---	------	--	---------	-----	--------------	----------

LOESTRIN FE 1.5/30

AB	+	APIL	0.03MG; 1.5MG	N017355	001		Apr CAHN
----	---	------	---------------	---------	-----	--	----------

LOESTRIN FE 1/20

AB		APIL	0.02MG; 1MG	N017354	001		Apr CAHN
----	--	------	-------------	---------	-----	--	----------

MICROGESTIN FE 1.5/30

AB		MAYNE PHARMA	0.03MG; 1.5MG	A075548	001	Feb 05, 2001	Aug CAHN
----	--	--------------	---------------	---------	-----	--------------	----------

MICROGESTIN FE 1/20

AB		MAYNE PHARMA	0.02MG; 1MG	A075647	001	Feb 05, 2001	Aug CAHN
----	--	--------------	-------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		MAYNE PHARMA	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A076629	001	Mar 18, 2010	Aug CAHN
----	--	--------------	--	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

MIBELAS 24 FE

AB		LUPIN ATLANTIS	0.02MG; 1MG	A206287	001	May 24, 2016	May NEWA
----	--	----------------	-------------	---------	-----	--------------	----------

MINASTRIN 24 FE

AB	+	APIL	0.02MG; 1MG	N203667	001	May 08, 2013	May CFTG
	+		0.02MG; 1MG	N203667	001	May 08, 2013	Jan CAHN

TABLET, CHEWABLE, TABLET; ORAL

LO MINASTRIN FE

	+	APIL	0.01MG, 0.01MG, N/A; 1MG, N/A, N/A	N204654	001	Jul 24, 2013	Jan CAHN
--	---	------	------------------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MILI

AB		AUROBINDO PHARMA LTD	0.035MG; 0.25MG	A205449	001	Jul 07, 2016	Jun NEWA
----	--	----------------------	-----------------	---------	-----	--------------	----------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		AMNEAL PHARMS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.25MG, 0.25MG	A203870	001	Nov 12, 2015	Sep CAHN
----	--	---------------	---	---------	-----	--------------	----------

AB			0.035MG; 0.25MG	A203865	001	Oct 27, 2015	May CAHN
----	--	--	-----------------	---------	-----	--------------	----------

AB		GLENMARK PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.25MG, 0.25MG	A204057	001	Feb 23, 2016	Jun CAHN
----	--	-----------------	---	---------	-----	--------------	----------

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016	Feb NEWA
AB	HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016	May NEWA
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016	Jan NEWA
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan NEWA
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205588	001	Apr 26, 2016	Apr NEWA
AB		0.035MG;0.25MG	A205630	001	Oct 27, 2016	Oct NEWA
	TRI-LO-MILI					
AB	AUROBINDO PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A205762	001	Nov 04, 2016	Oct NEWA
	TRI-MILI					
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205441	001	Jul 06, 2016	Jun NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

@ PELAGIUS

LOW-OGESTREL-21

@ MAYNE PHARMA

TABLET;ORAL-28

LO/OVRAL-28

@ WYETH PHARMS

LOW-OGESTREL-28

AB	MAYNE PHARMA	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Aug CAHN
	NORGESTREL AND ETHINYL ESTRADIOL					
AB	JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun NEWA

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001		Aug CPOT
---	---------	---	---------	-----	--	----------

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

ETIDRONATE DISODIUM

TABLET;ORAL

DIDRONEL

AB	APIL	200MG	N017831	001		Apr CAHN
AB	+	400MG	N017831	002		Apr CAHN

ETODOLAC

CAPSULE;ORAL

ETODOLAC

@ IDT AUSTRALIA LTD

@

@ LEHIGH VALLEY

TABLET;ORAL

ETODOLAC

>D>	AB	APOTEX INC	400MG	A076004	001	Dec 03, 2002	Dec CAHN
>A>	AB		400MG	A076004	001	Dec 03, 2002	Dec CAHN
>D>	AB		500MG	A076004	002	Dec 03, 2002	Dec CAHN
>A>	AB		500MG	A076004	002	Dec 03, 2002	Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

@ IDT AUSTRALIA LTD

@

@

400MG	A075943	001	Jul 26, 2002	Aug CAHN
500MG	A075943	002	Jul 26, 2002	Aug CAHN
600MG	A075943	003	Jul 26, 2002	Aug CAHN

ETOMIDATEINJECTABLE; INJECTION
ETOMIDATE

AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb NEWA
----	--------------------	--------	---------	-----	--------------	----------

ETOPOSIDEINJECTABLE; INJECTION
ETOPOSIDE

AP	WEST-WARD PHARMS INT	20MG/ML	A074290	001	Jul 17, 1995	Sep CAHN
----	----------------------	---------	---------	-----	--------------	----------

EXEMESTANETABLET; ORAL
EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN
AB	WEST-WARD PHARMS INT	25MG	A077431	001	Apr 01, 2011	Nov CAHN

EXENATIDE SYNTHETICFOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb NEWA
---	----------------	-----	---------	-----	--------------	----------

EZETIMIBETABLET; ORAL
EZETIMIBE

AB	GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Oct CMFD
----	---------------------	------	---------	-----	--------------	----------

AB	+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Oct CTEC
----	---	---------------	------	---------	-----	--------------	----------

FAMCICLOVIRTABLET; ORAL
FAMCICLOVIR

AB	WEST-WARD PHARMS INT	125MG	A090128	001	Mar 21, 2011	Nov CAHN
AB		250MG	A090128	002	Mar 21, 2011	Nov CAHN
AB		500MG	A090128	003	Mar 21, 2011	Nov CAHN

FAMOTIDINEINJECTABLE; INJECTION
FAMOTIDINE

AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN

	FAMOTIDINE PRESERVATIVE FREE					
AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET; ORAL
FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar CAHN
@		40MG	A075639	001	Dec 12, 2001	Mar CAHN

FELBAMATETABLET; ORAL
FELBAMATE

AB	ALVOGEN MALTA	400MG	A204595	001	Jan 11, 2016	Aug CAHN
AB		600MG	A204595	002	Jan 11, 2016	Aug CAHN

FELODIPINETABLET, EXTENDED RELEASE; ORAL
FELODIPINE

AB	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Aug NEWA
AB		5MG	A203983	002	Aug 19, 2016	Aug NEWA
AB		10MG	A203983	003	Aug 19, 2016	Aug NEWA
AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB	RHODES PHARMS	67MG	A075753	001	Sep 03, 2002	Nov CAHN
AB		134MG	A075753	002	Apr 09, 2002	Nov CAHN
AB	+	200MG	A075753	003	Apr 09, 2002	Nov CAHN

TABLET;ORAL

FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA
AB		145MG	A205118	002	May 05, 2016	Apr NEWA
>A> AB	CIPLA LTD	48MG	A208709	001	Dec 15, 2016	Dec NEWA
>A> AB		145MG	A208709	002	Dec 15, 2016	Dec NEWA
AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun NEWA
AB		145MG	A204598	002	Jul 12, 2016	Jun NEWA
AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun NEWA
AB		120MG	A204475	002	Jun 23, 2016	Jun NEWA
AB	RHODES PHARMS	54MG	A076433	001	May 13, 2005	Nov CAHN
AB	+	160MG	A076433	002	May 13, 2005	Nov CAHN
FENOGLIDE						
AB	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun CFTG
AB	+	120MG	N022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

	ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Apr CAHN
+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Oct CAHN
----	----------------------	-----------------	---------	-----	--------------	----------

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar CAHN
@	EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN
@ SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Oct NEWA
FENTANYL-12						
AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Oct NEWA
AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan NEWA
FENTANYL-25						
AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Oct NEWA
FENTANYL-50						
AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Oct NEWA
FENTANYL-75						
AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Oct NEWA

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Oct CAHN
----	---	----------------------	-------------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr NEWA
---	----------------------	-------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

@ ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan DISC
@	8MG	A204827	002	Dec 10, 2015	Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar DISC
@ IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar DISC

FINAFLOXACIN

SUSPENSION/DROPS;OTIC
XTORO

+ NOVARTIS PHARMS CORP	0.3%	N206307	001	Dec 17, 2014	Nov CAHN
------------------------	------	---------	-----	--------------	----------

FINASTERIDE

TABLET;ORAL
FINASTERIDE

>A> AB	ALKEM LABS LTD	1MG	A207750	001	Jan 06, 2017	Dec NEWA
>A> AB		5MG	A204304	001	Jan 05, 2017	Dec NEWA

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS
SMOFLIPID 20%

+ FRESenius KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001	Jul 13, 2016	Jul NEWA
+	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002	Jul 13, 2016	Jul NEWA
+	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003	Jul 13, 2016	Jul NEWA

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL
FLAVOXATE HYDROCHLORIDE
@ IMPAX PHARMS

100MG	A076234	001	Aug 28, 2003	Mar DISC
-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET;ORAL
FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May CAHN
@	100MG	A076030	002	Oct 28, 2002	May CAHN
@	150MG	A076030	003	Oct 28, 2002	May CAHN
AB WEST-WARD PHARMS INT	50MG	A076278	001	Jan 14, 2003	Nov CAHN
AB	100MG	A076278	002	Jan 14, 2003	Nov CAHN
AB +	150MG	A076278	003	Jan 14, 2003	Nov CAHN
TAMBOCOR					
AB CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Oct CMFD
AB	100MG	N018830	001	Oct 31, 1985	Oct CMFD
AB	150MG	N018830	003	Jun 03, 1988	Oct CMFD

FLORBETAPIR F-18

SOLUTION;INTRAVENOUS
AMYVID

@ AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012	Sep DISC
------------------------	----------------------	---------	-----	--------------	----------

FLOXURIDINE

INJECTABLE;INJECTION
FLOXURIDINE

AP + WEST-WARD PHARMS INT	500MG/VIAL	A075387	001	Apr 16, 2000	Oct CAHN
---------------------------	------------	---------	-----	--------------	----------

FLUCICLOVINE F-18

SOLUTION;INTRAVENOUS
AXUMIN

+ BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May NEWA
--------------	-------------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

	@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC
	@	200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC
AB	WEST-WARD PHARMS INT	50MG/5ML	A076246	001	Jul 29, 2004	Nov	CAHN
AB		200MG/5ML	A076246	002	Jul 29, 2004	Nov	CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan	DISC
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan	DISC
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CMS1
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CMS1

TABLET; ORAL

FLUCONAZOLE

	@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May	CAHN
	@	100MG	A076086	002	Jul 29, 2004	May	CAHN
	@	150MG	A076086	003	Jul 29, 2004	May	CAHN
	@	200MG	A076086	004	Jul 29, 2004	May	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP	SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003	Aug	CAHN
AP		50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Aug	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar	NEWA
AP	MEM SLOAN-KETTERING	20-300mCi/ML	A208679	001	Dec 08, 2016	Nov	NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar	CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb	CAHN

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

>D>	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Dec	CAHN
>A>	+	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Dec	CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr	NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr	NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May	NEWA
AT		0.01%	A209336	001	May 19, 2016	May	NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr	NEWA
----	------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

AT	ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Oct	NEWA
AT	G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Sep	NEWA

FLUOCINONIDE

OINTMENT; TOPICAL

LIDEX

AB	CNTY LINE PHARMS	0.05%	N016909	002		Sep	CMFD
----	------------------	-------	---------	-----	--	-----	------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCITE

AP	+ NOVARTIS PHARMS CORP	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Nov	CAHN
----	------------------------	--------------------------------------	---------	-----	--------------	-----	------

FLUOROMETHOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
FLAREX

+	NOVARTIS PHARMS CORP	0.1%	N019079	001	Feb 11, 1986	Nov CAHN
---	----------------------	------	---------	-----	--------------	----------

FLUOROURACILINJECTABLE;INJECTION
FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
+	SPECTRUM PHARMS	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016	Nov NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

@	SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar CAHN
@		EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar CAHN

FLUOXETINE HYDROCHLORIDE

MYLAN	EQ 10MG BASE	A078045	001	Nov 17, 2008	Sep CTEC
-------	--------------	---------	-----	--------------	----------

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

@	LANNETT	EQ 20MG BASE/5ML	A076458	001	May 14, 2004	Aug DISC
---	---------	------------------	---------	-----	--------------	----------

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

+	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar CRLD	
AB	+	MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001	Aug CTEC
AB		PAR FORM	EQ 10MG BASE	A203836	001	Aug 19, 2016	Aug NEWA
AB			EQ 20MG BASE	A203836	002	Aug 19, 2016	Aug NEWA
AB1		TORRENT PHARMS LTD	EQ 10MG BASE	A206937	001	Oct 21, 2016	Oct NEWA
AB1			EQ 20MG BASE	A206937	002	Oct 21, 2016	Oct NEWA
	SARAFEM						
AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN	
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN	
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN	

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO	WEST-WARD PHARMS INT	25MG/ML	A074531	001	Aug 30, 1996	Sep CAHN
----	----------------------	---------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	LANNETT	1MG	A089743	002	Aug 25, 1988	Sep NEWA
AB		2.5MG	A089743	003	Aug 25, 1988	Sep NEWA
AB		5MG	A089743	004	Aug 25, 1988	Sep NEWA
AB	SANDOZ	1MG	A089586	002	Oct 16, 1987	Oct CMS1
AB		2.5MG	A089586	003	Oct 16, 1987	Oct CMS1
AB		5MG	A089586	004	Oct 16, 1987	Oct CMS1

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

AT	+	AQUA PHARMS	0.05%	N012806	002	Mar CFTG
----	---	-------------	-------	---------	-----	----------

FLURANDRENOLIDE

AT		TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

LOTION;TOPICAL

CORDRAN

AT	+	AQUA PHARMS	0.05%	N013790	001	Aug CTEC
----	---	-------------	-------	---------	-----	----------

FLURANDRENOLIDE

AT		PERRIGO UK FINCO	0.05%	A207133	001	Aug 30, 2016	Aug NEWA
>A> AT		TELIGENT PHARMA INC	0.05%	A205343	001	Dec 22, 2016	Dec NEWA

OINTMENT;TOPICAL

CORDRAN

>D>	+	AQUA PHARMS	0.05%	N012806	001	Dec CFTG	
>A> AT	+		0.05%	N012806	001	Dec CFTG	
>A>		FLURANDRENOLIDE					
>A> AT		TELIGENT PHARMA INC	0.05%	A207851	001	Dec 30, 2016	Dec NEWA

TAPE; TOPICAL		CORDRAN							
	+	ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001			Apr	CAHN
<u>FLURANDRENOLIDE; NEOMYCIN SULFATE</u>									
CREAM; TOPICAL		CORDRAN N							
	@	LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001			Mar	CMS1
OINTMENT; TOPICAL		CORDRAN N							
	@	LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001			Mar	CMS1
<u>FLURAZEPAM HYDROCHLORIDE</u>									
CAPSULE; ORAL		FLURAZEPAM HYDROCHLORIDE							
	@	AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb	CAHN	
	@		30MG	A071717	001	Jul 31, 1991	Feb	CAHN	
	@	HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May	CAHN	
	@	SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986	Mar	CAHN	
	@		30MG	A070455	001	Aug 04, 1986	Mar	CAHN	
<u>FLURBIPROFEN</u>									
TABLET; ORAL		FLURBIPROFEN							
	@	AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb	CAHN	
	@		100MG	A074448	002	Jul 28, 1995	Feb	CAHN	
<u>FLUTAMIDE</u>									
CAPSULE; ORAL		FLUTAMIDE							
AB	+	CIPLA LTD	125MG	A075780	001	Sep 19, 2001	Sep	CAHN	
<u>FLUTICASONE FUROATE</u>									
POWDER; INHALATION		ARNUITY ELLIPTA							
	+	GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Mar	CRLD	
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE</u>									
POWDER; INHALATION		BREO ELLIPTA							
	+	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar	CRLD	
<u>FLUTICASONE PROPIONATE</u>									
SPRAY, METERED; NASAL		FLONASE							
	@	GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jun	DISC	
		FLUTICASONE PROPIONATE							
AB		APOTEX INC	0.05MG/SPRAY	A077538	001	Sep 12, 2007	Dec	CAHN	
AB			0.05MG/SPRAY	A077538	001	Sep 12, 2007	Dec	CAHN	
AB		WEST-WARD PHARMS INT	0.05MG/SPRAY	A076504	001	Feb 22, 2006	Nov	CAHN	
<u>FLUVASTATIN SODIUM</u>									
TABLET, EXTENDED RELEASE; ORAL		FLUVASTATIN SODIUM							
AB		MYLAN PHARMS INC	EQ 80MG BASE	A202458	001	Sep 11, 2015	May	CPOT	
AB		TEVA PHARMS USA	EQ 80MG BASE	A079011	001	Jan 27, 2016	May	CPOT	
AB			80MG	A079011	001	Jan 27, 2016	Jan	NEWA	
		LESCOL XL							
AB	+	NOVARTIS	EQ 80MG BASE	N021192	001	Oct 06, 2000	May	CPOT	
<u>FLUVOXAMINE MALEATE</u>									
TABLET; ORAL		FLUVOXAMINE MALEATE							
	@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb	CAHN	
	@		50MG	A075900	002	Feb 23, 2006	Feb	CAHN	
	@		100MG	A075900	003	Feb 23, 2006	Feb	CAHN	
	@	SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar	CAHN	
	@		50MG	A076125	002	Apr 29, 2002	Mar	CAHN	
	@		100MG	A076125	003	Apr 29, 2002	Mar	CAHN	
	@	UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Oct	CAHN	
AB			25MG	A075888	001	Nov 29, 2000	Oct	CAHN	
	@		50MG	A075887	002	Jan 05, 2001	Oct	CAHN	

TABLET;ORAL

FLUVOXAMINE MALEATE

AB		50MG	A075888	002	Nov 29, 2000	Oct CAHN
	@	100MG	A075887	003	Jan 05, 2001	Oct CAHN
AB	+	100MG	A075888	003	Nov 29, 2000	Oct CAHN

FOLIC ACID

INJECTABLE;INJECTION

FOLVITE

@ WYETH PHARMS INC

5MG/ML

N005897 008

May CAHN

TABLET;ORAL

FOLIC ACID

@ SUN PHARM INDS

1MG

A040582 001 Jul 18, 2005

Mar CAHN

FOLVITE

@ WYETH PHARMS INC

1MG

N005897 004

May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

FOLLISTIM AQ

@ ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005

Jun DISC

@

150 IU/0.5ML

N021273 002 Aug 26, 2005

Jun DISC

FOMEPIZOLE

INJECTABLE;INJECTION

ANTIZOL

AP	+	PAR PHARM INC	1.5GM/1.5ML (1GM/ML)
----	---	---------------	----------------------

N020696 001 Dec 04, 1997 Oct CAHN

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BEVESPI AEROSPHERE

+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH
---	-------------------	---------------------------

N208294 001 Apr 25, 2016 Apr NEWA

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

AB		MYLAN PHARMS INC	EQ 700MG BASE
----	--	------------------	---------------

A204060 001 Apr 15, 2016 Apr NEWA

LEXIVA

AB	+	VIIV HLTHCARE	EQ 700MG BASE
----	---	---------------	---------------

N021548 001 Oct 20, 2003 Apr CFTG

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

EMEND

AP	+	MERCK AND CO INC	EQ 150MG BASE/VIAL
----	---	------------------	--------------------

N022023 002 Nov 12, 2010 May CFTG

FOSAPREPITANT DIMEGLUMINE

AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL
----	--	--------------------	--------------------

A206197 001 Jun 09, 2016 May NEWA

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

@ ACTAVIS LABS FL INC

10MG

A076620 001 Oct 15, 2004

Jan DISC

@

20MG

A076620 002 Oct 15, 2004

Jan DISC

@

40MG

A076620 003 Oct 15, 2004

Jan DISC

>D>	AB	APOTEX INC	10MG
-----	----	------------	------

A076906 001 May 17, 2005 Dec CAHN

>A>	AB		10MG
-----	----	--	------

A076906 001 May 17, 2005 Dec CAHN

>D>	AB		20MG
-----	----	--	------

A076906 002 May 17, 2005 Dec CAHN

>A>	AB		20MG
-----	----	--	------

A076906 002 May 17, 2005 Dec CAHN

>D>	AB		40MG
-----	----	--	------

A076906 003 May 17, 2005 Dec CAHN

>A>	AB		40MG
-----	----	--	------

A076906 003 May 17, 2005 Dec CAHN

AB		PRINSTON INC	10MG
----	--	--------------	------

A205670 001 Aug 29, 2016 Aug NEWA

AB			20MG
----	--	--	------

A205670 002 Aug 29, 2016 Aug NEWA

AB			40MG
----	--	--	------

A205670 003 Aug 29, 2016 Aug NEWA

@ UPSHER-SMITH LABS

10MG

A076188 001 Oct 08, 2004

Nov CAHN

AB			10MG
----	--	--	------

A076483 001 Apr 23, 2004

Oct CAHN

@

20MG

A076188 002 Oct 08, 2004

Nov CAHN

AB			20MG
----	--	--	------

A076483 002 Apr 23, 2004

Oct CAHN

@

40MG

A076188 003 Oct 08, 2004

Nov CAHN

AB			40MG
----	--	--	------

A076483 003 Apr 23, 2004 Oct CAHN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan DISC
@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan DISC
@	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb DISC
@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP	+	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Aug CRLD
		FOSPHENYTOIN SODIUM					
		@ FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Aug DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP		AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul NEWA
AP		CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May CAHN
		@ EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
		@ WEST-WARD PHARMS INT	10MG/ML	A071439	001	Sep 14, 1990	Oct CAHN
		@	10MG/ML	N018267	001		Oct CAHN

SOLUTION; ORAL

FUROSEMIDE

AA	+	WEST-WARD PHARMS INT	10MG/ML	A070434	001	Apr 22, 1987	Nov CAHN
			40MG/5ML	A070433	001	Apr 22, 1987	Nov CAHN

TABLET; ORAL

FUROSEMIDE

		@ SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar CAHN
		@	80MG	A070100	001	Jan 26, 1988	Mar CAHN
AB		WEST-WARD PHARMS INT	80MG	A070086	001	Jan 24, 1986	Nov CAHN
		LASIX					
AB		US PHARM HOLDINGS	20MG	N016273	002		Jan CAHN
AB			40MG	N016273	001		Jan CAHN
AB	+		80MG	N016273	003		Jan CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

>D>	AB	APOTEX INC	100MG	A075360	001	Apr 06, 2005	Dec CAHN
>A>	AB		100MG	A075360	001	Apr 06, 2005	Dec CAHN
>D>	AB		300MG	A075360	002	Apr 06, 2005	Dec CAHN
>A>	AB		300MG	A075360	002	Apr 06, 2005	Dec CAHN
>D>	AB		400MG	A075360	003	Apr 06, 2005	Dec CAHN
>A>	AB		400MG	A075360	003	Apr 06, 2005	Dec CAHN
>D>	AB	HIKMA	100MG	A078150	001	Sep 25, 2007	Dec DISC
>A>		@	100MG	A078150	001	Sep 25, 2007	Dec DISC
>D>	AB		300MG	A078150	002	Sep 25, 2007	Dec DISC
>A>		@	300MG	A078150	002	Sep 25, 2007	Dec DISC
>D>	AB		400MG	A078150	003	Sep 25, 2007	Dec DISC
>A>		@	400MG	A078150	003	Sep 25, 2007	Dec DISC
	AB	SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb NEWA
	AB		300MG	A204989	002	Feb 18, 2016	Feb NEWA
	AB		400MG	A204989	003	Feb 18, 2016	Feb NEWA
		@ SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar CAHN
		@	300MG	A076537	002	Jun 30, 2005	Mar CAHN
		@	400MG	A076537	003	Jun 30, 2005	Mar CAHN
		@ SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Sep DISC
		@	300MG	A076606	002	Oct 07, 2005	Sep DISC
		@	400MG	A076606	003	Oct 07, 2005	Sep DISC

SOLUTION; ORAL

GABAPENTIN

AA		TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL
GABAPENTIN

>D>	AB	APOTEX INC	100MG	A077894	001	Oct 10, 2006	Dec CAHN
>A>	AB		100MG	A077894	001	Oct 10, 2006	Dec CAHN
>D>	AB		300MG	A077894	002	Oct 10, 2006	Dec CAHN
>A>	AB		300MG	A077894	002	Oct 10, 2006	Dec CAHN
>D>	AB		400MG	A077894	003	Oct 10, 2006	Dec CAHN
>A>	AB		400MG	A077894	003	Oct 10, 2006	Dec CAHN
>D>	AB		600MG	A077661	004	Sep 13, 2006	Dec CAHN
>A>	AB		600MG	A077661	004	Sep 13, 2006	Dec CAHN
>D>	AB		800MG	A077661	005	Sep 13, 2006	Dec CAHN
>A>	AB		800MG	A077661	005	Sep 13, 2006	Dec CAHN
	AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
	AB		800MG	A205101	002	Feb 04, 2016	Jan NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL
HORIZANT

		ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Jul CAHN
+			600MG	N022399	001	Apr 06, 2011	Jul CAHN

GADOFOSESET TRISODIUM

SOLUTION;INTRAVENOUS
ABLAVAR

@	LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008	Sep DISC
@		3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008	Sep DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL
GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul NEWA
AB		EQ 16MG BASE	A204895	002	Aug 05, 2016	Jul NEWA
AB		EQ 24MG BASE	A204895	003	Aug 05, 2016	Jul NEWA
	@ IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb DISC
	@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb DISC
	@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb DISC

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

+	ROXANE	4MG/ML	A078185	001	Jan 30, 2009	May CRLD
+	WEST-WARD PHARMS INT	4MG/ML	A078185	001	Jan 30, 2009	Nov CAHN
	RAZADYNE					
	@ JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May DISC

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB	WEST-WARD PHARMS INT	EQ 4MG BASE	A077608	001	Feb 11, 2009	Nov CAHN
AB		EQ 8MG BASE	A077608	002	Feb 11, 2009	Nov CAHN
AB		EQ 12MG BASE	A077608	003	Feb 11, 2009	Nov CAHN

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS
NETSPOT

+	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Aug NEWA
---	-------------	---------------	---------	-----	--------------	----------

GANCICLOVIR SODIUM

INJECTABLE;INJECTION
GANCICLOVIR

AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Nov NEWA
	GANCICLOVIR SODIUM					
	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Oct CAHN

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun NEWA
----	---------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar NEWA	
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar NEWA	
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar NEWA	
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
AP	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB		CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun NEWA
>A>	AB	CHARTWELL MOLECULES	600MG	A074270	001	Sep 27, 1993	Dec CAHN
>D>	AB	DAVA PHARMS INC	600MG	A074270	001	Sep 27, 1993	Dec CAHN

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE

>D>		@ G AND W LABS INC	EQ 0.1% BASE	A064056	001	Apr 29, 1994	Dec CMFD
>A>	AT		EQ 0.1% BASE	A064056	001	Apr 29, 1994	Dec CMFD

INJECTABLE; INJECTION
GENTAMICIN SULFATE

		@ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A062251	002		Oct CAHN
		@	EQ 40MG BASE/ML	A062251	001		Oct CAHN

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

		@ ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
		@	2MG	A076995	002	Apr 27, 2010	Jan DISC
		@	4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG; 4MG	A078709	001	Apr 01, 2016	Mar NEWA
		2MG; 4MG	A078709	002	Apr 01, 2016	Mar NEWA
		2MG; 8MG	A078709	004	Apr 01, 2016	Mar NEWA
		4MG; 4MG	A078709	003	Apr 01, 2016	Mar NEWA
		4MG; 8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

>A>	AB	UNIQUE PHARM LABS	2.5MG	A204720	001	Dec 29, 2016	Dec NEWA
>A>	AB		5MG	A204720	002	Dec 29, 2016	Dec NEWA
>A>	AB		10MG	A204720	003	Dec 29, 2016	Dec NEWA

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

		@ UPSHER-SMITH LABS	500MG	A083234	002		Nov CAHN
--	--	---------------------	-------	---------	-----	--	----------

GLYBURIDE

TABLET; ORAL
GLYBURIDE

AB1		PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr NEWA
AB1			2.5MG	A203581	002	Apr 14, 2016	Apr NEWA
AB1			5MG	A203581	003	Apr 14, 2016	Apr NEWA
AB1		ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr NEWA
AB1			2.5mg	A206749	002	May 10, 2016	Apr NEWA
AB1			5MG	A206749	003	May 10, 2016	Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

		@ COREPHARMA	1.25MG; 250MG	A076731	001	Nov 19, 2004	Jan DISC
		@	2.5MG; 500MG	A076731	002	Nov 19, 2004	Jan DISC
		@	5MG; 500MG	A076731	003	Nov 19, 2004	Jan DISC
AB		IMPAX LABS INC	1.25MG; 250MG	A076345	001	Feb 18, 2004	Aug CAHN
AB			2.5MG; 500MG	A076345	002	Feb 18, 2004	Aug CAHN
AB			5MG; 500MG	A076345	003	Feb 18, 2004	Aug CAHN
AB		ZYDUS PHARMS USA INC	1.25MG; 250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB			2.5MG; 500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB			5MG; 500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
		ROBINUL					
	@	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb DISC
	@	WEST-WARD PHARMS INT	0.2MG/ML	N017558	001		Oct CAHN

TABLET; ORAL

GLYCOPYRROLATE

>A>	AA		APPCO PHARMA LLC	1MG	A207201	001	Jan 03, 2017	Dec NEWA
>A>	AA			2MG	A207201	002	Jan 03, 2017	Dec NEWA
		@	HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May CAHN
		@		2MG	A040836	002	Mar 05, 2009	May CAHN
	AA		NATCO PHARMA LTD	1MG	A091413	001	Jun 20, 2016	Jun NEWA
	AA			2MG	A091413	002	Jun 20, 2016	Jun NEWA
	AA		RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
	AA			2MG	A040821	002	Dec 29, 2008	Jan CAHN
			ROBINUL					
	AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
			ROBINUL FORTE					
	AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRONFILM, EXTENDED RELEASE; TRANSDERMAL
SANCUSO

	+	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008	Aug CAHN
		INJECTION, EXTENDED RELEASE; SUBCUTANEOUS					
		SUSTOL					
	+	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@	CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May CAHN
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
		TABLET; ORAL					
		GRANISETRON HYDROCHLORIDE					
	@	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
AB		WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Nov CAHN

GRISOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISOFULVIN

AB		CIPLA LTD	125MG/5ML	A065354	001	Sep 10, 2007	Sep CAHN
----	--	-----------	-----------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

	+	MISSION PHARMACAL CO	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
--	---	----------------------	--------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

@	IMPAX LABS INC	EQ 1MG BASE
@		EQ 2MG BASE
@		EQ 3MG BASE
@		EQ 4MG BASE

A202238	001	Oct 20, 2015	Mar DISC
A202238	002	Oct 20, 2015	Mar DISC
A202238	003	Oct 20, 2015	Mar DISC
A202238	004	Oct 20, 2015	Mar DISC

HALOBETASOL PROPIONATE

LOTION; TOPICAL
ULTRAVATE

+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
@	FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
@		1MG	A071157	001	Jan 02, 1987	Jul CAHN
@		2MG	A071172	001	Jan 02, 1987	Jul CAHN
@		5MG	A071212	001	Jan 07, 1988	Jul CAHN
@		10MG	A071173	001	Jan 07, 1988	Jul CAHN
@	SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
@		1MG	A071157	001	Jan 02, 1987	Jun CAHN
@		2MG	A071172	001	Jan 02, 1987	Mar CAHN
@		5MG	A071212	001	Jan 07, 1988	Mar CAHN
@		10MG	A071173	001	Jan 07, 1988	Mar CAHN
@		20MG	A071177	001	Jan 07, 1988	Mar CAHN
@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
@		1MG	A071235	003	Nov 03, 1986	Jan CMS1
@		5MG	A071235	004	Nov 03, 1986	Jan CMS1
@		10MG	A071235	005	Jul 20, 1987	Jan CMS1

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Sep CAHN
AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Oct CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Oct CAHN
----	----------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
AP	+	WEST-WARD PHARMS INT	1,000 UNITS/ML	N017037	001	Oct CAHN
AP	+		5,000 UNITS/ML	N017037	002	Oct CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
AP	+		10,000 UNITS/ML	N017037	003	Oct CAHN

HEXACHLOROPHENE

EMULSION; TOPICAL
PHISOHEX

@	SANOFI AVENTIS US	3%	N006882	001		May DISC
---	-------------------	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@	ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000	Jan CMS1
---	-------------------	------------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	---------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
@		25MG	A091679	002	Mar 04, 2013	Apr DISC
@		50MG	A091679	003	Mar 04, 2013	Apr DISC
@		100MG	A091679	004	Mar 04, 2013	Apr DISC
@	FRONTIDA BIOPHARM	10MG	A089359	001	Jul 25, 1986	Jul CAHN
@		25MG	A089258	001	May 05, 1986	Jul CAHN
@		50MG	A089259	001	May 05, 1986	Jul CAHN
@		100MG	A088729	001	Apr 11, 1985	Jul CAHN
@	SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
@		25MG	A089258	001	May 05, 1986	Mar CAHN

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

@	50MG	A089259	001	May 05, 1986	Mar CAHN
@	100MG	A088729	001	Apr 11, 1985	Jun CAHN
@ UPSHER-SMITH LABS	10MG	A083241	001		Nov CAHN
@	25MG	A083560	001		Nov CAHN
@	50MG	A083561	001		Nov CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS	25MG;15MG	A085827	001		Feb CMS1
---------------	-----------	---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984	Mar CAHN
------------------	-----------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

@ LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Aug DISC
------------------------	--------	---------	-----	--------------	----------

MICROZIDE

AB +	ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN
------	--------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@ AUROLIFE PHARMA LLC	25MG	A083899	001		Feb CAHN
@	50MG	A085219	001		Feb CAHN
@ HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006	May CAHN
AB	50MG	A084878	001		May CAHN
@ LANNETT	25MG	A084325	001		Aug DISC
@	50MG	A084324	001		Aug DISC
@ SUN PHARM INDS	25MG	A083972	001		Mar CAHN
@	50MG	A083972	002		Mar CAHN
@	100MG	A083972	003		Mar CAHN
ORETIC					
@ ABBVIE	50MG	N011971	002		Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;150MG	A091370	001	Oct 15, 2012	Sep CAHN
AB		12.5MG;300MG	A091370	002	Oct 15, 2012	Sep CAHN
AB		25MG;300MG	A091370	003	Oct 12, 2016	Sep NEWA
AB		25MG;300MG	A091370	003	Oct 12, 2016	Sep CAHN
AB	AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar NEWA
AB	HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016	Oct NEWA
AB		12.5MG;300MG	A207896	002	Oct 14, 2016	Oct NEWA
AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan NEWA
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Jan NEWA
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar CTEC
		25MG;300MG	A203036	003	Jan 15, 2016	Jan NEWA
AB	MYLAN PHARMS INC	25MG;300MG	A077969	003	Jul 20, 2016	Jul NEWA
@	WATSON LABS INC	12.5MG;150MG	A091539	001	Oct 22, 2012	Nov DISC
@		12.5MG;300MG	A091539	002	Oct 22, 2012	Nov DISC
AB	WEST-WARD PHARMS INT	12.5MG;150MG	A090351	001	Oct 15, 2012	Nov CAHN
AB		12.5MG;300MG	A090351	002	Oct 15, 2012	Nov CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

>D> AB	APOTEX INC	12.5MG;10MG	A076674	001	Oct 05, 2004	Dec CAHN
>A> AB		12.5MG;10MG	A076674	001	Oct 05, 2004	Dec CAHN
>D> AB		12.5MG;20MG	A076674	002	Oct 05, 2004	Dec CAHN
>A> AB		12.5MG;20MG	A076674	002	Oct 05, 2004	Dec CAHN
>D> AB		25MG;20MG	A076674	003	Oct 05, 2004	Dec CAHN
>A> AB		25MG;20MG	A076674	003	Oct 05, 2004	Dec CAHN
ZESTORETIC						
AB	ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB +		12.5MG;20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB +		25MG;20MG	N019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WEST-WARD PHARMS INT	12.5MG;50MG	A077732	002	Oct 06, 2010	Nov CAHN
AB		12.5MG;100MG	A077732	001	Apr 06, 2010	Nov CAHN
AB		25MG;100MG	A077732	003	Oct 06, 2010	Nov CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	+ TEVA	25MG;15MG	A076980	002	Mar 07, 2007	Aug CRLD
----	--------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

AB	DAIICHI SANKYO	12.5MG;20MG	N021532	002	Jun 05, 2003	Oct CFTG
AB		12.5MG;40MG	N021532	003	Jun 05, 2003	Oct CFTG
AB	+	25MG;40MG	N021532	005	Jun 05, 2003	Oct CFTG
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE					
AB	MYLAN PHARMS INC	12.5MG;20MG	A078827	001	Oct 26, 2016	Oct NEWA
AB		12.5MG;40MG	A078827	002	Oct 26, 2016	Oct NEWA
AB		25MG;40MG	A078827	003	Oct 26, 2016	Oct NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar CAHN
----	----------------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	AUROBINDO PHARMA LTD	12.5MG;40MG	A208727	001	Dec 15, 2016	Dec NEWA
>A>	AB		12.5MG;80MG	A208727	002	Dec 15, 2016	Dec NEWA
>A>	AB		25MG;80MG	A208727	003	Dec 15, 2016	Dec NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan NEWA
AB		12.5MG;160MG	A206083	002	Feb 08, 2016	Jan NEWA
AB		12.5MG;320MG	A206083	003	Feb 08, 2016	Jan NEWA
AB		25MG;160MG	A206083	004	Feb 08, 2016	Jan NEWA
AB		25MG;320MG	A206083	005	Feb 08, 2016	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	@	ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010	Jan DISC
AB		AUROLIFE PHARMA LLC	7.5MG;200MG	A204575	001	Jun 02, 2016	May NEWA

HYDROCORTISONE

LOTION; TOPICAL

NUTRACORT

@ DOW PHARM

2.5%

A087644	001	Aug 24, 1982	Nov DISC
---------	-----	--------------	----------

TABLET; ORAL

HYDROCORTISONE

AB	IMPAX LABS INC	5MG	A040646	001	Mar 30, 2007	Nov CAHN
AB		10MG	A040646	002	Mar 30, 2007	Nov CAHN
AB		20MG	A040646	003	Mar 30, 2007	Nov CAHN
AB	PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr NEWA
AB		10MG	A207029	002	Apr 26, 2016	Apr NEWA
AB		20MG	A207029	003	Apr 26, 2016	Apr NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

PEDIOTIC

@ MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

A062822	001	Sep 29, 1987	Jan DISC
---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

AA	WEST-WARD PHARMS INT	5MG/5ML	A074653	001	Jul 29, 1998	Nov	CAHN
----	----------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May	NEWA
----	---------------------	-----	---------	-----	--------------	-----	------

AB		4MG	A205814	002	May 13, 2016	May	NEWA
----	--	-----	---------	-----	--------------	-----	------

AB		8MG	A205814	003	May 13, 2016	May	NEWA
----	--	-----	---------	-----	--------------	-----	------

>A>	AB	LANNETT	2MG	A077471	002	Dec 09, 2009	Dec	CMS1
-----	----	---------	-----	---------	-----	--------------	-----	------

>A>	AB		4MG	A077471	003	Dec 09, 2009	Dec	CMS1
-----	----	--	-----	---------	-----	--------------	-----	------

AB	MALLINCKRODT	2MG	A076855	002	Sep 19, 2007	Aug	CMS1
----	--------------	-----	---------	-----	--------------	-----	------

AB		4MG	A076855	003	Sep 19, 2007	Aug	CMS1
----	--	-----	---------	-----	--------------	-----	------

AB	WEST-WARD PHARMS INT	4MG	A074597	003	May 29, 2009	Nov	CAHN
----	----------------------	-----	---------	-----	--------------	-----	------

AB		8MG	A074597	001	Jul 29, 1998	Nov	CAHN
----	--	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

EXALGO

AB	+ MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Jun	CFTG
----	--------------------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	32MG	A202144	004	Jun 30, 2016	Jun	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

AB	OSMOTICA	8MG	A205629	001	Jul 07, 2016	Jun	NEWA
----	----------	-----	---------	-----	--------------	-----	------

AB		12MG	A205629	002	Jul 07, 2016	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		16MG	A205629	003	Jul 07, 2016	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		32MG	A205629	004	Jul 07, 2016	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

@ SERB SA 2.5GM/VIAL (5GM/KIT)

N022041	002	Dec 15, 2006	Jan	CAHN
---------	-----	--------------	-----	------

+ 5GM/VIAL (5GM/KIT)

N022041	001	Apr 08, 2011	Jan	CAHN
---------	-----	--------------	-----	------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

@ ALLERGAN SALES LLC 125MG/ML

N017439	001		Jul	CAHN
---------	-----	--	-----	------

@ 250MG/ML

N017439	002		Jul	CAHN
---------	-----	--	-----	------

+ ASPEN GLOBAL INC 250MG/ML

A200271	001	Aug 24, 2015	Jan	CAHN
---------	-----	--------------	-----	------

SOLUTION; INTRAMUSCULAR

MAKENA

+ AMAG PHARMA USA 1250MG/5ML (250MG/ML)

N021945	001	Feb 03, 2011	Jun	CAHN
---------	-----	--------------	-----	------

MAKENA PRESERVATIVE FREE

+ AMAG PHARMA USA 250MG/ML (250MG/ML)

N021945	002	Feb 19, 2016	Oct	CTNA
---------	-----	--------------	-----	------

+ 250MG/ML (250MG/ML)

N021945	002	Feb 19, 2016	Jun	CAHN
---------	-----	--------------	-----	------

+ LUMARA HEALTH INC 250MG/ML (250MG/ML)

N021945	002	Feb 19, 2016	Feb	NEWA
---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 10MG

A087869	001	Dec 20, 1982	Feb	CAHN
---------	-----	--------------	-----	------

@ 25MG

A087870	001	Dec 20, 1982	Feb	CAHN
---------	-----	--------------	-----	------

@ 50MG

A087871	001	Dec 20, 1982	Feb	CAHN
---------	-----	--------------	-----	------

AB	ECI PHARMS LLC	10MG	A040804	001	Jun 30, 2008	May	CAHN
----	----------------	------	---------	-----	--------------	-----	------

AB		25MG	A040804	002	Jun 30, 2008	May	CAHN
----	--	------	---------	-----	--------------	-----	------

AB		50MG	A040804	003	Jun 30, 2008	May	CAHN
----	--	------	---------	-----	--------------	-----	------

AB	ELITE LABS INC	10MG	A040604	002	Dec 28, 2004	Jun	NEWA
----	----------------	------	---------	-----	--------------	-----	------

AB		25MG	A040604	003	Dec 28, 2004	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

@ SUN PHARM INDS 10MG

A089381	001	May 19, 1986	Mar	CAHN
---------	-----	--------------	-----	------

@ 25MG

A089382	001	May 19, 1986	Mar	CAHN
---------	-----	--------------	-----	------

@ 50MG

A089383	001	May 19, 1986	Mar	CAHN
---------	-----	--------------	-----	------

@ 100MG

A087862	001	Apr 18, 1983	Mar	CAHN
---------	-----	--------------	-----	------

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	IMPAX LABS INC	EQ 25MG HCL	A040156	001	Jul 15, 1996	Aug CAHN
AB		EQ 50MG HCL	A040156	002	Jul 15, 1996	Aug CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan NEWA
	TABLET;ORAL					
	IBANDRONATE SODIUM					
AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar CAHN

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

AB	HI-TECH PHARMACAL	100MG/5ML	A205647	001	Nov 03, 2016	Oct NEWA
	TABLET;ORAL					
	IBUPROFEN					
AB	AIPING PHARM INC	400MG	A202413	001	Nov 23, 2016	Nov NEWA
AB		600MG	A202413	002	Nov 23, 2016	Nov NEWA
AB		800MG	A202413	003	Nov 23, 2016	Nov NEWA
	@ AUROLIFE PHARMA LLC	300MG	A070736	002	Jun 12, 1986	Nov CMS1
	@	400MG	A070736	003	Jun 12, 1986	Nov CMS1
	@	600MG	A070736	001	Jun 12, 1986	Feb CAHN
	@	800MG	A071938	001	Jan 14, 1988	Mar CAHN
AB	CONTRACT PHARMACAL	400MG	A071268	002	Oct 15, 1986	Sep CMS1
AB		800MG	A071268	003	Jul 01, 1988	Sep CMS1
	@ J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986	Jul CAHN
AB	STRIDES PHARMA	400MG	A078329	001	Feb 05, 2009	May CAHN
AB		600MG	A078329	002	Feb 05, 2009	May CAHN
AB		800MG	A078329	003	Feb 05, 2009	May CAHN
	@ SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985	Mar CAHN
	@	600MG	A070080	001	Jul 24, 1985	Mar CAHN
	@	800MG	A071448	001	Feb 18, 1987	Mar CAHN

IBUPROFEN LYISINE

INJECTABLE;INTRAVENOUS

IBUPROFEN LYISINE

AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar NEWA
	NEOPROFEN					
AP	+ RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar CFTG

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDARUBICIN HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	1MG/ML	A065275	001	Dec 14, 2006	Sep CAHN
AP		1MG/ML	A065288	001	May 15, 2007	Sep CAHN

IDOXURIDINE

SOLUTION/DROPS;OPHTHALMIC

DENDRID

+	ALCON	0.1%	N014169	001		Aug CTEC
	HERPLEX					
@	ALLERGAN	0.1%	N013935	002		Aug DISC

IFOSFAMIDE

INJECTABLE;INJECTION

IFOSFAMIDE

AP	WEST-WARD PHARMS INT	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Oct CAHN
AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Oct CAHN

ILOPERIDONE

TABLET;ORAL

FANAPT

AB	+ VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Nov CFTG
AB		2MG	N022192	002	May 06, 2009	Nov CFTG
AB		4MG	N022192	003	May 06, 2009	Nov CFTG
AB		6MG	N022192	004	May 06, 2009	Nov CFTG

TABLET;ORAL							
FANAPT							
AB		8MG	N022192	005	May 06, 2009	Nov	CFTG
AB		10MG	N022192	006	May 06, 2009	Nov	CFTG
AB		12MG	N022192	007	May 06, 2009	Nov	CFTG
ILOPERIDONE							
AB	INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Nov	NEWA
AB		2MG	A207231	002	Nov 28, 2016	Nov	NEWA
AB		4MG	A207231	003	Nov 28, 2016	Nov	NEWA
AB		6MG	A207231	004	Nov 28, 2016	Nov	NEWA
AB		8MG	A207231	005	Nov 28, 2016	Nov	NEWA
AB		10MG	A207231	006	Nov 28, 2016	Nov	NEWA
AB		12MG	A207231	007	Nov 28, 2016	Nov	NEWA
<u>IMATINIB MESYLATE</u>							
TABLET;ORAL							
IMATINIB MESYLATE							
AB	APOTEX INC	EQ 100MG BASE	A079179	001	Aug 05, 2016	Jul	NEWA
AB		EQ 400MG BASE	A079179	002	Aug 05, 2016	Jul	NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A204285	001	Aug 04, 2016	Jul	NEWA
AB		EQ 400MG BASE	A204285	002	Aug 04, 2016	Jul	NEWA
<u>IMIPRAMINE HYDROCHLORIDE</u>							
TABLET;ORAL							
IMIPRAMINE HYDROCHLORIDE							
AB	LUPIN LTD	10MG	A090441	002	Mar 11, 2010	Oct	CMS1
AB		25MG	A090441	003	Mar 11, 2010	Oct	CMS1
AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar	CAHN
AB		25MG	A081049	001	Jun 05, 1990	Mar	CAHN
AB		50MG	A081050	001	Jun 05, 1990	Mar	CAHN
<u>IMIPRAMINE PAMOATE</u>							
CAPSULE;ORAL							
IMIPRAMINE PAMOATE							
AB	+ ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb	CRLD
AB	+ WEST-WARD PHARMS INT	EQ 75MG HCL	A091099	001	Apr 16, 2010	Nov	CAHN
AB		EQ 100MG HCL	A091099	002	Apr 16, 2010	Nov	CAHN
AB		EQ 125MG HCL	A091099	003	Apr 16, 2010	Nov	CAHN
AB		EQ 150MG HCL	A091099	004	Apr 16, 2010	Nov	CAHN
<u>INAMRINONE LACTATE</u>							
INJECTABLE;INJECTION							
AMRINONE LACTATE							
+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Oct	CAHN
<u>INDAPAMIDE</u>							
TABLET;ORAL							
INDAPAMIDE							
AB	AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Sep	CMFD
AB		2.5MG	A075201	002	Dec 04, 1998	Sep	CMFD
<u>INDIUM IN-111 CHLORIDE</u>							
INJECTABLE;INJECTION							
INDIUM IN 111 CHLORIDE							
+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan	CAHN
<u>INDIUM IN-111 OXYQUINOLINE</u>							
INJECTABLE;INJECTION							
INDIUM IN 111 OXYQUINOLINE							
+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar	CMS1
<u>INDIUM IN-111 PENTETREOTIDE KIT</u>							
INJECTABLE;INJECTION							
OCTREOSCAN							
+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan	CAHN
<u>INDOCYANINE GREEN</u>							
INJECTABLE;INJECTION							
INDOCYANINE GREEN							
AP	DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan	CAHN

INDOMETHACINCAPSULE;ORAL
INDOMETHACIN@ SUN PHARM INDS 25MG
@ 50MGA070900 002 Feb 09, 1987 Sep CMS1
A070900 001 Feb 09, 1987 Sep CAHNCAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

>A> AB AUROBINDO PHARMA LTD 75MG

A204243 001 Dec 27, 2016 Dec NEWA

INDOMETHACIN SODIUMINJECTABLE;INJECTION
INDOMETHACIN SODIUMAP HOSPIRA INC EQ 1MG BASE/VIAL
AP WEST-WARD PHARMS INT EQ 1MG BASE/VIALA204118 001 Apr 19, 2016 Apr NEWA
A078713 001 Jul 16, 2008 Oct CAHNINGENOL MEBUTATEGEL;TOPICAL
PICATO>A> + LEO LABS 0.015%
>A> + 0.05%
>D> + LEO PHARMA AS 0.015%
>D> + 0.05%N202833 001 Jan 23, 2012 Dec CAHN
N202833 002 Jan 23, 2012 Dec CAHN
N202833 001 Jan 23, 2012 Dec CAHN
N202833 002 Jan 23, 2012 Dec CAHNINSULIN DEGLUDEC; LIRAGLUTIDESOLUTION;SUBCUTANEOUS
XULTOPHY 100/3.6+ NOVO NORDISK INC 300 UNITS/3ML;10.8MG/3ML (100
UNITS/ML;3.6MG/ML)

N208583 001 Nov 21, 2016 Nov NEWA

INSULIN DETEMIR RECOMBINANTINJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

@ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 002 Jun 16, 2005 Feb DISC

INSULIN GLARGINE; LIXISENATIDESOLUTION;SUBCUTANEOUS
SOLIQUA 100/33+ SANOFI-AVENTIS US 300 UNITS/3ML;99MCG/3ML (100
UNITS/ML;33MCG/ML)

N208673 001 Nov 21, 2016 Nov NEWA

INSULIN HUMANSOLUTION;SUBCUTANEOUS
HUMULIN R+ LILLY 10000 UNITS/20ML (500 UNITS/ML)
HUMULIN R KWIKPEN

N018780 004 Mar 31, 1994 Jan CAIN

+ LILLY 1500 UNITS/3ML (500 UNITS/ML)

N018780 002 Dec 29, 2015 Jan NEWA

INSULIN RECOMBINANT HUMANPOWDER;INHALATION
AFREZZA+ MANNKIND 4 UNITS/INH
8 UNITS/INH
12 UNITS/INHN022472 001 Jun 27, 2014 Mar CAHN
N022472 002 Jun 27, 2014 Mar CAHN
N022472 003 Apr 17, 2015 Mar CAHNIOXILANINJECTABLE;INJECTION
OXILAN-300

@ GUERBET 62%

N020316 001 Dec 21, 1995 Jun DISC

OXILAN-350

@ GUERBET 73%

N020316 002 Dec 21, 1995 Jun DISC

IPRATROPIUM BROMIDESOLUTION;INHALATION
IPRATROPIUM BROMIDEAN AUROBINDO PHARMA LTD 0.02%
>D> AN BAUSCH AND LOMB 0.02%
>A> AN BAUSCH AND LOMB INC 0.02%
@ MYLAN SPECLT 0.02%
AN + RITEDOSE CORP 0.02%
>A> AN SUN PHARMA GLOBAL 0.02%A206543 001 Oct 27, 2016 Oct NEWA
A075835 001 Oct 15, 2001 Dec CAHN
A075835 001 Oct 15, 2001 Dec CAHN
A074755 001 Jan 10, 1997 Jul DISC
A075693 001 Jan 26, 2001 Jul CRLD
A207903 001 Jan 03, 2017 Dec NEWA

SPRAY, METERED;NASAL						
IPRATROPIUM BROMIDE						
AB	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Nov CAHN
AB		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Nov CAHN
<u>IRBESARTAN</u>						
TABLET;ORAL						
IRBESARTAN						
AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May NEWA
AB		150MG	A206194	002	Jun 14, 2016	May NEWA
AB		300MG	A206194	003	Jun 14, 2016	May NEWA
	@ WATSON LABS INC	75MG	A090720	001	Oct 12, 2012	Nov DISC
	@	150MG	A090720	002	Oct 12, 2012	Nov DISC
	@	300MG	A090720	003	Oct 12, 2012	Nov DISC
AB	WEST-WARD PHARMS INT	75MG	A090201	001	Oct 15, 2012	Nov CAHN
AB		150MG	A090201	002	Oct 15, 2012	Nov CAHN
AB		300MG	A090201	003	Oct 15, 2012	Nov CAHN
<u>IRINOTECAN HYDROCHLORIDE</u>						
INJECTABLE;INJECTION						
CAMPTOSAR						
AP	+ PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
IRINOTECAN HYDROCHLORIDE						
AP	QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
AP		100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
AP		300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
AP	SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
AP		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN
<u>IRON DEXTRAN</u>						
INJECTABLE;INJECTION						
INFED						
BP	+ ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr CAHN
<u>ISONIAZID</u>						
TABLET;ORAL						
ISONIAZID						
AA	MIKART	100MG	A040090	001	Jun 26, 1997	Jun CMFD
AA		300MG	A040090	002	Jun 26, 1997	Jun CMFD
	@ SUN PHARM INDS	100MG	A080136	001		Mar CAHN
	@	300MG	A083633	001		Mar CAHN
<u>ISOSORBIDE DINITRATE</u>						
CAPSULE, EXTENDED RELEASE;ORAL						
DILATRATE-SR						
	+ AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar CAHN
	+ AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul CAHN
TABLET;ORAL						
ISOSORBIDE DINITRATE						
	@ SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar CAHN
	@	10MG	A086169	001	Sep 19, 1986	Jun CAHN
	@	20MG	A086167	001	Sep 19, 1986	Jun CAHN
	@	30MG	A087564	001	Sep 18, 1986	Jun CAHN
TABLET;SUBLINGUAL						
ISOSORBIDE DINITRATE						
	@ SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun CAHN
	@	5MG	A086168	001	Sep 18, 1986	Jun CAHN
	@	10MG	A087545	001	Sep 18, 1986	Jun CAHN
TABLET, EXTENDED RELEASE;ORAL						
ISOSORBIDE DINITRATE						
	@ COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar DISC
	+ SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar CTEC
<u>ISOSORBIDE MONONITRATE</u>						
TABLET, EXTENDED RELEASE;ORAL						
ISOSORBIDE MONONITRATE						
AB	DEXCEL LTD	30MG	A075522	002	Sep 20, 2016	Sep NEWA

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE

AP	AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan	NEWA
AP	+ MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan	CTEC

ISOTRETINOIN

CAPSULE; ORAL
ABSORICA

BX	RANBAXY	10MG	N021951	001	May 25, 2012	Aug	CAHN
BX		20MG	N021951	002	May 25, 2012	Aug	CAHN
		25MG	N021951	005	Aug 15, 2014	Aug	CAHN
BX		30MG	N021951	003	May 25, 2012	Aug	CAHN
		35MG	N021951	006	Aug 15, 2014	Aug	CAHN
BX	+	40MG	N021951	004	May 25, 2012	Aug	CAHN
BX	RANBAXY LABS LTD	10MG	N021951	001	May 25, 2012	Jul	CAHN
BX		20MG	N021951	002	May 25, 2012	Jul	CAHN
		25MG	N021951	005	Aug 15, 2014	Aug	CAHN
		25MG	N021951	005	Aug 15, 2014	Jul	CAHN
BX		30MG	N021951	003	May 25, 2012	Jul	CAHN
		35MG	N021951	006	Aug 15, 2014	Aug	CAHN
		35MG	N021951	006	Aug 15, 2014	Jul	CAHN
BX	+	40MG	N021951	004	May 25, 2012	Jul	CAHN
	SOTRET						
	@ SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Sep	DISC
	@	20MG	A076041	002	Dec 24, 2002	Sep	DISC
	@	30MG	A076503	001	Jun 20, 2003	Sep	DISC
	@	40MG	A076041	003	Dec 24, 2002	Sep	DISC

ITRACONAZOLE

CAPSULE; ORAL
ITRACONAZOLE

AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May	NEWA
AB	ALEMBIC PHARMS LTD	100MG	A206741	001	Dec 13, 2016	Nov	NEWA
AB	AMNEAL PHARMS	100MG	A205080	001	Sep 26, 2016	Sep	NEWA
AB	PAR PHARM INC	100MG	A205724	001	Dec 13, 2016	Nov	NEWA

SOLUTION; ORAL

ITRACONAZOLE

@ AMNEAL PHARMS 10MG/ML

A205573 001 Oct 30, 2015 Apr DISC

SPORANOX

+ JANSSEN PHARMS 10MG/ML

N020657 001 Feb 21, 1997 Apr CTEC

TABLET; ORAL

ONMEL

>D> + MERZ PHARMS 200MG

N022484 001 Apr 29, 2010 Dec CAHN

>A> + SEBELA IRELAND LTD 200MG

N022484 001 Apr 29, 2010 Dec CAHN

IVACAFTOR; LUMACFTOR

TABLET; ORAL

ORKAMBI

VERTEX PHARMS INC 125MG; 100MG

N206038 002 Sep 28, 2016 Sep NEWA

IVERMECTIN

LOTION; TOPICAL

SKLICE

+ ARBOR PHARMS LLC 0.5%

N202736 001 Feb 07, 2012 May CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT EQ 50MG BASE/ML

A074524 001 Mar 22, 1996 Sep CAHN

AP EQ 100MG BASE/ML

A074524 002 Mar 22, 1996 Sep CAHN

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

@ SUN PHARM INDS 200MG

A075314 001 Jun 15, 1999 Jan CAHN

KETOPROFENCAPSULE; ORAL
KETOPROFEN@ AUROLIFE PHARMA LLC
@50MG
75MGA074024 001 Dec 29, 1995 Feb CAHN
A074024 002 Dec 29, 1995 Feb CAHNKETOROLAC TROMETHAMINEINJECTABLE; INJECTION
KETOROLAC TROMETHAMINEAP GLAND PHARMA LTD
AP15MG/ML
30MG/MLA204216 001 Nov 01, 2016 Oct NEWA
A204216 002 Nov 01, 2016 Oct NEWASOLUTION/DROPS; OPHTHALMIC
KETOROLAC TROMETHAMINE>D> AT APOTEX INC 0.4%
>A> AT 0.4%
>D> AT 0.5%
>A> AT 0.5%A077308 001 Nov 05, 2009 Dec CAHN
A077308 001 Nov 05, 2009 Dec CAHN
A076109 001 Nov 05, 2009 Dec CAHN
A076109 001 Nov 05, 2009 Dec CAHNKETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDESOLUTION; IRRIGATION
OMIDRIA

+ OMEROS EQ 0.3% BASE; EQ 1% BASE

N205388 001 May 30, 2014 Aug CPOT

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
LABETALOL HYDROCHLORIDEAP SAGENT STRIDES 5MG/ML
AP WEST-WARD PHARMS INT 5MG/MLA079134 001 Feb 03, 2010 Jan CTNA
A075303 001 May 28, 1999 Oct CAHNTABLET; ORAL
LABETALOL HYDROCHLORIDE>A> AB ALLIED PHARMA INC 100MG
>A> AB 200MG
>A> AB 300MG
>D> AB NOSTRUM LABS INC 100MG
AB 100MG
>D> AB 200MG
AB 200MG
>D> AB 300MG
AB 300MGA075215 001 Jul 29, 1999 Dec CAHN
A075215 002 Jul 29, 1999 Dec CAHN
A075215 003 Jul 29, 1999 Dec CAHN
A075215 001 Jul 29, 1999 Dec CAHN
A075215 001 Jul 29, 1999 Jan CAHN
A075215 002 Jul 29, 1999 Dec CAHN
A075215 002 Jul 29, 1999 Jan CAHN
A075215 003 Jul 29, 1999 Dec CAHN
A075215 003 Jul 29, 1999 Jan CAHNLACOSAMIDESOLUTION; ORAL
LACOSAMIDEAA AMNEAL PHARMS 10MG/ML
VIMPAT

A204839 001 Apr 28, 2016 Apr NEWA

AA + UCB INC 10MG/ML
TABLET; ORAL

N022255 001 Apr 20, 2010 Apr CFTG

LACOSAMIDE

AB ACTAVIS LABS FL INC 50MG
AB 100MG
AB 150MG
AB 200MG
AB ALEMBIC PHARMS LTD 50MG
AB 100MG
AB 150MG
AB 200MG
AB AMNEAL PHARMS 50MG
AB 100MG
AB 150MG
AB 200MG
AB AUROBINDO PHARMA LTD 50MG
AB 100MG
AB 150MG
AB 200MG
AB MSN LABS PVT LTD 50MG
AB 100MG
AB 150MG
AB 200MG
AB MYLAN PHARMS INC 50MG
AB 100MG
AB 150MGA204855 001 Apr 28, 2016 Apr NEWA
A204855 002 Apr 28, 2016 Apr NEWA
A204855 003 Apr 28, 2016 Apr NEWA
A204855 004 Apr 28, 2016 Apr NEWA
A204974 001 Apr 28, 2016 Apr NEWA
A204974 002 Apr 28, 2016 Apr NEWA
A204974 003 Apr 28, 2016 Apr NEWA
A204974 004 Apr 28, 2016 Apr NEWA
A204857 001 Sep 09, 2016 Aug NEWA
A204857 002 Sep 09, 2016 Aug NEWA
A204857 003 Sep 09, 2016 Aug NEWA
A204857 004 Sep 09, 2016 Aug NEWA
A204994 001 Apr 28, 2016 Apr NEWA
A204994 002 Apr 28, 2016 Apr NEWA
A204994 003 Apr 28, 2016 Apr NEWA
A204994 004 Apr 28, 2016 Apr NEWA
A204921 001 Apr 28, 2016 Apr NEWA
A204921 002 Apr 28, 2016 Apr NEWA
A204921 003 Apr 28, 2016 Apr NEWA
A204921 004 Apr 28, 2016 Apr NEWA
A205026 001 Apr 28, 2016 Apr NEWA
A205026 002 Apr 28, 2016 Apr NEWA
A205026 003 Apr 28, 2016 Apr NEWA

TABLET;ORAL
LACOSAMIDE

AB		200MG	A205026	004	Apr 28, 2016	Apr NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr NEWA
	VIMPAT					
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr CFTG

LACTULOSE

SOLUTION;ORAL
CONSTULOSE

	@ ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988	Aug DISC
	LACTULOSE					
AA	+ HI TECH PHARMA	10GM/15ML	A074076	001	Jul 03, 1995	Aug CRLD
AA	WEST-WARD PHARMS INT	10GM/15ML	A073591	001	May 29, 1992	Nov CAHN

LAMIVUDINE

SOLUTION;ORAL
LAMIVUDINE

AA	AUROBINDO PHARMA LTD	10MG/ML	A077695	001	Nov 21, 2016	Nov NEWA
	TABLET;ORAL					
	LAMIVUDINE					
AB	APPCO PHARMA LLC	150MG	A206974	001	Nov 21, 2016	Nov NEWA
AB		300MG	A206974	002	Nov 21, 2016	Nov NEWA
AB	AUROBINDO PHARMA LTD	150MG	A077464	001	Nov 21, 2016	Nov NEWA
AB		300MG	A077464	002	Nov 21, 2016	Nov NEWA
AB	CENTAUR PHARMS PVT	150MG	A203586	001	Nov 21, 2016	Nov NEWA
AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb NEWA

LAMOTRIGINE

TABLET;ORAL
LAMOTRIGINE

AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009	Jun CAHN
AB		100MG	A079132	002	Jan 27, 2009	Jun CAHN
AB		150MG	A079132	003	Jan 27, 2009	Jun CAHN
AB		200MG	A079132	004	Jan 27, 2009	Jun CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	LAMICTAL XR					
AB	+ GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan CRLD
	TABLET, ORALLY DISINTEGRATING;ORAL					
	LAMOTRIGINE					
AB	SCIEGEN PHARMS INC	25MG	A206382	001	Jun 17, 2016	Jun NEWA
AB		50MG	A206382	002	Jun 17, 2016	Jun NEWA
AB		100MG	A206382	003	Jun 17, 2016	Jun NEWA
AB		200MG	A206382	004	Jun 17, 2016	Jun NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016	Oct NEWA
AB		30MG	A203957	002	Oct 14, 2016	Oct NEWA
>D> AB	ANCHEN PHARMS	15MG	A203203	001	Jul 25, 2016	Dec CAHN
AB		15MG	A203203	001	Jul 25, 2016	Jul NEWA
>D> AB		30MG	A203203	002	Jul 25, 2016	Dec CAHN
AB		30MG	A203203	002	Jul 25, 2016	Jul NEWA
>A> AB	LABS LICONSA	15MG	A203203	001	Jul 25, 2016	Dec CAHN
>A> AB		30MG	A203203	002	Jul 25, 2016	Dec CAHN
AB	SUN PHARM INDS LTD	15MG	A202637	001	Sep 13, 2013	Nov CAHN
AB		30MG	A091509	001	Sep 13, 2013	Nov CAHN

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT	FDC LTD	0.005%	A202442	001	Apr 22, 2016	Apr NEWA
----	---------	--------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

>D>	AB	APOTEX INC	10MG	A077090	001	Sep 13, 2005	Dec CAHN
>A>	AB		10MG	A077090	001	Sep 13, 2005	Dec CAHN
>D>	AB		20MG	A077090	002	Sep 13, 2005	Dec CAHN
>A>	AB		20MG	A077090	002	Sep 13, 2005	Dec CAHN

LESINURAD

TABLET; ORAL

ZURAMPIC

+	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Aug CAHN
---	---------------------	-------	---------	-----	--------------	----------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016	May NEWA
AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan CAHN
AB	WEST-WARD PHARMS INT	2.5MG	A090838	001	Jun 03, 2011	Nov CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	+	WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Oct CAHN
AP	+		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Oct CAHN
			LEUCOVORIN CALCIUM PRESERVATIVE FREE				
	+	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep CAHN
AP	+		EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Sep CAHN
AP	+		EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Sep CAHN

TABLET; ORAL

LEUCOVORIN CALCIUM

	@	IDT AUSTRALIA LTD	EQ 15MG BASE	A075327	001	Mar 24, 1999	May CAHN
		ROXANE	EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun CTEC
AB		WEST-WARD PHARMS INT	EQ 5MG BASE	A072733	001	Feb 22, 1993	Nov CAHN
			EQ 10MG BASE	A072734	001	Feb 22, 1993	Nov CAHN
			EQ 15MG BASE	A072735	001	Feb 22, 1993	Nov CAHN
AB	+		EQ 25MG BASE	A072736	001	Feb 22, 1993	Nov CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A>	AN	AUROBINDO PHARMA LTD	EQ 0.0103% BASE	A207625	001	Dec 30, 2016	Dec NEWA
>A>	AN		EQ 0.021% BASE	A207625	002	Dec 30, 2016	Dec NEWA
>A>	AN		EQ 0.042% BASE	A207625	003	Dec 30, 2016	Dec NEWA
		IMPAX LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug CAHN
			EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug CAHN
			EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug CAHN
		RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar NEWA
			EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar NEWA
			EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP		AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan NEWA
AP		JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May NEWA
AP		MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Sep NEWA

LEVETIRACETAM IN SODIUM CHLORIDE

>A>	AP	AUROBINDO PHARMA LTD	500MG/100ML (5MG/ML)	A207160	001	Jan 04, 2017	Dec NEWA
>A>	AP		1000MG/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Dec NEWA
>A>	AP		1500MG/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Dec NEWA
>D>		+	HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011
>A>	AP	+		500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011
>D>		+		1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011
>A>	AP	+		1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011
>D>		+		1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011
>A>	AP	+		1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011

TABLET; ORAL

LEVETIRACETAM

AB		SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Oct NEWA
----	--	--------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May NEWA
AB		750MG	A202095	001	Jun 06, 2016	May NEWA
AB	NOSTRUM LABS INC	500MG	A204754	001	Aug 26, 2016	Aug NEWA
AB		750MG	A204754	002	Aug 26, 2016	Aug NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar CAHN

TABLET, FOR SUSPENSION;ORAL
SPRITAM

	APRECIA PHARMS CO	250MG
		500MG
		750MG
+		1GM
		1GM

N207958	001	Jul 31, 2015	Feb CDFR
N207958	002	Jul 31, 2015	Feb CDFR
N207958	003	Jul 31, 2015	Feb CDFR
N207958	004	Jul 31, 2015	Mar CRLD
N207958	004	Jul 31, 2015	Feb CDFR

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

AT	ALCON LABS INC	0.25%
----	----------------	-------

A074851	001	Oct 28, 1996	Jul CAHN
---------	-----	--------------	----------

LEVOCARNITINE

INJECTABLE;INJECTION
LEVOCARNITINE

AP	WEST-WARD PHARMS INT	200MG/ML
----	----------------------	----------

A075567	001	Mar 29, 2001	Oct CAHN
---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A> AB	NOSTRUM LABS INC	5MG
--------	------------------	-----

A204323	001	Dec 20, 2016	Dec NEWA
---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

	@ HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)
	@	EQ 750MG/30ML (EQ 25MG/ML)
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	
AP	+	ACS DOBFAR INFO SA
AP	+	EQ 250MG/50ML (EQ 5MG/ML)
AP	+	EQ 500MG/100ML (EQ 5MG/ML)
AP	+	EQ 750MG/150ML (EQ 5MG/ML)
AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)
AP		EQ 500MG/100ML (EQ 5MG/ML)
AP		EQ 750MG/150ML (EQ 5MG/ML)

A078577	001	Aug 12, 2015	Oct DISC
A078577	002	Aug 12, 2015	Oct DISC
A090343	001	Jul 07, 2011	Nov CRLD
A090343	002	Jul 07, 2011	Nov CRLD
A090343	003	Jul 07, 2011	Nov CRLD
A206919	001	Feb 10, 2016	Jan NEWA
A206919	002	Feb 10, 2016	Jan NEWA
A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+	RISENG PHARMS INC	0.5%
----	---	-------------------	------

A077700	001	Dec 20, 2010	Jan CAHN
---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

FUSILEV

AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL
		LEVOLEUCOVORIN CALCIUM	
		ACTAVIS LLC	EQ 175MG BASE/VIAL
AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL
AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL

N020140	001	Mar 07, 2008	Jun CFTG
N208723	001	Sep 29, 2016	Sep NEWA
A206263	001	Jun 16, 2016	Jun NEWA
A206263	001	Jun 16, 2016	Oct CAHN

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE
KYLEENA

+	BAYER HLTHCARE	19.5MG
---	----------------	--------

N208224	001	Sep 16, 2016	Sep NEWA
---------	-----	--------------	----------

TABLET;ORAL

LEVONORGESTREL

AB	JAI PHARMA LTD	0.75MG
AB	LOTUS PHARM CO LTD	0.75MG
AB	+	PERRIGO R AND D
+		0.75MG

A202740	001	Sep 02, 2016	Aug NEWA
A202684	001	Sep 02, 2016	Aug NEWA
A090740	001	Dec 30, 2010	Aug CTEC
A090740	001	Dec 30, 2010	Apr CRLD

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun	NEWA
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jun	NEWA
AP	+ FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun	CFTG
AP	+	500MCG/VIAL	N202231	003	Jun 24, 2011	Jun	CFTG
>A>	SOLUTION; ORAL						
>A>	TIROSINT-SOL						
>A>	IBSA INST BIO	13MCG/ML	N206977	001	Dec 15, 2016	Dec	NEWA
>A>		25MCG/ML	N206977	002	Dec 15, 2016	Dec	NEWA
>A>		50MCG/ML	N206977	003	Dec 15, 2016	Dec	NEWA
>A>		75MCG/ML	N206977	004	Dec 15, 2016	Dec	NEWA
>A>		88MCG/ML	N206977	005	Dec 15, 2016	Dec	NEWA
>A>		100MCG/ML	N206977	006	Dec 15, 2016	Dec	NEWA
>A>		112MCG/ML	N206977	007	Dec 15, 2016	Dec	NEWA
>A>		125MCG/ML	N206977	008	Dec 15, 2016	Dec	NEWA
>A>		137MCG/ML	N206977	009	Dec 15, 2016	Dec	NEWA
>A>		150MCG/ML	N206977	010	Dec 15, 2016	Dec	NEWA
>A>		175MCG/ML	N206977	011	Dec 15, 2016	Dec	NEWA
>A>	+	200MCG/ML	N206977	012	Dec 15, 2016	Dec	NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOLET

@ LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul	CAHN
@	0.05MG	N021137	002	Jun 06, 2003	Jul	CAHN
@	0.075MG	N021137	003	Jun 06, 2003	Jul	CAHN
@	0.088MG	N021137	004	Jun 06, 2003	Jul	CAHN
@	0.1MG	N021137	005	Jun 06, 2003	Jul	CAHN
@	0.112MG	N021137	006	Jun 06, 2003	Jul	CAHN
@	0.125MG	N021137	007	Jun 06, 2003	Jul	CAHN
@	0.137MG	N021137	008	Jun 06, 2003	Jul	CAHN
@	0.15MG	N021137	009	Jun 06, 2003	Jul	CAHN
@	0.175MG	N021137	010	Jun 06, 2003	Jul	CAHN
@	0.2MG	N021137	011	Jun 06, 2003	Jul	CAHN
@	0.3MG	N021137	012	Jun 06, 2003	Jul	CAHN

LEVOTHROID

@ LLOYD	0.025MG	N021116	001	Oct 24, 2002	May	DISC
@	0.05MG	N021116	002	Oct 24, 2002	May	DISC
@	0.075MG	N021116	003	Oct 24, 2002	May	DISC
@	0.088MG	N021116	010	Oct 24, 2002	May	DISC
@	0.1MG	N021116	004	Oct 24, 2002	May	DISC
@	0.112MG	N021116	011	Oct 24, 2002	May	DISC
@	0.125MG	N021116	005	Oct 24, 2002	May	DISC
@	0.137MG	N021116	012	Dec 07, 2004	May	DISC
@	0.15MG	N021116	006	Oct 24, 2002	May	DISC
@	0.175MG	N021116	007	Oct 24, 2002	May	DISC
@	0.2MG	N021116	008	Oct 24, 2002	May	DISC
@	0.3MG	N021116	009	Oct 24, 2002	May	DISC

LEVOTHYROXINE SODIUM

AB1, MYLAN	0.3MG	A076187	011	Jun 05, 2002	May	CRLD
AB2,						
AB3,						
AB4 +						

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT GLENMARK PHARMS LTD	5%	A206498	001	Sep 09, 2016	Aug	NEWA
AT SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun	CAHN
AT TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	400MG/100ML	N018388	002		Feb	DISC
-----------	-------------	---------	-----	--	-----	------

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982	Feb	DISC
-----------	-------------	---------	-----	--------------	-----	------

	JELLY; TOPICAL								
	ANESTACON								
	@ BIONPHARMA INC	2%		A080429	001			Jan	CAHN
	SOLUTION; ORAL								
	LIDOCAINE HYDROCHLORIDE VISCOUS								
AT	+ VINTAGE	2%		A040708	001	Feb 27, 2007		Aug	CRLD
	LIDOCAINE VISCOUS								
AT	WEST-WARD PHARMS INT	2%		A088802	001	Apr 26, 1985		Nov	CAHN
	SOLUTION; TOPICAL								
	LIDOCAINE HYDROCHLORIDE								
AT	TELIGENT PHARMA INC	4%		A204494	001	Mar 12, 2014		May	CAHN
AT	WEST-WARD PHARMS INT	4%		A088803	001	Apr 03, 1985		Nov	CAHN
	<u>LIFITEGRAST</u>								
	SOLUTION/DROPS; OPHTHALMIC								
	XIIDRA								
	+ SHIRE DEV LLC	5%		N208073	001	Jul 11, 2016		Jul	NEWA
	<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE; ORAL								
	JENTADUETO XR								
	BOEHRINGER INGELHEIM	2.5MG; 1GM		N208026	001	May 27, 2016		May	NEWA
	+	5MG; 1GM		N208026	002	May 27, 2016		May	NEWA
	<u>LINEZOLID</u>								
	FOR SUSPENSION; ORAL								
	LINEZOLID								
AB	WEST-WARD PHARMS INT	100MG/5ML		A200068	001	Jun 03, 2015		Nov	CAHN
	SOLUTION; IV (INFUSION)								
	LINEZOLID								
AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)		A206917	001	Aug 04, 2016		Jul	NEWA
AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)		A204764	001	Mar 15, 2016		Feb	NEWA
>A> AP	NANG KUANG PHARM CO	200MG/100ML (2MG/ML)		A207354	001	Dec 20, 2016		Dec	NEWA
>A> AP		600MG/300ML (2MG/ML)		A207354	002	Dec 20, 2016		Dec	NEWA
	TABLET; ORAL								
	LINEZOLID								
AB	GATE PHARMS	600MG		A091210	001	Feb 05, 2016		Jan	NEWA
AB	GLENMARK PHARMS	600MG		A078987	001	Dec 21, 2015		Mar	CAHN
AB	NOVEL LABS INC	600MG		A207526	001	Aug 22, 2016		Aug	NEWA
	<u>LIOTHYRONINE SODIUM</u>								
	TABLET; ORAL								
	LIOTHYRONINE SODIUM								
AB	MAYNE PHARMA INC	EQ 0.005MG BASE		A090097	001	Mar 20, 2009		Mar	CAHN
AB		EQ 0.025MG BASE		A090097	002	Mar 20, 2009		Mar	CAHN
AB		EQ 0.05MG BASE		A090097	003	Mar 20, 2009		Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 0.005MG BASE		A091382	001	Apr 20, 2016		Apr	NEWA
AB		EQ 0.025MG BASE		A091382	002	Apr 20, 2016		Apr	NEWA
AB		EQ 0.05MG BASE		A091382	003	Apr 20, 2016		Apr	NEWA
	<u>LISINOPRIL</u>								
	SOLUTION; ORAL								
	QBRELIS								
	+ SILVERGATE PHARMS	1MG/ML		N208401	001	Jul 29, 2016		Jul	NEWA
	TABLET; ORAL								
	LISINOPRIL								
>D> AB	APOTEX INC	2.5MG		A076102	001	Sep 30, 2002		Dec	CAHN
>A> AB		2.5MG		A076102	001	Sep 30, 2002		Dec	CAHN
>D> AB		5MG		A076102	002	Sep 30, 2002		Dec	CAHN
>A> AB		5MG		A076102	002	Sep 30, 2002		Dec	CAHN
>D> AB		10MG		A076102	003	Sep 30, 2002		Dec	CAHN
>A> AB		10MG		A076102	003	Sep 30, 2002		Dec	CAHN
>D> AB		20MG		A076102	004	Sep 30, 2002		Dec	CAHN
>A> AB		20MG		A076102	004	Sep 30, 2002		Dec	CAHN
>D> AB		30MG		A076102	005	Sep 30, 2002		Dec	CAHN
>A> AB		30MG		A076102	005	Sep 30, 2002		Dec	CAHN
>D> AB		40MG		A076102	006	Sep 30, 2002		Dec	CAHN
>A> AB		40MG		A076102	006	Sep 30, 2002		Dec	CAHN
	ZESTRIL								
AB	ALVOGEN MALTA	2.5MG		N019777	005	Apr 29, 1993		Jan	CAHN
AB		5MG		N019777	001	May 19, 1988		Jan	CAHN
AB		10MG		N019777	002	May 19, 1988		Jan	CAHN

TABLET;ORAL
ZESTRIL

AB		20MG	N019777	003	May 19, 1988	Jan CAHN
AB		30MG	N019777	006	Jan 20, 1999	Jan CAHN
AB	+	40MG	N019777	004	May 19, 1988	Jan CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

AB	HERITAGE PHARMA	300MG	A205532	001	Sep 29, 2016	Sep NEWA
AB	WEST-WARD PHARMS INT	300MG	A076832	001	Oct 28, 2004	Nov CAHN
AB	+	450MG	A076691	001	Jan 05, 2004	Nov CAHN

LIXISENATIDE

SOLUTION;SUBCUTANEOUS
ADLYXIN

+	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016	Aug CPOT
+		0.05MG/ML	N208471	001	Jul 27, 2016	Jul NEWA
+		0.1MG/ML	N208471	002	Jul 27, 2016	Jul NEWA
+		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016	Aug CPOT

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC
ALOMIDE

+	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020191	001	Sep 23, 1993	Nov CAHN
---	----------------------	--------------	---------	-----	--------------	----------

LOMITAPIDE MESYLATE

CAPSULE;ORAL
JUXTAPID

	AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CRLD
+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CRLD

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
IMODIUM

	@ J AND J CONSUMER INC	2MG	N017694	001		Feb DISC
AB	+	MYLAN	A072741	001	Sep 18, 1991	Feb CRLD

LOPINAVIR; RITONAVIR

SOLUTION;ORAL
KALETRA

>D>	+	ABBVIE	80MG/ML;20MG/ML	N021251	001	Sep 15, 2000	Dec CFTG
>A> AA	+		80MG/ML;20MG/ML	N021251	001	Sep 15, 2000	Dec CFTG
>A>		LOPINAVIR AND RITONAVIR					
>A> AA		SILARX PHARMS INC	80MG/ML;20MG/ML	A207407	001	Dec 27, 2016	Dec NEWA

LORAZEPAM

CONCENTRATE;ORAL
LORAZEPAM INTENSOL

AA	+	WEST-WARD PHARMS INT	2MG/ML	A072755	001	Jun 28, 1991	Nov CAHN
----	---	----------------------	--------	---------	-----	--------------	----------

INJECTABLE;INJECTION
ATIVAN

AP	+	WEST-WARD PHARMS INT	2MG/ML	N018140	001		Oct CAHN
AP	+		4MG/ML	N018140	002		Oct CAHN

TABLET;ORAL
LORAZEPAM

	@ FRONTIDA BIOPHARM	0.5MG	A072553	001	Mar 29, 1991	Sep CAHN
	@	1MG	A072554	001	Mar 29, 1991	Sep CAHN
	@	2MG	A072555	001	Mar 29, 1991	Jul CAHN

LORCASERIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR

+	EISAI INC	20MG	N208524	001	Jul 15, 2016	Jul NEWA
---	-----------	------	---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr CTEC
BX		50MG	A203835	002	Aug 12, 2015	Apr CTEC
BX		100MG	A203835	003	Aug 12, 2015	Apr CTEC
AB	LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Oct CTEC
BX		25MG	A078232	001	Oct 06, 2010	Apr CTEC
AB		50MG	A078232	002	Oct 06, 2010	Oct CTEC
BX		50MG	A078232	002	Oct 06, 2010	Apr CTEC
AB		100MG	A078232	003	Oct 06, 2010	Oct CTEC
BX		100MG	A078232	003	Oct 06, 2010	Apr CTEC
AB	WEST-WARD PHARMS INT	25MG	A077459	001	Oct 06, 2010	Nov CAHN
AB		50MG	A077459	002	Oct 06, 2010	Nov CAHN
AB		100MG	A077459	003	Oct 06, 2010	Nov CAHN

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar CAHN
AB		20MG	A077520	002	Apr 14, 2006	Mar CAHN
AB		40MG	A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINE

POWDER; INHALATION

ADASUVE

+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb CAHN
---	---------------	------	---------	-----	--------------	----------

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

@	WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012	Aug CAHN
---	-----------------	-------	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA
AP	+ HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
AP	HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA
AP		4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
AP		2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar NEWA
AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

>A> POWDER; ORAL

>A> COLPREP KIT

>A>	+	GATOR PHARMS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N204553	001	Dec 27, 2016	Dec NEWA
-----	---	--------------	-----------------------------------	---------	-----	--------------	----------

MARAVIROC

SOLUTION; ORAL

SELZENTRY

+	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016	Nov NEWA
---	---------------	---------	---------	-----	--------------	----------

TABLET; ORAL

SELZENTRY

	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Nov NEWA
		75MG	N022128	004	Nov 04, 2016	Nov NEWA

MEBENDAZOLETABLET, CHEWABLE;ORAL
EMVERM

+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Aug CTNA
	VERMOX					
+	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Oct NEWA

MECLIZINE HYDROCHLORIDETABLET;ORAL
MECLIZINE HYDROCHLORIDE

@	RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan CAHN
@		25MG	A040179	002	Jan 30, 1997	Jan CAHN

TABLET, CHEWABLE;ORAL
ANTIVERT

@	CASPER PHARMA LLC	25MG	N010721	005		Jun DISC
---	-------------------	------	---------	-----	--	----------

MEFLOQUINE HYDROCHLORIDETABLET;ORAL
MEFLOQUINE HYDROCHLORIDE

	@	HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May CAHN
AB		WEST-WARD PHARMS INT	250MG	A076523	001	Oct 01, 2004	Nov CAHN

MEGESTROL ACETATESUSPENSION;ORAL
MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN
		MEGESTROL ACETATE					
AB		WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Nov CAHN

TABLET;ORAL
MEGESTROL ACETATE

AB		WEST-WARD PHARMS INT	20MG	A074458	001	Sep 29, 1995	Nov CAHN
AB			40MG	A074458	002	Sep 29, 1995	Nov CAHN

MELOXICAMTABLET;ORAL
MELOXICAM

>D>	AB	APOTEX INC	7.5MG	A077882	001	Jul 20, 2006	Dec CAHN
>A>	AB		7.5MG	A077882	001	Jul 20, 2006	Dec CAHN
>D>	AB		15MG	A077882	002	Jul 20, 2006	Dec CAHN
>A>	AB		15MG	A077882	002	Jul 20, 2006	Dec CAHN
>D>	AB	CARLSBAD	7.5MG	A077918	001	Dec 07, 2006	Dec CAHN
>D>	AB		15MG	A077918	002	Dec 07, 2006	Dec CAHN
		@ FRONTIDA BIOPHARM	7.5MG	A077935	001	Jul 19, 2006	Jul CAHN
		@	15MG	A077935	002	Jul 19, 2006	Jul CAHN
		@ SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
		@	15MG	A077935	002	Jul 19, 2006	Jan CAHN
>A>	AB	YUNG SHIN PHARM	7.5MG	A077918	001	Dec 07, 2006	Dec CAHN
>A>	AB		15MG	A077918	002	Dec 07, 2006	Dec CAHN

MELPHALANTABLET;ORAL
ALKERAN

+	APOTEX INC	2MG	N014691	002		Jan CAHN
---	------------	-----	---------	-----	--	----------

MELPHALAN HYDROCHLORIDEINJECTABLE;INJECTION
ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan CAHN
		MELPHALAN HYDROCHLORIDE					
>A>	AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206018	001	Dec 19, 2016	Dec NEWA
AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Aug NEWA
AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Oct CAHN
		POWDER; IV (INFUSION)					
		EVOMELA					
		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar NEWA

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

AB	AMNEAL PHARMS	7MG	A205825	001	Oct 12, 2016	Oct	NEWA
AB		14MG	A205825	002	Oct 12, 2016	Oct	NEWA
AB		21MG	A205825	003	Oct 12, 2016	Oct	NEWA
AB		28MG	A205825	004	Oct 12, 2016	Oct	NEWA
AB	APOTEX INC	7MG	A206135	001	Nov 22, 2016	Nov	NEWA
AB		14MG	A206135	002	Nov 22, 2016	Nov	NEWA
AB		21MG	A206135	003	Nov 22, 2016	Nov	NEWA
AB		28MG	A206135	004	Nov 22, 2016	Nov	NEWA
AB	LUPIN LTD	7MG	A206028	001	Sep 28, 2016	Sep	NEWA
AB		14MG	A206028	002	Sep 28, 2016	Sep	NEWA
AB		21MG	A206028	003	Sep 28, 2016	Sep	NEWA
AB		28MG	A206028	004	Sep 28, 2016	Sep	NEWA
AB	MYLAN PHARMS INC	7MG	A206032	001	Sep 28, 2016	Sep	NEWA
AB		14MG	A206032	002	Sep 28, 2016	Sep	NEWA
AB		21MG	A206032	003	Sep 28, 2016	Sep	NEWA
AB		28MG	A206032	004	Sep 28, 2016	Sep	NEWA
AB	SUN PHARMA GLOBAL	7MG	A205905	001	Sep 28, 2016	Sep	NEWA
AB		14MG	A205905	002	Sep 28, 2016	Sep	NEWA
AB		21MG	A205905	003	Sep 28, 2016	Sep	NEWA
AB		28MG	A205905	004	Sep 28, 2016	Sep	NEWA
	NAMENDA XR						
AB	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Sep	CFTG
AB		14MG	N022525	002	Jun 21, 2010	Sep	CFTG
AB		21MG	N022525	003	Jun 21, 2010	Sep	CFTG
AB	+	28MG	N022525	004	Jun 21, 2010	Sep	CFTG
	TABLET;ORAL						
	MEMANTINE HYDROCHLORIDE						
AB	SILARX PHARMS INC	5MG	A207236	001	Nov 10, 2016	Oct	NEWA
AB		10MG	A207236	002	Nov 10, 2016	Oct	NEWA

MEPERIDINE HYDROCHLORIDEINJECTABLE;INJECTION
DEMEROL

@	US PHARM HOLDINGS	25MG/ML	N005010	007		Jan	CAHN
@		50MG/ML	N005010	002		Jan	CAHN
@		75MG/ML	N005010	009		Jan	CAHN
@		100MG/ML	N005010	003		Jan	CAHN

SYRUP;ORAL

DEMEROL

@	US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan	CAHN
---	-------------------	----------	---------	-----	--	-----	------

MEPERIDINE HYDROCHLORIDE

+ WEST-WARD PHARMS INT 50MG/5ML

A088744	001	Jan 30, 1985	Nov	CAHN
---------	-----	--------------	-----	------

TABLET;ORAL

DEMEROL

AA	+	US PHARM HOLDINGS	50MG	N005010	001		Jan	CAHN
AA	+		100MG	N005010	004		Jan	CAHN
		MEPERIDINE HYDROCHLORIDE						
	@	SUN PHARM INDS	50MG	A080448	001		Mar	CAHN
	@		100MG	A080448	002		Mar	CAHN
AA		WEST-WARD PHARMS INT	50MG	A040110	001	Mar 12, 1997	Nov	CAHN
AA			100MG	A040110	002	Mar 12, 1997	Nov	CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

@	WEST-WARD PHARMS INT	25MG/ML;25MG/ML	N011730	001		Oct	CAHN
---	----------------------	-----------------	---------	-----	--	-----	------

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPIVACAINE HYDROCHLORIDE

>D>	@	INTL MEDICATION	1%	A087509	001	Oct 05, 1982	Dec	CAHN
>A>	@	INTL MEDICATION SYS	1%	A087509	001	Oct 05, 1982	Dec	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ AUROLIFE PHARMA LLC	400MG	A080655	001		Feb	CAHN
@ SUN PHARM INDS	200MG	A080699	001		Mar	CAHN
@	400MG	A080699	002		Mar	CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr	CAHN
AB	+ WEST-WARD PHARMS INT	50MG	A040528	001	Feb 13, 2004	Nov	CAHN
	PURINETHOL						
AB	STASON PHARMS	50MG	N009053	002		Aug	CMFD
	@	50MG	N009053	002		Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar	NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May	NEWA
AP		1GM/VIAL	A206141	002	Jun 08, 2016	May	NEWA
AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May	NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016	May	NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr	NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr	NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+ APIL	400MG	N204412	001	Feb 01, 2013	Jan	CAHN
--------	-------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

ASACOL

@ APIL	400MG	N019651	001	Jan 31, 1992	Jan	CAHN
ASACOL HD						
+ APIL	800MG	N021830	001	May 29, 2008	Jan	CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	WEST-WARD PHARMS INT	100MG/ML	A075739	001	Jan 09, 2004	Oct	CAHN
----	----------------------	----------	---------	-----	--------------	-----	------

METAXALONE

TABLET; ORAL

METAXALONE

AB	LANNETT HOLDINGS INC	800MG	A204770	001	Nov 22, 2016	Nov	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016	Jun	NEWA
AB		850MG	A205096	002	Jul 11, 2016	Jun	NEWA
AB		1GM	A205096	003	Jul 11, 2016	Jun	NEWA
AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar	CAHN
AB		850MG	A076038	002	Feb 21, 2002	Mar	CAHN
AB		1GM	A076038	003	Feb 21, 2002	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

AB3	SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan	CTEC
AB3	+	1GM	N021748	002	Jun 03, 2005	Jan	CTEC
	METFORMIN HYDROCHLORIDE						
AB3	ACTAVIS LABS FL INC	500MG	A203755	001	Aug 01, 2016	Jul	NEWA
AB3		1GM	A203755	002	Aug 01, 2016	Jul	NEWA
AB1	BEXIMCO PHARMS USA	500MG	A207427	001	Dec 13, 2016	Nov	NEWA
AB		750MG	A207427	002	Dec 13, 2016	Nov	NEWA
	@ IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar	DISC
	@	750MG	A076985	001	Sep 13, 2005	Mar	DISC
AB1	MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	Nov	NEWA
AB		750MG	A206955	002	Dec 07, 2016	Nov	NEWA
AB1	MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL							
METFORMIN HYDROCHLORIDE							
AB		750MG	A090295	002	Apr 29, 2016	Apr	NEWA
	@ SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar	CAHN
AB3	SUN PHARMA GLOBAL	500MG	A202917	001	Aug 01, 2016	Jul	NEWA
AB3		1GM	A202917	002	Aug 01, 2016	Jul	NEWA
<u>METHACHOLINE CHLORIDE</u>							
FOR SOLUTION;INHALATION							
PROVOCHOLINE							
	METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016	Oct	NEWA
<u>METHADONE HYDROCHLORIDE</u>							
CONCENTRATE;ORAL							
METHADONE HYDROCHLORIDE							
AA	WEST-WARD PHARMS INT	10MG/ML	A040180	001	Apr 30, 1998	Nov	CAHN
METHADONE HYDROCHLORIDE INTENSOL							
AA	WEST-WARD PHARMS INT	10MG/ML	A089897	001	Sep 06, 1988	Nov	CAHN
INJECTABLE;INJECTION							
METHADONE HYDROCHLORIDE							
+	MYLAN INSTITUTIONAL	10MG/ML	N021624	001		Nov	CTNA
SOLUTION;ORAL							
METHADONE HYDROCHLORIDE							
AA	+ WEST-WARD PHARMS INT	5MG/5ML	A087393	001		Nov	CAHN
AA	+	10MG/5ML	A087997	001	Aug 30, 1982	Nov	CAHN
TABLET, FOR SUSPENSION;ORAL							
METHADOSE							
AA	MALLINCKRODT INC	40MG	A074184	001	Apr 29, 1993	Aug	CAHN
<u>METHAMPHETAMINE HYDROCHLORIDE</u>							
TABLET;ORAL							
METHAMPHETAMINE HYDROCHLORIDE							
AA	MAYNE PHARMA INC	5MG	A091189	001	Apr 21, 2010	Aug	CAHN
AA	WEST-WARD PHARMS INT	5MG	A203846	001	Nov 17, 2015	Nov	CAHN
<u>METHENAMINE HIPPURATE</u>							
TABLET;ORAL							
HIPREX							
AB	+ US PHARM HOLDINGS	1GM	N017681	001		Jan	CAHN
METHENAMINE HIPPURATE							
AB	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun	NEWA
<u>METHIMAZOLE</u>							
TABLET;ORAL							
METHIMAZOLE							
AB	ECI PHARMS LLC	5MG	A040547	001	Feb 18, 2005	Jul	CAHN
AB		10MG	A040547	002	Feb 18, 2005	Jul	CAHN
	@	20MG	A040547	004	Feb 18, 2005	Jul	CAHN
AB	RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan	CAHN
AB		10MG	A202068	002	Mar 07, 2012	Jan	CAHN
<u>METHOCARBAMOL</u>							
SOLUTION;IM-IV							
METHOCARBAMOL							
AP	AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May	NEWA
AP	MONTEREY PHARMS LLC	1GM/10ML (100MG/ML)	A205354	001	Oct 27, 2016	Oct	NEWA
ROBAXIN							
AP	+ WEST-WARD PHARMS INT	1GM/10ML (100MG/ML)	N011790	001		Oct	CAHN
TABLET;ORAL							
METHOCARBAMOL							
	@ LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Aug	DISC
	@	750MG	A084756	001		Aug	DISC
	@ SANDOZ	500MG	A084616	001		Feb	DISC
	@	750MG	A084615	001		Feb	DISC
	@ SUN PHARM INDS	500MG	A084488	001		Mar	CAHN
	@	750MG	A084486	001		Mar	CAHN
ROBAXIN							
AA	+ AUXILIUM PHARMS INC	500MG	N011011	004		Mar	CAHN
AA	+ AUXILIUM PHARMS LLC	500MG	N011011	004		Jul	CAHN
ROBAXIN-750							
AA	+ AUXILIUM PHARMS INC	750MG	N011011	006		Mar	CAHN

TABLET;ORAL							
ROBAXIN-750							
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Jul CAHN
<u>METHOHEXITAL SODIUM</u>							
INJECTABLE;INJECTION							
BREVITAL SODIUM							
	@	PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC
<u>METHOTREXATE</u>							
SOLUTION;SUBCUTANEOUS							
OTREXUP							
	@	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Sep DISC
			12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May NEWA
			17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May NEWA
			22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May NEWA
<u>METHOTREXATE SODIUM</u>							
INJECTABLE;INJECTION							
METHOTREXATE SODIUM							
AP	+	WEST-WARD PHARMS INT	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Oct CAHN
	+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Oct CAHN
METHOTREXATE SODIUM PRESERVATIVE FREE							
AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN
AP	+	WEST-WARD PHARMS INT	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Oct CAHN
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Oct CAHN
	+		EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Sep CAHN
TABLET;ORAL							
METHOTREXATE SODIUM							
AB		WEST-WARD PHARMS INT	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Nov CAHN
<u>METHOXSALEN</u>							
CAPSULE;ORAL							
METHOXSALEN							
	@	IDT AUSTRALIA LTD	10MG	A087781	001	Jun 08, 1982	Aug CAHN
INJECTABLE;INJECTION							
UVADEX							
	+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr CAHN
<u>METHYLDOPA</u>							
TABLET;ORAL							
METHYLDOPA							
	@	SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar CAHN
	@		250MG	A070060	001	Oct 09, 1986	Mar CAHN
	@		500MG	A070074	001	Oct 09, 1986	Mar CAHN
<u>METHYLENE BLUE</u>							
SOLUTION;INTRAVENOUS							
PROVAYBLUE							
	+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr NEWA
<u>METHYLERGONOVINE MALEATE</u>							
TABLET;ORAL							
METHERGINE							
	@	EDISON THERAPS LLC	0.2MG	N006035	003		Jan DISC
METHYLERGONOVINE MALEATE							
	+	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan CRLD
<u>METHYLNALTREXONE BROMIDE</u>							
SOLUTION;SUBCUTANEOUS							
RELISTOR							
	+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Jul CRLD
TABLET;ORAL							
RELISTOR							
	+	SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016	Jul NEWA

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB2	COREPHARMA	10MG	A205105	001	Jul 28, 2016	Jul	NEWA
AB2		20MG	A205105	002	Jul 28, 2016	Jul	NEWA
AB2		30MG	A205105	003	Jul 28, 2016	Jul	NEWA
AB2		40MG	A205105	004	Jul 28, 2016	Jul	NEWA
AB2		50MG	A205105	005	Jul 28, 2016	Jul	NEWA
AB2		60MG	A205105	006	Jul 28, 2016	Jul	NEWA
AB1	MAYNE PHARMA	20MG	A078458	001	Dec 01, 2011	Aug	CAHN
AB1		30MG	A078458	002	Dec 01, 2011	Aug	CAHN
AB1		40MG	A078458	003	Dec 01, 2011	Aug	CAHN
AB1		60MG	A078458	004	Jun 23, 2016	Aug	CAHN
AB1	WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun	NEWA
	RITALIN LA						
AB1	+ NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun	CFTG

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ABHAI	5MG/5ML	A207485	001	Nov 18, 2016	Nov	NEWA
AA		10MG/5ML	A207485	002	Nov 18, 2016	Nov	NEWA
AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016	Sep	NEWA
AB		10MG	A206840	002	Sep 15, 2016	Sep	NEWA
AB		20MG	A206840	003	Sep 15, 2016	Sep	NEWA

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Oct	CTEC
AB		5MG	A204115	002	Feb 25, 2015	Oct	CTEC
AB	+	10MG	A204115	003	Feb 25, 2015	Oct	CTEC
AB	TEDOR PHARMA INC	2.5MG	A205756	001	Nov 07, 2016	Oct	NEWA
AB		5MG	A205756	002	Nov 07, 2016	Oct	NEWA
AB		10MG	A205756	003	Nov 07, 2016	Oct	NEWA

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

AB	JANSSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Oct	CTEC
AB		27MG	N021121	004	Apr 01, 2002	Oct	CTEC
AB		36MG	N021121	002	Aug 01, 2000	Oct	CTEC
AB	+	54MG	N021121	003	Dec 08, 2000	Oct	CTEC

METHYLPHENIDATE HYDROCHLORIDE

AB	CNTY LINE PHARMS	10MG	A204772	001	Feb 29, 2016	Aug	CAHN
AB		20MG	A204772	002	Feb 29, 2016	Aug	CAHN
AB	MYLAN PHARMS INC	18MG	A206726	001	Oct 21, 2016	Oct	NEWA
AB		27MG	A206726	002	Oct 21, 2016	Oct	NEWA
AB		36MG	A206726	003	Oct 21, 2016	Oct	NEWA
AB		54MG	A206726	004	Oct 21, 2016	Oct	NEWA
AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb	NEWA
AB		20MG	A204772	002	Feb 29, 2016	Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	AMNEAL PHARMS CO	EQ 40MG BASE/VIAL	A207549	001	Nov 09, 2016	Oct	NEWA
AP		EQ 125MG BASE/VIAL	A207549	002	Nov 09, 2016	Oct	NEWA
AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb	NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb	NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan	CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan	CAHN

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 10

	@ VALEANT PHARM INTL	10MG	A086450	001		Apr	DISC
	METHYLTESTOSTERONE						
	@ IMPAX LABS	25MG	A084310	001		Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

REGLAN

@ WEST-WARD PHARMS INT EQ 5MG BASE/ML

N017862 001

Oct CAHN

@ EQ 10MG BASE/ML

N017862 004

May 28, 1987

Oct CAHN

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ SILARX EQ 5MG BASE/5ML

A073680 001

Oct 27, 1992

Aug DISC

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A> AB IMPAX LABS INC EQ 5MG BASE

A071250 002

Dec 28, 1995

Dec CMS1

AB EQ 10MG BASE

A071250 001

Feb 03, 1988

Aug CAHN

AB SUN PHARM INDS EQ 5MG BASE

A071536 002

Jan 16, 1997

Mar CAHN

@ EQ 10MG BASE

A071536 001

Apr 28, 1993

Mar CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB ACTAVIS ELIZABETH EQ 25MG TARTRATE

A204161 001

Nov 25, 2016

Nov NEWA

AB EQ 50MG TARTRATE

A204161 002

Nov 25, 2016

Nov NEWA

AB EQ 100MG TARTRATE

A204161 003

Nov 25, 2016

Nov NEWA

AB EQ 200MG TARTRATE

A204161 004

Nov 25, 2016

Nov NEWA

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

@ SANDOZ 50MG

A073288 001

Mar 25, 1994

May DISC

@ 100MG

A073289 001

Mar 25, 1994

May DISC

AB SUN PHARM INDS 25MG

A073654 002

Jul 15, 2009

Mar CAHN

AB 100MG

A073654 001

Dec 21, 1993

Mar CAHN

METRONIDAZOLE

GEL; VAGINAL

NUVESSA

+ ALLERGAN SALES LLC 1.3%

N205223 001

Mar 24, 2014

Apr CAHN

TABLET; ORAL

METRONIDAZOLE

>A> AB ALLIED PHARMA INC 250MG

A070772 001

Jul 16, 1986

Dec CAHN

>A> AB 500MG

A070773 001

Jul 16, 1986

Dec CAHN

AB FLAMINGO PHARMS 250MG

A207309 001

May 16, 2016

May NEWA

AB 500MG

A207309 002

May 16, 2016

May NEWA

>D> AB NOSTRUM LABS INC 250MG

A070772 001

Jul 16, 1986

Dec CAHN

AB 250MG

A070772 001

Jul 16, 1986

Jan CAHN

>D> AB 500MG

A070773 001

Jul 16, 1986

Dec CAHN

AB 500MG

A070773 001

Jul 16, 1986

Jan CAHN

AB STRIDES PHARMA 250MG

A208162 001

May 25, 2016

May NEWA

AB 500MG

A208162 002

May 25, 2016

May NEWA

AB VIVIMED LABS 250MG

A070040 001

Jan 29, 1985

May CMFD

AB 500MG

A070039 001

Jan 29, 1985

May CMFD

AB ZYDUS PHARMS USA INC 250MG

A206560 001

Nov 16, 2016

Oct NEWA

AB 500MG

A206560 002

Nov 16, 2016

Oct NEWA

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+ ASTELLAS EQ 50MG BASE/VIAL

N021506 002

Mar 16, 2005

Sep CPOT

+ EQ 100MG BASE/VIAL

N021506 003

Jun 27, 2006

Sep CPOT

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ MIDATECH PHARMA US 50MG

N022404 001

Apr 16, 2010

Jan CAHN

MIDAZOLAM HYDROCHLORIDE

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

AA + WEST-WARD PHARMS INT EQ 2MG BASE/ML

A075873 001

Apr 30, 2002

Nov CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

>D>	AB	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Dec CAHN
>A>	AB		2.5MG	A077746	001	Sep 12, 2006	Dec CAHN
>D>	AB		5MG	A077746	002	Sep 12, 2006	Dec CAHN
>A>	AB		5MG	A077746	002	Sep 12, 2006	Dec CAHN
>D>	AB		10MG	A077746	003	Sep 12, 2006	Dec CAHN
>A>	AB		10MG	A077746	003	Sep 12, 2006	Dec CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb CRLD
AB			100MG	N020682	003	Dec 18, 1996	Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr NEWA
AB			25MG	A205081	002	Apr 22, 2016	Apr NEWA
AB			50MG	A205081	003	Apr 22, 2016	Apr NEWA
AB			100MG	A205081	004	Apr 22, 2016	Apr NEWA
	@	LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan DISC
			12.5MG	A205071	001	Jan 27, 2016	Jan NEWA
	@		25MG	A205071	002	Jan 27, 2016	Jan DISC
			25MG	A205071	002	Jan 27, 2016	Jan NEWA
	@		50MG	A205071	003	Jan 27, 2016	Jan DISC
			50MG	A205071	003	Jan 27, 2016	Jan NEWA
	@		100MG	A205071	004	Jan 27, 2016	Jan DISC
			100MG	A205071	004	Jan 27, 2016	Jan NEWA
		SAVELLA					
AB		CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr CFTG
AB			25MG	N022256	002	Jan 14, 2009	Apr CFTG
AB	+		50MG	N022256	003	Jan 14, 2009	Apr CFTG
AB			100MG	N022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

AP		CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004	Sep DISC
	@	CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

@ CNTY LINE PHARMS EQ 50MG BASE

MINOCYCLINE HYDROCHLORIDE

AB		ZYDUS WORLDWIDE	EQ 50MG BASE	A063011	001	Mar 02, 1992	Aug CAHN
AB			EQ 75MG BASE	A063009	002	Aug 12, 2003	Aug CAHN
AB	+		EQ 100MG BASE	A063009	001	Mar 02, 1992	Aug CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB			EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB			EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 45MG BASE	A204453	001	Sep 28, 2016	Sep NEWA
AB			EQ 80MG BASE	A204453	002	Sep 28, 2016	Sep NEWA
AB			EQ 90MG BASE	A204453	003	Sep 28, 2016	Sep NEWA
AB			EQ 105MG BASE	A204453	004	Sep 28, 2016	Sep NEWA
AB			EQ 135MG BASE	A204453	005	Sep 28, 2016	Sep NEWA
AB		AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May NEWA
AB			EQ 105MG BASE	A202261	007	Jun 13, 2016	May NEWA
>D>	AB	BARR LABS INC	EQ 45MG BASE	A065485	001	Mar 17, 2009	Dec DISC
>A>	@		EQ 45MG BASE	A065485	001	Mar 17, 2009	Dec DISC

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

>D>	AB		EQ 65MG BASE	A065485	004	May 18, 2012	Dec	DISC
>A>		@	EQ 65MG BASE	A065485	004	May 18, 2012	Dec	DISC
>D>	AB		EQ 90MG BASE	A065485	002	Mar 17, 2009	Dec	DISC
>A>		@	EQ 90MG BASE	A065485	002	Mar 17, 2009	Dec	DISC
>D>	AB		EQ 115MG BASE	A065485	005	May 18, 2012	Dec	DISC
>A>		@	EQ 115MG BASE	A065485	005	May 18, 2012	Dec	DISC
>D>	AB		EQ 135MG BASE	A065485	003	Mar 17, 2009	Dec	DISC
>A>		@	EQ 135MG BASE	A065485	003	Mar 17, 2009	Dec	DISC
		@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar	DISC
		@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar	DISC
		@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar	DISC
		SOLODYN						
>D>	AB		EQ 65MG BASE	N050808	004	Jul 23, 2009	Dec	CTEC
>A>			EQ 65MG BASE	N050808	004	Jul 23, 2009	Dec	CTEC
>D>	AB	+	EQ 115MG BASE	N050808	005	Jul 23, 2009	Dec	CTEC
>A>		+	EQ 115MG BASE	N050808	005	Jul 23, 2009	Dec	CTEC

MINOXIDIL

TABLET;ORAL
MINOXIDIL

AB		SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS
KYNAMRO

+		KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun	CAHN
---	--	--------------------	---------------------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET;ORAL
MIRTAZAPINE

		@ ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan	DISC
		@	30MG	A076336	002	Jun 20, 2003	Jan	DISC
		@	45MG	A076336	003	Jun 20, 2003	Jan	DISC
>D>	AB		15MG	A077666	001	Aug 22, 2007	Dec	CAHN
>A>	AB		15MG	A077666	001	Aug 22, 2007	Dec	CAHN
>D>	AB		30MG	A077666	002	Aug 22, 2007	Dec	CAHN
>A>	AB		30MG	A077666	002	Aug 22, 2007	Dec	CAHN
>D>	AB		45MG	A077666	003	Aug 22, 2007	Dec	CAHN
>A>	AB		45MG	A077666	003	Aug 22, 2007	Dec	CAHN
		@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Oct	CAHN
AB			15MG	A076219	001	Jun 19, 2003	Oct	CAHN
		@	30MG	A076189	002	Jun 19, 2003	Oct	CAHN
AB			30MG	A076219	002	Jun 19, 2003	Oct	CAHN
		@	45MG	A076189	003	Jun 19, 2003	Oct	CAHN
AB			45MG	A076219	003	Jun 19, 2003	Oct	CAHN
		TABLET, ORALLY DISINTEGRATING;ORAL						
		MIRTAZAPINE						
AB		IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005	Aug	CAHN
AB			30MG	A076901	002	Jun 28, 2005	Aug	CAHN
AB			45MG	A076901	003	Jun 28, 2005	Aug	CAHN

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

AP		EUROHLTH INTL SARL	5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
AP			20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION
MITOXANTRONE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Oct	CAHN
AP			EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Oct	CAHN
AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Oct	CAHN

MODAFINILTABLET;ORAL
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOEXIPRIL HYDROCHLORIDETABLET;ORAL
MOEXIPRIL HYDROCHLORIDE

AB	+ TEVA	15MG	A076204	002	May 08, 2003	Aug CRLD
----	--------	------	---------	-----	--------------	----------

MOMETASONE FUROATECREAM;TOPICAL
ELOCON

AB	+ @ MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987	Aug DISC
		0.1%	N019625	002	Apr 19, 2013	Aug CRLD

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
	NASONEX					
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MONTELUKAST SODIUMTABLET;ORAL
MONTELUKAST SODIUM

AB	CIPLA LTD	EQ 10MG BASE	A207463	001	Oct 28, 2016	Oct NEWA
AB	WEST-WARD PHARMS INT	EQ 10MG BASE	A090655	001	Aug 03, 2012	Nov CAHN

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

AB	WEST-WARD PHARMS INT	EQ 4MG BASE	A091128	001	Aug 03, 2012	Nov CAHN
AB		EQ 5MG BASE	A091128	002	Aug 03, 2012	Nov CAHN

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB		20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB		30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB		40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB		50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB		60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB		70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB		80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+	100MG	N020616	003	Jul 03, 1996	Feb CTEC
	+	200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+ ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB		20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB		30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB		40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB		50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB		60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB		70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB		80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+	100MG	N020616	003	Jul 03, 1996	Apr CAHN
		130MG	N020616	011	Jul 09, 2012	Apr CAHN
		150MG	N020616	012	Jul 09, 2012	Apr CAHN
	+	200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB		30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB		30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb CTEC

INJECTABLE;INJECTION
DURAMORPH PF

AP	+	WEST-WARD PHARMS INT	0.5MG/ML	N018565	001	Sep 18, 1984	Oct CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Oct CAHN
		INFUMORPH					
	+	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991	Oct CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Oct CAHN

SOLUTION;ORAL

MORPHINE SULFATE

AA		NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA			20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
AA			100MG/5ML	A204053	001	Oct 06, 2016	Sep NEWA
AA		PHARM ASSOC	100MG/5ML	A206573	001	Nov 14, 2016	Oct NEWA
AA		RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun NEWA
AA		TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHABOND

>A>		DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Dec CAHN
>A>			30MG	N206544	002	Oct 02, 2015	Dec CAHN
>A>			60MG	N206544	003	Oct 02, 2015	Dec CAHN
>A>	+		100MG	N206544	004	Oct 02, 2015	Dec CAHN
>D>		IDT	15MG	N206544	001	Oct 02, 2015	Dec CAHN
>D>			30MG	N206544	002	Oct 02, 2015	Dec CAHN
>D>			60MG	N206544	003	Oct 02, 2015	Dec CAHN
>D>	+		100MG	N206544	004	Oct 02, 2015	Dec CAHN

MORPHINE SULFATE

AB		COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun NEWA
AB			30MG	A091357	002	Jun 23, 2016	Jun NEWA
AB			60MG	A091357	003	Jun 23, 2016	Jun NEWA
AB			100MG	A091357	004	Jun 23, 2016	Jun NEWA
AB			200MG	A091357	005	Jun 23, 2016	Jun NEWA
AB		MAYNE PHARMA INC	15MG	A205386	001	Oct 28, 2016	Oct NEWA
AB			30MG	A205386	002	Oct 28, 2016	Oct NEWA
AB			60MG	A205386	003	Oct 28, 2016	Oct NEWA
AB			100MG	A205386	004	Oct 28, 2016	Oct NEWA
AB		SUN PHARM INDS LTD	15MG	A205634	001	Aug 25, 2016	Aug NEWA
AB			30MG	A205634	002	Aug 25, 2016	Aug NEWA
AB			60MG	A205634	003	Aug 25, 2016	Aug NEWA
AB			100MG	A205634	004	Aug 25, 2016	Aug NEWA
AB			200MG	A205634	005	Aug 25, 2016	Aug NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

AT2	+	NOVARTIS PHARMS CORP	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Nov CAHN	
		VIGAMOX						
>D>	AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Dec CAHN
>A>	AT1	+	NOVARTIS PHARMS CORP	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Dec CAHN

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan NEWA
----	--	----------------	---------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun CAHN
AB	WEST-WARD PHARMS INT	250MG	A065410	001	Jul 29, 2008	Nov CAHN

TABLET;ORAL

MYCOPHENOLATE MOFETIL

AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun CAHN
AB	WEST-WARD PHARMS INT	500MG	A065413	001	Jul 29, 2008	Nov CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

CELLCEPT

AP	+	ROCHE PALO	500MG/VIAL	N050758	001	Aug 12, 1998	Oct CFTG
AP		MYCOPHENOLATE MOFETIL HYDROCHLORIDE					
AP		PAR STERILE PRODUCTS	500MG/VIAL	A203575	001	Oct 28, 2016	Oct NEWA

NABUMETONE

TABLET;ORAL

NABUMETONE

>A>	AB	CHARTWELL MOLECULES	500MG	A076009	001	Jan 24, 2003	Dec CAHN
>A>	AB		750MG	A076009	002	Jan 24, 2003	Dec CAHN
	AB	IMPAX LABS INC	500MG	A075189	001	May 26, 2000	Aug CAHN
	AB	+	750MG	A075189	002	Sep 24, 2001	Aug CAHN
>D>	AB	PAR PHARM	500MG	A076009	001	Jan 24, 2003	Dec CAHN
>D>	AB		750MG	A076009	002	Jan 24, 2003	Dec CAHN

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		TARO	1%	A205975	001	Sep 08, 2016	Aug NEWA	
		NAFTIN						
>D>	AB	+	MERZ PHARMS	1%	N019599	001	Feb 29, 1988	
	AB	+		1%	N019599	001	Feb 29, 1988	Aug CFTG
>D>	AB	+		2%	N019599	002	Jan 13, 2012	Dec CAHN
>A>	AB	+	SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988	Dec CAHN
>A>	AB	+		2%	N019599	002	Jan 13, 2012	Dec CAHN

GEL;TOPICAL

NAFTIN

>D>	+	MERZ PHARMS	1%	N019356	001	Jun 18, 1990	Dec CAHN
>D>	+		2%	N204286	001	Jun 27, 2013	Dec CAHN
>A>	+	SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Dec CAHN
>A>	+		2%	N204286	001	Jun 27, 2013	Dec CAHN

NALIDIXIC ACID

TABLET;ORAL

NALIDIXIC ACID

@	SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar CAHN
@		500MG	A070271	001	Jun 29, 1988	Jun CAHN
@		1GM	A070272	001	Jun 29, 1988	Mar CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

AP	WEST-WARD PHARMS INT	0.4MG/ML	A070299	001	Sep 24, 1986	Oct CAHN
	NALOXONE HYDROCHLORIDE					

AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun NEWA
----	---------------------	----------	---------	-----	--------------	----------

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO

+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014	Oct CPOT
+		2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Oct NEWA

SPRAY, METERED;NASAL

NARCAN

>A>	+	ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	Dec CAHN
>D>	+	ADAPT PHARMA	4MG/SPRAY	N208411	001	Nov 18, 2015	Dec CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL							
NALTREXONE HYDROCHLORIDE							
AB	+	MALLINCKRODT	50MG	A076264	002	Mar 22, 2002	Oct CRLD
REVIA							
	@	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984	Oct DISC

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL							
TROXYCA ER							
PFIZER INC							
			1.2MG; 10MG	N207621	001	Aug 19, 2016	Aug NEWA
			2.4MG; 20MG	N207621	002	Aug 19, 2016	Aug NEWA
			3.6MG; 30MG	N207621	003	Aug 19, 2016	Aug NEWA
			4.8MG; 40MG	N207621	004	Aug 19, 2016	Aug NEWA
			7.2MG; 60MG	N207621	005	Aug 19, 2016	Aug NEWA
			9.6MG; 80MG	N207621	006	Aug 19, 2016	Aug NEWA

NAPROXEN

SUSPENSION; ORAL							
NAPROSYN							
AB	+	ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun CAHN
NAPROXEN							
AB		WEST-WARD PHARMS INT	25MG/ML	A074190	001	Mar 30, 1994	Nov CAHN
TABLET; ORAL							
NAPROSYN							
AB		ATNAHS PHARMA US	250MG	N017581	002		Feb CAHN
AB			375MG	N017581	003		Feb CAHN
AB	+		500MG	N017581	004	Apr 15, 1982	Feb CAHN
NAPROXEN							
	@	SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb DISC
	@		375MG	A074140	002	Dec 21, 1993	Feb DISC
	@		500MG	A074140	003	Dec 21, 1993	Feb DISC
TABLET, DELAYED RELEASE; ORAL							
EC-NAPROSYN							
AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb CAHN
AB	+		500MG	N020067	003	Oct 14, 1994	Feb CAHN
NAPROXEN							
	@	SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb DISC
	@		500MG	A075061	002	Feb 18, 1998	Feb DISC

NAPROXEN SODIUM

TABLET; ORAL							
ANAPROX							
AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb CAHN
ANAPROX DS							
AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb CAHN
NAPROXEN SODIUM							
>D> AB		HIKMA	EQ 250MG BASE	A074480	002	Feb 18, 1998	Dec DISC
>A>	@		EQ 250MG BASE	A074480	002	Feb 18, 1998	Dec DISC
>D> AB			EQ 500MG BASE	A074480	001	May 14, 1996	Dec DISC
>A>	@		EQ 500MG BASE	A074480	001	May 14, 1996	Dec DISC
TABLET, EXTENDED RELEASE; ORAL							
NAPRELAN							
AB	+	ALVOGEN MALTA	EQ 750MG BASE	N020353	003	Jan 05, 1996	Aug CFTG
NAPROXEN SODIUM							
AB		ACTAVIS LABS FL INC	EQ 750MG BASE	A075416	003	Aug 11, 2016	Aug NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL							
NARATRIPTAN							
AB		WEST-WARD PHARMS INT	EQ 1MG BASE	A090381	001	Jul 07, 2010	Nov CAHN
AB			EQ 2.5MG BASE	A090381	002	Jul 07, 2010	Nov CAHN

NATEGLINIDE

TABLET; ORAL							
NATEGLINIDE							
AB		ZYDUS PHARMS USA INC	60MG	A205248	001	Jul 06, 2016	Jun NEWA
AB			120MG	A205248	002	Jul 06, 2016	Jun NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

FOREST LABS LLC

EQ 5MG BASE; 80MG

N206302 001 Jun 03, 2016 Jun NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@ SUN PHARM INDS LTD 50MG

A076409 001 Sep 16, 2003 Feb DISC

@ 100MG

A076409 002 Sep 16, 2003 Feb DISC

@ 150MG

A076409 003 Sep 16, 2003 Feb DISC

@ 200MG

A076409 004 Sep 16, 2003 Feb DISC

@ 250MG

A076409 005 Sep 16, 2003 Feb DISC

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA LANNETT HOLDINGS INC 500MG

A204435 001 Jun 10, 2016 May NEWA

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+ NOVARTIS PHARMS CORP 0.3%

N203491 001 Oct 16, 2012 Nov CAHN

NEVANAC

>D> + ALCON PHARMS LTD 0.1%

N021862 001 Aug 19, 2005 Dec CAHN

>A> + NOVARTIS PHARMS CORP 0.1%

N021862 001 Aug 19, 2005 Dec CAHN

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB AUROBINDO PHARMA LTD 100MG

A208616 001 Nov 23, 2016 Nov NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

@ CHIESI USA INC 20MG

N019488 001 Dec 21, 1988 May DISC

@ 30MG

N019488 002 Dec 21, 1988 May DISC

NICARDIPINE HYDROCHLORIDE

AB + MYLAN 30MG

A074642 002 Jul 18, 1996 May CRLD

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB VALIDUS PHARMS 10MG

A073250 001 Oct 08, 1991 Jul CMFD

@ 10MG

A073250 001 Oct 08, 1991 Mar CAHN

AB 20MG

A074045 001 Apr 30, 1992 Jul CMFD

@ 20MG

A074045 001 Apr 30, 1992 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

AB1 ALVOGEN 30MG

N020198 001 Apr 21, 1993 Feb CAHN

AB1 + 60MG

N020198 002 Apr 21, 1993 Feb CAHN

AB1 + 90MG

N020198 003 Apr 21, 1993 Feb CAHN

NIFEDIPINE

AB1 NOVAST LABS LTD 30MG

A202987 001 Aug 25, 2016 Aug NEWA

AB1 60MG

A202987 002 Aug 25, 2016 Aug NEWA

AB1 90MG

A202987 003 Aug 25, 2016 Aug NEWA

AB2 OSMOTICA PHARM US 30MG

A077127 001 Nov 21, 2005 Jun CAHN

AB2 60MG

A077127 002 Nov 21, 2005 Jun CAHN

AB1 VALEANT PHARMS NORTH 30MG

A075269 001 Dec 04, 2000 Jan CAHN

AB1 60MG

A075269 002 Dec 04, 2000 Jan CAHN

AB1 90MG

A076070 001 Aug 16, 2002 Jan CAHN

NILUTAMIDE

TABLET; ORAL

NILANDRON

AB + CONCORDIA PHARMS INC 150MG

N020169 002 Apr 30, 1999 Jul CFTG

NILUTAMIDE

AB ANI PHARMS INC 150MG

A207631 001 Jul 15, 2016 Jul NEWA

NIMODIPINECAPSULE;ORAL
NIMODIPINE

AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan CAHN
AB		HERITAGE PHARMS INC	30MG	A077811	001	May 02, 2007	Aug CAHN

NISOLDIPINETABLET, EXTENDED RELEASE;ORAL
SULAR

AB	+	COVIS PHARMA SARL	8.5MG	N020356	008	Jan 02, 2008	Nov CAHN
		@	10MG	N020356	001	Feb 02, 1995	Nov CAHN
AB	+		17MG	N020356	007	Jan 02, 2008	Nov CAHN
		@	20MG	N020356	002	Feb 02, 1995	Nov CAHN
		@	25.5MG	N020356	006	Jan 02, 2008	Nov CAHN
		@	30MG	N020356	003	Feb 02, 1995	Nov CAHN
AB	+		34MG	N020356	005	Jan 02, 2008	Nov CAHN
		@	40MG	N020356	004	Feb 02, 1995	Nov CAHN

NITISINONECAPSULE;ORAL
ORFADIN

+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun NEWA
---	----------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL
ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr NEWA
---	----------------	--------	---------	-----	--------------	----------

NITRIC OXIDEGAS; INHALATION
INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan CAHN
---	-------------------	--------	---------	-----	--------------	----------

NITROFURANTOINSUSPENSION;ORAL
FURADANTIN

AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun CAHN
----	---	-------------------	----------	---------	-----	--	----------

NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr NEWA
AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
NITROFURANTOIN

AB		IMPAX LABS INC	50MG	A073671	001	Jan 28, 1993	Aug CAHN
AB			100MG	A073652	001	Jan 28, 1993	Aug CAHN
AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb NEWA
AB			50MG	A201722	002	Feb 16, 2016	Feb NEWA
AB			100MG	A201722	003	Feb 16, 2016	Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACROBID

AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan CAHN
----	---	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May CAHN
-----	--	----------------------	----------	---------	-----	--------------	----------

POWDER;SUBLINGUAL
GONITRO

+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun NEWA
---	--------------	--------------	---------	-----	--------------	----------

TABLET;SUBLINGUAL
NITROGLYCERIN

AB		DR REDDYS LABS INC	0.3MG	A208191	001	Aug 26, 2016	Aug NEWA
AB			0.4MG	A208191	002	Aug 26, 2016	Aug NEWA
AB			0.6MG	A208191	003	Aug 26, 2016	Aug NEWA

NITROSTAT

AB		PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000	Aug CFTG
AB			0.4MG	N021134	002	May 01, 2000	Aug CFTG
AB	+		0.6MG	N021134	003	May 01, 2000	Aug CFTG

NIZATIDINESOLUTION;ORAL
NIZATIDINE

+ AMNEAL PHARMS 15MG/ML

A090576 001 Nov 18, 2009 Feb CRLD

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP CLARIS EQ 1MG BASE/ML

A040859 001 Mar 27, 2012 Jan CAHN

NORETHINDRONETABLET;ORAL-28
CAMILA

AB1 MAYNE PHARMA 0.35MG

A076177 001 Oct 21, 2002 Aug CAHN

ERRIN

AB2 MAYNE PHARMA 0.35MG

A076225 001 Oct 21, 2002 Aug CAHN

INCASSIA

AB1 AUROBINDO PHARMA LTD 0.35MG

A207304 001 Sep 23, 2016 Sep NEWA

NOR-QD

AB1 + APIL 0.35MG

N017060 001 Jan CAHN

NORETHINDRONE

AB1 ACCORD HLTHCARE 0.35MG

A206807 001 Dec 13, 2016 Nov NEWA

AB1 AMNEAL PHARMS 0.35MG

A202260 001 Aug 01, 2013 Aug CAHN

AB2 GLENMARK GENERICS 0.35MG

A091209 001 Jul 22, 2010 Oct CMS1

NORETHINDRONE ACETATETABLET;ORAL
NORETHINDRONE ACETATE

AB JAI PHARMA LTD 5MG

A205278 001 Nov 10, 2016 Oct NEWA

NORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC EQ 10MG BASE

A074835 001 Jun 30, 1997 Feb CAHN

@ EQ 25MG BASE

A074835 002 Jun 30, 1997 Feb CAHN

@ EQ 50MG BASE

A074835 003 Jun 30, 1997 Feb CAHN

@ EQ 75MG BASE

A074835 004 Jun 30, 1997 Feb CAHN

@ IDT AUSTRALIA LTD EQ 10MG BASE

A074054 001 Dec 31, 1992 May CAHN

@ EQ 25MG BASE

A074054 002 Dec 31, 1992 May CAHN

@ EQ 50MG BASE

A074054 003 Dec 31, 1992 May CAHN

@ EQ 75MG BASE

A074054 004 Dec 31, 1992 May CAHN

AB MAYNE PHARMA EQ 10MG BASE

A073553 001 Mar 30, 1992 Aug CAHN

AB EQ 25MG BASE

A073554 001 Mar 30, 1992 Aug CAHN

AB EQ 50MG BASE

A073555 001 Mar 30, 1992 Aug CAHN

AB EQ 75MG BASE

A073556 001 Mar 30, 1992 Aug CAHN

>A> NUSINERSEN SODIUM>A> SOLUTION;INTRATHECAL
>A> SPINRAZA

>A> + BIOGEN IDEC 12MG/5ML (2.4MG/ML)

N209531 001 Dec 23, 2016 Dec NEWA

NYSTATINPOWDER;TOPICAL
NYSTATIN

AT + MAYNE PHARMA INC 100,000 UNITS/GM

A065203 001 Jul 15, 2004 Aug CAHN

TABLET;ORAL
NYSTATIN

AA SUN PHARM INDS 500,000 UNITS

A062838 001 Dec 22, 1988 Mar CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT DR REDDYS LABS LTD 100,000 UNITS/GM;0.1%

A208326 001 Oct 26, 2016 Oct NEWA

AT GLENMARK PHARMS LTD 100,000 UNITS/GM;0.1%

A208136 001 Oct 24, 2016 Oct NEWA

NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM 100,000 UNITS/GM;0.1%

A062596 001 Oct 08, 1985 Mar CMS1

OINTMENT;TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM;0.1%

A062733 001 Mar 06, 1987 May CMS1

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jun NEWA	
>A>	AT	PERRIGO UK FINCO	100,000 UNITS/GM;0.1%	A207380	001	Dec 20, 2016	Dec NEWA
>A>	AT	RICONPHARMA LLC	100,000 UNITS/GM;0.1%	A206785	001	Dec 29, 2016	Dec NEWA
>A>	AT	TELIGENT PHARMA INC	100,000 UNITS/GM;0.1%	A208287	001	Dec 30, 2016	Dec NEWA

OBETICHOLIC ACID

TABLET;ORAL

OCALIVA

	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May NEWA
+		10MG	N207999	002	May 27, 2016	May NEWA

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	+	WEST-WARD PHARMS INT	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005	Oct CAHN
AP	+		EQ 1MG BASE/ML	A076330	002	Apr 08, 2005	Oct CAHN
	@	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan DISC
	@		EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan DISC
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
AP	+	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005	Oct CAHN
AP	+		EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005	Oct CAHN
AP	+		EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005	Oct CAHN
	@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan DISC
	@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan DISC
	@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan DISC
		OCTREOTIDE ACETATE PRESERVATIVE FREE					
	@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb CMS1
	@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb CMS1
	@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb CMS1

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar CAHN
	SOLUTION/DROPS;OTIC					
	OFLOXACIN					
AT	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar CAHN
AT	+ BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb CRLD

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016	Aug NEWA
AB		5MG	A206711	002	Aug 30, 2016	Aug NEWA
AB		7.5MG	A206711	003	Aug 30, 2016	Aug NEWA
AB		10MG	A206711	004	Aug 30, 2016	Aug NEWA
AB		15MG	A206711	005	Aug 30, 2016	Aug NEWA
AB		20MG	A206711	006	Aug 30, 2016	Aug NEWA
AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb NEWA
AB		5MG	A203333	002	Mar 15, 2016	Feb NEWA
AB		7.5MG	A203333	003	Mar 15, 2016	Feb NEWA
AB		10MG	A203333	004	Mar 15, 2016	Feb NEWA
AB		15MG	A203333	005	Mar 15, 2016	Feb NEWA
AB		20MG	A203333	006	Mar 15, 2016	Feb NEWA
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan NEWA
AB		5MG	A204319	002	Jan 27, 2016	Jan NEWA
AB		7.5MG	A204319	003	Jan 27, 2016	Jan NEWA
AB		10MG	A204319	004	Jan 27, 2016	Jan NEWA
AB		15MG	A204319	005	Jan 27, 2016	Jan NEWA
AB		20MG	A204319	006	Jan 27, 2016	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb NEWA
AB		10MG	A203456	002	Mar 16, 2016	Feb NEWA
AB		15MG	A203456	003	Mar 16, 2016	Feb NEWA
AB		20MG	A203456	004	Mar 16, 2016	Feb NEWA

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

AB		DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002	Oct CFTG
AB			20MG	N021286	003	Apr 25, 2002	Oct CFTG
AB	+		40MG	N021286	004	Apr 25, 2002	Oct CFTG
		OLMESARTAN MEDOXOMIL					
AB		MYLAN PHARMS INC	5MG	A078276	001	Oct 26, 2016	Oct NEWA
AB			20MG	A078276	002	Oct 26, 2016	Oct NEWA
AB			40MG	A078276	003	Oct 26, 2016	Oct NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>A>	AT	AKORN INC	EQ 0.1% BASE	A204532	001	Jan 10, 2017	Dec NEWA
	AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN
		PATADAY					
>D>	AT	+	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004
>A>	AT	+	NOVARTIS PHARMS CORP	EQ 0.2% BASE	N021545	001	Dec 22, 2004
		PATANOL					
>D>	AT	+	ALCON	EQ 0.1% BASE	N020688	001	Dec 18, 1996
>A>	AT	+	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020688	001	Dec 18, 1996
		PAZEO					
>D>		+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015
>A>		+	NOVARTIS PHARMS CORP	EQ 0.7% BASE	N206276	001	Jan 30, 2015
		SPRAY, METERED; NASAL					
		PATANASE					
AB	+	NOVARTIS PHARMS CORP	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Nov CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	--	---------------	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	20MG; 1.1GM	A204228	001	Jul 15, 2016	Jul NEWA
AB			40MG; 1.1GM	A204228	002	Jul 15, 2016	Jul NEWA
AB		AUROLIFE PHARMA LLC	20MG; 1.1GM	A204922	001	Aug 19, 2016	Aug NEWA
AB			40MG; 1.1GM	A204922	002	Aug 19, 2016	Aug NEWA
AB		DR REDDYS LABS LTD	20MG; 1.1GM	A204068	001	Jul 15, 2016	Jul NEWA
AB			40MG; 1.1GM	A204068	002	Jul 15, 2016	Jul NEWA
AB		SCIEGEN PHARMS INC	20MG; 1.1GM	A207476	001	Dec 06, 2016	Nov NEWA
AB			40MG; 1.1GM	A207476	002	Dec 06, 2016	Nov NEWA

FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AA		AJANTA PHARMA LTD	20MG/PACKET; 1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul NEWA
AA			40MG/PACKET; 1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul NEWA
		ZEGERID					
AA		SANTARUS INC	20MG/PACKET; 1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul CTEC
AA	+		40MG/PACKET; 1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul CTEC

ONDANSETRON

FILM; ORAL

ZUPLENZ

		MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun CAHN
	+		8MG	N022524	002	Jul 02, 2010	Jun CAHN
		TABLET, ORALLY DISINTEGRATING; ORAL					
		ONDANSETRON					
>A>	@	CHARTWELL PHARMS LLC	4MG	A076506	001	Dec 26, 2006	Dec CAHN
>A>	@		8MG	A076506	002	Dec 26, 2006	Dec CAHN
>A>	@		16MG	A077406	001	Dec 26, 2006	Dec CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

>A>	@	24MG	A077406	002	Dec 26, 2006	Dec CAHN
>D>	@ PAR PHARM	4MG	A076506	001	Dec 26, 2006	Dec CAHN
>D>	@	8MG	A076506	002	Dec 26, 2006	Dec CAHN
>D>	@	16MG	A077406	001	Dec 26, 2006	Dec CAHN
>D>	@	24MG	A077406	002	Dec 26, 2006	Dec CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	+	CLARIS	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CRLD
		@ LANNETT	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010	Aug DISC

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
AP	+	CLARIS	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CRLD

ZOFRAN

		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug DISC
--	--	------------------------	----------------	---------	-----	--------------	----------

ZOFRAN PRESERVATIVE FREE

		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Aug DISC
--	--	------------------------	----------------	---------	-----	--------------	----------

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA		WEST-WARD PHARMS INT	EQ 4MG BASE/5ML	A076960	001	Dec 26, 2006	Nov CAHN
----	--	----------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

>A>	@	CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25, 2007	Dec CAHN
>A>	@		EQ 8MG BASE	A077303	002	Jun 25, 2007	Dec CAHN
>A>	@		EQ 24MG BASE	A077303	004	Jun 25, 2007	Dec CAHN
	@	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
	@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
	@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN
>D>	@	PAR PHARM	EQ 4MG BASE	A077303	001	Jun 25, 2007	Dec CAHN
>D>	@		EQ 8MG BASE	A077303	002	Jun 25, 2007	Dec CAHN
>D>	@		EQ 24MG BASE	A077303	004	Jun 25, 2007	Dec CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

AP		WEST-WARD PHARMS INT	30MG/ML	A040463	001	Mar 04, 2003	Sep CAHN
----	--	----------------------	---------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul NEWA
AB			EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul NEWA
AB			EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul NEWA

TAMIFLU

AB		ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul CFTG
AB			EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul CFTG
AB	+		EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul CFTG

OXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

AP		QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
AP			50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
AP			100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
	+		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
AP			200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
	@	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Aug DISC
	@		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Aug DISC

OXAPROZIN

TABLET;ORAL

OXAPROZIN

>D>	AB	APOTEX INC	600MG	A075987	001	Sep 02, 2004	Dec CAHN
>A>	AB		600MG	A075987	001	Sep 02, 2004	Dec CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

@ FRONTIDA BIOPHARM	10MG	A 071026	002	Aug 10, 1987	Oct CAHN
@	15MG	A 071026	003	Aug 10, 1987	Oct CAHN
@	30MG	A 071026	001	Aug 10, 1987	Oct CAHN
@ SUN PHARM INDS	10MG	A 071026	002	Aug 10, 1987	Mar CAHN
@	15MG	A 071026	003	Aug 10, 1987	Mar CAHN
@	30MG	A 071026	001	Aug 10, 1987	Mar CAHN

TABLET;ORAL

OXAZEPAM

@ FRONTIDA BIOPHARM	15MG	A 070683	001	Jan 16, 1987	Jul CAHN
@ SUN PHARM INDS	15MG	A 070683	001	Jan 16, 1987	Jun CAHN

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB WEST-WARD PHARMS INT	300MG/5ML	A 201193	001	Oct 03, 2012	Nov CAHN
-------------------------	-----------	----------	-----	--------------	----------

TABLET;ORAL

OXCARBAZEPINE

AB ANI PHARMS INC	150MG	A 078005	001	Dec 11, 2007	Jun CMFD
AB	300MG	A 078005	002	Dec 11, 2007	Jun CMFD
AB	600MG	A 078005	003	Dec 11, 2007	Jun CMFD
AB WEST-WARD PHARMS INT	150MG	A 077795	001	Oct 09, 2007	Nov CAHN
AB	300MG	A 077795	002	Oct 09, 2007	Nov CAHN
AB	600MG	A 077795	003	Oct 09, 2007	Nov CAHN

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB TARO	EQ 1% BASE	A 205076	001	Mar 07, 2016	Feb NEWA
AB + OXISTAT					
AB + FOUGERA PHARMS	EQ 1% BASE	N 019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

AB + ALLERGAN SALES LLC	3.9MG/24HR	N 021351	002	Feb 26, 2003	Apr CAHN
-------------------------	------------	----------	-----	--------------	----------

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

+ ALLERGAN SALES LLC	3%	N 202513	001	Dec 07, 2011	Apr CAHN
----------------------	----	----------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

+ ALLERGAN SALES LLC	10%(100MG/PACKET)	N 022204	001	Jan 27, 2009	Apr CAHN
----------------------	-------------------	----------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB ACCORD HLTHCARE	5MG	A 207138	001	Feb 29, 2016	Feb NEWA
AB	10MG	A 207138	002	Feb 29, 2016	Feb NEWA
AB	15MG	A 207138	003	Feb 29, 2016	Feb NEWA
AB OSMOTICA PHARM US	5MG	A 078503	001	Feb 04, 2009	Jun CAHN
AB	10MG	A 078503	002	Feb 04, 2009	Jun CAHN
AB	15MG	A 078503	003	Feb 04, 2009	Jun CAHN
AB UNIQUE PHARM LABS	5MG	A 206121	001	May 27, 2016	May NEWA
AB	10MG	A 206121	002	May 27, 2016	May NEWA
AB	15MG	A 206121	003	May 27, 2016	May NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

COLLEGIUM PHARM INC	9MG	N 208090	001	Apr 26, 2016	May CAIN
	13.5MG	N 208090	002	Apr 26, 2016	May CAIN
	18MG	N 208090	003	Apr 26, 2016	May CAIN
	27MG	N 208090	004	Apr 26, 2016	May CAIN
+	36MG	N 208090	005	Apr 26, 2016	May CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar	NEWA
AB	MAYNE PHARMA INC	5MG	A203107	001	Jul 26, 2012	Aug	CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

COLLEGIUM PHARM INC

EQ 9MG BASE

N208090 001 Apr 26, 2016 Apr NEWA

EQ 13.5MG BASE

N208090 002 Apr 26, 2016 Apr NEWA

EQ 18MG BASE

N208090 003 Apr 26, 2016 Apr NEWA

EQ 27MG BASE

N208090 004 Apr 26, 2016 Apr NEWA

+

EQ 36MG BASE

N208090 005 Apr 26, 2016 May CRLD

EQ 36MG BASE

N208090 005 Apr 26, 2016 Apr NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA MAYNE PHARMA INC 100MG/5ML

A204092 001 Jun 05, 2014 Aug CAHN

AA WES PHARMA INC 5MG/5ML

A207511 001 Nov 23, 2016 Nov NEWA

AA WEST-WARD PHARMS INT 5MG/5ML

A204037 001 Jul 15, 2013 Nov CAHN

AA 100MG/5ML

A203208 001 Jul 12, 2013 Nov CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB ALVOGEN MALTA 5MG

A202116 001 Dec 30, 2011 Jan CAHN

AB 15MG

A202116 002 Dec 30, 2011 Jan CAHN

AB 30MG

A202116 003 Dec 30, 2011 Jan CAHN

AB COASTAL PHARMS 10MG

A091313 004 Apr 29, 2016 Apr NEWA

AB 20MG

A091313 005 Apr 29, 2016 Apr NEWA

AB KEN LIFESCIENCE 5MG

A207119 001 Apr 12, 2016 Mar NEWA

AB 10MG

A207119 002 Apr 12, 2016 Mar NEWA

AB 15MG

A207119 003 Apr 12, 2016 Mar NEWA

AB 20MG

A207119 004 Apr 12, 2016 Mar NEWA

AB 30MG

A207119 005 Apr 12, 2016 Mar NEWA

AB MAYNE PHARMA INC 5MG

A091313 001 Feb 18, 2011 Aug CAHN

AB 10MG

A091313 004 Apr 29, 2016 Aug CAHN

AB 15MG

A091313 002 Feb 18, 2011 Aug CAHN

AB 20MG

A091313 005 Apr 29, 2016 Aug CAHN

AB 30MG

A091313 003 Feb 18, 2011 Aug CAHN

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

+ ST RENATUS 0.1MG/SPRAY;6MG/SPRAY

N208032 001 Jun 29, 2016 Jun NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB AUROLIFE PHARMA LLC 5MG

A204459 001 Apr 26, 2016 Apr NEWA

AB 10MG

A204459 002 Apr 26, 2016 Apr NEWA

AB WEST-WARD PHARMS INT 5MG

A090964 001 Sep 27, 2010 Nov CAHN

AB 10MG

A090964 002 Sep 27, 2010 Nov CAHN

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB WEST-WARD PHARMS INT 5MG

A200822 002 Jul 15, 2013 Nov CAHN

AB 7.5MG

A200822 003 Jul 15, 2013 Nov CAHN

AB 10MG

A200822 004 Jul 15, 2013 Nov CAHN

AB 15MG

A200822 005 Jul 15, 2013 Nov CAHN

AB 20MG

A200822 006 Jul 15, 2013 Nov CAHN

AB 30MG

A200822 007 Jul 15, 2013 Nov CAHN

AB 40MG

A200822 001 Jul 15, 2013 Nov CAHN

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP + WEST-WARD PHARMS INT 10USP UNITS/ML (10USP UNITS/ML)

N018243 001 Oct CAHN

AP + 100USP UNITS/10ML (10USP UNITS/ML)

N018243 002 Jan 10, 2007 Oct CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACITAXEL

AP GLAND PHARMA LTD 6MG/ML

A207326 001 Aug 23, 2016 Aug NEWA

PACLITAXEL

AP SANDOZ INC 6MG/ML

A078167 001 Dec 26, 2007 Jan CAHN

INJECTABLE; INJECTION							
PACLITAXEL							
AP	WEST-WARD PHARMS INT	6MG/ML	A075190	001	Jan 28, 2002	Oct	CAHN
<u>PALIPERIDONE PALMITATE</u>							
SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR							
INVEGA SUSTENNA							
	JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CRLD
+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar	CRLD
<u>PALONOSETRON HYDROCHLORIDE</u>							
INJECTABLE; INTRAVENOUS							
PALONOSETRON HYDROCHLORIDE							
AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr	NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	NEWA
SOLUTION; INTRAVENOUS							
PALONOSETRON HYDROCHLORIDE							
	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar	NEWA
		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar	NEWA
	EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Aug	NEWA
<u>PAMIDRONATE DISODIUM</u>							
INJECTABLE; INJECTION							
PAMIDRONATE DISODIUM							
AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan	CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan	CAHN
AP	WEST-WARD PHARMS INT	30MG/VIAL	A075290	001	Apr 30, 2001	Oct	CAHN
AP	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Sep	CAHN
AP		90MG/VIAL	A075290	003	Apr 30, 2001	Oct	CAHN
AP	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Sep	CAHN
<u>PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)</u>							
CAPSULE, DELAYED RELEASE; ORAL							
PERTZYE							
	DIGESTIVE CARE INC	15,125USP UNITS; 4,000USP UNITS; 14,375USP UNITS	N022175	003	Oct 06, 2016	Oct	NEWA
<u>PANTOPRAZOLE SODIUM</u>							
INJECTABLE; IV (INFUSION)							
PANTOPRAZOLE SODIUM							
AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar	NEWA
TABLET, DELAYED RELEASE; ORAL							
PANTOPRAZOLE SODIUM							
AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan	NEWA
AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan	NEWA
<u>PARICALCITOL</u>							
CAPSULE; ORAL							
PARICALCITOL							
AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN
AB	ECI PHARMS LLC	1MCG	A206710	001	Feb 24, 2016	Oct	CAHN
AB		2MCG	A206710	002	Feb 24, 2016	Oct	CAHN
AB		4MCG	A206710	003	Feb 24, 2016	Oct	CAHN
AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb	NEWA
AB		2MCG	A206710	002	Feb 24, 2016	Feb	NEWA
AB		4MCG	A206710	003	Feb 24, 2016	Feb	NEWA
AB	MARKSANS PHARMA	1MCG	A204948	001	Oct 07, 2016	Sep	NEWA
AB		2MCG	A204948	002	Oct 07, 2016	Sep	NEWA
AB		4MCG	A204948	003	Oct 07, 2016	Sep	NEWA
AB	+	TEVA PHARMS USA	A090829	003	Sep 27, 2013	Aug	CRLD
ZEMPLAR							
	@ ABBVIE	4MCG	N021606	003	May 26, 2005	Aug	DISC
SOLUTION; INTRAVENOUS							
PARICALCITOL							
AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb	NEWA
AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb	NEWA

SOLUTION;INTRAVENOUS							
PARICALCITOL							
AP		0.01MG/2ML (0.005MG/ML)		N207174	003	Feb 04, 2016	Feb NEWA
AP	DR REDDYS LABS LTD	0.002MG/ML (0.002MG/ML)		A204910	001	Aug 17, 2016	Aug NEWA
AP		0.005MG/ML (0.005MG/ML)		A204910	002	Aug 17, 2016	Aug NEWA
AP		0.01MG/2ML (0.005MG/ML)		A204910	003	Aug 17, 2016	Aug NEWA
<u>PAROXETINE HYDROCHLORIDE</u>							
TABLET;ORAL							
PAROXETINE HYDROCHLORIDE							
	@ UPSHER-SMITH LABS	EQ 10MG BASE		A075566	001	Mar 08, 2004	Oct CAHN
	@	EQ 20MG BASE		A075566	002	Mar 08, 2004	Oct CAHN
	@	EQ 30MG BASE		A075566	003	Mar 08, 2004	Oct CAHN
	@	EQ 40MG BASE		A075566	004	Mar 08, 2004	Oct CAHN
TABLET, EXTENDED RELEASE;ORAL							
PAROXETINE HYDROCHLORIDE							
AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE		A204744	001	Jun 10, 2016	May NEWA
AB		EQ 25MG BASE		A204744	002	Jun 10, 2016	May NEWA
AB		EQ 37.5MG BASE		A204744	003	Jun 10, 2016	May NEWA
<u>PAROXETINE MESYLATE</u>							
CAPSULE;ORAL							
BRISDELLE							
+	SEBELA IRELAND LTD	EQ 7.5MG BASE		N204516	001	Jun 28, 2013	Aug CAHN
TABLET;ORAL							
PEXEVA							
	SEBELA IRELAND LTD	EQ 10MG BASE		N021299	001	Jul 03, 2003	Aug CAHN
		EQ 20MG BASE		N021299	002	Jul 03, 2003	Aug CAHN
		EQ 30MG BASE		N021299	003	Jul 03, 2003	Aug CAHN
+		EQ 40MG BASE		N021299	004	Jul 03, 2003	Aug CAHN
<u>PENBUTOLOL SULFATE</u>							
TABLET;ORAL							
LEVATOL							
	@ AUXILIUM PHARMS INC	10MG		N018976	001	Dec 30, 1987	Mar CAHN
	@	20MG		N018976	004	Jan 05, 1989	Mar CAHN
	@ AUXILIUM PHARMS LLC	10MG		N018976	001	Dec 30, 1987	Aug CAHN
	@	20MG		N018976	004	Jan 05, 1989	Aug CAHN
<u>PENTETATE CALCIUM TRISODIUM</u>							
SOLUTION;INHALATION, INTRAVENOUS							
PENTETATE CALCIUM TRISODIUM							
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Apr CMFD
	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Feb CAHN
<u>PENTETATE ZINC TRISODIUM</u>							
SOLUTION;INHALATION, INTRAVENOUS							
PENTETATE ZINC TRISODIUM							
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Apr CMFD
	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Feb CAHN
<u>PENTOBARBITAL SODIUM</u>							
INJECTABLE;INJECTION							
NEMBUTAL SODIUM							
AP	+	OAK PHARMS	50MG/ML	A083246	001		May CTEC
PENTOBARBITAL SODIUM							
AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May NEWA
<u>PENTOSTATIN</u>							
INJECTABLE;INJECTION							
PENTOSTATIN							
AP		WEST-WARD PHARMS INT	10MG/VIAL	A077841	001	Aug 07, 2007	Oct CAHN
<u>PENTOXIFYLLINE</u>							
TABLET, EXTENDED RELEASE;ORAL							
PENTOXIFYLLINE							
AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar DISC

PERAMPANELSUSPENSION;ORAL
FYCOMPA

+ EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016 Apr NEWA

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

AB	WEST-WARD PHARMS INT	2MG	A090072	001	Nov 10, 2009	Nov CAHN
AB		4MG	A090072	002	Nov 10, 2009	Nov CAHN
AB		8MG	A090072	003	Nov 10, 2009	Nov CAHN

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

>A>	@ ANI PHARMS INC	2MG	A089707	001	Sep 10, 1987	Dec CAHN
>A>	@	16MG	A089457	001	Sep 10, 1987	Dec CAHN
AB	SANDOZ	2MG	A089685	002	Dec 08, 1988	Sep CMS1
AB		4MG	A089685	003	Dec 08, 1988	Sep CMS1
AB	+	16MG	A089685	004	Dec 08, 1988	Sep CMS1
>D>	@ TEVA PHARMS USA	2MG	A089707	001	Sep 10, 1987	Dec CAHN
>D>	@	16MG	A089457	001	Sep 10, 1987	Dec CAHN
AB	WATSON LABS INC	2MG	A207582	001	Oct 17, 2016	Oct NEWA
AB		4MG	A207582	002	Oct 17, 2016	Oct NEWA
AB		8MG	A207582	003	Oct 17, 2016	Oct NEWA
AB		16MG	A207582	004	Oct 17, 2016	Oct NEWA
AB	WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan CAHN
AB		4MG	A205973	002	Dec 17, 2015	Jan CAHN
AB		8MG	A205973	003	Dec 17, 2015	Jan CAHN
AB		16MG	A205973	004	Dec 17, 2015	Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@ ABLE 200MG,N/A,N/A;N/A,800MG,160MG N021105 001 Jun 26, 2001 Jan CMS1

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB WEST-WARD PHARMS INT 10MG A201050 001 Jul 16, 2012 Nov CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	15MG	A204318	001	Nov 09, 2016	Oct NEWA
AA		30MG	A204318	002	Nov 09, 2016	Oct NEWA
AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar CAHN
	@	37.5MG	A040527	001	Oct 23, 2003	Mar CAHN

TABLET;ORAL

LOMAIRA

+ AVANTHI INC 8MG A203495 001 Sep 12, 2016 Aug NEWA

PHENTERMINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan CAHN
AA	POLYGEN PHARMS	37.5MG	A206342	001	Nov 18, 2016	Nov NEWA
AA	SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

SUPRENZA

@	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun DISC
@		30MG	N202088	002	Jun 13, 2011	Jun DISC
@		37.5MG	N202088	003	Mar 27, 2012	Jun DISC

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE RESIN COMPLEX

@	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Aug DISC
@		EQ 30MG BASE	A040872	002	Jul 28, 2011	Aug DISC

PHENTOLAMINE MESYLATE

	INJECTABLE; INJECTION						
	PHENTOLAMINE MESYLATE						
AP	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Sep	CAHN

PHENYLBUZAZONE

CAPSULE; ORAL

PHENYLBUZAZONE

@ SUN PHARM INDS

100MG

A088994 001 Dec 04, 1985 Mar CAHN

TABLET; ORAL

PHENYLBUZAZONE

@ SUN PHARM INDS

100MG

A088863 001 Dec 04, 1985 Mar CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

>D>	ALCON RES	1%	N200890	001	Jun 22, 2010	Dec	CAHN
>D>		2%	N200890	002	Jun 22, 2010	Dec	CAHN
>D>	+	4%	N200890	003	Jun 22, 2010	Dec	CAHN
>A>	NOVARTIS PHARMS CORP	1%	N200890	001	Jun 22, 2010	Dec	CAHN
>A>		2%	N200890	002	Jun 22, 2010	Dec	CAHN
>A>	+	4%	N200890	003	Jun 22, 2010	Dec	CAHN

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+ ACADIA PHARMS INC EQ 17MG BASE

N207318 001 Apr 29, 2016 Apr NEWA

PINDOLOL

TABLET; ORAL

PINDOLOL

@ IDT AUSTRALIA LTD

5MG

A073608 001 Mar 29, 1993 May CAHN

@

10MG

A073609 001 Mar 29, 1993 May CAHN

AB SUN PHARM INDS

5MG

A074063 001 Jan 27, 1994 Mar CAHN

AB

10MG

A074063 002 Jan 27, 1994 Mar CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB FLAMINGO PHARMS 10MG

A207938 001 Sep 09, 2016 Aug NEWA

AB 20MG

A207938 002 Sep 09, 2016 Aug NEWA

AB MYLAN IRELAND LTD 10MG

A074116 001 Jun 15, 1993 Aug CAHN

AB 20MG

A074118 001 Jun 15, 1993 Aug CAHN

AB MYLAN PHARMS INC 20MG

A074118 001 Jun 15, 1993 Jan CAHN

@ SUN PHARM INDS 20MG

A073536 001 Mar 12, 1993 Mar CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

>D>	KOWA CO	EQ 1MG BASE	N022363	001	Aug 03, 2009	Dec	CFTG
>A> AB		EQ 1MG BASE	N022363	001	Aug 03, 2009	Dec	CFTG
>D>		EQ 2MG BASE	N022363	002	Aug 03, 2009	Dec	CFTG
>A> AB		EQ 2MG BASE	N022363	002	Aug 03, 2009	Dec	CFTG
>D>	+	EQ 4MG BASE	N022363	003	Aug 03, 2009	Dec	CFTG
>A> AB	+	EQ 4MG BASE	N022363	003	Aug 03, 2009	Dec	CFTG
>A>	PITAVASTATIN CALCIUM						
>A> AB	AUROBINDO PHARMA LTD	EQ 1MG BASE	A206015	001	Dec 20, 2016	Dec	NEWA
>A> AB		EQ 2MG BASE	A206015	002	Dec 20, 2016	Dec	NEWA
>A> AB		EQ 4MG BASE	A206015	003	Dec 20, 2016	Dec	NEWA

PODOFILOX

GEL; TOPICAL

CONDYLOX

+ ALLERGAN SALES LLC 0.5%

N020529 001 Mar 13, 1997 Mar CAHN

SOLUTION; TOPICAL

CONDYLOX

AT + ALLERGAN SALES LLC 0.5%

N019795 001 Dec 13, 1990 Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

@ MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	May DISC
---------------	---	---------	-----	--------------	----------

COLYTE WITH FLAVOR PACKS

AA MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. 84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CTEC
----------------	--	---------	-----	--------------	----------

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar NEWA
AP GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr NEWA
AP + WEST-WARD PHARMS INT	EQ 500,000 UNITS BASE/VIAL	A060716	001		Sep CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan NEWA
AB KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar NEWA
AB	10MEQ	A204210	002	Mar 28, 2016	Mar NEWA
AB NOVEL LABS INC	8MEQ	A204828	001	Aug 16, 2016	Aug NEWA
AB	10MEQ	A204828	002	Aug 16, 2016	Aug NEWA
AB TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb NEWA
AB	10MEQ	A201944	002	Mar 04, 2016	Feb NEWA

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

+ PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Jul CRLD
-----------------------	-------	---------	-----	--------------	----------

SOLUTION;ORAL

POTASSIUM CHLORIDE

>A> LEHIGH VALLEY	20MEQ/15ML	N206814	001	Dec 22, 2014	Dec CAHN
>A> +	40MEQ/15ML	N206814	002	Dec 22, 2014	Dec CAHN
>D> PHARMA-MED INC	20MEQ/15ML	N206814	001	Dec 22, 2014	Dec CAHN
>D> +	40MEQ/15ML	N206814	002	Dec 22, 2014	Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1 GLENMARK PHARMS LTD	10MEQ	A203562	001	Jul 26, 2016	Jul NEWA
AB1	20MEQ	A203562	002	Jul 26, 2016	Jul NEWA
AB2 NOVEL LABS INC	8MEQ	A206759	001	Aug 09, 2016	Jul NEWA
AB1	10MEQ	A206347	001	Jan 21, 2016	Jan NEWA
AB2	10MEQ	A206759	002	Aug 09, 2016	Jul NEWA
AB1	20MEQ	A206347	002	Jan 21, 2016	Jan NEWA
AB2 SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016	Aug NEWA
AB2	10MEQ	A207528	002	Aug 19, 2016	Aug NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr NEWA
AB	0.75MG	A201963	002	Apr 21, 2016	Apr NEWA
AB	1.5MG	A201963	003	Apr 21, 2016	Apr NEWA
AB	2.25MG	A203615	001	Oct 14, 2016	Oct NEWA
AB	3MG	A201963	004	Apr 21, 2016	Apr NEWA
>A> AB	3.75MG	A203615	002	Jan 03, 2017	Dec NEWA
AB	4.5MG	A201963	005	Apr 21, 2016	Apr NEWA
AB MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun NEWA
AB	0.75MG	A206156	002	Jun 24, 2016	Jun NEWA
AB	1.5MG	A206156	003	Jun 24, 2016	Jun NEWA
AB	2.25MG	A206156	004	Jun 24, 2016	Jun NEWA
AB	3MG	A206156	005	Jun 24, 2016	Jun NEWA
AB	4.5MG	A206156	007	Jun 24, 2016	Jun NEWA
AB SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul CDFFR
AB	0.75MG	A202353	002	Dec 04, 2014	Jul CDFFR
AB	1.5MG	A202353	003	Dec 04, 2014	Jul CDFFR
AB	3MG	A202353	004	Dec 04, 2014	Jul CDFFR
AB	4.5MG	A202353	005	Dec 04, 2014	Jul CDFFR

PRASTERONEINSERT;VAGINAL
INTRAROSA

+	ENDOCEUTICS INC	6.5MG	N208470	001	Nov 16, 2016	Nov NEWA
---	-----------------	-------	---------	-----	--------------	----------

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	ACCORD HLTHCARE	10MG	A207068	001	Nov 17, 2016	Nov NEWA
AB		20MG	A207068	002	Nov 17, 2016	Nov NEWA
AB		40MG	A207068	003	Nov 17, 2016	Nov NEWA
AB		80MG	A207068	004	Nov 17, 2016	Nov NEWA
AB	APOTEX INC	10MG	A076341	001	Oct 23, 2006	Nov CAHN
AB		20MG	A076341	002	Oct 23, 2006	Nov CAHN
AB		40MG	A076341	003	Oct 23, 2006	Nov CAHN
AB		80MG	A076341	004	Dec 28, 2007	Nov CAHN
AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
	@	EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
	@	EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN
AB	TEVA PHARMS	EQ 1MG BASE	A071745	002	Sep 12, 1988	Sep CMS1
AB		EQ 2MG BASE	A071745	003	Sep 12, 1988	Sep CMS1

PREDNISOLONE

TABLET;ORAL

PREDNISOLONE

@	AUROLIFE PHARMA LLC	5MG	A084773	001		Feb CAHN
---	---------------------	-----	---------	-----	--	----------

PREDNISOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
OMNIPRED

AB	NOVARTIS PHARMS CORP	1%	N017469	001		Nov CAHN
----	----------------------	----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

>A>	AA	EDENBRIDGE PHARMS	EQ 10MG BASE/5ML	A203559	001	Dec 20, 2016	Dec NEWA
>A>	AA		EQ 20MG BASE/5ML	A203559	002	Dec 20, 2016	Dec NEWA
>D>	+	PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008	Dec CTEC
>A>	AA	+	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008	Dec CTEC
>D>	+		EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008	Dec CTEC
>A>	AA	+	EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008	Dec CTEC
	AA	+	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD

PREDNISONE

SOLUTION;ORAL

PREDNISONE

+	WEST-WARD PHARMS INT	5MG/5ML	A088703	001	Nov 08, 1984	Nov CAHN
---	----------------------	---------	---------	-----	--------------	----------

PREDNISONE INTENSOL

+	WEST-WARD PHARMS INT	5MG/ML	A088810	001	Feb 20, 1985	Nov CAHN
---	----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

PREDNISONE

	@ AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN	
	@	10MG	A089983	001	Jan 12, 1989	Mar CAHN	
	@	20MG	A085813	001		Mar CAHN	
	@	50MG	A089984	001	Jan 12, 1989	Mar CAHN	
AB	SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar CAHN	
	@	50MG	A086596	001		Jun CAHN	
AB	+	WEST-WARD PHARMS INT	1MG	A087800	001	Apr 22, 1982	Nov CAHN
AB	+	2.5MG	A087801	001	Apr 22, 1982	Nov CAHN	
AB	+	5MG	A080352	001		Nov CAHN	
AB	+	10MG	A084122	001		Nov CAHN	
AB	+	20MG	A087342	001		Nov CAHN	

TABLET;ORAL							
PREDNISONE							
AB	+	50MG	A084283	001		Nov	CAHN
<u>PRIMAQUINE PHOSPHATE</u>							
TABLET;ORAL							
PRIMAQUINE PHOSPHATE							
AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016	Jun	NEWA
<u>PRIMIDONE</u>							
TABLET;ORAL							
PRIMIDONE							
AB	FRONTIDA BIOPHARM	50MG	A040626	001	Sep 29, 2005	Jul	CAHN
AB		250MG	A040626	002	Sep 29, 2005	Jul	CAHN
	@ HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006	Jul	CAHN
AB		250MG	A040667	002	Jul 27, 2006	Jul	CAHN
	@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar	DISC
	@	250MG	A040717	002	Feb 12, 2008	Mar	DISC
AB	SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Mar	CAHN
AB		250MG	A040626	002	Sep 29, 2005	Mar	CAHN
<u>PROCAINAMIDE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
PROCAINAMIDE HYDROCHLORIDE							
	@ IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May	CAHN
INJECTABLE;INJECTION							
PROCAINAMIDE HYDROCHLORIDE							
>D>	+	HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Dec CTEC
>A>	AP	+	100MG/ML	A089069	001	Feb 12, 1986	Dec CTEC
>D>		@ INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984	Dec CMFD
>A>	AP		100MG/ML	A088636	001	Jul 31, 1984	Dec CMFD
<u>PROCHLORPERAZINE EDISYLATE</u>							
INJECTABLE;INJECTION							
PROCHLORPERAZINE EDISYLATE							
	@ AMPHASTAR PHARMS INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Aug	DISC
AP		EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jun	CAHN
AP	+	EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Oct CTEC
	+		EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Sep CTEC
AP	+		EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Aug CRLD
AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr	CAHN
AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Oct	CMFD
	@	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Aug	DISC
<u>PROGESTERONE</u>							
CAPSULE;ORAL							
PROGESTERONE							
AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan	CAHN
PROMETRIUM							
AB	VIRTUS PHARMS	100MG	N019781	001	May 14, 1998	Jun	CAHN
AB	+	200MG	N019781	002	Oct 15, 1999	Jun	CAHN
	@	300MG	N019781	003	Oct 15, 1999	Jun	CAHN
GEL;VAGINAL							
CRINONE							
	+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr CAHN
	+		8%	N020701	002	Jul 31, 1997	Apr CAHN
INJECTABLE;INJECTION							
PROGESTERONE							
AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002		Apr CAHN
<u>PROMETHAZINE HYDROCHLORIDE</u>							
SYRUP;ORAL							
PROMETHAZINE HYDROCHLORIDE							
AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Feb	CAHN
TABLET;ORAL							
PROMETHAZINE HYDROCHLORIDE							
	@ IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008	Mar	DISC
	@	25MG	A040724	002	Feb 12, 2008	Mar	DISC
	@	50MG	A040791	001	May 20, 2008	Mar	DISC
AB	KVK TECH	50MG	A040712	003	Jul 31, 2006	Nov	CMS1
	@ SUN PHARM INDS	12.5MG	A084555	001		Mar	CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

@ 25MG
@ 50MG

A084554 001
A084557 001

Mar CAHN
Jan CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB MYLAN PHARMS INC 225MG
AB 325MG
AB 425MG

A203803 001 Apr 29, 2016 Apr NEWA
A203803 002 Apr 29, 2016 Apr NEWA
A203803 003 Apr 29, 2016 Apr NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB ORION CORP ORION 150MG
AB 225MG
AB 300MG
AB SUN PHARM INDS 150MG
AB 225MG
AB 300MG

A202445 001 May 11, 2016 Apr NEWA
A202445 002 May 11, 2016 Apr NEWA
A202445 003 May 11, 2016 Apr NEWA
A075998 001 Nov 29, 2001 Mar CAHN
A075998 002 Nov 29, 2001 Mar CAHN
A075998 003 Nov 29, 2001 Mar CAHN

PROPANTHELINE BROMIDE

TABLET;ORAL

PROPANTHELINE BROMIDE

@ WEST-WARD PHARMS INT 7.5MG
+ 15MG

A080927 001
A080927 002

Nov CAHN
Nov CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

>D> AT + ALCON 0.5%
>A> AT + NOVARTIS PHARMS CORP 0.5%

A080027 001
A080027 001

Dec CAHN
Dec CAHN

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

AB SAGENT PHARMS 10MG/ML
@ WEST-WARD PHARMS INT 10MG/ML

A075102 001 Jan 04, 1999 Aug CAHN
A074848 001 Apr 19, 2005 Sep CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB ANI PHARMS INC 60MG
AB 80MG
AB 120MG
AB + 160MG

N018553 004 Mar 18, 1987 Apr CAHN
N018553 002 Apr 19, 1983 Apr CAHN
N018553 003 Apr 19, 1983 Apr CAHN
N018553 001 Apr 19, 1983 Apr CAHN

PROPRANOLOL HYDROCHLORIDE

BX UPSHER SMITH 60MG
@ 60MG
BX 60MG
BX 80MG
@ 80MG
BX 80MG
BX 120MG
@ 120MG
BX 120MG
BX 160MG
@ 160MG
BX 160MG

A078311 001 Mar 06, 2009 Jun CMFD
A078311 001 Mar 06, 2009 May DISC
A078311 001 Mar 06, 2009 Mar CTEC
A078311 002 Mar 06, 2009 Jun CMFD
A078311 002 Mar 06, 2009 May DISC
A078311 002 Mar 06, 2009 Mar CTEC
A078311 003 Mar 06, 2009 Jun CMFD
A078311 003 Mar 06, 2009 May DISC
A078311 003 Mar 06, 2009 Mar CTEC
A078311 004 Mar 06, 2009 Jun CMFD
A078311 004 Mar 06, 2009 May DISC
A078311 004 Mar 06, 2009 Mar CTEC

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP AMPHASTAR PHARMS INC 1MG/ML
AP EUROHLTH INTL SARL 1MG/ML
@ SANDOZ 1MG/ML

A075792 001 Aug 29, 2000 Jun CAHN
A075792 001 Aug 29, 2000 Apr CAHN
A076400 001 Feb 26, 2003 Mar DISC

SOLUTION;ORAL

PROPRANOLOL HYDROCHLORIDE

+ WEST-WARD PHARMS INT 20MG/5ML
+ 40MG/5ML

A070979 001 May 15, 1987 Nov CAHN
A070690 001 May 15, 1987 Nov CAHN

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

@ FRONTIDA BIOPHARM 10MG
@ 20MG
@ 40MG

A070319 001 Oct 22, 1985 Jul CAHN
A070320 001 Oct 22, 1985 Jul CAHN
A070103 001 Oct 22, 1985 Jul CAHN

TABLET;ORAL									
PROPRANOLOL HYDROCHLORIDE									
	@	60MG	A070321	001	Sep 24, 1986	Jul	CAHN		
	@	80MG	A070322	001	Aug 04, 1986	Jul	CAHN		
AB	IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988	Aug	CAHN		
AB		20MG	A071973	001	Apr 06, 1988	Aug	CAHN		
AB		40MG	A071974	001	Apr 06, 1988	Aug	CAHN		
AB		60MG	A071975	001	Apr 06, 1988	Aug	CAHN		
AB	+	80MG	A071976	001	Apr 06, 1988	Aug	CAHN		
	@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar	CAHN		
	@	20MG	A070320	001	Oct 22, 1985	Mar	CAHN		
	@	40MG	A070103	001	Oct 22, 1985	Mar	CAHN		
	@	60MG	A070321	001	Sep 24, 1986	Jun	CAHN		
	@	80MG	A070322	001	Aug 04, 1986	Mar	CAHN		
<u>PROPYLTHIOURACIL</u>									
TABLET;ORAL									
PROPYLTHIOURACIL									
	@ HIKMA INTL PHARMS	50MG	A080154	001		Jul	CAHN		
	@ SUN PHARM INDS	50MG	A083982	001		Mar	CAHN		
<u>PROTRIPTYLINE HYDROCHLORIDE</u>									
TABLET;ORAL									
PROTRIPTYLINE HYDROCHLORIDE									
AB	WEST-WARD PHARMS INT	5MG	A078913	001	Sep 16, 2008	Nov	CAHN		
AB		10MG	A078913	002	Sep 16, 2008	Nov	CAHN		
<u>PYRIDOSTIGMINE BROMIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
PYRIDOSTIGMINE BROMIDE									
AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan	CAHN		
<u>PYRIDOXINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
PYRIDOXINE HYDROCHLORIDE									
AP	+	FRESENIUS KABI USA	100MG/ML	A080618	001		Jul	CTEC	
AP		MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016	Jul	NEWA	
<u>QUAZEPAM</u>									
TABLET;ORAL									
DORAL									
	@ CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar	CAHN		
	+	15MG	N018708	001	Dec 27, 1985	Apr	CMFD		
	@	15MG	N018708	001	Dec 27, 1985	Mar	CAHN		
<u>QUETIAPINE FUMARATE</u>									
TABLET;ORAL									
QUETIAPINE FUMARATE									
	@ ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr	DISC		
	@	EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr	DISC		
	@	EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr	DISC		
	@	EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr	DISC		
	@	EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr	DISC		
	@	EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr	DISC		
	@	EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr	DISC		
AB	MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May	NEWA		
AB		EQ 50MG BASE	A203359	002	May 17, 2016	May	NEWA		
AB		EQ 100MG BASE	A203359	003	May 17, 2016	May	NEWA		
AB		EQ 200MG BASE	A203359	004	May 17, 2016	May	NEWA		
AB		EQ 300MG BASE	A203359	005	May 17, 2016	May	NEWA		
AB		EQ 400MG BASE	A203359	006	May 17, 2016	May	NEWA		
AB	UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb	NEWA		
AB		EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb	NEWA		
AB		EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb	NEWA		
AB		EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb	NEWA		
AB		EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb	NEWA		
AB		EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb	NEWA		
AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A090120	001	Mar 27, 2012	Nov	CAHN		
AB		EQ 50MG BASE	A090749	001	Mar 27, 2012	Nov	CAHN		
AB		EQ 100MG BASE	A090749	002	Mar 27, 2012	Nov	CAHN		
AB		EQ 200MG BASE	A090749	003	Mar 27, 2012	Nov	CAHN		
AB		EQ 300MG BASE	A090749	004	Mar 27, 2012	Nov	CAHN		
AB		EQ 400MG BASE	A090749	005	Mar 27, 2012	Nov	CAHN		

TABLET, EXTENDED RELEASE;ORAL									
QUETIAPINE FUMARATE									
AB	ACCORD HLTHCARE INC	EQ 400MG BASE	A090681	004	Nov 01, 2016	Oct	NEWA		
SEROQUEL XR									
AB	ASTRAZENECA	EQ 400MG BASE	N022047	004	May 17, 2007	Oct	CFTG		
<u>QUINAPRIL HYDROCHLORIDE</u>									
TABLET;ORAL									
QUINAPRIL HYDROCHLORIDE									
	@ ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan	DISC		
	@	EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan	DISC		
	@	EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan	DISC		
	@	EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan	DISC		
AB	PRINSTON INC	EQ 5MG BASE	A205823	001	Sep 15, 2016	Sep	NEWA		
AB		EQ 10MG BASE	A205823	002	Sep 15, 2016	Sep	NEWA		
AB		EQ 20MG BASE	A205823	003	Sep 15, 2016	Sep	NEWA		
AB		EQ 40MG BASE	A205823	004	Sep 15, 2016	Sep	NEWA		
<u>QUINIDINE GLUCONATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
QUINIDINE GLUCONATE									
	@ AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar	CAHN		
BX	+ SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar	CAHN		
<u>QUINIDINE SULFATE</u>									
TABLET;ORAL									
QUINIDINE SULFATE									
	@ SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun	CAHN		
AB		200MG	A081030	001	Apr 14, 1989	Mar	CAHN		
AB		300MG	A081031	001	Apr 14, 1989	Mar	CAHN		
<u>QUININE SULFATE</u>									
CAPSULE;ORAL									
QUALAQUIN									
AB	+ SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun	CAHN		
<u>RABEPRAZOLE SODIUM</u>									
CAPSULE, DELAYED RELEASE;ORAL									
ACIPHEX SPRINKLE									
	FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun	CAHN		
	+	10MG	N204736	002	Mar 26, 2013	Jun	CAHN		
<u>RALOXIFENE HYDROCHLORIDE</u>									
TABLET;ORAL									
RALOXIFENE HYDROCHLORIDE									
AB	AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar	NEWA		
AB	GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar	NEWA		
AB	SCIEGEN PHARMS INC	60MG	A206384	001	Oct 12, 2016	Oct	NEWA		
<u>RAMELTEON</u>									
TABLET;ORAL									
RAMELTEON									
AB	DR REDDYS LABS INTL	8MG	A091693	001	Jul 26, 2013	Aug	CAHN		
<u>RAMIPRIL</u>									
CAPSULE;ORAL									
RAMIPRIL									
	@ SANDOZ	1.25MG	A077514	001	Jun 18, 2008	Aug	DISC		
	@	2.5MG	A077514	002	Jun 18, 2008	Aug	DISC		
	@	5MG	A077514	003	Jun 18, 2008	Aug	DISC		
	@	10MG	A077514	004	Jun 18, 2008	Aug	DISC		
AB	WEST-WARD PHARMS INT	1.25MG	A077900	001	Jun 18, 2008	Nov	CAHN		
AB		2.5MG	A077900	002	Jun 18, 2008	Nov	CAHN		
AB		5MG	A077900	003	Jun 18, 2008	Nov	CAHN		
AB		10MG	A077900	004	Jun 18, 2008	Nov	CAHN		
<u>RANITIDINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
RANITIDINE HYDROCHLORIDE									
AP	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May	NEWA		
AP	WEST-WARD PHARMS INT	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Sep	CAHN		
AP		EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	Oct	CAHN		

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP		ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May CPOT
----	--	----------------------	-----------------	---------	-----	--------------	----------

ZANTAC

AP	+	IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
----	---	--------------	-----------------	---------	-----	--------------	----------

ZANTAC IN PLASTIC CONTAINER

	@	IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
--	---	--------------	----------------	---------	-----	--------------	----------

	@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN
--	---	--	--------------------	---------	-----	--------------	----------

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar CAHN
----	--	------------------	-----------------	---------	-----	--------------	----------

	@	WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
--	---	-----------	-----------------	---------	-----	--------------	----------

	@		EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC
--	---	--	-----------------	---------	-----	--------------	----------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997	Dec DISC
-----	----	-------	---------------	---------	-----	--------------	----------

>A>		@	EQ 150MG BASE	A074023	001	Aug 22, 1997	Dec DISC
-----	--	---	---------------	---------	-----	--------------	----------

>D>	AB		EQ 300MG BASE	A074023	002	Aug 22, 1997	Dec DISC
-----	----	--	---------------	---------	-----	--------------	----------

>A>		@	EQ 300MG BASE	A074023	002	Aug 22, 1997	Dec DISC
-----	--	---	---------------	---------	-----	--------------	----------

	AB	STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Aug NEWA
--	----	----------------	---------------	---------	-----	--------------	----------

	AB		EQ 300MG BASE	A205512	002	Aug 22, 2016	Aug NEWA
--	----	--	---------------	---------	-----	--------------	----------

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB		ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
----	--	-----------------	---------------	---------	-----	--------------	----------

AB			EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA
----	--	--	-------------	---------	-----	--------------	----------

AB		WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Nov CMFD
----	--	-----------------	---------------	---------	-----	--------------	----------

AB			EQ 1MG BASE	A201823	002	Jul 01, 2013	Nov CMFD
----	--	--	-------------	---------	-----	--------------	----------

RESERPINE

TABLET;ORAL

RESERPINE

	@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
--	---	-------------------	-------	---------	-----	--	----------

	@		0.25MG	A080975	002		Feb CAHN
--	---	--	--------	---------	-----	--	----------

	@		1MG	A080975	003		Feb CAHN
--	---	--	-----	---------	-----	--	----------

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan CAHN
---	-----------------	----	---------	-----	--------------	----------

RIBAVIRIN

FOR SOLUTION;INHALATION

RIBAVIRIN

AN		NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016	Sep NEWA
----	--	-------------	----------	---------	-----	--------------	----------

VIRAZOLE

AN	+	VALEANT PHARM INTL	6GM/VIAL	N018859	001	Dec 31, 1985	Sep CFTG
----	---	--------------------	----------	---------	-----	--------------	----------

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

+	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr NEWA
---	------------	--------	---------	-----	--------------	----------

+	PHOTREXA VISCOUS IN DEXTRAN 20%					
---	---------------------------------	--	--	--	--	--

+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun CMS1
---	------------	--------	---------	-----	--------------	----------

+	PHOTREXA VISCOUS IN DEXTROSE 20%					
---	----------------------------------	--	--	--	--	--

+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Apr NEWA
---	------------	--------	---------	-----	--------------	----------

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb NEWA
----	--	--------------	------------	---------	-----	--------------	----------

AP		WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan NEWA
----	--	-------------------	------------	---------	-----	--------------	----------

RILUZOLE

TABLET;ORAL

RILUZOLE

AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar NEWA
----	--	----------------	------	---------	-----	--------------	----------

RIMEXOLONESUSPENSION/DROPS;OPHTHALMIC
VEXOL

@ ALCON	1%	N020474	001	Dec 30, 1994	Jun DISC
---------	----	---------	-----	--------------	----------

RISEDRONATE SODIUMTABLET;ORAL
ACTONEL

AB	APIL	5MG	N020835	002	Apr 14, 2000	Jan CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jan CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jan CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jan CAHN
AB	+	150MG	N020835	005	Apr 22, 2008	Jan CAHN

RISEDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	150MG	A206768	001	Oct 21, 2016	Oct NEWA
AB	MACLEODS PHARMS LTD	35MG	A203533	003	Nov 29, 2016	Nov NEWA

TABLET, DELAYED RELEASE;ORAL
ATELVIA

AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan CAHN
----	---	------	------	---------	-----	--------------	----------

RISPERIDONESOLUTION;ORAL
RISPERIDONE

>D>	AA	APOTEX INC	1MG/ML	A077719	001	Jul 29, 2009	Dec CAHN
>A>	AA		1MG/ML	A077719	001	Jul 29, 2009	Dec CAHN
	AA	LIFESTAR PHARMA	1MG/ML	A078452	001	Sep 04, 2009	Nov CAHN
		@ SILARX PHARMS INC	1MG/ML	A202386	001	Jan 12, 2015	Aug DISC
	AA	WEST-WARD PHARMS INT	1MG/ML	A076904	001	Jul 29, 2009	Nov CAHN
		@ WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009	Apr DISC

RITONAVIRTABLET;ORAL
RITONAVIR

AB	WEST-WARD PHARMS INT	100MG	A202573	001	Jan 15, 2015	Nov CAHN
----	----------------------	-------	---------	-----	--------------	----------

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN

RIVASTIGMINE TARTRATECAPSULE;ORAL
EXELON

AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
		RIVASTIGMINE TARTRATE					
AB		AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar NEWA
AB			EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar NEWA
AB			EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar NEWA
AB			EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar NEWA

RIZATRIPTAN BENZOATETABLET;ORAL
RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

ROPINIROLE HYDROCHLORIDETABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	WEST-WARD PHARMS INT	EQ 0.25MG BASE	A077852	001	May 05, 2008	Nov CAHN
AB		EQ 0.5MG BASE	A077852	002	May 05, 2008	Nov CAHN
AB		EQ 1MG BASE	A077852	003	May 05, 2008	Nov CAHN
AB		EQ 2MG BASE	A077852	004	May 05, 2008	Nov CAHN
AB		EQ 3MG BASE	A077852	005	May 05, 2008	Nov CAHN
AB		EQ 4MG BASE	A077852	006	May 05, 2008	Nov CAHN
AB		EQ 5MG BASE	A077852	007	May 19, 2008	Nov CAHN

ROPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar	NEWA
	SOLUTION; INJECTION						
	NAROPIN						
	@ FRESenius KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May	DISC
		50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May	NEWA
AP		20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May	CMS1
AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar	CDFR
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar	NEWA
	@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr	DISC
		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr	NEWA
AP		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun	CFTG
		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May	CMS1
		100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar	CDFR
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar	NEWA
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar	CDFR
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar	NEWA
AP		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun	CFTG
		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar	NEWA
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar	NEWA
		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar	NEWA
		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr	CMS1
		500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar	NEWA
		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr	CMS1
		1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar	NEWA
	ROPIVACAINE HYDROCHLORIDE						
AP	AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun	NEWA
AP		100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun	NEWA
AP		100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun	NEWA
AP		150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun	NEWA
AP		150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun	NEWA
AP		200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun	NEWA
AP		200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun	NEWA
AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar	CDFR
AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar	NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar	CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar	CDFR

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr	CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr	CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr	CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG
	ROSUVASTATIN CALCIUM						
AB	ACCORD HLTHCARE INC	5MG	A206434	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A206434	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A206434	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A206434	004	Oct 31, 2016	Oct	NEWA
AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079145	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079145	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079145	004	Jul 19, 2016	Jul	NEWA
AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079170	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079170	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079170	004	Jul 19, 2016	Jul	NEWA
AB	BIOCON LTD	5MG	A207752	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207752	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A207752	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207752	004	Oct 31, 2016	Oct	NEWA

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB	CADILA PHARMS LTD	5MG	A207453	001	Nov 23, 2016	Nov	NEWA
AB		10MG	A207453	002	Nov 23, 2016	Nov	NEWA
AB		20MG	A207453	003	Nov 23, 2016	Nov	NEWA
AB		40MG	A207453	004	Nov 23, 2016	Nov	NEWA
AB	CHANGZHOU PHARM	5MG	A207408	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207408	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A207408	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207408	004	Oct 31, 2016	Oct	NEWA
AB	GLENMARK PHARMS	5MG	A079172	001	Jul 19, 2016	Sep	CAHN
AB		10MG	A079172	002	Jul 19, 2016	Sep	CAHN
AB		20MG	A079172	003	Jul 19, 2016	Sep	CAHN
AB		40MG	A079172	004	Jul 19, 2016	Sep	CAHN
AB	GLENMARK PHARMS LTD	5MG	A079172	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079172	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079172	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079172	004	Jul 19, 2016	Jul	NEWA
AB	HETERO LABS LTD V	5MG	A207616	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207616	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A207616	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207616	004	Oct 31, 2016	Oct	NEWA
AB	JUBILANT GENERICS	5MG	A207062	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207062	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A207062	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207062	004	Oct 31, 2016	Oct	NEWA
AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079161	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079161	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079161	004	Jul 19, 2016	Jul	NEWA
AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079168	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079168	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079168	004	Jul 19, 2016	Jul	NEWA
AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079171	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079171	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079171	004	Jul 19, 2016	Jul	NEWA
AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079169	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079169	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079169	004	Jul 19, 2016	Jul	NEWA
AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079166	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079166	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079166	004	Jul 19, 2016	Jul	NEWA
AB	TORRENT PHARMS LLC	5MG	A201619	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A201619	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A201619	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A201619	004	Oct 31, 2016	Oct	NEWA
AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
AB		10MG	A079167	002	Apr 29, 2016	Apr	NEWA
AB		20MG	A079167	003	Apr 29, 2016	Apr	NEWA
AB		40MG	A079167	004	Apr 29, 2016	Apr	NEWA

RUBIDIUM CHLORIDE RB-82

SOLUTION;INTRAVENOUS

RUBY-FILL

JUBILANT DRAXIMAGE

N/A

N202153 001 Sep 30, 2016 Sep NEWA

>A> RUCAPARIB CAMSYLATE

>A> TABLET;ORAL

>A> RUBRACA

>A> CLOVIS ONCOLOGY INC EQ 200MG BASE

N209115 001 Dec 19, 2016 Dec NEWA

>A> + EQ 300MG BASE

N209115 002 Dec 19, 2016 Dec NEWA

RUFINAMIDE

TABLET;ORAL

BANZEL

AB EISAI INC 200MG

N021911 002 Nov 14, 2008 May CFTG

AB + 400MG

N021911 003 Nov 14, 2008 May CFTG

RUFINAMIDE

AB GLENMARK PHARMS LTD 200MG

A205075 001 May 16, 2016 May NEWA

TABLET;ORAL
RUFINAMIDE

AB		400MG	A205075	002	May 16, 2016	May NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May NEWA
AB		400MG	A205095	002	May 16, 2016	May NEWA
AB	ROXANE	200MG	A204988	001	May 16, 2016	May NEWA
AB		400MG	A204988	002	May 16, 2016	May NEWA
AB	WEST-WARD PHARMS INT	200MG	A204988	001	May 16, 2016	Nov CAHN
AB		400MG	A204988	002	May 16, 2016	Nov CAHN

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
TRANSDERM SCOP

AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001	May CAHN
----	---	---------------------	----------	---------	-----	----------

SECOBARBITAL SODIUM

CAPSULE;ORAL
SECONAL SODIUM

+	VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983	Aug CAHN
+		100MG	A086101	002	Oct 03, 1983	Aug CAHN

SELEGILINE HYDROCHLORIDE

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

>D>	AB	+	APOTEX INC	5MG	A074871	001	Jun 06, 1997	Dec CAHN
>A>	AB	+		5MG	A074871	001	Jun 06, 1997	Dec CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

@	FRONTIDA BIOPHARM	EQ 25MG BASE	A077818	001	Feb 06, 2007	Jul CAHN
@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Jul CAHN
@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Jul CAHN
@	SUN PHARM INDS	EQ 25MG BASE	A077818	001	Feb 06, 2007	Mar CAHN
@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Mar CAHN
@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Mar CAHN

SILDENAFIL CITRATE

TABLET;ORAL
SILDENAFIL CITRATE

AB	@	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr DISC
		RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun NEWA
	@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb DISC
			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb NEWA
	@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb DISC
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb NEWA
	@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb DISC
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb NEWA

SILODOSIN

CAPSULE;ORAL
RAPAFLO

+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr CAHN
		8MG	N022206	002	Oct 08, 2008	Apr CAHN

SIMVASTATIN

SUSPENSION;ORAL
SIMVASTATIN

+	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr NEWA
		40MG/5ML	N206679	002	Apr 21, 2016	Apr NEWA

TABLET;ORAL
SIMVASTATIN

@	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb DISC
@		10MG	A076285	002	Dec 20, 2006	Feb DISC
@		20MG	A076285	003	Dec 20, 2006	Feb DISC
@		40MG	A076285	004	Dec 20, 2006	Feb DISC
@		80MG	A076285	005	Jun 23, 2006	Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)
AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
		SODIUM PHENYLACETATE AND SODIUM BENZOATE					
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb NEWA
AP		NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	Jul NEWA

SODIUM BICARBONATEINJECTABLE; INJECTION
SODIUM BICARBONATE

HOSPIRA INC 0.5MEQ/ML

A202981 001 Mar 04, 2016 Feb NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	HOSPIRA	450MG/100ML	N018090	001		Aug CRLD
		SODIUM CHLORIDE 0.9%					
		B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016	Aug NEWA
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May NEWA
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Aug CRLD

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May NEWA
AP		ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE 0.009-0.1mCi
@ 2-200mCiN021305 006 May 19, 2005 Mar CMS1
N021305 004 Nov 18, 2004 Mar CMS1SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
NITROPRESS

AP	+	HOSPIRA	25MG/ML	A071961	001	Aug 01, 1988	Nov CTEC
		SODIUM NITROPRUSSIDE					
AP		NAMIGEN LLC	25MG/ML	A207426	001	Dec 08, 2016	Nov NEWA

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB	+	HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CAHN
		SODIUM PHENYLBUTYRATE					
AB		PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun NEWA
		TABLET; ORAL					
		BUPHENYL					
AB	+	HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar CAHN
		SODIUM PHENYLBUTYRATE					
AB		FERA PHARMS LLC	500MG	A090910	001	Nov 18, 2011	Nov CAHN
AB		PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb NEWA
AA		INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb NEWA
		SUSPENSION; ORAL, RECTAL					
		SODIUM POLYSTYRENE SULFONATE					
AA		WEST-WARD PHARMS INT	15GM/60ML	A089049	001	Nov 17, 1986	Nov CAHN

SOFOSBUVIR; VELPATASVIR

TABLET; ORAL

EPCLUSA

+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016	Jun NEWA
---	---------------------	-------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

>D>	AB1	APOTEX INC	80MG	A076140	001	Sep 26, 2002	Dec CAHN
>A>	AB1		80MG	A076140	001	Sep 26, 2002	Dec CAHN
>D>	AB1		120MG	A076140	002	Sep 26, 2002	Dec CAHN
>A>	AB1		120MG	A076140	002	Sep 26, 2002	Dec CAHN
>D>	AB1		160MG	A076140	003	Sep 26, 2002	Dec CAHN
>A>	AB1		160MG	A076140	003	Sep 26, 2002	Dec CAHN
>D>	AB1		240MG	A076140	004	Sep 26, 2002	Dec CAHN
>A>	AB1		240MG	A076140	004	Sep 26, 2002	Dec CAHN
	AB1	BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	Oct NEWA
	AB1		120MG	A207428	002	Oct 21, 2016	Oct NEWA
	AB1		160MG	A207428	003	Oct 21, 2016	Oct NEWA
	@	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar DISC
	@		120MG	A075663	002	Nov 07, 2000	Mar DISC
	@		160MG	A075663	003	Nov 07, 2000	Mar DISC
	@		240MG	A075663	004	Nov 07, 2000	Mar DISC
	@	SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar CAHN
	@		80MG	A076576	001	Apr 08, 2004	Mar CAHN
	@		120MG	A075515	004	Oct 15, 2001	Mar CAHN
	@		120MG	A076576	002	Apr 08, 2004	Mar CAHN
	@		160MG	A075515	002	Oct 15, 2001	Mar CAHN
	@		160MG	A076576	003	Apr 08, 2004	Mar CAHN
	@		240MG	A075515	003	Oct 15, 2001	Mar CAHN
	AB1	UPSHER-SMITH LABS	80MG	A075366	001	May 01, 2000	Oct CAHN
	AB1		120MG	A075366	002	May 01, 2000	Oct CAHN
	AB1		160MG	A075366	003	May 01, 2000	Oct CAHN
	AB1		240MG	A075366	004	May 01, 2000	Oct CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB	ACCORD HLTHCARE INC	25MG	A203512	001	Sep 19, 2016	Sep NEWA
AB		50MG	A203512	002	Sep 19, 2016	Sep NEWA
AB		100MG	A203512	003	Sep 19, 2016	Sep NEWA
AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan CAHN
----	-------------------	-----	---------	-----	--------------	----------

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

AP	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Oct CAHN
----	----------------------	-------------------	---------	-----	--------------	----------

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan CPOT

SULCONAZOLE NITRATE

SOLUTION; TOPICAL

EXELDERM

+	SUN PHARM INDS LTD	1%	N018738	001	Aug 30, 1985	Oct CAHN
---	--------------------	----	---------	-----	--------------	----------

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A085844 001

Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ WEST-WARD PHARMS INT 80MG/ML; 16MG/ML

A070627 001 Dec 29, 1987

Oct CAHN

@ 80MG/ML; 16MG/ML

A070628 001 Dec 29, 1987

Oct CAHN

SUSPENSION; ORAL

BACTRIM

@ SUN PHARM INDS 200MG/5ML; 40MG/5ML

N017560 001

Jun CAHN

BACTRIM PEDIATRIC

@ SUN PHARM INDS 200MG/5ML; 40MG/5ML

N017560 002

Jun CAHN

TABLET; ORAL

BACTRIM

AB SUN PHARM INDS 400MG; 80MG

N017377 001

Mar CAHN

BACTRIM DS

AB + SUN PHARM INDS 800MG; 160MG

N017377 002

Mar CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB SUN PHARM INDS 800MG; 160MG

A071017 001 Aug 25, 1986

Mar CAHN

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@ SUN PHARM INDS 500MG

A089590 001 Oct 19, 1987

Mar CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A085628 001

Feb CAHN

SULINDAC

TABLET; ORAL

SULINDAC

AB SUN PHARM INDS 150MG

A072050 001 Apr 17, 1991

Mar CAHN

AB 200MG

A072051 001 Apr 17, 1991

Mar CAHN

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB + GLAXOSMITHKLINE 5MG/SPRAY

N020626 001 Aug 26, 1997

Feb CFTG

AB + 20MG/SPRAY

N020626 003 Aug 26, 1997

Feb CFTG

SUMATRIPTAN

AB LANNETT 5MG/SPRAY

A204841 001 Feb 19, 2016

Feb NEWA

AB 20MG/SPRAY

A204841 002 Feb 19, 2016

Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

@ MERIDIAN MEDCL EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022377 001 Jun 29, 2010

Sep DISC

POWDER; INHALATION

ONZETRA XSAIL

+ AVANIR PHARMS EQ 11MG BASE

N206099 001 Jan 27, 2016

Jan NEWA

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

DR REDDYS LABS LTD EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

N208223 001 Jan 28, 2016

Jan NEWA

TABLET; ORAL

SUMATRIPTAN SUCCINATE

>D> AB HIKMA PHARMS EQ 25MG BASE

A078298 001 May 21, 2013

Dec DISC

>A> @ EQ 25MG BASE

A078298 001 May 21, 2013

Dec DISC

>D> AB EQ 50MG BASE

A078298 002 May 21, 2013

Dec DISC

>A> @ EQ 50MG BASE

A078298 002 May 21, 2013

Dec DISC

>D> AB EQ 100MG BASE

A078298 003 May 21, 2013

Dec DISC

>A> @ EQ 100MG BASE

A078298 003 May 21, 2013

Dec DISC

TACROLIMUSOINTMENT; TOPICAL
PROTOPIC

AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN

TALCAEROSOL, METERED; INTRAPLEURAL
SCLEROSOL

>D>	+	BRYAN	400MG/SPRAY	N020587	001	Dec 24, 1997	Dec CAHN
>A>	+	LYMOL MEDCL	400MG/SPRAY	N020587	001	Dec 24, 1997	Dec CAHN

POWDER; INTRAPLEURAL
TALC

>D>	+	BRYAN	5GM/BOT	N021388	001	Dec 15, 2003	Dec CAHN
>A>	+	LYMOL MEDCL	5GM/BOT	N021388	001	Dec 15, 2003	Dec CAHN

TAMOXIFEN CITRATESOLUTION; ORAL
SOLTAMOX

MIDATECH PHARMA US EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005 Jan CAHN

TABLET; ORAL

TAMOXIFEN CITRATE

@ ACTAVIS LABS FL INC EQ 10MG BASE

A076179 001 Feb 20, 2003 Jan DISC

@ EQ 20MG BASE

A076179 002 Feb 20, 2003 Jan DISC

AB MAYNE PHARMA EQ 10MG BASE

A075797 001 Feb 20, 2003 Aug CAHN

AB + EQ 20MG BASE

A074858 001 Feb 20, 2003 Aug CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS
ULTRA-TECHNEKOW FM+ MALLINKRODT NUCLEAR 1-19 CI/GENERATOR
@ 0.25-3 CI/GENERATOR

N017243	003	Feb 18, 2014	Jan CAHN
N017243	002		Jan CAHN

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

@ GE HEALTHCARE N/A

N017944 001 May 18, 1982 Aug DISC

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

@ US WORLDMEDS LLC EQ 2MG BASE

N021200 001 Jul 24, 2002 Jan CAHN

@ EQ 6MG BASE

N021200 002 Jul 24, 2002 Jan CAHN

TELITHROMYCIN

TABLET; ORAL

KETEK

@ SANOFI AVENTIS US 300MG

N021144 002 Feb 09, 2005 Mar DISC

@ 400MG

N021144 001 Apr 01, 2004 Mar DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB HETERO LABS LTD V 20MG

A205901 001 Apr 22, 2016 Apr NEWA

AB 40MG

A205901 002 Apr 22, 2016 Apr NEWA

AB 80MG

A205901 003 Apr 22, 2016 Apr NEWA

AB JUBILANT GENERICS 20MG

A204164 001 Aug 22, 2016 Aug NEWA

AB 40MG

A204164 002 Aug 22, 2016 Aug NEWA

AB 80MG

A204164 003 Aug 22, 2016 Aug NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB AMNEAL PHARMS 7.5MG

A203482 001 May 23, 2016 May NEWA

AB 15MG

A203482 002 May 23, 2016 May NEWA

AB 22.5MG

A203482 003 May 23, 2016 May NEWA

AB 30MG

A203482 004 May 23, 2016 May NEWA

AB SUN PHARM INDS 7.5MG

A078581 001 Sep 08, 2009 Mar CAHN

@ 15MG

A071174 001 Jul 10, 1986 Mar CAHN

AB 22.5MG

A071175 002 Sep 14, 2009 Mar CAHN

@ 30MG

A071175 001 Jul 10, 1986 Mar CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB	AMERIGEN PHARMS LTD	5MG	A203490	001	Jul 13, 2016	Jul	NEWA
AB		20MG	A203490	002	Jul 13, 2016	Jul	NEWA
AB		100MG	A203490	003	Jul 13, 2016	Jul	NEWA
AB		140MG	A203490	004	Jul 13, 2016	Jul	NEWA
AB		180MG	A203490	005	Jul 13, 2016	Jul	NEWA
AB		250MG	A203490	006	Jul 13, 2016	Jul	NEWA
AB	CHEMI SPA	5MG	A204639	001	Nov 23, 2016	Nov	NEWA
AB		20MG	A204639	002	Nov 23, 2016	Nov	NEWA
AB		100MG	A204639	003	Nov 23, 2016	Nov	NEWA
AB		140MG	A204639	004	Nov 23, 2016	Nov	NEWA
AB		180MG	A204639	005	Nov 23, 2016	Nov	NEWA
AB		250MG	A204639	006	Nov 23, 2016	Nov	NEWA
AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA
AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA
AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA
AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA
AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA
AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA
>D> AB	LOTUS PHARM CO LTD	5MG	A206309	001	Apr 27, 2016	Dec	CAHN
AB		5MG	A206309	001	Apr 27, 2016	Apr	NEWA
>D> AB		20MG	A206309	002	Apr 27, 2016	Dec	CAHN
AB		20MG	A206309	002	Apr 27, 2016	Apr	NEWA
>D> AB		100MG	A206309	003	Apr 27, 2016	Dec	CAHN
AB		100MG	A206309	003	Apr 27, 2016	Apr	NEWA
>D> AB		140MG	A206309	004	Apr 27, 2016	Dec	CAHN
AB		140MG	A206309	004	Apr 27, 2016	Apr	NEWA
>D> AB		180MG	A206309	005	Apr 27, 2016	Dec	CAHN
AB		180MG	A206309	005	Apr 27, 2016	Apr	NEWA
>D> AB		250MG	A206309	006	Apr 27, 2016	Dec	CAHN
AB		250MG	A206309	006	Apr 27, 2016	Apr	NEWA
AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun	NEWA
AB		20MG	A205227	002	Jun 29, 2016	Jun	NEWA
AB		100MG	A205227	003	Jun 29, 2016	Jun	NEWA
AB		140MG	A205227	004	Jun 29, 2016	Jun	NEWA
AB		180MG	A205227	005	Jun 29, 2016	Jun	NEWA
AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA
>A> AB	RISING PHARMS INC	5MG	A206309	001	Apr 27, 2016	Dec	CAHN
>A> AB		20MG	A206309	002	Apr 27, 2016	Dec	CAHN
>A> AB		100MG	A206309	003	Apr 27, 2016	Dec	CAHN
>A> AB		140MG	A206309	004	Apr 27, 2016	Dec	CAHN
>A> AB		180MG	A206309	005	Apr 27, 2016	Dec	CAHN
>A> AB		250MG	A206309	006	Apr 27, 2016	Dec	CAHN

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

VEMLIDY

+ GILEAD SCIENCES INC EQ 25MG BASE

N208464 001 Nov 10, 2016 Nov NEWA

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP + AMPHASTAR PHARMS INC 1MG/ML
 AP + EUROHLTH INTL SARL 1MG/ML

A076770 001 Apr 23, 2004 Jun CAHN
 A076770 001 Apr 23, 2004 Apr CAHN

TABLET;ORAL

TERBUTALINE SULFATE

@ IMPAX LABS 2.5MG
 @ 5MG
 LANNETT 2.5MG
 5MG

A075877 001 Jun 26, 2001 Mar DISC
 A075877 002 Jun 26, 2001 Mar DISC
 A077152 001 Mar 25, 2005 Mar CTEC
 A077152 002 Mar 25, 2005 Mar CTEC

TESTOSTERONEFILM, EXTENDED RELEASE;TRANSDERMAL
ANDRODERM

+	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar CAHN
@		2.5MG/24HR	N020489	001	Sep 29, 1995	Mar CAHN
+		4MG/24HR	N020489	004	Oct 20, 2011	Mar CAHN
@		5MG/24HR	N020489	002	May 02, 1997	Mar CAHN

GEL, METERED;NASAL
NATESTO

	AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun CAHN
--	---------------------	-------------------------	---------	-----	--------------	----------

PELLET;IMPLANTATION
TESTOPEL

+	AUXILIUM PHARMS INC	75MG	A080911	001		Mar CAHN
---	---------------------	------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;BUCCAL
STRIANT

+	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar CAHN
---	---------------------	------	---------	-----	--------------	----------

TETRABENAZINETABLET;ORAL
TETRABENAZINE

AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan NEWA

TETRACAINE HYDROCHLORIDESOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

>D>	+	ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Dec CAHN
	+		0.5%	N208135	001	Feb 29, 2016	Feb NEWA
>A>	+	NOVARTIS PHARMS CORP	0.5%	N208135	001	Feb 29, 2016	Dec CAHN

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr CMFD
	@ IDT AUSTRALIA LTD	250MG	A061471	001		Aug CAHN
	@ SUN PHARM INDS	250MG	A060736	001		Mar CAHN
	@	500MG	A060736	002		Mar CAHN

THEOPHYLLINECAPSULE, EXTENDED RELEASE;ORAL
THEO-24

	AUXILIUM PHARMS INC	200MG	A087943	001	Aug 22, 1983	Mar CAHN
		300MG	A087944	001	Aug 22, 1983	Mar CAHN
+		400MG	A081034	001	Feb 28, 1992	Mar CAHN
	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Jul CAHN
		300MG	A087944	001	Aug 22, 1983	Jul CAHN

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

>D>	+	NOSTRUM LABS INC	80MG/15ML	A085186	001		Dec CTEC
>A> AA	+		80MG/15ML	A085186	001		Dec CTEC
	+		80MG/15ML	A085186	001		Jan CAHN

THEOPHYLLINE

>A> AA	PHARM ASSOC	80MG/15ML	A206344	001	Dec 16, 2016	Dec NEWA
--------	-------------	-----------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan CAHN

THEOPHYLLINE

AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan CAHN	
AB	+	600MG	A040560	002	Apr 21, 2006	Jan CAHN	
AB	RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Aug CTNA	
>D> AB	+	TEVA PHARMS	450MG	A081236	001	Nov 09, 1992	Dec DISC
>A>	@	450MG	A081236	001	Nov 09, 1992	Dec DISC	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

+	WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Sep CAHN
---	----------------------	-----------	---------	-----	--------------	----------

THIOTHIXENE

CAPSULE; ORAL

NAVANE

@	PFIZER	1MG	N016584	001		Aug DISC
@		2MG	N016584	002		Aug DISC
@		5MG	N016584	003		Aug DISC
@		10MG	N016584	004		Aug DISC

THIOTHIXENE

	MYLAN	1MG	A071093	002	Jun 23, 1987	Aug CTEC
		2MG	A071093	003	Jun 23, 1987	Aug CTEC
+		5MG	A071093	004	Jun 23, 1987	Aug CRLD
		10MG	A071093	001	Jun 23, 1987	Aug CTEC
@	SANDOZ	1MG	A071529	002	Jun 24, 1987	Sep CMS1
@		2MG	A071529	003	Jun 24, 1987	Sep CMS1
@		5MG	A071529	001	Jun 24, 1987	Mar DISC
@		10MG	A071529	004	Jun 24, 1987	Sep CMS1

TIGECYCLINE

>A>	POWDER; IV (INFUSION)					
>A>	TIGECYCLINE					
>A>	AP FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Dec NEWA

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

AT	+	OAK PHARMS INC	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Sep CFTG
AT	+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Sep CFTG

TIMOLOL

AT		AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Sep NEWA
AT			EQ 0.5% BASE	A205309	002	Sep 30, 2016	Sep NEWA

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

BX		UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr CTEC
BX			500MG	A202489	002	Oct 09, 2013	Apr CTEC
AB		WEST-WARD PHARMS INT	250MG	A201172	001	Apr 30, 2012	Nov CAHN
AB			500MG	A201172	002	Apr 30, 2012	Nov CAHN

TIROFIBAN HYDROCHLORIDE

SOLUTION; INJECTION

AGGRASTAT

+	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016	Aug NEWA
---	----------	---	---------	-----	--------------	----------

TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

>D>	+	ALCON	0.3%	N050555	001		Dec CAHN
>A>	+	NOVARTIS PHARMS CORP	0.3%	N050555	001		Dec CAHN

SOLUTION; INHALATION

BETHKIS

+	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Sep CRLD
---	----------------	-----------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC
TOBEX

>D>	AT	+	ALCON LABS INC	0.3%	N050541	001			Dec CAHN
>A>	AT	+	NOVARTIS PHARMS CORP	0.3%	N050541	001			Dec CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION
TOBRAMYCIN SULFATE

AP			CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun	NEWA
			@ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991	Oct	CAHN
			@	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991	Oct	CAHN
AP				EQ 40MG BASE/ML	A063117	001	Apr 26, 1991	Oct	CAHN
			@	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991	Oct	CAHN
			@	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991	Oct	CAHN

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR

			+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb	NEWA
--	--	--	---	------------	--------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET;ORAL
TOLAZAMIDE

			@	SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
			@		250MG	A071358	001	Jul 16, 1987	Mar	CAHN
			@		500MG	A071359	001	Jul 16, 1987	Mar	CAHN

TOLMETIN SODIUM

CAPSULE;ORAL
TOLMETIN SODIUM

			@	SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar	CAHN
--	--	--	---	----------------	---------------	---------	-----	--------------	-----	------

TABLET;ORAL

AB				TOLMETIN SODIUM						
				SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar	CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
TOLTERODINE TARTRATE

AB				TEVA PHARMS USA	2MG	A079141	001	Nov 22, 2016	Nov	NEWA
AB					4MG	A079141	002	Nov 22, 2016	Nov	NEWA

TOPIRAMATE

TABLET;ORAL
TOPIRAMATE

			@	ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr	DISC
AB					25MG	A078637	001	Feb 27, 2013	Jan	CAHN
			@		50MG	A078637	002	Feb 27, 2013	Apr	DISC
AB					50MG	A078637	002	Feb 27, 2013	Jan	CAHN
			@		100MG	A078637	003	Feb 27, 2013	Apr	DISC
AB					100MG	A078637	003	Feb 27, 2013	Jan	CAHN
			@		200MG	A078637	004	Feb 27, 2013	Apr	DISC
AB					200MG	A078637	004	Feb 27, 2013	Jan	CAHN
>D>	AB			APOTEX INC	25MG	A077733	001	Mar 27, 2009	Dec	CAHN
>A>	AB				25MG	A077733	001	Mar 27, 2009	Dec	CAHN
>D>	AB				50MG	A077733	002	Mar 27, 2009	Dec	CAHN
>A>	AB				50MG	A077733	002	Mar 27, 2009	Dec	CAHN
>D>	AB				100MG	A077733	003	Mar 27, 2009	Dec	CAHN
>A>	AB				100MG	A077733	003	Mar 27, 2009	Dec	CAHN
>D>	AB				200MG	A077733	004	Mar 27, 2009	Dec	CAHN
>A>	AB				200MG	A077733	004	Mar 27, 2009	Dec	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION
TOPOTECAN HYDROCHLORIDE

AP				INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Nov	NEWA
----	--	--	--	--------------------	------------------	---------	-----	--------------	-----	------

TORSEMIDE

INJECTABLE;INJECTION
TORSEMIDE

			@	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Oct	CAHN
			@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Oct	CAHN

TABLET;ORAL
TORSEMIDE

>D>	AB	APOTEX INC	5MG	A076894	001	May 31, 2005	Dec CAHN
>A>	AB		5MG	A076894	001	May 31, 2005	Dec CAHN
>D>	AB		10MG	A076894	002	May 31, 2005	Dec CAHN
>A>	AB		10MG	A076894	002	May 31, 2005	Dec CAHN
>D>	AB		20MG	A076894	003	May 31, 2005	Dec CAHN
>A>	AB		20MG	A076894	003	May 31, 2005	Dec CAHN
>D>	AB		100MG	A076894	004	May 31, 2005	Dec CAHN
>A>	AB		100MG	A076894	004	May 31, 2005	Dec CAHN
	AB	WEST-WARD PHARMS INT	5MG	A076943	001	Mar 01, 2005	Nov CAHN
	AB		10MG	A076943	002	Mar 01, 2005	Nov CAHN
	AB		20MG	A076943	003	Mar 01, 2005	Nov CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar CAHN
AB		SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB1	+	LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Oct CRLD
		ULTRAM ER					
		@ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Oct DISC
AB1	+		100MG	N021692	001	Sep 08, 2005	Mar CAHN
		@	200MG	N021692	002	Sep 08, 2005	Oct DISC
AB1			200MG	N021692	002	Sep 08, 2005	Mar CAHN
		@	300MG	N021692	003	Sep 08, 2005	Oct DISC
AB1			300MG	N021692	003	Sep 08, 2005	Mar CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP		AKORN	100MG/ML	A206634	001	Jun 09, 2016	May NEWA
AP		AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan NEWA
AP		NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb NEWA

TABLET;ORAL

TRANEXAMIC ACID

		@ AMERIGEN PHARMS LTD	650MG	A203256	001	Jul 25, 2016	Jul DISC
AB			650MG	A203256	001	Jul 25, 2016	Jul NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

>D>		@ ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Dec CAHN
>A>		@ NOVARTIS PHARMS CORP	0.003%	N204822	001	May 15, 2014	Dec CAHN
		TRAVATAN Z					
>D>	AT	+ ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Dec CAHN
>A>	AT	+ NOVARTIS PHARMS CORP	0.004%	N021994	001	Sep 21, 2006	Dec CAHN

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

		@ AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb CAHN
AB		SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar CAHN
AB			100MG	A073137	001	Mar 24, 1993	Mar CAHN
AB			150MG	A073137	003	Dec 22, 1995	Mar CAHN

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

		UNITED THERAP	EQ 5MG BASE	N203496	005	Oct 07, 2016	Oct NEWA
--	--	---------------	-------------	---------	-----	--------------	----------

TRETINOIN

CAPSULE;ORAL

TRETINOIN

>A>	AB	GLENMARK GENERICS	10MG	A208279	001	Dec 23, 2016	Dec NEWA
		CREAM;TOPICAL					
		TRETINOIN					
	+	ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Jul CAHN
			0.075%	A202209	001	Oct 11, 2012	Jul CAHN
AB		ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb CAHN

CREAM; TOPICAL
TRETINOIN

AB1		0.05%	A075265	001	Dec 24, 1998	Feb CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Feb CAHN
AB	PERRIGO PHARMA INTL	0.025%	A075264	001	Dec 24, 1998	Jul CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Jul CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Jul CAHN

GEL; TOPICAL
TRETINOIN

AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Feb CAHN
AB	PERRIGO PHARMA INTL	0.01%	A075589	001	Jun 11, 2002	Jul CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Jul CAHN

TRIAMCINOLONE ACETONIDECREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul NEWA
----	---------------------	------	---------	-----	--------------	----------

INJECTABLE; INTRAVITREAL
TRIESENCE

>D>	+ ALCON	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007	Dec CAHN
>A>	+ NOVARTIS PHARMS CORP	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007	Dec CAHN

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	TELIGENT PHARMA INC	0.025%	A204608	001	Jul 07, 2016	Jun NEWA
AT		0.1%	A204606	001	Jul 07, 2016	Jun NEWA

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul NEWA
AT	TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May NEWA

SPRAY; TOPICAL
KENALOG

AT	+ RANBAXY LABS LTD	0.147MG/GM	N012104	001		Jul CAHN
	TRIAMCINOLONE ACETONIDE					
AT	AKORN	0.147MG/GM	A207094	001	Dec 07, 2016	Nov NEWA
	SPRAY, METERED; NASAL					
	TRIAMCINOLONE ACETONIDE					
	@ TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Oct DISC

TRIAZOLAMTABLET; ORAL
TRIAZOLAM

AB	WEST-WARD PHARMS INT	0.125MG	A074224	001	Jun 01, 1994	Nov CAHN
AB		0.25MG	A074224	002	Jun 01, 1994	Nov CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDECAPSULE; ORAL
TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar CAHN
----	----------------	-------	---------	-----	--------------	----------

TRIMETHOPRIMTABLET; ORAL
TRIMETHOPRIM

AB	+ MAYNE PHARMA	100MG	N018679	001	Jul 30, 1982	Aug CAHN
	@ SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun CAHN
	@	200MG	A070495	001	Sep 24, 1986	Mar CAHN

TRIMETHOPRIM HYDROCHLORIDESOLUTION; ORAL
PRIMSOL

	+ AYU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun CAHN
	@ AYU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun CMS2
	@	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jan CAHN
	+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan CAHN

TRIMIPRAMINE MALEATECAPSULE; ORAL
TRIMIPRAMINE MALEATE

AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr NEWA

TRIPTORELIN PAMOATEINJECTABLE; INTRAMUSCULAR
TRELSTAR

+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN

TROPICAMIDESOLUTION/DROPS; OPHTHALMIC
MYDRIACYL

>D>	AT	+	ALCON	1%	A084306	001		Dec CAHN
>A>	AT	+	NOVARTIS PHARMS CORP	1%	A084306	001		Dec CAHN

TROSPIMUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
TROSPIMUM CHLORIDE

AB	+	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Aug CRLD
		@ SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr DISC
		@ UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Oct CAHN

TABLET; ORAL

TROSPIMUM CHLORIDE

AB	+	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Aug CRLD
AB		HERITAGE PHARMS INC	20MG	A204945	001	Aug 30, 2016	Aug NEWA
AB		INVAGEN PHARMS	20MG	A091688	001	Aug 23, 2016	Aug NEWA

URSODIOL

CAPSULE; ORAL

ACTIGALL

		@ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
AB	+		300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		WEST-WARD PHARMS INT	EQ 500MG BASE	A078656	001	May 24, 2010	Nov CAHN
AB			EQ 1GM BASE	A078656	002	May 24, 2010	Nov CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	Jul CFTG
		VALGANCICLOVIR HYDROCHLORIDE					

AB		ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016	Jul NEWA
----	--	---------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB		HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

AP		AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
AP		EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB		BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	--	----------------	-------	---------	-----	--------------	----------

SYRUP; ORAL

VALPROIC ACID

>D>		@ APOTEX INC	250MG/5ML	A077105	001	Jul 29, 2005	Dec CAHN
>A>		@	250MG/5ML	A077105	001	Jul 29, 2005	Dec CAHN
AA		NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN

VALSARTAN

TABLET; ORAL

VALSARTAN

AB		MACLEODS PHARMS LTD	40MG	A202696	001	Sep 16, 2016	Sep NEWA
AB			80MG	A202696	002	Sep 16, 2016	Sep NEWA
AB			160MG	A202696	003	Sep 16, 2016	Sep NEWA
AB			320MG	A202696	004	Sep 16, 2016	Sep NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOLED

@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Oct CAHN
@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Oct CAHN
@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Oct CAHN
@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Oct CAHN
@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Oct CAHN

VANCOMYCIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
AP	CFT PHARMS LLC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Jul CAHN
AP		EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Jul CAHN
AP		EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Jul CAHN
AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Jul CAHN
AP	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A062663	005	Aug 17, 2016	Aug NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA
	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988	Oct CAHN
	@	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988	Oct CAHN

VANDETANIB

TABLET; ORAL

CAPRELSA

GENZYME CORP	100MG	N022405	001	Apr 06, 2011	Jun CAHN
+	300MG	N022405	002	Apr 06, 2011	Jun CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
AP		20MG/VIAL	A205390	002	May 26, 2016	May NEWA
AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAX

TABLET; ORAL

VENCLEXTA

ABBVIE INC	10MG	N208573	001	Apr 11, 2016	Apr NEWA
	50MG	N208573	002	Apr 11, 2016	Apr NEWA
+	100MG	N208573	003	Apr 11, 2016	Apr NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr CMFD
	TABLET; ORAL					
	CALAN					
	@ GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988	Sep DISC
	VERAPAMIL HYDROCHLORIDE					
	@ SUN PHARM INDS	80MG	A071489	002	Jan 13, 1988	Jun CAHN
	@	120MG	A071489	001	Jan 13, 1988	Jun CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	VERAPAMIL HYDROCHLORIDE					
AB	+ GLENMARK GENERICS	180MG	A090700	002	Aug 03, 2011	Aug CRLD

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

+	WEST-WARD PHARMS INT	10MG/VIAL	A089395	001	Apr 09, 1987	Oct CAHN
---	----------------------	-----------	---------	-----	--------------	----------

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+	ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014	Sep CAHN
---	---------------	----------------	---------	-----	--------------	----------

VORICONAZOLEFOR SUSPENSION; ORAL
VORICONAZOLE

AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May NEWA

INJECTABLE; IV (INFUSION)
VORICONAZOLE

AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar NEWA
----	-------------	------------	---------	-----	--------------	----------

TABLET; ORAL
VORICONAZOLE

AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May NEWA
AB		200MG	A206181	002	May 24, 2016	May NEWA
AB	AKORN	50MG	A207049	001	Sep 07, 2016	Nov CAHN
AB		200MG	A207049	002	Sep 07, 2016	Nov CAHN
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May NEWA
AB		200MG	A206762	002	May 24, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan NEWA
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May NEWA
AB		200MG	A207371	002	May 24, 2016	May NEWA
AB	PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul NEWA
AB		200MG	A206654	002	Aug 08, 2016	Jul NEWA
AB	VERSAPHARM INC	50MG	A207049	001	Sep 07, 2016	Aug NEWA
AB		200MG	A207049	002	Sep 07, 2016	Aug NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May NEWA
AB		200MG	A206747	002	May 24, 2016	May NEWA

VORTIOXETINE HYDROBROMIDETABLET; ORAL
TRINTELLIX

TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun CTNA
	EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun CTNA
	EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun CTNA
+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun CTNA

XENON XE-133GAS; INHALATION
XENON XE 133

LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb CTEC
MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb CMFD
	20mCi/VIAL	N018327	002	Mar 09, 1982	Feb CMFD

ZALEPLONCAPSULE; ORAL
ZALEPLON

@ UPSHER SMITH	5MG	A078706	001	Jun 06, 2008	Nov DISC
@	10MG	A078706	002	Jun 06, 2008	Nov DISC
@ UPSHER-SMITH LABS	5MG	A078095	001	Jun 06, 2008	Oct CAHN
@	10MG	A078095	002	Jun 06, 2008	Oct CAHN
AB WEST-WARD PHARMS INT	5MG	A077237	001	Jun 06, 2008	Nov CAHN
AB	10MG	A077237	002	Jun 06, 2008	Nov CAHN

ZIDOVUDINETABLET; ORAL
ZIDOVUDINE

@ SUNSHINE LAKE	300MG	A202058	001	Oct 07, 2011	Aug DISC
AB WEST-WARD PHARMS INT	300MG	A076844	001	Sep 19, 2005	Nov CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	APOTEX INC	EQ 20MG BASE	A077561	001	Mar 02, 2012	Nov CAHN
AB		EQ 40MG BASE	A077561	002	Mar 02, 2012	Nov CAHN
AB		EQ 60MG BASE	A077561	003	Mar 02, 2012	Nov CAHN
AB		EQ 80MG BASE	A077561	004	Mar 02, 2012	Nov CAHN
>A> AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A204117	001	Dec 27, 2016	Dec NEWA
>A> AB		EQ 40MG BASE	A204117	002	Dec 27, 2016	Dec NEWA
>A> AB		EQ 60MG BASE	A204117	003	Dec 27, 2016	Dec NEWA
>A> AB		EQ 80MG BASE	A204117	004	Dec 27, 2016	Dec NEWA

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Nov NEWA
AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Sep NEWA
AP	GLAND PHARMA LTD	EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Aug NEWA

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May NEWA
AB		5MG	A204041	002	May 20, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr NEWA
AB		5MG	A207021	002	May 11, 2016	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

AB	ALEMBIC PHARMS LTD	2.5MG	A205074	001	Dec 01, 2016	Nov NEWA
AB		5MG	A205074	002	Dec 01, 2016	Nov NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

>D>	AB	CARLSBAD	5MG	A077990	001	Apr 23, 2007	Dec CAHN
>D>	AB		10MG	A077990	002	Apr 23, 2007	Dec CAHN
	AB	SANDOZ INC	5MG	A077322	001	Apr 23, 2007	Aug CAHN
	AB		10MG	A077322	002	Apr 23, 2007	Aug CAHN
		@ SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar CAHN
		@	10MG	A077288	002	Apr 23, 2007	Mar CAHN
>A>	AB	YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007	Dec CAHN
>A>	AB		10MG	A077990	002	Apr 23, 2007	Dec CAHN

TABLET;SUBLINGUAL
EDLUAR

AB	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009	Jul CFTG
AB	+	10MG	N021997	002	Mar 13, 2009	Jul CFTG
		ZOLPIDEM TARTRATE				
AB	DR REDDYS LABS INC	1.75MG	A204503	001	Nov 18, 2016	Nov NEWA
AB		3.5MG	A204503	002	Nov 18, 2016	Nov NEWA
AB	MYLAN PHARMS INC	5MG	A202657	001	Aug 08, 2016	Jul NEWA
AB		10MG	A202657	002	Aug 08, 2016	Jul NEWA
AB	PAR FORM	5MG	A201509	001	Aug 01, 2016	Jul NEWA
AB		10MG	A201509	002	Aug 01, 2016	Jul NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN

ZONISAMIDE

>D>	AB	APOTEX INC	25MG	A077642	001	Dec 22, 2005	Dec CAHN
>A>	AB		25MG	A077642	001	Dec 22, 2005	Dec CAHN
>D>	AB		50MG	A077642	002	Dec 22, 2005	Dec CAHN
>A>	AB		50MG	A077642	002	Dec 22, 2005	Dec CAHN
>D>	AB		100MG	A077642	003	Dec 22, 2005	Dec CAHN
>A>	AB		100MG	A077642	003	Dec 22, 2005	Dec CAHN
	AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
	AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
	AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
		@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar CAHN
		@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
		@	100MG	A077635	003	Dec 22, 2005	Mar CAHN
		@ UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Oct CAHN
		@	50MG	A077644	002	Dec 22, 2005	Oct CAHN
		@	100MG	A077644	003	Dec 22, 2005	Oct CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

AUROBINDO PHARMA LTD 650MG

A207229 001 Nov 09, 2016 Oct NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG;250MG;65MG

N020802 001 Jan 14, 1998 Feb CAHN

ADAPALENE

GEL;TOPICAL

DIFFERIN

+ GALDERMA LABS LP 0.1%

N020380 002 Jul 08, 2016 Aug NEWA

BUDESONIDE

SPRAY, METERED;NASAL
BUDESONIDE

>D> APOTEX INC 0.032MG/SPRAY

A078949 002 Nov 20, 2015 Dec CAHN

>A> 0.032MG/SPRAY

A078949 002 Nov 20, 2015 Dec CAHN

0.032MG/SPRAY

A078949 002 Nov 20, 2015 Apr NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG

A077355 001 Feb 06, 2008 Aug CTNA

800MG;10MG;165MG

A204782 001 Aug 29, 2016 Aug NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX INC 10MG

A207235 001 Aug 12, 2016 Aug NEWA

BIONPHARMA INC 5MG

N022429 001 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG

N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 002 Jul 23, 2009 Jan CAHN

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG

A206793 001 Mar 08, 2016 Feb NEWA

10MG

A206793 002 Mar 08, 2016 Feb NEWA

CHLORHEXIDINE GLUCONATE

SPONGE;TOPICAL

CHLORHEXIDINE GLUCONATE

+ BECTON DICKINSON 4%

A072525 001 Oct 24, 1989 Jun CRLD

PHARMASEAL SCRUB CARE

@ CAREFUSION 4%

N019793 001 Dec 02, 1988 Jun DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ BECTON DICKINSON CO 2%;70% (3ML)

N020832 001 Jul 14, 2000 May CAHN

+ 2%;70% (10.5ML)

N020832 004 Aug 20, 2003 May CAHN

+ 2%;70% (26ML)

N020832 006 Nov 21, 2006 May CAHN

CHLORAPREP ONE-STEP FREPP

+ BECTON DICKINSON CO 2%;70% (1.5ML)

N020832 003 Apr 26, 2002 May CAHN

CHLORAPREP WITH TINT

+ BECTON DICKINSON CO 2%;70% (26ML)

N020832 002 May 03, 2005 May CAHN

+ 2%;70% (10.5ML)

N020832 005 Apr 03, 2006 May CAHN

+ 2%;70% (3ML)

N020832 007 Oct 10, 2006 May CAHN

SWAB; TOPICAL					
CHLORAPREP ONE-STEP SEPP					
+	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002 May CAHN
CHLORAPREP SINGLE SWABSTICK					
+	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005 May CAHN
CHLORAPREP TRIPLE SWABSTICK					
+	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009 May CAHN
<u>CHLORPHENIRAMINE MALEATE</u>					
CAPSULE, EXTENDED RELEASE; ORAL					
CHLORPHENIRAMINE MALEATE					
@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988 Feb CAHN
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN</u>					
CAPSULE; ORAL					
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE					
	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010 Jan CAHN
<u>FAMOTIDINE</u>					
TABLET; ORAL					
FAMOTIDINE					
	AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016 Apr NEWA
		20MG	A206531	002	Apr 26, 2016 Apr NEWA
<u>FEXOFENADINE HYDROCHLORIDE</u>					
TABLET; ORAL					
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016 Aug NEWA
FEXOFENADINE HYDROCHLORIDE ALLERGY					
	HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016 Aug NEWA
		180MG	A204097	003	Aug 19, 2016 Aug NEWA
<u>FLUTICASONE FUROATE</u>					
SPRAY, METERED; NASAL					
FLONASE SENSIMIST ALLERGY RELIEF					
+	GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051	002	Aug 02, 2016 Aug NEWA
<u>FLUTICASONE PROPIONATE</u>					
SPRAY, METERED; NASAL					
FLUTICASONE PROPIONATE					
	APOTEX INC	0.05MG/SPRAY	A208150	001	Feb 29, 2016 Jul CAHN
	APOTEX TECHNOLOGIES	0.05MG/SPRAY	A208150	001	Feb 29, 2016 Feb NEWA
	ROXANE	0.05MG/SPRAY	A207957	001	May 26, 2016 May NEWA
	WEST-WARD PHARMS INT	0.05MG/SPRAY	A207957	001	May 26, 2016 Nov CAHN
<u>IBUPROFEN</u>					
CAPSULE; ORAL					
IBUPROFEN					
	BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009 Jan CAHN
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016 Sep CAHN
	PURACAP PHARM LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016 Jun NEWA
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016 Aug NEWA
MIDOL LIQUID GELS					
+	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002 Jan CAHN
TABLET; ORAL					
IBUPROFEN					
	GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016 Sep NEWA
	STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011 May CAHN
		200MG	A091355	001	Apr 04, 2011 May CAHN
@	SUN PHARM INDS	200MG	A070493	001	Dec 24, 1985 Mar CAHN
@		200MG	A070908	001	Sep 26, 1986 Mar CAHN
@		200MG	A071462	001	Oct 02, 1986 Mar CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
KETOTIFEN FUMARATE

+	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Aug CRLD
	ZADITOR					
@	ALCON PHARMA	EQ 0.025% BASE	N021066	002	Oct 19, 2006	Aug DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

	MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016	May NEWA
	PREVACID 24 HR					
+	GLAXOSMITHKLINE CONS	15MG	N022327	001	May 18, 2009	Aug CAHN
	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
	LANSOPRAZOLE					
	DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016	Jun NEWA

LEVONORGESTREL

TABLET;ORAL
HER STYLE

	NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb NEWA
	LEVONORGESTREL					
	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016	Mar NEWA
	JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug NEWA
	LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

	BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan CAHN
+		2MG	N021855	002	Aug 04, 2005	Jan CAHN

LORATADINE

CAPSULE;ORAL
LORATADINE

	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016	Sep NEWA
--	-----------------	------	---------	-----	--------------	----------

TABLET;ORAL
LORATADINE

>D>	APOTEX INC	10MG	A076471	001	Feb 14, 2006	Dec CAHN
>A>		10MG	A076471	001	Feb 14, 2006	Dec CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
LORATADINE

	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003	Oct CAHN
--	---------------------	------	---------	-----	--------------	----------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE

	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003	Oct CAHN
		10MG;240MG	A075989	001	Mar 04, 2004	Oct CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
MONISTAT 3 COMBINATION PACK

+	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996	Mar CMS1
---	------------------	----------	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

+	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar CAHN
---	----------------	---------------	---------	-----	--------------	----------

TABLET;ORAL
NAPROXEN SODIUM

	AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar NEWA
--	----------------------	---------------	---------	-----	--------------	----------

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
HABITROL

	DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999	Aug CRLD
		14MG/24HR	N020076	005	Nov 12, 1999	Aug CRLD

FILM, EXTENDED RELEASE;TRANSDERMAL
NICODERM CQ

SANOFI AVENTIS US 7MG/24HR
14MG/24HR

N020165 006 Aug 02, 1996 Aug CRLD
N020165 005 Aug 02, 1996 Aug CRLD

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE
EQ 4MG BASE
>A> PERRIGO R AND D EQ 2MG BASE
>A> EQ 4MG BASE

A204794 001 May 10, 2016 Apr NEWA
A204833 001 Feb 26, 2016 Feb NEWA
A206394 001 Dec 15, 2016 Dec NEWA
A206393 001 Dec 15, 2016 Dec NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

ACTAVIS ELIZABETH 20MG;1.1GM
AUROLIFE PHARMA LLC 20MG;1.1GM
PAR PHARM 20MG;1.1GM
PERRIGO R AND D 20MG;1.1GM

A204137 001 Jul 15, 2016 Jul NEWA
A204923 001 Nov 07, 2016 Oct NEWA
A201946 001 Jul 15, 2016 Jul NEWA
A201361 001 Jul 15, 2016 Jul NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

NUVO PHARM INC 17GM/SCOOPFUL
STRIDES PHARMA 17GM/SCOOPFUL
17GM/PACKET

A206105 001 Oct 28, 2016 Oct NEWA
A203928 001 Aug 24, 2016 Aug NEWA
A203928 002 Aug 24, 2016 Aug NEWA

POTASSIUM IODIDE

SOLUTION;ORAL
POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL
THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

APOTEX INC EQ 75MG BASE
STRIDES PHARMA EQ 75MG BASE

A075167 001 May 04, 2000 Nov CAHN
A201745 001 Feb 29, 2012 May CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL
TRIAMCINOLONE ACETONIDE

TEVA PHARMS 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Oct NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2016

NO DECEMBER 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - ABACAVIR SULFATE AND LAMIVUDINE</u>						
A 079246 001					PC	Mar 28, 2017
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP			
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031	U-1882			
	9399012*PED	Mar 11, 2032				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	9468636	May 16, 2032	U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jul 24, 2018	DP U-1006			
	6514980	Jul 24, 2018	DP U-1484			
	7223387	Nov 13, 2022	DP U-1006			
	7223387	Nov 13, 2022	DP U-1484			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 002					RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	9463289	May 18, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
	9440922	Jun 09, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	9474752	Dec 11, 2027	U-1754			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	9474752	Dec 11, 2027	U-1754			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	6559183	Nov 12, 2019	DP U-804		NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>APREPITANT - EMEND</u>						
N 207865 001	6096742	Jul 01, 2018	DS DP U-1916			
	8258132	Sep 26, 2027	DP U-1916			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9452131	Mar 19, 2035	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9452131	Mar 19, 2035	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9452131	Mar 19, 2035	U-543			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					PC	Nov 28, 2016
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP		U-1893	
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP		U-1893	
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032			U-1731	
	9226892	Sep 29, 2032			U-1732	
	9226892	Sep 29, 2032			U-1733	
	9351984	Dec 19, 2021	DP			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	6926907	Feb 28, 2023	DP		U-1902	
	8206741	Feb 28, 2023	DP		U-1902	
					NC	Sep 14, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9364439	May 31, 2022	DP U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81		PED	Aug 20, 2018
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
	8163723*PED	Feb 29, 2024				
	9259428	Jun 13, 2023	U-644			
	9259428*PED	Dec 13, 2023				
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	9463289	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	9463289	May 18, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9504704	Jun 03, 2029	DP U-124			
	9504704	Jun 03, 2029	DP U-134			
	9504704	Jun 03, 2029	DP U-818			
	9504704	Jun 03, 2029	DP U-916			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006					M-186	Sep 23, 2019
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9421265	Jun 17, 2030	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9474751	Apr 19, 2022	DP U-1524			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
>A>	9439900	Sep 18, 2032	DP	Y		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	>A> 9522188	Apr 24, 2035	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	>A> 9522188	Apr 24, 2035	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	>A> 9522188	Apr 24, 2035	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	>A> 7579473	Aug 14, 2026	DS DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	>A> 7579473	Aug 14, 2026	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 001	>A> 7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 002	>A> 7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 003	>A> 7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
>A>	9498486	Apr 25, 2028	U-1920			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
>A>	9498486	Apr 25, 2028	U-1920			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
>A>	9427448	Nov 10, 2030	U-1926			
>A>	9439921	Jul 10, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	7635773	Mar 13, 2029	DP		ODE	Oct 07, 2023
	8410077	Mar 13, 2029	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9463246	Dec 26, 2028	DP U-219			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	>A> 9522191	Mar 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	8129346	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
	>A> 9511109	Oct 21, 2029	U-1924			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	7232818	Apr 14, 2025	DS DP		I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	7491704	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
	7737112	Dec 07, 2027	DP		NCE	Jul 20, 2017
	8129346	Apr 14, 2025	U-1260		ODE	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
	>A> 9511109	Oct 21, 2029	U-1924			
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u>						
N 050803 001	>A> 9492384	Aug 31, 2025	DP U-1412			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9457036	Jan 13, 2024	DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9399036	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	9415007	Jul 28, 2024	U-1896			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
	>A> 9517219	Nov 18, 2033	U-1033			
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003	9138456	Nov 23, 2030	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9415085	Apr 27, 2032	U-1895			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9415085	Apr 27, 2032	U-1895			
<u>DESONIDE - VERDESO</u>						
N 021978 001 >A>	9492384	Aug 31, 2025	DP U-1412			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202842 005				>A> PC		Jul 04, 2017
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202842 007				>A> PC		Jul 04, 2017
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 003	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	>A> 9511031	Oct 23, 2034	DP			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	>A> 9511031	Oct 23, 2034	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM</u>						
A 203593 001					PC	Apr 09, 2017
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9457036	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELBASVIR; GRAZOPREXIN - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	9364489	Jul 07, 2028	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	9364489	Jul 07, 2028	U-1709			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 8551957	Oct 14, 2029	U-1651		>A> I-739 M-174	Dec 02, 2019 Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 8551957	Oct 14, 2029	U-1651		>A> I-739 M-174	Dec 02, 2019 Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP		>A> I-739	Dec 02, 2019
	8551957	Oct 14, 2029	DP U-1651			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP		>A> I-739	Dec 02, 2019
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001					>A> I-739 M-174	Dec 02, 2019 Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002					>A> I-739 M-174	Dec 02, 2019 Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003					>A> I-739 M-174	Dec 02, 2019 Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004					>A> I-739 M-174	Dec 02, 2019 Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 6488962	Jun 20, 2020	DP		>A> I-739	Dec 02, 2019
	>A> 7579449	Nov 05, 2025	DS		>A> NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 6488962	Jun 20, 2020	DP		>A> I-739	Dec 02, 2019
	>A> 7579449	Nov 05, 2025	DS		>A> NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 6488962	Jun 20, 2020	DP		>A> I-739	Dec 02, 2019
	>A> 7579449	Nov 05, 2025	DS		>A> NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 6488962	Jun 20, 2020	DP		>A> I-739	Dec 02, 2019
	>A> 7579449	Nov 05, 2025	DS		>A> NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 6488962	Jun 20, 2020	DP		>A> I-739	Dec 02, 2019
	>A> 7579449	Nov 05, 2025	DS		>A> NCE	Aug 01, 2019
	>A> 7713938	Apr 15, 2027	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	7125879	Apr 21, 2025	DS DP U-257			
	9457036	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	9457036	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-1892			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001 >A>	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002 >A>	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
					M-181	Jun 01, 2019
					M-190	Oct 18, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
					M-181	Jun 01, 2019
					M-190	Oct 18, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	003				D-164 M-181 M-190	May 20, 2019 Jun 01, 2019 Oct 18, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	001	5753646	Jun 27, 2017	DS DP U-1451		
		5753646	Jun 27, 2017	DS DP U-1746		
		5753646	Jun 27, 2017	DS DP U-1842		
		9206135	Apr 21, 2026	DS		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	002	5753646	Jun 27, 2017	DS DP U-1451		
		5753646	Jun 27, 2017	DS DP U-1746		
		5753646	Jun 27, 2017	DS DP U-1842		
		9206135	Apr 21, 2026	DS		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	003	5753646	Jun 27, 2017	DS DP U-1451		
		5753646	Jun 27, 2017	DS DP U-1746		
		5753646	Jun 27, 2017	DS DP U-1842		
		9206135	Apr 21, 2026	DS		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	004	5753646	Jun 27, 2017	DS DP U-1451		
		5753646	Jun 27, 2017	DS DP U-1746		
		5753646	Jun 27, 2017	DS DP U-1842		
		9206135	Apr 21, 2026	DS		
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703	001	6310094	Jan 12, 2021	DP		
		6528540	Jan 12, 2021	DP		
		8829054	Mar 15, 2033	DP		
		8835505	Mar 15, 2033	DP		
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703	002	6310094	Jan 12, 2021	DP		
		6528540	Jan 12, 2021	DP		
		8829054	Mar 15, 2033	DP		
		8835505	Mar 15, 2033	DP		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655	001	6369085	May 25, 2018	DS DP U-1509		
		6369085	May 25, 2018	DS DP U-1875		
		6369085*PED	Nov 25, 2018			
		6428810	Nov 03, 2019	DP U-1509		
		6428810	Nov 03, 2019	DP U-1874		
		6428810*PED	May 03, 2020			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	001	9220698	Mar 10, 2031		U-1781	
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029		U-1781	
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	002	9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029		U-1781	
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488	001	8486907	Jun 28, 2025		NCE	Sep 19, 2021
		9018368	Jun 28, 2025	DS DP	ODE	Sep 19, 2023
		9416361	May 04, 2021	DS		
		9506058	Mar 14, 2034		U-1918	
		9506058	Mar 14, 2034		U-1919	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025	U-1904		NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025	U-1904		NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE - EZETIMIBE</u>						
A 078560 001					>A> PC	Jun 10, 2017
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 001	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	>A> 9328133	Feb 18, 2024	DS DP U-1577			
	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FINAFLORACIN - XTORO</u>						
N 206307 001	>A> 9504691	Nov 21, 2033	DP U-1679			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	9468639	Oct 16, 2022	U-1734			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2017	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026	U-1879			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	>A> 7270800	Sep 03, 2025	DS DP U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	>A> 7270800	Sep 03, 2025	DS DP U-336			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	6858596	Aug 03, 2021	DP U-1890			
	7101866	Aug 03, 2021	DS DP U-1890			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	7541350	Aug 03, 2021	DP U-1890			
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
	9415009	May 28, 2030	U-1841			
	9463161	May 28, 2030	DP U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001					NCE ODE	Jun 01, 2021 Jun 01, 2023
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP		NCE	Jul 01, 2016
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 001					PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 002					PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 003					PC	Apr 24, 2017
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165	May 06, 2019
					I-729	Mar 04, 2019
					I-736	May 06, 2019
					I-737	May 06, 2019
					ODE	Mar 04, 2023
					ODE	May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	9469643	Sep 02, 2033	DS		>A> ODE	Jul 23, 2021
	9492449	Mar 11, 2030	U-1914		>A> ODE	Jul 23, 2021
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	9469643	Sep 02, 2033	DS		>A> ODE	Jul 23, 2021
	9492449	Mar 11, 2030	U-1914		>A> ODE	Jul 23, 2021
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9457154	Sep 27, 2027	DP		>A> NPP	Dec 16, 2019
	9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	9457154	Sep 27, 2027	DP		>A> NPP	Dec 16, 2019
	9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9457154	Sep 27, 2027	DP		>A> NPP	Dec 16, 2019
	9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	6268343	Aug 22, 2022	DS DP		NC	Nov 21, 2019
	6458924	Aug 22, 2017	DS DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7235627	Aug 22, 2017	DS			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5866538	Jun 20, 2017	DP			
	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024		U-1832		
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	>A> 9526844	Mar 02, 2024	DP			
	>A> 9533105	Aug 17, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024		U-1832		
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP	U-1855		
	9408979	Mar 02, 2024	DP			
	>A> 9526844	Mar 02, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	>A> 9533105	Aug 17, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	>A> 7918833	Sep 23, 2027	DP		NC	Nov 21, 2019
	>A> 8512297	Sep 15, 2024	DP		NCE	Jul 27, 2021
	>A> 8556864	Mar 03, 2024	DP			
	>A> 8603044	Mar 02, 2024	DP			
	>A> 8679069	Apr 12, 2025	DP			
	>A> 8992486	Jun 05, 2024	DP			
	>A> 9011391	Mar 26, 2024	U-1923			
	>A> 9233211	Mar 02, 2024	DP			
	>A> 9408979	Mar 02, 2024	DP			
	>A> 9526844	Mar 02, 2024	DP			
	>A> 9533105	Aug 17, 2024	DP			
	>A> RE45313	Jul 12, 2020	DS DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	>A> 9526844	Mar 02, 2024	DP			
	>A> 9533105	Aug 17, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	>A> 9511198	Feb 16, 2030	U-1929			
	>A> 9511198	Feb 16, 2030	U-1930			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	>A> 9511198	Feb 16, 2030	U-1929			
	>A> 9511198	Feb 16, 2030	U-1930			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	>A> 9511198	Feb 16, 2030	U-1929			
	>A> 9511198	Feb 16, 2030	U-1930			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1848			
	9492442	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1917			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1848			
	9492442	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1917			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		>A> I-740	Feb 21, 2017
	8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8324242	Aug 05, 2027	U-1311		>A> I-740	Feb 21, 2017
	8324242	Aug 05, 2027	U-1906		NCE	Jan 31, 2017
	8354427	Jul 06, 2026	U-1311		>A> ODE	Jan 31, 2019
	8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8324242	Aug 05, 2027	U-1311		>A> I-740	Feb 21, 2017
	8324242	Aug 05, 2027	U-1906		NCE	Jan 31, 2017
	8354427	Jul 06, 2026	U-1311		>A> ODE	Jan 31, 2019
	8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8324242	Aug 05, 2027	U-1311		ODE	Sep 28, 2023
	8324242	Aug 05, 2027	U-1911			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8846718	Dec 04, 2028	U-1717			
	8846718	Dec 04, 2028	U-1908			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Aug 05, 2027	U-1911		NPP	Sep 28, 2019
	8410274	Dec 28, 2026	DP		ODE	Jul 02, 2022
	8507534	Sep 20, 2030	DS DP		ODE	Sep 28, 2023
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
	9486406	Oct 23, 2033	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158	Feb 12, 2019
	9393256	Sep 14, 2032	U-1470		D-159	Feb 12, 2019
>A>	9511056	May 12, 2030	DP U-1470		D-160	Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 206263 001					PC	Feb 11, 2017
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	7252839	Nov 13, 2023	DP		NP	Sep 16, 2019
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7691411	Mar 14, 2024	DP			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP U-1880			
	7790743	Nov 05, 2024	U-1880			
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029	U-1880			
	8367701	Apr 15, 2029	DP U-1880			
	8592450	May 17, 2026	U-1880			
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	9447077	Apr 15, 2029	U-1900			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8802628	Nov 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8802628	Nov 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
	9486526	Aug 05, 2029	U-1915			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					M-188	Oct 14, 2019
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	9463183	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
>A>	9511193	Jan 19, 2032	DP			
	RE45313	Jul 12, 2020	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
>A>	9511193	Jan 19, 2032	DP			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1884			
	9169213	Dec 06, 2032	U-1885			
	9169213	Dec 06, 2032	U-1886			
	9169213	Dec 06, 2032	U-1887			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
	9439907	Oct 26, 2021	DP			
	9440034	Oct 26, 2021	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	>A> 8729085	May 26, 2026	DP			
	>A> 8729085*PED	Nov 26, 2026				
	>A> 8883794	May 26, 2026	DP			
	>A> 8883794*PED	Nov 26, 2026				
	>A> 9174975	Jun 25, 2026	U-1770			
	>A> 9174975*PED	Dec 25, 2026				
	>A> 9259423	May 23, 2031	U-1822			
	>A> 9259423*PED	Nov 23, 2031				
	>A> RE45573	Jun 23, 2025	DS			
	>A> RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	>A> 8729085	May 26, 2026	DP			
	>A> 8729085*PED	Nov 26, 2026				
	>A> 8883794	May 26, 2026	DP			
	>A> 8883794*PED	Nov 26, 2026				
	>A> 9174975	Jun 25, 2026	U-1770			
	>A> 9174975*PED	Dec 25, 2026				
	>A> 9259423	May 23, 2031	U-1822			
	>A> 9259423*PED	Nov 23, 2031				
	>A> RE45573	Jun 23, 2025	DS			
	>A> RE45573*PED	Dec 23, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	>A> 8729085	May 26, 2026	DP			
	>A> 8729085*PED	Nov 26, 2026				
	>A> 8883794	May 26, 2026	DP			
	>A> 8883794*PED	Nov 26, 2026				
	>A> 9174975	Jun 25, 2026	U-1770			
	>A> 9174975*PED	Dec 25, 2026				
	>A> 9259423	May 23, 2031	U-1822			
	>A> 9259423*PED	Nov 23, 2031				
	>A> RE45573	Jun 23, 2025	DS			
	>A> RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	>A> 8729085	May 26, 2026	DP			
	>A> 8729085*PED	Nov 26, 2026				
	>A> 8883794	May 26, 2026	DP			
	>A> 8883794*PED	Nov 26, 2026				
	>A> 9174975	Jun 25, 2026	U-1770			
	>A> 9174975*PED	Dec 25, 2026				
	>A> 9259423	May 23, 2031	U-1822			
	>A> 9259423*PED	Nov 23, 2031				
	>A> RE45573	Jun 23, 2025	DS			
	>A> RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	>A> 5532372	Jul 02, 2018	DS			
	>A> 5532372*PED	Jan 02, 2019				
	>A> 8729085	May 26, 2026	DP			
	>A> 8729085*PED	Nov 26, 2026				
	>A> 8883794	May 26, 2026	DP			
	>A> 8883794*PED	Nov 26, 2026				
	>A> 9174975	Jun 25, 2026	U-1770			
	>A> 9174975*PED	Dec 25, 2026				
	>A> 9259423	May 23, 2031	U-1822			
	>A> 9259423*PED	Nov 23, 2031				
	>A> RE45573	Jun 23, 2025	DS			
	>A> RE45573*PED	Dec 23, 2025				
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001	6586430	Dec 01, 2019	DS DP U-824			
	6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MEBENDAZOLE - VERMOX</u>						
N 208398 001					NS	Oct 19, 2019
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	9382191	Mar 07, 2026	DP			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	>A> 9526734	Mar 31, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002 >A>	9526734	Mar 31, 2033	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>MESALAMINE - CANASA</u>						
N 021252 001					M-187	Sep 02, 2019
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9421333	Mar 19, 2030	DP U-1442			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	6559158	Nov 03, 2017	U-1185		NP	Jul 19, 2019
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	7438930	Dec 16, 2019	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	>A> 7511131	Jan 29, 2027	DS			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001					M-185	Sep 27, 2019
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001					M-185	Sep 27, 2019
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599 002					M-191	Nov 10, 2019
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7786133	Dec 19, 2027	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7786133	Dec 19, 2027	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	>A> 9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	>A> 9517307	Jul 18, 2034	DP U-1925			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9468747	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	>A> 9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	>A> 9517307	Jul 18, 2034	DP U-1925			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9474750	Dec 22, 2018	DP U-1556			
	9511066	May 10, 2022	U-1921			
	>A> 9522919	Mar 30, 2025	DS DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
	9511066	May 10, 2022	U-1921			
	>A> 9522919	Mar 30, 2025	DS DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
	9511066	May 10, 2022	U-1921			
	>A> 9522919	Mar 30, 2025	DS DP			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 001	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 002	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 003	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 004	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 005	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 006	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	9061029	Apr 07, 2032	DP U-1374			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	9061029	Apr 07, 2032	DP U-1374			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001					>A> NCE	Dec 23, 2021
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022		U-1854	ODE	May 27, 2023
	8377916	Feb 21, 2022		U-1854		
	9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022		U-1854	ODE	May 27, 2023
	8377916	Feb 21, 2022		U-1854		
	9238673	Jun 17, 2033	DP			
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 001					PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 002					PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 003					PC	Apr 24, 2017
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-588	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623	Y		
	6489346	Jul 15, 2016	DP U-624	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	U-623	Y		
	6699885	Jul 15, 2016	U-624	Y		
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2017	DS DP U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
>A>	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
>A>	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
>A>	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
>A>	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
>A>	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
>A>	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
>A>	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DS DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020			U-1876	
	8580282	Apr 02, 2030	DP		U-1876	
	9308191	Apr 02, 2030	DP		U-1876	
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Aug 03, 2032			U-1290	
>A>	9511046	Oct 17, 2033			U-1434	

NC

Jun 29, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457021	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 001					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 002					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 003					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
	9393237	Aug 04, 2026		U-904		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	9492476	Oct 08, 2033		U-1766		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	9492476	Oct 08, 2033		U-1766		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	9492476	Oct 08, 2033		U-1766		
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026		U-1844		
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024		U-1845		
	8921393	Jan 15, 2024		U-1846		
	9296694	Mar 06, 2021	DS DP			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	9480652	May 12, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	>A> 9493470	Dec 12, 2033	DS DP U-1700			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	>A> 9493470	Dec 12, 2033	DS DP U-1700			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	>A> 9493470	Dec 12, 2033	DS DP U-1700		>A> NCE	Dec 14, 2017
					>A> ODE	Dec 14, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	>A> 9493470	Dec 12, 2033	DS DP U-1700		>A> NCE >A> ODE	Dec 14, 2017 Dec 14, 2019
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
	>A> 9493582	Feb 27, 2033	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					PC	Jan 01, 2017
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	8268806	Mar 19, 2031	DP		NCE	Nov 16, 2021
	8629129	Aug 07, 2028	DP			
	8957054	Aug 07, 2028	U-1922			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PREDNISONE - RAYOS</u>						
N 202020 001	>A> 9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	>A> 9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	>A> 9504699	Aug 03, 2027	U-1362			
<u>PREGABALIN - LYRICA</u>						
N 021446 001					>A> M-193	Dec 22, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 002					>A> M-193	Dec 22, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 003					>A> M-193	Dec 22, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 004					>A> M-193	Dec 22, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 005					>A> M-193	Dec 22, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 006					>A> M-193	Dec 22, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 007					>A> M-193	Dec 22, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 008					>A> M-193	Dec 22, 2019
<u>PREGABALIN - LYRICA</u>						
N 022488 001					>A> M-193	Dec 22, 2019
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>QUETIAPINE FUMARATE - QUETIAPINE FUMARATE</u>						
A 090681 004					PC	Apr 30, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	9458107	Apr 08, 2031	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	8207191	Aug 30, 2024	U-805			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
	9421195	Mar 10, 2030	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	>A> 6495541	Jan 10, 2020	DS DP		>A> NCE	Dec 19, 2021
	>A> 7351701	Jul 23, 2024		U-1927		
	>A> 7531530	Jul 23, 2024		U-1927		
	>A> 8071579	Aug 12, 2027		U-1927		
	>A> 8143241	Aug 12, 2027		U-1927		
	>A> 8754072	Feb 10, 2031	DS DP			
	>A> 8859562	Aug 04, 2031		U-1927		
	>A> 9045487	Feb 10, 2031	DS DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	>A> 6495541	Jan 10, 2020	DS DP		>A> NCE	Dec 19, 2021
	>A> 7351701	Jul 23, 2024		U-1927		
	>A> 7531530	Jul 23, 2024		U-1927		
	>A> 8071579	Aug 12, 2027		U-1927		
	>A> 8143241	Aug 12, 2027		U-1927		
	>A> 8754072	Feb 10, 2031	DS DP			
	>A> 8859562	Aug 04, 2031		U-1927		
	>A> 9045487	Feb 10, 2031	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	9388134	Nov 08, 2026		U-1723		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9388134	Nov 08, 2026		U-1723		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	9388134	Nov 08, 2026		U-1723		
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	9433624	Nov 17, 2024		U-1589		
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024		U-1589		
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024		U-1010		
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024		U-1589		
	RE43797	Nov 17, 2024		U-1590		
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP	U-995	M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP	U-1837		
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP	U-995	M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP	U-1837		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP	U-1797	ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001					NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	>A> 9486426	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2017	DS U-1468			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2017	DS DP		I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	8536130	Sep 22, 2028	U-1276			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	9439985	Sep 27, 2033	DS DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	May 07, 2022	DS DP		NCE	Nov 05, 2020
	7803788	Feb 02, 2022	U-999		NP	Nov 11, 2019
	8754065	Aug 15, 2032	DS DP U-999			
	9296769	Aug 15, 2032	DS DP U-999			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001 >A>	6794410	Sep 12, 2026	U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002 >A>	6794410	Sep 12, 2026	U-1285			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001					>A> NP	Sep 24, 2017
					>A> PED	Mar 24, 2018
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002					>A> NP	Sep 15, 2018
					>A> PED	Mar 15, 2019
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 002	5733919	Oct 23, 2016	DS			
	5965581	Oct 23, 2016	DP			
	5972967	Oct 23, 2016	DP			
	5978698	Oct 08, 2017	U-1897			
	6136794	Jan 29, 2019	U-1898			
	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	May 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956041	Dec 08, 2020	DP		NCE	Nov 06, 2017
	6965027	Mar 25, 2023	DS			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-183 >A> M-192	Aug 12, 2019 Dec 16, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-183 >A> M-192	Aug 12, 2019 Dec 16, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035	U-1857			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	9447089	Jun 06, 2032	DP		M-184	Aug 31, 2019
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm